(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 September 2020 (24.09.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/191342 A1

(51) International Patent Classification:
C07K 16/30 (2006.01) *C07K 16/28* (2006.01)
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:
PCT/US2020/023981

(22) International Filing Date:
20 March 2020 (20.03.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/821,391 20 March 2019 (20.03.2019) US

(71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US).


(72) Inventors; and
(71) Applicants: **CONKLIN, Dylan** [US/US]; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). **MCDERMOTT, Martina, S.** [—/US]; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). **O'BRIEN, Neil, A.** [IE/US]; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). **PALAZZOLO, Michael, J.** [US/US]; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). **SLAMON, Dennis** [US/US]; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). **VON EUW, Erika** [AR/US]; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). **BOWERS, Peter** [US/US]; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US).

(74) Agent: **HALSTEAD, David, P.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES

FIG. 42A



(57) Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

WO 2020/191342 A1

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/821,391, filed on March 20, 2019, the entire contents of said application are incorporated in their entirety by this reference.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 338,714 ASCII (Text) file named "54086P1_Seqlisting.txt"; created on March 20, 2019.

BACKGROUND

[0003] Antibodies constitute powerful therapeutic agents characterized by limited side effects due to their ability to specifically target a distinct antigen on a cell, bacteria, virus, or toxin. In 1986, the first therapeutic monoclonal antibody, Orthoclone OKT3, was introduced into the market. Since then, this class of biopharmaceutical products has significantly grown. In late 2014, forty-seven monoclonal antibody products had received approval in the U.S. or Europe for the treatment of a variety of diseases, including cancer and inflammatory, cardiovascular, respiratory, and infectious diseases.

[0004] More than a dozen monoclonal antibodies are currently approved by the U.S. Food and Drug Administration to treat cancers. Among these agents are alemtuzumab (Campath®), which is indicated for chronic lymphocytic leukemia (CLL), and trastuzumab (Herceptin®), which is used for treating breast cancer. Some antibodies are labeled with chemotherapeutic drugs, including, for example, brentuximab vedotin (Adcetris®) and Ado-trastuzumab emtansine (Kadcyla®). Other antibody products, such as blinatumomab (Blincyto) are designed to recognize and bind to two different antigens. Despite the commercial availability of such antibody products, the current cancer incidence and cancer deaths remain high. It has been reported that cancer incidence is greater than 450 per 100,000 men and women per year, and cancer mortality is just over 170 per 100,000 men and women per year.

SUMMARY

[0005] Provided herein are antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding protein of the present disclosure binds to a human CLDN6 and optionally binds to a mouse CLDN6. In various aspects, the antigen-binding protein binds to the extracellular domain (ECD) of CLDN6. In various instances, the antigen-binding protein binds to Extracellular Loop 2 (EL2) of the ECD of CLDN6. In various aspects, the antigen-binding protein binds to EL2 and does not bind to Extracellular Loop 1 (EL1) of the ECD of CLDN6. In various instances, the antigen binding protein binds to additional members of the human Claudin family, including, for example, Claudin-3 (CLDN3), Claudin-4 (CLDN4), and Claudin-9 (CLDN9). In various instances, the antigen binding protein binds to CLDN6 and at least one of CLDN4 and CLDN9. In various instances, the antigen binding protein binds to CLDN6 and does not bind to any other member of the Claudin family. In various aspects, the antigen binding protein binds to CLDN6 endogenously expressed by human ovarian cancer cells, e.g., OVCA429 cells, and exhibits an IC50 less than about 1200 nM in a FACS affinity assay with OVCA429 cells. In various instances, the antigen-binding proteins of the present disclosure inhibit tumor growth in a subject, e.g., a human, without any other moiety attached to the antigen-binding protein.

[0006] In various aspects, an antigen-binding protein comprises (a) a heavy chain CDR1 amino acid sequence of SEQ ID NO: 504 or SEQ ID NO: 507, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; (b) a heavy chain CDR2 amino acid sequence of: SEQ ID NOs: 505 or SEQ ID NO: 508, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; (c) a heavy chain CDR3 amino acid sequence of SEQ ID NO: 506 or SEQ ID NO: 509, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; (d) a light chain CDR1 amino acid sequence of: SEQ ID NO: 449 or SEQ ID NO: 476, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; (e) a light chain CDR2 amino acid sequence of: SEQ ID NO: 450 or SEQ ID NO: 477, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; (f) light chain CDR3 amino acid sequence of: SEQ ID NO: 451 or SEQ ID NO: 454, or a variant sequence

thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; and/or (g) a combination of any two or more of (a)-(f).

[0007] In various aspects, an antigen-binding protein comprises (a) a heavy chain variable region amino acid sequence of any one of SEQ ID NOs: 490-503, or a heavy chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or (b) a light chain variable region amino acid sequence of any one of SEQ ID NOs: 380-383, 388-390, 479, and 481, or a light chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or both (a) and (b).

[0008] In various aspects, an antigen binding protein comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 389 and 490; (b) SEQ ID NOs: 389 and 491; (c) SEQ ID NOs: 389 and 492; (d) SEQ ID NOs: 389 and 493; (e) SEQ ID NOs: 389 and 494; (f) SEQ ID NOs: 389 and 495; (g) SEQ ID NOs: 383 and 496; (h) SEQ ID NOs: 383 and 497; (i) SEQ ID NOs: 383 and 498; (j) SEQ ID NOs: 383 and 499; (k) SEQ ID NOs: 383 and 500; (l) SEQ ID NOs: 383 and 501; (m) SEQ ID NOs: 383 and 503; (n) SEQ ID NOs: 389 and 502; (o) the heavy chain variable region sequence labeled as S1 in FIG. 22 and the light chain variable region sequence labeled as S1 in FIG. 22; (p) the heavy chain variable region sequence labeled as S2 in FIG. 22 and the light chain variable region sequence labeled as S2 in FIG. 22; (q) the heavy chain variable region sequence labeled as S3 in FIG. 22 and the light chain variable region sequence labeled as S3 in FIG. 22; (r) the heavy chain variable region sequence labeled as S4 in FIG. 22 and the light chain variable region sequence labeled as S4 in FIG. 22; (s) the heavy chain variable region sequence labeled as S5 in FIG. 22 and the light chain variable region sequence labeled as S5 in FIG. 22; (t) the heavy chain variable region sequence labeled as S6 in FIG. 22 and the light chain variable region sequence labeled as S6 in FIG. 22; (u) the heavy chain variable region sequence labeled as S7 in FIG. 22 and the light chain variable region sequence labeled as S7 in FIG. 22; (v) the heavy chain variable region sequence labeled as S78 in FIG. 22 and the light chain variable region sequence labeled as S8 in FIG. 22; (w) the heavy chain variable region sequence labeled as S89 in FIG. 22 and the light chain variable region sequence labeled as S9 in FIG. 22; (x) the heavy chain variable region

sequence labeled as S910 in FIG. 22 and the light chain variable region sequence labeled as S10 in FIG. 22; (y) the heavy chain variable region sequence labeled as S11 in FIG. 22 and the light chain variable region sequence labeled as S11 in FIG. 22; or (z) the heavy chain variable region sequence labeled as S12 in FIG. 22 and the light chain variable region sequence labeled as S12 in FIG. 22.

[0009] In various instances, an antigen-binding protein comprises (a) a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 510 or 513 or in FIG. 23 or FIG. 25, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or (b) a light chain variable region amino acid sequence set forth as SEQ ID NO: 511 or 512 or in FIG. 24 or FIG. 26, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or (c) both (a) and (b).

[0010] In various instances, an antigen-binding protein comprises a pair of amino acid sequences wherein the pair comprises (a) a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 510 and a light chain variable region amino acid sequence set forth as SEQ ID NO: 511, or a variant sequence thereof which differs by only 1-5 amino acids or which has at least or about 70% sequence identity; optionally, wherein the 1-5 amino acids which differ are as shown in FIG. 23 for the heavy chain or FIG. 24 for the light chain, or (b) a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 513 and a light chain variable region amino acid sequence set forth as SEQ ID NO: 512, or a variant sequence thereof which differs by only 1-5 amino acids or which has at least or about 70% sequence identity; or optionally, wherein the 1-5 amino acids which differ are as shown in FIG. 25 for the heavy chain or FIG. 26 for the light chain.

[0011] Further provided herein are antigen-binding proteins conjugated to a heterologous moiety (e.g., conjugated to any chemotherapeutic agent, drug or toxic moiety) inhibit tumor growth in a subject, e.g., a human. In various instances, the conjugated antigen-binding protein is a monoclonal antibody. In various instances, the antibody is conjugated to an agent that alters the microtubule dynamics, *e.g.,* MMAE. In various instances, the conjugate comprises a cleavable linker, *e.g.,* MC-VC-PAB. In various aspects, the conjugate is a homogeneous conjugate or a heterogeneous conjugate. In various aspects, the heterologous moiety is conjugated at a specific site of the antigen-binding protein.

[0012] In various aspects, the antigen-binding protein binds to CLDN6 expressed by human cancer cells. In various aspects, the antigen-binding protein inhibits a binding interaction between human CLDN6 and a reference anti-CLDN6 antibody. Without being bound to a particular theory, the inhibiting action of the antigen-binding proteins provided herein allow such entities to be useful in methods of reducing tumor growth and treating a subject with a tumor or cancer. As further discussed herein, in various aspects, the antigen-binding protein is an antibody, antigen-binding antibody fragment thereof, or antibody protein product.

[0013] The present disclosure also provides antigen-binding proteins comprising at least 3, 4, 5, or all amino acid sequences of a specified group of amino acid sequences. In various aspects, the antigen-binding proteins comprise at least 3, 4, 5, or 6 complementary determining region (CDR) amino acid sequences of CLDN6 antibodies disclosed herein.

[0014] The present disclosure further provides antigen-binding proteins comprising amino acid sequences as detailed herein. In various aspects, the antigen-binding protein comprises an amino acid sequence of any one of SEQ ID NOs: 490-512, or an amino acid sequence as shown in any one of FIG. 22-FIG. 26, or a combination thereof, as further described herein.

[0015] Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover contemplated.

[0016] Also provided are methods of making an antigen-binding protein. In various embodiments, the method comprises culturing a host cell comprising a nucleic acid encoding a antigen-binding protein or a polypeptide as described herein so as to express the antigen-binding protein or polypeptide.

[0017] Methods of treating a subject having cancer are additionally provided herein. In various embodiments, the method comprises administering to the subject the pharmaceutical composition of the present disclosure in an amount effective for treating the cancer in the subject.

[0018] Also provided are methods of treating a subject with a CLDN6-expressing cancer comprising administering to the subject a pharmaceutical composition described herein.

Further contemplated is a method of inhibiting tumor growth in a subject, comprising administering to the subject a pharmaceutical composition described herein.

[0019] A method of reducing tumor size in a subject, or preventing the recurrence of cancer in a subject comprising administering to the subject a pharmaceutical composition described herein.

[0020] Also provided herein is a method of treating cancer in a subject diagnosed to be a low over-expresser of CLDN6, comprising administering to the subject a pharmaceutical composition described herein.

[0021] In various embodiments, the administering induces apoptosis in tumor cells, for example in cells expressing CLDN6. In various embodiments, the administration induces antibody-dependent cell-mediated cytotoxicity (ADCC) or Complement-dependent cytotoxicity (CDC), tumor necrosis and death or depletion of cells, and/or disruption of tumor cell adherence, each of which result tumor regression or slowing of tumor growth.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] FIG. 1 represents a graph of CLDN6 expression in normal (non-cancerous) tissues.

[0023] FIG. 2 represents a graph of CLDN6 expression in cancer cell lines as determined by Agilent44K methodology.

[0024] FIG. 3 represents a graph of CLDN6 expression in cancer cell lines as determined by RNASeq.

[0025] FIG. 4 represents a set of fluorescent images depicting CLDN6-GFP localization in different cell models.

[0026] FIG. 5 represents a sequence alignment of human CLDN6, human CLDN3, human CLDN4, human CLDN9, and mouse CLDN6. The sequences of the EL1 and EL2 are shown.

[0027] FIG. 6A represents a graph of tumor volume (mm^3) of tumors in mice bearing endometrial tumors as a function of time (days) after treatment with control IgG2 antibody, AB3, Reference Ab1, Reference Ab2, Reference Ab3, AB2, and AB3. FIG. 6B represents a graph of the mean change in tumor volume (mm^3) at Day 14 of tumors in mice bearing

endometrial tumors treated with control IgG2 antibody, AB3, Reference Ab1, Reference Ab2, Reference Ab3, AB2, or AB3.

[0028] FIG. 7A represents a graph of tumor volume (mm^3) of tumors in mice bearing bladder tumors as a function of time (days) after treatment with control IgG2 antibody, AB3, Reference Ab1, Reference Ab2, and AB3. FIG. 7B represents a graph of the mean change in tumor volume (mm^3) at Day 35 of tumors in mice bearing bladder tumors treated with control IgG2 antibody, AB3, Reference Ab1, Reference Ab2, or AB3.

[0029] FIG. 8A represents a graph of tumor volume (mm^3) of tumors in mice bearing ovarian tumors as a function of time (days) after treatment with control IgG2 antibody, AB3, Reference Ab1, AB2, and AB3. FIG. 8B represents a graph of the mean change in tumor volume (mm^3) at Day 20 of tumors in mice bearing ovarian tumors treated with control IgG2 antibody, AB3, Reference Ab1, AB2, or AB3.

[0030] FIG. 9A represents a graph of tumor volume (mm^3) of tumors in mice bearing melanoma tumors as a function of time (days) after treatment with control IgG2 antibody, AB3, Reference Ab1, Reference Ab2, Reference Ab3, and AB3. FIG. 9B represents a graph of the mean change in tumor volume (mm^3) at Day 21 of tumors in mice bearing melanoma tumors treated with control IgG2 antibody, AB3, Reference Ab1, Reference Ab2, Reference Ab3, or AB3.

[0031] FIG. 10A represents a graph of the % tumor growth inhibition achieved in tumor-bearing mice treated with AB3, relative to mice treated with control antibody. FIG. 10B represents an image of a Western blot demonstrating the different levels of CLDN6 id endometrial cancer cell lines (ARK2), bladder cancer cell lines (UMUC4), ovarian cancer cell lines (OV90) and melanoma cell lines (M202) and control cells. The levels of α-tubulin were approximately the same, demonstrating equal protein loading.

[0032] FIG. 11 represents a graph of the % change in body weight of tumor-bearing mice treated with vehicle control, control antibody, Reference Ab1, Reference Ab2, Reference Ab3, and AB3 as a function of time (days).

[0033] FIG. 12A represents a graph of tumor volume (mm^3) of tumors in mice bearing ovarian tumors as a function of time (days) after treatment with vehicle control, control IgG2 antibody, AB3, Reference Ab1, or one of the indicated anti-CLDN6 antibodies. FIG. 12B represents a graph of the mean change in tumor volume (mm^3) at Day 28 of tumors in

mice bearing ovarian tumors treated with vehicle control, control IgG2 antibody, AB3, Reference Ab1, or one of the indicated anti-CLDN6 antibodies.

[0034] FIG. 13 represents a graph of the % change in body weight of tumor-bearing mice treated with vehicle control, control antibody, Reference Ab1, and the indicated anti-CLDN6 antibodies as a function of time (days).

[0035] FIG. 14 represents a series of dose response curves for several anti-CLDN6 antibodies of the invention and Reference Ab1 and Reference 2. Mouse IgG was used as a control.

[0036] FIG. 15A represents a graph of the mean change in tumor volume (mm^3) at Day 35 of tumors in mice bearing bladder tumors treated with vehicle control, control IgG antibody, a mouse form of AB3, a first humanized form of AB3, and a second humanized form of AB3. FIG. 15B represents a graph of the changes in tumor volume(mm^3) for each of the groups in FIG. 15A.

[0037] FIG. 16A represents a graph of the mean change in tumor volume (mm^3) at Day 35 of tumors in mice bearing bladder tumors treated with vehicle control, control IgG antibody, a mouse form of AB3, a first humanized form of AB3, and a second humanized form of AB3. Two control antibodies (one mouse and one chimeric) are also tested in this experiment. FIG. 16B represents a graph of the changes in tumor volume(mm^3) for each of the groups in FIG. 16A.

[0038] FIG. 17A represents a graph of the mean change in tumor volume (mm^3) at Day 35 of tumors in mice bearing bladder tumors treated with vehicle control, control IgG antibody, a mouse form of AB1, and a humanized form of AB1. FIG. 17B represents a graph of the changes in tumor volume(mm^3) for each of the groups in FIG. 17A.

[0039] FIG. 18A represents a graph of the mean change in tumor volume (mm^3) at Day 35 of tumors in mice bearing bladder tumors treated with vehicle control, control IgG antibody, a mouse form of AB4, and a humanized form of AB4. FIG. 18B represents a graph of the changes in tumor volume (mm^3) for each of the groups in FIG. 18A.

[0040] FIG. 19A represents a graph of the mean change in tumor volume (mm^3) at Day 35 of tumors in mice bearing bladder tumors treated with vehicle control, control IgG antibody, a mouse form of AB3, a chimeric form of AB3, a first humanized form of AB3, a second humanized form of AB3, a mouse form of Ab 1, a humanized form of AB1, a

mouse form of AB4, a humanized form of AB4, and four control antibodies (one antibody have either a mouse form or a chimeric form and one antibody having a mouse or human form) are also tested in this experiment. FIG. 19B represents a graph of the changes in tumor volume(mm^3) for each of the groups in FIG. 19A.

[0041] FIG. 20 represents a graph of the mean change in tumor volume (mm^3) at Day 55 of tumors in mice bearing bladder tumors treated as described in FIG. 19A.

[0042] FIG. 21 represents a graph of the % change in body weight of tumor-bearing mice treated at Day 32 treated as described in FIG. 19A.

[0043] FIG. 22 is a listing of sequences of the heavy chain variable region and light chain variable region of 12 CLDN6 antibodies (named S1-S12) made and characterized. S1-S6 were based on a humanized version of AB3 (humanized AB3-7) and S7-S12 were based on a humanized version of AB1 (humanized AB1-11).

[0044] FIG. 23-FIG. 26 are schematic illustrations of exemplary next generation sequencing (NGS)-identified somatic hypermutation (SHM) of CLDN6 antibodies of the present disclosure. FIG. 23 is the illustration of an AB-3-based antibody and NGS-identified SHM in the heavy chain. FIG. 24 is the illustration of an AB-3-based antibody and NGS-identified SHM in the light chain. FIG. 25 is the illustration of an AB-1-based antibody and NGS-identified SHM in the heavy chain. FIG. 26 is the illustration of an AB-1-based antibody and NGS-identified SHM in the light chain. Mutations are listed in Chothia numbering.

[0045] FIG. 27 is a table of FACS binding assay results for antibodies S1-S12 based on humanized AB3-7 (AB S1-S6) or humanized AB1-11 (AB S7-S12). Concentrations tested are shown in Column D.

[0046] FIG. 28 is a table of FACS binding assay results for antibodies S1-S12 at varied concentrations in different cell lines.

[0047] FIG. 29A is an illustration of the three types of N-glycans (oligomannose, complex and hybrid) and commonly used symbols for such saccharides. FIG. 29B is a diagram of the salvage pathway and the de novo pathway of fucose metabolism. In the salvage pathway, free L -fucose is converted to GDP-fucose, while in the de novo pathway, GDP-fucose is synthesized via three reactions catalyzed by GMD and FX. GDP-fucose is then transported from the cytosol to the Golgi lumen by GDP-Fuc Transferase and

transferred to acceptor oligosaccharides and proteins. The other reaction product, GDP, is converted by a luminal nucleotide diphosphatase to guanosine 5 -monophosphate (GMP) and inorganic phosphate (Pi). The former is exported to the cytosol (via an antiport system that is coupled with the transport of GDP-fucose), whereas the latter is postulated to leave the Golgi lumen via the Golgi anion channel, GOLAC. See, e.g., Nordeen et al. 2000; Hirschberg et al. 2001.

[0048] FIG. 30 is a graph of the tumor volume in mice subcutaneously injected with human cancer cells followed by treatment as described herein.

[0049] FIG. 31 is a graph of the tumor volume in mice subcutaneously injected with human cancer cells followed by treatment as described herein.

[0050] FIG. 32 is a graph of the tumor volume in mice subcutaneously injected with human cancer cells followed by treatment as described herein.

[0051] FIG. 33 is a graph of the tumor volume in mice subcutaneously injected with human cancer cells followed by treatment as described herein.

[0052] FIG. 34A-FIG. 34H show biochemical characterization of the CLDN6 antibody-drug conjugates (ADC) comprising AB3-7 (also referred to as AB23). FIG. 34A is a table summarizing the biochemical properties of the CLDN6 ADCs. FIG. 34B-FIG. 34H represent chromatograms of HIC-HPLC showing the relative abundance of the antibody conjugated to different numbers of drugs.

[0053] FIG. 35 shows the molecular integrity of the CLDN6 ADCs comprising AB3-7 analyzed by Native PAGE.

[0054] FIG. 36 shows the binding activity (flow cytometry) of the CLDN6 antibody-drug conjugate (ADC) comprising AB3-7 to native CLDN6-positive cells or cells artificially overexpressing CLDN6.

[0055] FIG. 37 shows the binding affinity of the CLDN6 ADCs comprising AB3-7 to cells expressing CLDN6. The KD (dissociation constant) measurements were made by KinExA 4000 (Sapidyne Instrument, Boise, Idaho) using HEK293T CLDN6-mGFP A11 cells.

[0056] FIG. 38 shows the *in vitro* characterization of the CLDN6 ADCs comprising AB3-7. The panels demonstrate cell internalization of CLDN6 ADCs. H23-7 refers to AB3-7.

[0057] FIG. 39A-FIG. 39N show the *in vitro* anti-cancer activity of CLDN6 ADCs. FIG. 39A-FIG. 39G show the two-dimensional (2D) anti-proliferative effect of different CLDN6 ADCs comprising AB-3-7 on cancer cells: MC-VC-PAB-MMAE (conventional) (FIG. 39A); MC-VC-PAB-MMAE (D4 technology) (FIG. 39B); MC-GGFG-MMAE (D4 technology) (FIG. 39C); CL2A-SN38 (conventional) (FIG. 39D); CL2A-SN38 (D4 technology) (FIG. 39E); MC-GGFG-DXD (FIG. 39F); and MC-VC-PAB-DXD (FIG. 39G). FIG. 39H-FIG. 39N show the 2D anti-proliferative effect of CLDN6 ADC-11 (AB1-11 conjugated to VC-PAB-MMAE) on different cancer cell lines: ARK2 (FIG. 39H); OVCA429 (FIG. 39I); H841 (FIG. 39J); OV90 (FIG. 39K); H1693 (FIG. 39L); M202 (FIG. 39M); and MCF7 (FIG. 39N).

[0058] FIG. 40 shows the *in vivo* anti-cancer efficacy of CLDN6 ADC-11 against CLDN6-positive ovarian cancer cell line (OV90) xenografts.

[0059] FIG. 41A-FIG. 41B show no anti-cancer activity of CLDN6 ADC-11 against CLDN6-negative melanoma cancer cell line (M202) xenografts.

[0060] FIG. 42A-FIG. 42B show the *in vivo* anti-cancer efficacy of the CLDN6 ADC-23 (AB3-7-VC-PAB-MMAE) against cancer cell line xenografts. FIG. 42A shows the anti-cancer activity of CLDN6 ADC-23 against the CLDN6-positive bladder cell line (UMUC4) xenografts. FIG. 42B shows the haemotoxylin and eosin (H&E) staining of the xenograft tissues collected at the indicated time points post-treatment with either control antibody or 5 mg/kg ADC-23.

[0061] FIG. 43A-FIG. 43E show the *in vivo* anti-cancer efficacy of the CLDN6 ADC-23 against ovarian cancer patient-derived xenografts (PDX). FIG. 43A shows a panel of ovarian PDX samples that were screened for CLDN6 expression by the Western Blot analysis. FIG. 43B is a schematic diagram showing the injection of the ovarian cancer cells of PDX transfected with a luciferase enzyme into the intraperitoneal space of immunocompromised mice (NSG). FIG. 43C-FIG. 43E show the survival rate of the mice treated with CLDN6 ADC-23 as described herein.

[0062] FIG. 44A-FIG. 44C show the dose-dependent anti-cancer efficacy of CLDN6 ADC-23 against CLDN6-positive ovarian cancer cell line (OV90) xenografts. FIG. 44A and FIG. 44B show the regression of the tumor size at the indicated dose and time. FIG. 44C shows the percent change in the body weight of mice dosed with CLDN6 ADC-23.

[0063] FIG. 45A-FIG. 45C show that there is no off-target activity of CLDN6 ADC-23 in CLDN6-negative melanoma cancer cell line (M202) xenografts. FIG. 45A and FIG. 45B show a change in tumor volume. The tumor volume shown in FIG. 45B was taken on day 21. FIG. 45C shows the percent change in the body weight of the mice dosed with CLDN6 ADC-23.

DETAILED DESCRIPTION

[0064] *The Claudin Family*

[0065] Tight junctions, also known as occluding junctions or zonulae occludentes, are vertebrate structures located between two adjacent cells that regulate paracellular permeability and maintain cell polarity in epithelial and endothelial cell sheets. The claudin (CLDN) family of genes encodes membrane proteins that are important components of tight junctions. CLDN proteins comprise four transmembrane (TM) helices (TM1, TM2, TM3, and TM4) and two extracellular loops (EL1 and EL2). The extracellular loops of the CLDN proteins of adjacent cells interact with one another to seal the cellular sheet and regulate paracellular transport between the luminal and basolateral spaces.

[0066] CLDN proteins play a role in various human diseases and pathologies. For example, mutations in the *CLDN1* gene have been shown to result in progressive scaling of the skin along with obstruction of bile ducts. Mutants of the *CLDN16* gene cause a magnesium wasting disorder. *CLDN19* mutations lead to ocular conditions, such as macular colobomata and myopia, while *CLDN14* mutations can lead to nonsyndromic recessive deafness. CLDN3 and CLDN4 are known to be surface receptors for the *Clostridium perfringens* enterotoxin in the gut, and CLDN1, CLDN6, and CLDN9 are co-receptors for hepatitis C virus (HCV) entry. Several CLDN proteins have been shown to be abnormally expressed in cancers. For instance, CLDN1 is downregulated in breast and colon cancer, whereas CLDN3 and CLDN4 are highly upregulated in multiple cancers.

[0067] Claudin-6 (CLDN6) is a member of the CLDN family. The gene encoding the human CLDN6 protein is located on the p arm of human chromosome 16 at 16p13.3 and is

conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, rat, zebrafish, and frog. CLDN6 is generally expressed in humans as a 220-amino acid precursor protein; the first 21 amino acids of which constitute the signal peptide. The amino acid sequence of the CLDN6 precursor protein is publically available at the National Center for Biotechnology Information (NCBI) website as NCBI Reference Sequence NP_067018.2 and is provided herein as SEQ ID NO: 1. The amino acid at position 143 of SEQ ID NO: 1 is Ile. In some instances, due to a single-nucleotide polymorphism (SNP) in the DNA sequence encoding CLDN6, the amino acid at position 143 is a Val. The amino acid sequence of human CLDN6 having a Val at position 143 is provided herein as SEQ ID NO: 178.

[0068] *Antigen binding proteins*

[0069] Provided herein are antigen-binding proteins that bind to Claudin-6 (CLDN6). The antigen-binding proteins of the present disclosure can take any one of many forms of antigen-binding proteins known in the art. In various embodiments, the antigen-binding proteins of the present disclosure take the form of an antibody, or antigen-binding antibody fragment, or an antibody protein product.

[0070] In various embodiments of the present disclosure, the antigen-binding protein comprises, consists essentially of, or consists of an antibody. As used herein, the term "antibody" refers to a protein having a conventional immunoglobulin format, comprising heavy and light chains, and comprising variable and constant regions. For example, an antibody may be an IgG which is a "Y-shaped" structure of two identical pairs of polypeptide chains, each pair having one "light" (typically having a molecular weight of about 25 kDa) and one "heavy" chain (typically having a molecular weight of about 50-70 kDa). An antibody has a variable region and a constant region. In IgG formats, the variable region is generally about 100-110 or more amino acids, comprises three complementarity determining regions (CDRs), is primarily responsible for antigen recognition, and substantially varies among other antibodies that bind to different antigens. The constant region allows the antibody to recruit cells and molecules of the immune system. The variable region is made of the N-terminal regions of each light chain and heavy chain, while the constant region is made of the C-terminal portions of each of the heavy and light chains. (Janeway et al., "Structure of the Antibody Molecule and the Immunoglobulin Genes", Immunobiology: The Immune System in Health and Disease, 4th ed. Elsevier Science Ltd./Garland Publishing, (1999)).

[0071] The general structure and properties of CDRs of antibodies have been described in the art. Briefly, in an antibody scaffold, the CDRs are embedded within a framework in the heavy and light chain variable region where they constitute the regions largely responsible for antigen binding and recognition. A variable region typically comprises at least three heavy or light chain CDRs (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Public Health Service N.I.H., Bethesda, Md.; see also Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342: 877-883), within a framework region (designated framework regions 1-4, FR1, FR2, FR3, and FR4, by Kabat et al., 1991; see also Chothia and Lesk, 1987, supra).

[0072] Antibodies can comprise any constant region known in the art. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to IgG1, IgG2, IgG3, and IgG4. IgM has subclasses, including, but not limited to, IgM1 and IgM2. Embodiments of the present disclosure include all such classes or isotypes of antibodies. The light chain constant region can be, for example, a kappa- or lambda-type light chain constant region, e.g., a human kappa- or lambda-type light chain constant region. The heavy chain constant region can be, for example, an alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constant regions, e.g., a human alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constant region. Accordingly, in various embodiments, the antibody is an antibody of isotype IgA, IgD, IgE, IgG, or IgM, including any one of IgG1, IgG2, IgG3 or IgG4. In various aspects, the antibody comprises a constant region comprising one or more amino acid modifications, relative to the naturally-occurring counterpart, in order to improve half-life/stability or to render the antibody more suitable for expression/manufacturability. In various instances, the antibody comprises a constant region wherein the C-terminal Lys residue that is present in the naturally-occurring counterpart is removed or clipped.

[0073] The antibody can be a monoclonal antibody. In some embodiments, the antibody comprises a sequence that is substantially similar to a naturally-occurring antibody produced by a mammal, e.g., mouse, rabbit, goat, horse, chicken, hamster, human, and the like. In this regard, the antibody can be considered as a mammalian antibody, e.g., a mouse antibody, rabbit antibody, goat antibody, horse antibody, chicken antibody, hamster

antibody, human antibody, and the like. In certain aspects, the antigen-binding protein is an antibody, such as a human antibody. In certain aspects, the antigen-binding protein is a chimeric antibody or a humanized antibody. The term "chimeric antibody" refers to an antibody containing domains from two or more different antibodies. A chimeric antibody can, for example, contain the constant domains from one species and the variable domains from a second, or more generally, can contain stretches of amino acid sequence from at least two species. A chimeric antibody also can contain domains of two or more different antibodies within the same species. The term "humanized" when used in relation to antibodies refers to antibodies having at least CDR regions from a non-human source which are engineered to have a structure and immunological function more similar to true human antibodies than the original source antibodies. For example, humanizing can involve grafting a CDR from a non-human antibody, such as a mouse antibody, into a human antibody. Humanizing also can involve select amino acid substitutions to make a non-human sequence more similar to a human sequence. Information, including sequence information for human antibody heavy and light chain constant regions is publicly available through the Uniprot database as well as other databases well-known to those in the field of antibody engineering and production. For example, the IgG2 constant region is available from the Uniprot database as Uniprot number P01859, incorporated herein by reference.

[0074] An antibody can be cleaved into fragments by enzymes, such as, e.g., papain and pepsin. Papain cleaves an antibody to produce two Fab fragments and a single Fc fragment. Pepsin cleaves an antibody to produce a $F(ab')_2$ fragment and a pFc' fragment. In various aspects of the present disclosure, the antigen-binding protein of the present disclosure is an antigen-binding fragment of an antibody (a.k.a., antigen-binding antibody fragment, antigen-binding fragment, antigen-binding portion). In various instances, the antigen-binding antibody fragment is a Fab fragment or a $F(ab')_2$ fragment.

[0075] The architecture of antibodies has been exploited to create a growing range of alternative antibody formats that spans a molecular-weight range of at least about 12–150 kDa and has a valency (n) range from monomeric (n = 1), to dimeric (n = 2), to trimeric (n = 3), to tetrameric (n = 4), and potentially higher; such alternative antibody formats are referred to herein as “antibody protein products”. Antibody protein products include those based on the full antibody structure and those that mimic antibody fragments which retain full antigen-binding capacity, e.g., scFvs, Fabs and VHH/VH (discussed below). The

smallest antigen-binding fragment that retains its complete antigen binding site is the Fv fragment, which consists entirely of variable (V) regions. A soluble, flexible amino acid peptide linker is used to connect the V regions to a scFv (single chain fragment variable) fragment for stabilization of the molecule, or the constant (C) domains are added to the V regions to generate a Fab fragment [fragment, antigen-binding]. Both scFv and Fab fragments can be easily produced in host cells, e.g., prokaryotic host cells. Other antibody protein products include disulfide-bond stabilized scFv (ds-scFv), single chain Fab (scFab), as well as di- and multimeric antibody formats like dia-, tria- and tetra-bodies, or minibodies (miniAbs) that comprise different formats consisting of scFvs linked to oligomerization domains. The smallest fragments are VHH/VH of camelid heavy chain Abs as well as single domain Abs (sdAb). The building block that is most frequently used to create novel antibody formats is the single-chain variable (V)-domain antibody fragment (scFv), which comprises V domains from the heavy and light chain (VH and VL domain) linked by a peptide linker of ~15 amino acid residues. A peptibody or peptide-Fc fusion is yet another antibody protein product. The structure of a peptibody consists of a biologically active peptide grafted onto an Fc domain. Peptibodies are well-described in the art. See, e.g., Shimamoto et al., mAbs 4(5): 586-591 (2012).

[0076] Other antibody protein products include a single chain antibody (SCA); a diabody; a triabody; a tetrabody; bispecific or trispecific antibodies, and the like. Bispecific antibodies can be divided into five major classes: BsIgG, appended IgG, bispecific antibody (BsAb) fragments, bispecific fusion proteins, and BsAb conjugates. See, e.g., Spiess et al., Molecular Immunology 67(2) Part A: 97-106 (2015).

[0077] In various aspects, the antigen-binding protein of the present disclosure comprises, consists essentially of, or consists of any one of these antibody protein products. In various aspects, the antigen-binding protein of the present disclosure comprises, consists essentially of, or consists of any one of an scFv, Fab VHH/VH, Fv fragment, ds-scFv, scFab, dimeric antibody, multimeric antibody (e.g., a diabody,, triabody, tetrabody), miniAb, peptibody VHH/VH of camelid heavy chain antibody, sdAb, diabody; a triabody; a tetrabody; a bispecific or trispecific antibody, BsIgG, appended IgG, BsAb fragment, bispecific fusion protein, and BsAb conjugate.

[0078] In various instances, the antigen-binding protein of the present disclosure is an antibody protein product in monomeric form, or polymeric, oligomeric, or multimeric form.

In certain embodiments in which the antibody comprises two or more distinct antigen binding regions fragments, the antibody is considered bispecific, trispecific, or multi-specific, or bivalent, trivalent, or multivalent, depending on the number of distinct epitopes that are recognized and bound by the antibody.

[0079] In various embodiments, an anti-CLDN6 antibody or antibody variant thereof is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

[0080] In various aspects, the antigen-binding protein of the present disclosure is linked to a therapeutic agent. As described below, the therapeutic agent may be any known in the art, including, but not limited to, chemotherapeutic agents, cytokines and growth factors, cytotoxic agents, and the like. See "*Conjugates*" below.

[0081] *CLDN6 and Epitopes*

[0082] The antigen-binding proteins of the present disclosure bind to CLDN6. In various aspects, the CLDN6 is a human CLDN6 having the amino acid sequence of:

> MASAGMQILGVVLTLLGWVNGLVSCALPMWKVTAFIGNSIVVAQV
> VWEGLWMSCVVQSTGQMQCKVYDSLLALPQDLQAARALCVIALL
> VALFGLLVYLAGAKCTTCVEEKDSKARLVLTSGIVFVISGVLTLIPVC
> WTAHA**X**IRDFYNPLVAEAQKRELGASLYLGWAASGLLLLGGGLLC
> CTCPSGGSQGPSHYMARYSTSAPAISRGPSEYPTKNYV, wherein X is
> Ile or Val (SEQ ID NO: 202).

[0083] In various aspects, the human CLDN6 comprises the amino acid sequence of any one of SEQ ID NOs: 1, 178, and 200-202.

[0084] In various aspects, the antigen-binding proteins of the present disclosure bind to an epitope within an amino acid sequence of CLDN6. In various aspects, CLDN6 is a human CLDN6 and the antigen-binding proteins of the present disclosure bind to an epitope within an amino acid sequence of human CLDN6, e.g., SEQ ID NOs: 1, 178, and 200-202. By "epitope" is meant the region of or within CLDN6 which is bound by the antigen-binding protein. In some embodiments, the epitope is a linear epitope. "Linear epitope"

refers to the region of or within the CLDN6 which is bound by the antigen-binding protein and which region is composed of contiguous amino acids of the amino acid sequence of the CLDN6. The amino acids of a linear epitope are adjacent to each other in the primary structure of the CLDN6. Accordingly, a linear epitope is a fragment or portion of the amino acid sequence of the antigen, i.e., CLDN6. In other various embodiments, the epitope is a conformational or structural epitope. By "conformational epitope" or "structural epitope" is meant an epitope which is composed of amino acids which are located in close proximity to one another only when the CLDN6 is in its properly folded state. Unlike linear epitopes, the amino acids of a conformational or structural epitope are not adjacent to each other in the primary structure (i.e., amino acid sequence) of the CLDN6. A conformational or structural epitope is not made of contiguous amino acids of the amino acid sequence of the antigen (CLDN6).

[0085] In various aspects, the epitope is located within the extracellular domain (ECD) of CLDN6, e.g., human CLDN6. In various aspects, the antigen binding protein binds to Extracellular Loop 2 (EL2) of the ECD of CLDN6 having the amino acid sequence of WTAHAIIRDFYNPLVAEAQKREL (SEQ ID NO: 2). In various aspects, the epitope to which the antigen-binding protein binds is within SEQ ID NO: 2. In various aspects, the antigen-binding protein of the present disclosure binds to an N-terminal portion of SEQ ID NO: 2, e.g., TAHAIIRDFYNPL (SEQ ID NO: 3). In various aspects, the antigen-binding protein of the present disclosure binds to a C-terminal portion of SEQ ID NO: 2, e.g., LVAEAQKREL (SEQ ID NO: 4). In various instances, the antigen-binding protein of the present disclosure binds to EL2, but not to Extracellular Loop 1 (EL1) of CLDN6. In various aspects, the epitope(s) to which the antigen binding proteins of the present disclosure bind to is different from the epitope bound by an anti-CLDN6 antibody comprising a light chain variable region comprising the sequence of SEQ ID NO: 185 and a heavy chain variable region comprising the sequence of SEQ ID NO: 186. In various aspects, the epitope(s) to which the antigen binding proteins of the present disclosure bind to is different from the epitope bound by an anti-CLDN6 antibody comprising a light chain variable region comprising the sequence of SEQ ID NO: 181 and a heavy chain variable region comprising the sequence of SEQ ID NO: 182.

[0086] In various aspects, the antigen-binding proteins bind to human CLDN6 and a non-human CLDN6. In various instances, the non-human CLDN6 is a CLDN6 of chimpanzee,

Rhesus monkey, dog, cow, mouse, rat, zebrafish, or frog. In various instances, the antigen-binding proteins bind to human CLDN6 and mouse CLDN6.

[0087] *Affinity and Avidity*

[0088] The antigen-binding proteins provided herein bind to CLDN6 in a non-covalent and reversible manner. In various embodiments, the binding strength of the antigen-binding protein to CLDN6 may be described in terms of its affinity, a measure of the strength of interaction between the binding site of the antigen-binding protein and the epitope. In various aspects, the antigen-binding proteins provided herein have high-affinity for CLDN6 and thus will bind a greater amount of CLDN6 in a shorter period of time than low-affinity antigen-binding proteins. In various aspects, the antigen-binding protein has an equilibrium association constant, K_A, which is at least 10^5 mol^{-1}, at least 10^6 mol^{-1}, at least 10^7 mol^{-1}, at least 10^8 mol^{-1}, at least 10^9 mol^{-1}, or at least 10^{10} mol^{-1} or at least 10^{10} mol^{-1} least 10^{10} mol^{-1}. As understood by the artisan of ordinary skill, K_A can be influenced by factors including pH, temperature and buffer composition.

[0089] In various embodiments, the binding strength of the antigen-binding protein to CLDN6 may be described in terms of its sensitivity. K_D is the equilibrium dissociation constant, a ratio of k_{off}/k_{on}, between the antigen-binding protein and CLDN6. K_D and K_A are inversely related. The K_D value relates to the concentration of the antigen-binding protein (the amount of antigen-binding protein needed for a particular experiment) and so the lower the K_D value (lower concentration) the higher the affinity of the antigen-binding protein. In various aspects, the binding strength of the antigen-binding protein to CLDN6 may be described in terms of K_D. In various aspects, the K_D of the antigen-binding proteins provided herein is about 10^{-1}, about 10^{-2}, about 10^{-3}, about 10^{-4}, about 10^{-5}, about 10^{-6}, or less. In various aspects, the K_D of the antigen-binding proteins provided herein is micromolar, nanomolar, picomolar or femtomolar. In various aspects, the K_D of the antigen-binding proteins provided herein is within a range of about 10^{-4} to 10^{-6} or 10^{-7} to 10^{-9} or 10^{-10} to 10^{-12} or 10^{-13} to 10^{-15}. In various aspects, the K_D of the antigen-binding proteins provided herein is within a range of about 1.0×10^{-12} M to about 1.0×10^{-8} M. In various aspects, the K_D of the antigen-binding proteins is within a range of about 1.0×10^{-11} M to about 1.0×10^{-9} M.

[0090] In various aspects, the affinity of the antigen-binding proteins are measured or ranked using a flow cytometry- or Fluorescence-Activated Cell Sorting (FACS)-based

assay. Flow cytometry-based binding assays are known in the art. See, e.g., Cedeno-Arias et al., Sci Pharm 79(3): 569-581 (2011); Rathanaswami et al., Analytical Biochem 373: 52-60 (2008); and Geuijen et al., J Immunol Methods 302(1-2): 68-77 (2005). In various aspects, the affinity of the antigen-binding proteins are measured or ranked using a competition assay as described in Trikha et al., Int J Cancer 110: 326-335 (2004) and Tam et al., Circulation 98(11): 1085-1091 (1998), as well as below. See section titled "*Competition Assays*" below. In Trikh et al., cells that express the antigen were used in a radioassay. The binding of ^{125}I-labeled antigen-binding protein (e.g., antibody) to the cell surface antigen is measured with the cells in suspension. In various aspects, the relative affinity of a CLDN6 antibody is determined via a FACS-based assay in which different concentrations of a CLDN6 antibody conjugated to a fluorophore are incubated with cells expressing CLDN6 and the fluorescence emitted (which is a direct measure of antibody-antigen binding) is determined. A curve plotting the fluorescence for each dose or concentration is made. The max value is the lowest concentration at which the fluorescence plateaus or reaches a maximum, which is when binding saturation occurs. Half of the max value is considered an EC50 or an IC50 and the antibody with the lowest EC50/IC50 is considered as having the highest affinity relative to other antibodies tested in the same manner. Such an assay is described herein at Example 5.

[0091] In various aspects, the IC_{50} value, as determined in a competitive binding inhibition assay, approximates the K_D of the antigen-binding protein. In various instances, as discussed below, the competition assay is a FACS-based assay carried out with a reference antibody, fluorophore-conjugated secondary antibody, and cells which express CLDN6. In various aspects, the cells are genetically-engineered to overexpress CLDN6. In some aspects, the cells are HEK293T cells transduced with a viral vector to express CLDN6. In alternative aspects, the cells endogenously express CLDN6. Before the FACS-based assay is carried out, in some aspects, the cells which endogenously express CLDN6 are pre-determined as low CLDN6-expressing cells or high CLDN6-expressing cells. In some aspects, the cells are cancer or tumor cells. In various aspects, the cells are cells from a cell line, e.g., an ovarian cell line, endometrial cell line, bladder cell line, lung cell line, gastrointestinal (GI) cell line, liver cell line, lung cell line, and the like. In various aspects, the cells which endogenously express CLDN6 as selected from the group consisting of OVCA429 ovarian cells, ARK2 endometrial cells, OAW28 ovarian cells, UMUC-4 bladder cells, PEO14 ovarian cells, OV177 ovarian cells, H1693 lung cells, MKN7 upper GI cells,

OV-90 ovarian cells, HUH-7 liver cells, JHOS-4 ovarian cells, H1435 lung cells, and NUGC3 upper GI cells. In various aspects, the antigen-binding protein inhibits the binding interaction between human CLDN6 expressed by the cells and the reference antibody, which reference antibody is known to bind to CLDN6 but is not an antigen-binding protein of the present disclosure. In various instances, the antigen-binding proteins of the present disclosure compete with the reference antibody for binding to human CLDN6 and thereby reduce the amount of human CLDN6 bound to the reference antibody as determined by an *in vitro* competitive binding assay. In various aspects, the antigen-binding proteins of the present disclosure inhibit the binding interaction between human CLDN6 and the reference antibody and the inhibition is characterized by an IC_{50}. In various aspects, the antigen-binding proteins exhibit an IC_{50} of less than about 2500 nM for inhibiting the binding interaction between human CLDN6 and the reference antibody. In various aspects, the antigen-binding proteins exhibit an IC_{50} of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm. In various aspects, the antigen-binding proteins exhibit an IC_{50} of less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, or less than about 10 nM. In various instances, the antigen binding proteins of the present disclosure compete against a reference antibody known to bind to CLDN6 (which reference antibody is different from any of the antigen-binding proteins of the present disclosure) for binding to CLDN6. See further description under *Competition assays.*

[0092] Avidity gives a measure of the overall strength of an antibody-antigen complex. It is dependent on three major parameters: affinity of the antigen-binding protein for the epitope, valency of both the antigen-binding protein and CLDN6, and structural arrangement of the parts that interact. The greater an antigen-binding protein's valency (number of antigen binding sites), the greater the amount of antigen (CLDN6) it can bind. In various aspects, the antigen-binding proteins have a strong avidity for CLDN6. In various aspects, the antigen-binding proteins are multivalent. In various aspects, the antigen-binding proteins are bivalent. In various instances, the antigen antigen-binding proteins are monovalent.

[0093] *Cross-reactivity*

[0094] In various embodiments, the antigen-binding proteins of the present disclosure bind to CLDN6 and do not bind to any other member of the CLDN family, e.g., do not cross-react with any other member of the CLDN family. In various instances, the antigen-binding proteins of the present disclosure are CLDN-6 specific. In various embodiments, the antigen-binding proteins of the present disclosure have a selectivity for CLDN6 which is at least 10-fold, 5-fold, 4-fold, 3-fold, 2-fold greater than the selectivity of the antigen-binding protein for CLDN3, CLDN4, CLDN9, or a combination thereof. In various embodiments, the antigen-binding proteins of the present disclosure have a selectivity for CLDN6 which is at least 10-fold, 5-fold, 4-fold, 3-fold, 2-fold greater than the selectivity of the antigen-binding protein for each of CLDN3, CLDN4, and CLDN9. Selectivity may be based on the K_D exhibited by the antigen binding protein for CLDN6, or a CLDN family member, wherein the K_D may be determined by techniques known in the art, e.g., surface plasmon resonance, FACS-based affinity assays.

[0095] In various aspects, the antigen-binding proteins of the present disclosure bind to CLDN6 and do not bind to any of Claudin3 (CLDN3), Claudin4 (CLDN4), and Claudin9 (CLDN9). In various aspects, the antigen-binding proteins do not bind to any of CLDN3, CLDN4, and CLDN9 and exhibit an IC_{50} of less than about 1200 nM (e.g., less than about 1000 nM, less than about 750 nM, less than about 500 nM, less than about 250 nM) in a FACS-based assay with OVCA429 cells endogenously expressing CLDN6. In various aspects, the antigen-binding proteins do not bind to any of CLDN3, CLDN4, and CLDN9 and the concentration at which 50% of binding saturation is achieved with OVCA429 cells endogenously expressing CLDN6 is less than about 1200 nM (e.g., less than about 1000 nM, less than about 750 nM, less than about 500 nM, less than about 250 nM). In various aspects, the antigen-binding proteins exhibit at least a 5-fold selectivity for CLDN 6 greater than that for CLDN3, CLDN4, and CLDN9 and the concentration at which 50% of binding saturation is achieved with OVCA429 cells endogenously expressing CLDN6 is less than about 1200 nM(e.g., less than about 1000 nM, less than about 750 nM, less than about 500 nM, less than about 250 nM). In various aspects, the antigen-binding proteins exhibit an IC50 of less than about 1200 nM (e.g., less than about 1000 nM, less than about 750 nM, less than about 500 nM, less than about 250 nM) for CLDN6 artificial and endogenous models and exhibit a greater than about 5-fold ratio separating CLDN6 IC50s from

CLDN3, CLDN4 and/or CLDN9. In various instances, the antigen-binding proteins exhibit an IC50 of less than about 1200 nM (e.g., less than about 1000 nM, less than about 750 nM, less than about 500 nM, less than about 250 nM) for CLDN6 and exhibit an IC50 for any one of CLDN3, CLDN4, and CLDN9 at least 5-fold greater than the IC50.

[0096] In various embodiments, the antigen-binding proteins of the present disclosure bind to CLDN6 and cross-react with (e.g., bind to) at least one other member of the CLDN family. In various aspects, the antigen-binding proteins of the present disclosure bind to CLDN6 and one or more of CLDN3, CLDN4, and CLDN9. In various aspects, the antigen-binding proteins of the present disclosure bind to CLDN6 and CLDN4 or CLDN9, but do not bind to CLDN3. In various instances, the antigen-binding proteins of the present disclosure bind to CLDN6 and CLDN4 but binds to neither CLDN3 nor CLDN9. In various instances, the antigen-binding proteins of the present disclosure bind to CLDN6 and CLDN9 but do not bind to either CLDN3 or CLDN4.

[0097] *Competition assays*

[0098] In various embodiments, the antigen-binding protein inhibits a binding interaction between human CLDN6 and a reference antibody, which reference antibody is known to bind to CLDN6 but is not an antigen-binding protein of the present disclosure. In various instances, the antigen-binding proteins of the present disclosure compete with the reference antibody for binding to human CLDN6 and thereby reduce the amount of human CLDN6 bound to the reference antibody as determined by an *in vitro* competitive binding assay. In various embodiments, the reference antibody binds to an epitope within the amino acid sequence of the extracellular domain of human CLDN6, optionally, within EL2 or EL1. In various aspects, the reference antibody comprises a light chain variable sequence encoded by SEQ ID NO: 179, and a heavy chain variable sequence encoded by SEQ ID NO: 180. In various aspects, the reference antibody comprises a light chain variable sequence of SEQ ID NO: 181, and a heavy chain variable sequence of SEQ ID NO: 182. In various aspects, the antigen-binding proteins of the present disclosure inhibit the binding interaction between human CLDN6 and the reference antibody and the inhibition is characterized by an IC_{50}. In various aspects, the antigen-binding proteins exhibit an IC_{50} of less than about 2500 nM for inhibiting the binding interaction between human CLDN6 and the reference antibody. In various aspects, the antigen-binding proteins exhibit an IC_{50} of less than about 2000 nM, less than about 1500 nM, less than about 1000 nM, less than about 900 nm, less

than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm. In various aspects, the antigen-binding proteins exhibit an IC_{50} of less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, or less than about 10 nM.

[0099] In various instances, the antigen-binding proteins of the present disclosure compete with the reference antibody for binding to human CLDN6 and thereby reduce the amount of human CLDN6 bound to the reference antibody as determined by an *in vitro* competitive binding assay. In various aspects, the *in vitro* competitive binding assay is a FACS-based assay in which the fluorescence of a fluorophore-conjugated secondary antibody which binds to the Fc of the reference antibody is measured in the absence or presence of a particular amount of the antigen-binding protein of the present disclosure. Such a FACS-based assay is described herein in the EXAMPLES. In various aspects, the FACS-based assay is carried out with the reference antibody, fluorphore-conjugated secondary antibody and cells which express CLDN6. In various aspects, the cells are genetically-engineered to overexpress CLDN6. In some aspects, the cells are HEK293T cells transduced with a viral vector to express CLDN6. In alternative aspects, the cells endogenously express CLDN6. Before the FACS-based assay is carried out, in some aspects, the cells which endogenously express CLDN6 are pre-determined as low CLDN6-expressing cells or high CLDN6-expressing cells. In some aspects, the cells are cancer or tumor cells. In various aspects, the cells are cells from a cell line, e.g., an ovarian cell line, endometrial cell line, bladder cell line, lung cell line, gastrointestinal (GI) cell line, liver cell line, lung cell line, and the like. In various aspects, the cells which endogenously express CLDN6 as selected from the group consisting of OVCA429 ovarian cells, ARK2 endometrial cells, OAW28 ovarian cells, UMUC-4 bladder cells, PEO14 ovarian cells, OV177 ovarian cells, H1693 lung cells, MKN7 upper GI cells, OV-90 ovarian cells, HUH-7 liver cells, JHOS-4 ovarian cells, H1435 lung cells, and NUGC3 upper GI cells. In various instances, the antigen binding proteins of the present disclosure bind to CLDN6 endogenously expressed by one or more of ARK2 cells, OVCA429 cells, LS513 cells, or MCF7 cells with high affinity. In various aspects, the antigen binding proteins exhibit an IC_{50} of less than about 3000 nM as determined in a FACS-based competitive binding inhibition assay using one or more of ARK2 cells, OVCA429 cells, LS513 cells, or MCF7

cells. In various aspects, the antigen binding proteins exhibit an IC_{50} of less than about 2500 nM, less than about 2000 nM, less than about 1750 nM, less than about 1500 nM, less than about 1250 nM, less than about 1000 nM, less than about 750 nM, or less than about 500 nM, as determined in a FACS-based competitive binding inhibition assay using one or more of ARK2 cells, OVCA429 cells, LS513 cells, or MCF7 cells. In various aspects, the antigen binding proteins exhibit an IC_{50} of less than about 400 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 75 nM, less than about 50 nM, less than about 25 nM, or less than about 10 nM, as determined in a FACS-based competitive binding inhibition assay using one or more of ARK2 cells, OVCA429 cells, LS513 cells, or MCF7 cells.

[00100] Other binding assays, e.g., competitive binding assays or competition assays, which test the ability of an antibody to compete with a second antibody for binding to an antigen, or to an epitope thereof, are known in the art. See, e.g., Trikha et al., Int J Cancer 110: 326-335 (2004); Tam et al., Circulation 98(11): 1085-1091 (1998). U.S. Patent Application Publication No. US20140178905, Chand et al., Biologicals 46: 168-171 (2017); Liu et al., Anal Biochem 525: 89-91 (2017); and Goolia et al., J Vet Diagn Invest 29(2): 250-253 (2017). Also, other methods of comparing two antibodies are known in the art, and include, for example, surface plasmon resonance (SPR). SPR can be used to determine the binding constants of the antibody and second antibody and the two binding constants can be compared.

[00101] *Methods of Antibody Production and Related Methods*

[00102] Suitable methods of making antigen-binding proteins (e.g., antibodies, antigen-binding antibody fragments, and antibody protein products) are known in the art. For instance, standard hybridoma methods for producing antibodies are described in, e.g., Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH Press (1988), and CA. Janeway et al. (eds.), Immunobiology, 5th Ed., Garland Publishing, New York, NY (2001)). An various method of preparing CLDN6 monoclonal antibodies or the present disclosure is provided herein in EXAMPLES.

[00103] Depending on the host species, various adjuvants can be used to increase the immunological response leading to greater antibody production by the host. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil

emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are potentially useful human adjuvants.

[00104] Other methods of antibody production are summarized in Table 1.

TABLE 1

Technique	Various references
EBV-hybridoma methods and Bacteriophage vector expression systems	Haskard and Archer, J. Immunol. Methods, 74(2), 361-67 (1984), Roder et al., Methods Enzymol., 121, 140-67 (1986), and Huse et al., Science, 246, 1275-81 (1989)).
methods of producing antibodies in non-human animals	U.S. Patents 5,545,806, 5,569,825, and 5,714,352, and U.S. Patent Application Publication No. 2002/0197266
inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents	Orlandi et al (Proc Natl Acad Sci 86: 3833-3837; 1989), and Winter G and Milstein C (Nature 349: 293-299, 1991).
methods of producing recombinant proteins	Protein production and purification" Nat Methods 5(2): 135-146 (2008).
Phage display	Janeway et al., supra, Huse et al., supra, and U.S. Patent 6,265,150). Related methods also are described in U.S. Patent No. 5,403,484; U.S. Patent No. 5,571,698; U.S. Patent No. 5,837,500; U.S. Patent No. 5,702,892. The techniques described in U.S. Patent No. 5,780,279; U.S. Patent No. 5,821,047; U.S. Patent No. 5,824,520; U.S. Patent No. 5,855,885; U.S. Patent No. 5,858,657; U.S. Patent No. 5,871,907; U.S. Patent No. 5,969,108; U.S. Patent No. 6,057,098; and U.S. Patent No. 6,225,447
Antibodies can be produced by transgenic mice	U.S. Patent Nos. 5,545,806 and 5,569,825, and Janeway et al., supra.

[00105] Methods of testing antibodies for the ability to bind to the epitope of CLDN6 regardless of how the antibodies are produced are known in the art and include any antibody-antigen binding assay, such as, for example, radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation, SPR, and competitive inhibition assays (see, e.g., Janeway et al., infra, and U.S. Patent Application Publication No. 2002/0197266, and the above section relating to competition assays).

[00106] *Sequences/Structure*

[00107] Provided herein are antigen-binding proteins comprising (a) a heavy chain (HC) complementarity-determining region (CDR) 1 amino acid sequence set forth in Table A or a sequence selected from the group consisting of: SEQ ID NOs: 11, 17, 23, 29, 35, 41, 47, 53, 59, 65, 71, 77, 83, 89, 95, 101, 107, 113, 119, 125, and 131, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (b) an HC CDR2 amino acid sequence set forth in Table A or a sequence selected from the group consisting of: SEQ ID NOs: 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 86, 102, 108, 114, 120, 126, and 132, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (c) an HC CDR3 amino acid sequence set forth in Table A or a sequence selected from the group consisting of: SEQ ID NOs: 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, and 133, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (d) a light chain (LC) CDR1 amino acid sequence set forth in Table A or a sequence selected from the group consisting of: SEQ ID NOs: 8, 14, 20, 32, 38, 44, 50, 56, 62, 68, 74, 80, 86, 92, 98, 104, 110, 116, 122, and 128, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (e) an LC CDR2 amino acid sequence set forth in Table A or a sequence selected from the group consisting of: SEQ ID NOs: 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81, 87, 93, 99, 105, 111, 117, 123, and 129, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at

least about 95%) sequence identity; (f) an LC CDR3 amino acid sequence set forth in Table A or a sequence selected from the group consisting of: SEQ ID NOs: 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76, 82, 88, 94, 100, 106, 112, 118, 124, and 130, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; or (g) a combination of any two or more of (a)-(f).

TABLE A

	LC CDR1	LC CDR2	LC CDR3	HC CDR1	HC CDR2	HC CDR3
AB1	8	9	10	11	12	13
AB2	14	15	16	17	18	19
AB3	20	21	22	23	24	25
AB4	26	27	28	29	30	31
AB5	32	33	34	35	36	37
AB6	38	39	40	41	42	43
AB7	44	45	46	47	48	49
AB8	50	51	52	53	54	55
AB9	56	57	58	59	60	61
AB10	62	63	64	65	66	67
AB11	68	69	70	71	72	73
AB12	74	75	76	77	78	79
AB13	80	81	82	83	84	85
AB14	86	87	88	89	90	91
AB15	92	93	94	95	96	97
AB16	98	99	100	101	102	103
AB17	104	105	106	107	108	109
AB18	110	111	112	113	114	115
AB19	116	117	118	119	120	121
AB20	122	123	124	125	126	127
AB21	128	129	130	131	132	133

[00108] In various aspects, the antigen-binding protein comprises a LC CDR1 amino acid sequence, a LC CDR2 amino acid sequence, and a LC CDR3 amino acid sequence set forth in Table A and at least 1 or 2 of the HC CDR amino acid sequences set forth in Table

A. In various aspects, the antigen-binding protein comprises a HC CDR1 amino acid sequence, a HC CDR2 amino acid sequence, and a HC CDR3 amino acid sequence set forth in Table A and at least 1 or 2 of the LC CDR amino acid sequences set forth in Table A.

[00109] In various embodiments, the antigen-binding protein comprises at least 3, 4, or 5 of the amino acid sequences designated by the SEQ ID NOs: in a single row of Table A. In various embodiments, the antigen-binding protein comprises each of the LC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A and at least 1 or 2 of the HC CDR amino acid sequences designated by the SEQ ID NOs: in of a single row of Table A. In various embodiments, the antigen-binding protein comprises each of the HC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A and at least 1 or 2 of the LC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A. In various embodiments, the antigen-binding protein comprises all 6 of the CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A. In various embodiments, the antigen-binding protein comprises six CDR amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 74-79; (b) SEQ ID NOs: 50-55; (c) SEQ ID NOs: 122-127; (d) SEQ ID NOs: 26-31; (e) SEQ ID NOs: 128-133; (f) SEQ ID NOs: 38-43; (g) SEQ ID NOs: 62-67; (h) SEQ ID NOs: 80-85; (i) SEQ ID NOs: 44-49; (j) SEQ ID NOs: 86-91; (k) SEQ ID NOs: 104-109; (l) SEQ ID NOs: 56-61; (m) SEQ ID NOs: 32-37; (n) SEQ ID NOs: 110-115; (o) SEQ ID NOs: 98-103; (p) SEQ ID NOs: 92-97; (q) SEQ ID NOs: 116-121; (r) SEQ ID NOs: 8-13; (s) SEQ ID NOs: 68-73; (t) SEQ ID NOs: 14-19; and (u) SEQ ID NOs: 20-25.

[00110] In various instances, the amino acid sequences of Table A are separated by at least one or more (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) intervening amino acid(s). In various instances, there are about 10 to about 20 amino acids between the sequences of the LC CDR1 and the LC CDR2 and about 25 to about 40 amino acids between the sequences of the LC CDR2 and the LC CDR3. In various instances, there are about 14 to about 16 amino acids between the sequences of the LC CDR1 and the LC CDR2 and about 30 to about 35 amino acids between the sequences of LC CDR2 and the LC CDR3. In various instances, there are about 10 to about 20 amino acids between the sequences of the HC CDR1 and HC CDR2 and about 25 to about 40 amino acids between the sequences of the HC CDR2 and the HC CDR3. In various instances, there are about 14 to about 16 amino acids between the sequences of the HC CDR1 and HC CDR2 and about 30 to about 35 amino acids between the sequences of the HC CDR2 and HC CDR3.

[00111] In various embodiments, the antigen-binding protein comprises (a) a heavy chain variable region amino acid sequence set forth in in Table B or a sequence selected from the group consisting of: SEQ ID NOs: 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, and 175, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; or (b) a light chain variable region amino acid sequence set forth in Table B or a sequence selected from the group consisting of: SEQ ID NOs: 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, and 176, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; or (c) both (a) and (b).

TABLE B

	Light Chain Variable Region	Heavy Chain Variable Region
AB1	134	135
AB2	136	137
AB3	138	139
AB4	140	141
AB5	142	143
AB6	144	145
AB7	146	147
AB8	148	149
AB9	150	151
AB10	152	153
AB11	154	155
AB12	156	157
AB13	158	159
AB14	160	161
AB15	162	163
AB16	164	165
AB17	166	167

AB18	168	169
AB19	170	171
AB20	172	173
AB21	174	175

[00112] In various embodiments, the antigen-binding protein comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 156 and 157; (b) SEQ ID NOs: 148 and 149; (c) SEQ ID NOs: 172 and 173; (d) SEQ ID NOs: 140 and 141; (e) SEQ ID NOs: 174 and 175; (f) SEQ ID NOs: 144 and 145; (g) SEQ ID NOs: 152 and 153; (h) SEQ ID NOs: 158 and 159; (i) SEQ ID NOs: 146 and 147; (j) SEQ ID NOs: 160 and 161; (k) SEQ ID NOs: 166 and 167; (l) SEQ ID NOs: 150 and 151; (m) SEQ ID NOs: 142 and 143; (n) SEQ ID NOs: 168 and 169; (o) SEQ ID NOs: 164 and 165; (p) SEQ ID NOs: 162 and 163; (q) SEQ ID NOs: 170 and 171; (r) SEQ ID NOs: 134 and 135; (s) SEQ ID NOs: 154 and 155; (t) SEQ ID NOs: 136 and 137; and (u) SEQ ID NOs: 138 and 139.

[00113] In various aspects, the antigen-binding protein does not comprise a pair of amino acid sequences encoded by the sequences of SEQ ID NOs: 179 and 180. In various aspects, the antigen-binding protein does not comprise a pair of amino acid sequences of SEQ ID NOs: 181 and 182. In various aspects, the antigen-binding protein does not comprise a pair of amino acid sequences encoded by the sequences of SEQ ID NOs: 183 and 184. In various aspects, the antigen-binding protein does not comprise a pair of amino acid sequences of SEQ ID NOs: 185 and 186.

[00114] In various aspects, the antigen-binding protein comprises an amino acid sequence which is similar to an above-referenced amino acid sequence, yet the antigen-binding protein substantially retains its biological function, e.g., its ability to bind to human CLDN6, reduce tumor growth, treat cancer.

[00115] In various aspects, the antigen-binding protein comprises an amino acid sequence which differs by only 1, 2, 3, 4, 5, 6, or more amino acids, relative to the above-referenced amino acid sequence(s). In various aspects, the antigen-binding protein comprises a variant sequence of the referenced sequence, which variant sequence differs by only one or two amino acids, relative to the referenced sequence. In various aspects, the antigen-binding protein comprising one or more amino acid substitutions that occur outside of the CDRs, e.g, the one or more amino acid substitutions occur within the framework region(s) of the heavy or light chain. In various aspects, the antigen-binding protein

comprising one or more amino acid substitutions yet the antigen-binding protein retains the amino acid sequences of the six CDRs. In various aspects, the antigen-binding protein comprises an amino acid sequence having only 1, 2, 3, 4, 5, 6, or more conservative amino acid substitutions, relative to the above-referenced amino acid sequence(s). As used herein, the term "conservative amino acid substitution" refers to the substitution of one amino acid with another amino acid having similar properties, e.g., size, charge, hydrophobicity, hydrophilicity, and/or aromaticity, and includes exchanges within one of the following five groups:

I. Small aliphatic, nonpolar or slightly polar residues:

Ala, Ser, Thr, Pro, Gly;

II. Polar, negatively charged residues and their amides and esters:

Asp, Asn, Glu, Gln, cysteic acid and homocysteic acid;

III. Polar, positively charged residues:

His, Arg, Lys; Ornithine (Orn)

IV. Large, aliphatic, nonpolar residues:

Met, Leu, Ile, Val, Cys, Norleucine (Nle), homocysteine

V. Large, aromatic residues:

Phe, Tyr, Trp, acetyl phenylalanine

[00116] In various aspects, the conservative amino acid substitution is an exchange within one of the following groups of amino acids:

I. aliphatic amino acids: Gly, Ala, Val, Leu, Ile
II. non-aromatic amino acids comprising a side chain hydroxyl: Serc Thr
III. amino acids comprising a sulfur side chain: Cys, Met
IV: amino acids comprising a side chain aromatic ring: Phe, Tyr, Trp
V: acidic amino acid: Glu; Asp
VI: basic amino acid: Arg; Lys
VII: amino acid comprising a side chain amide: Gln, Asn
VIII: amino acid comprising a side chain imidazole: His, alpha-dimethyl imidiazole acetic acid (DMIA)
IX: imino acid: Pro, 4-hydroxy-Pro, 4-amino-Pro

[00117] In various aspects, the antigen-binding protein comprises an amino acid sequence which has greater than or about 30%, greater than or about 50%, or greater than or about 70% sequence identity to the above-referenced amino acid sequence. In various aspects, the antigen-binding protein comprises an amino acid sequence which has at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90% or has greater than 90% sequence identity to the above-referenced amino acid sequence. In various aspects, the antigen-binding protein comprises an amino acid sequence that has at least 70%, at least 80%, at least 85%, at least 90% or has greater than 90% sequence identity along the full-length of the above-referenced amino acid sequence. In various aspects, the antigen-binding protein comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity along the full-length of the above-referenced amino acid sequence.

[00118] In various aspects, the antigen-binding protein comprises a variant sequence of the referenced sequence, which variant sequence has at least or about 70% sequence identity, relative to the above-referenced sequence. In various aspects, the antigen-binding protein comprises a variant sequence of the referenced sequence, which variant sequence has at least or about 80% sequence identity, relative to the above-referenced sequence. In various aspects, the antigen-binding protein comprises a variant sequence of the referenced sequence, which variant sequence has at least or about 90% sequence identity, relative to the above-referenced sequence. In various aspects, the antigen-binding protein comprises a variant sequence of the referenced sequence, which variant sequence has at least or about 95% sequence identity, relative to the above-referenced sequence.

[00119] In various embodiments, the antigen-binding protein comprises one, two, three, four, or five sequences of the SEQ ID NOs. in a single row of Table A and at least one variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to any of SEQ ID NOs: 8-133. In various embodiments, the antigen-binding protein comprises one, two, three, four, or five sequences of a set of sequences selected from: (a) SEQ ID NOs: 74-79; (b) SEQ ID NOs: 50-55; (c) SEQ ID NOs: 122-127; (d) SEQ ID NOs: 26-31; (e) SEQ ID NOs: 128-133; (f) SEQ ID NOs: 38-43; (g) SEQ ID NOs: 62-67; (h) SEQ ID NOs: 80-85; (i) SEQ ID NOs: 44-49; (j) SEQ ID NOs: 86-91; (k) SEQ ID NOs: 104-109; (l) SEQ ID NOs: 56-61; (m) SEQ ID NOs: 32-37; (n) SEQ ID NOs: 110-115; (o) SEQ ID NOs: 98-103; (p) SEQ ID

NOs: 92-97; (q) SEQ ID NOs: 116-121; (r) SEQ ID NOs: 8-13; (s) SEQ ID NOs: 68-73; (t) SEQ ID NOs: 14-19; and (u) SEQ ID NOs: 20-25, wherein the antigen-binding protein further comprises at least one variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to at least one of the sequences of the set. For instance, in various aspects, the antigen-binding protein comprises four sequences of SEQ ID NOs: 74-79, namely, SEQ ID NOs: 74-77, wherein the antigen-binding protein comprises two variant sequences: one variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to SEQ ID NO: 78 and another variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to SEQ ID NO: 79.

[00120] In various embodiments, the antigen-binding protein comprises a pair of variant sequences having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to any of SEQ ID NOs: 134-175. In various instances, the antigen binding protein comprises a pair of variant sequences which have at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to (a) SEQ ID NOs: 156 and 157; (b) SEQ ID NOs: 148 and 149; (c) SEQ ID NOs: 172 and 173; (d) SEQ ID NOs: 140 and 141; (e) SEQ ID NOs: 174 and 175; (f) SEQ ID NOs: 144 and 145; (g) SEQ ID NOs: 152 and 153; (h) SEQ ID NOs: 158 and 159; (i) SEQ ID NOs: 146 and 147; (j) SEQ ID NOs: 160 and 161; (k) SEQ ID NOs: 166 and 167; (l) SEQ ID NOs: 150 and 151; (m) SEQ ID NOs: 142 and 143; (n) SEQ ID NOs: 168 and 169; (o) SEQ ID NOs: 164 and 165; (p) SEQ ID NOs: 162 and 163; (q) SEQ ID NOs: 170 and 171; (r) SEQ ID NOs: 134 and 135; (s) SEQ ID NOs: 154 and 155; (t) SEQ ID NOs: 136 and 137; and (u) SEQ ID NOs: 138 and 139. In various embodiments, the antigen-binding protein comprises a pair of sequences: one sequence of Table B and another sequence which is a variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to any of SEQ ID NOs: 134-175. In various embodiments, the antigen-binding protein comprises a pair of sequences: one sequence selected from (a) SEQ ID NOs: 156 and 157; (b) SEQ ID NOs: 148 and 149; (c) SEQ ID NOs: 172 and 173; (d) SEQ ID NOs: 140 and 141; (e) SEQ ID NOs: 174 and 175; (f) SEQ ID NOs: 144 and 145; (g) SEQ ID NOs: 152 and 153; (h) SEQ ID NOs: 158 and 159; (i) SEQ ID NOs: 146 and 147; (j) SEQ ID NOs: 160 and 161; (k) SEQ ID NOs: 166 and 167; (l) SEQ ID NOs: 150 and

151; (m) SEQ ID NOs: 142 and 143; (n) SEQ ID NOs: 168 and 169; (o) SEQ ID NOs: 164 and 165; (p) SEQ ID NOs: 162 and 163; (q) SEQ ID NOs: 170 and 171; (r) SEQ ID NOs: 134 and 135; (s) SEQ ID NOs: 154 and 155; (t) SEQ ID NOs: 136 and 137; and (u) SEQ ID NOs: 138 and 139, and another sequence which is a variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to a sequence of (a) – (u). For instance, in various aspects, the antigen-binding protein comprises a sequences of SEQ ID NO: 134 and the antigen-binding protein further comprises a variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to SEQ ID NO 135.

[00121] In various instances, the antigen-binding protein comprises an amino acid sequence of an above-referenced amino acid sequence with one or more amino acid substitutions to reduce or eliminate reactive amino acids to decrease or prevent unwanted side chain reactions. For instance, the antigen-binding protein comprises an amino acid sequence of an above-referenced amino acid sequence with one or more (i) Trp residues substituted with His, Tyr, or Phe; (ii) Asn residues substituted with Gln, Ser, Ala, or Asp; (iii) Asp residues occurring immediately before a Pro residue substituted with Ala, Ser, or Glu, (iv) Asn residues substituted with Gln, Ser, or Ala; and/or (v) Cys residues substituted with Tyr, Ser, or Ala. In various aspects, the antigen-binding protein comprises an amino acid sequence of an above-referenced amino acid sequence with an amino acid substitution predicted to have greater binding affinity, greater stability, or other positive attribute, based on SHM events or based on statistical analyses of a multitude of other similar antibody sequences. In some aspects, the antigen-binding protein comprises (a) an HC CDR1 amino acid sequence set forth in Table A1 or a sequence selected from the group consisting of: SEQ ID NOs: 452, 455, 461, 465, 71, and 472, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70(e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (b) an HC CDR2 amino acid sequence set forth in Table A1 or a sequence selected from the group consisting of: SEQ ID NOs: 475, 456, 462, 466, 468, and 473; or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (c) an HC CDR3 amino acid sequence set forth in Table A1 or a sequence selected from the group consisting of: SEQ ID NOs: 453, 457, 463, 467, 469, and

474; or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (d) a LC CDR1 amino acid sequence set forth in Table A1 or a sequence selected from the group consisting of: SEQ ID NOs: 449, 476, 458, 464, 68, and 470; or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (e) an LC CDR2 amino acid sequence set forth in Table A1 or a sequence selected from the group consisting of: SEQ ID NOs: 450, 477, 459, 57, 69, and 471; or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; (f) an LC CDR3 amino acid sequence set forth in Table A1 or a sequence selected from the group consisting of: SEQ ID NOs: 451, 454, 460, 58, 70, and 112, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70%(e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity or (g) a combination of any two or more of (a)-(f).

TABLE A1

	LC CDR1	LC CDR2	LC CDR3	HC CDR1	HC CDR2	HC CDR3
AB1*	449	450	451	452	475	453
AB3*	476	477	454	455	456	457
AB4*	458	459	460	461	462	463
AB9*	464	57	58	465	466	467
AB11*	68	69	70	71	468	469
AB18*	470	471	112	472	473	474

[00122] In some aspects, the HC CDR1 comprises Gly immediately N-terminal of SEQ ID NO: 452 and, optionally, in some aspects, the HC CDR1 comprises MX immediately C-terminal of SEQ 452, wherein X is H, N, or S. In various aspects, the HC CDR3 comprises Ala immediately N-terminal of SEQ ID NO: 453. In various aspects, the LC CDR1 further comprises TAS immediately N-terminal of SEQ ID NO: 449, and, optionally, XH immediately C-terminal of SEQ ID NO: 449, wherein X is H, S, Y, or Q. In some aspects, as described below, the first amino acid of SEQ ID NO: 449 is S or Q. In some aspects, as described below, the first amino acid of SEQ ID NO: 451 is S or Q.

[00123] In various aspects, the HC CDR1 comprises Gly immediately N-terminal of SEQ ID NO: 455, and optionally, in various aspects, the HC CDR1 comprises MX immediately C-terminal of SEQ ID NO: 455, wherein X is N, S, or H. In some aspects, HC CDR2 comprises Gln immediately N-terminal of SEQ ID NO: SEQ ID NO: 456, and optionally H immediately C-terminal of SEQ ID NO: 456. In various aspects, the LC CDR1 comprises RIS immediately N-terminal of SEQ ID NO: 476, and optionally, comprises LA immediately C-terminal of SEQ ID NO: 476. In various aspects, the LC CDR2 comprises XLVE immediately C-terminal of SEQ ID NO: 477, wherein X is I or S.

[00124] In various aspects, the HC CDR1 comprises MH immediately C-terminal of SEQ ID NO: 461. In various aspects, the HC CDR2 comprises Tyr immediately N-terminal of SEQ ID NO: 462, and optionally, TH immediately C-terminal of SEQ ID NO: 462. In exemplary aspects, the HC CDR3 does not include the first two amino acids of SEQ ID NO: 463. In various aspects, the LC CDR1 comprises RSS immediately N-terminal of SEQ ID NO: 458, and optionally, LN immediately C-terminal of SEQ ID NO: 458. In various aspects, the LC CDR2 comprises XRFS immediately C-terminal of SEQ ID NO: 459, wherein X is Q, S, A, or D.

[00125] In various aspects, the HC CDR1 comprises MH immediately C-terminal of SEQ ID NO: 465. In various aspects, the HC CDR2 comprises YI immediately N-terminal of SEQ ID NO: 466, and optionally, Xaa immediately C-terminal of SEQ ID NO: 466, wherein Xaa is N, S, Q, or A. In various aspects, the LC CDR1 comprises LAS immediately N-terminal of SEQ ID NO: 464, and optionally, LA immediately C-terminal of SEQ ID NO: 464. In various aspects, the LC CDR2 comprises SLAD immediately C-terminal of SEQ ID NO: 57.

[00126] In various aspects, the HC CDR1 comprises MH immediately C-terminal of SEQ ID NO: 71. In various aspects, the HC CDR2 comprises Tyr immediately N-terminal of SEQ ID NO: 468 and optionally IY immediately C-terminal of SEQ ID NO: 468. In various aspects, the LC CDR1 comprises RAS immediately N-terminal of SEQ ID NO: 68, and optionally SYIH immediately C-terminal to SEQ 68. In various aspects, the LC CDR2 comprises XLES immediately C-terminal to SEQ ID NO: 69, wherein X is N, Q, S, A, or D.

[00127] In various aspects, the LC CDR1 comprises KSS immediately N-terminal of SEQ ID NO: 470, and optionally YLA immediately C-terminal to SEQ 470. In various

aspects, the LC CDR2 comprises TRES immediately C-terminal of SEQ I DNO: 471. In various aspects, the HC CDR1 comprises MN immediately C-terminal of SEQ ID NO: 472. In various aspects, the HC CDR2 comprises Xaa immediately N-terminal of SEQ 473, wherein Xaa is N, Q, S, or A, and optionally, Thr immediately C-terminal of SEQ 473.

[00128] In various aspects, the antigen-binding protein comprises a LC CDR1 amino acid sequence, a LC CDR2 amino acid sequence, and a LC CDR3 amino acid sequence set forth in Table A1 and at least 1 or 2 of the HC CDR amino acid sequences set forth in Table A1. In various aspects, the antigen-binding protein comprises a HC CDR1 amino acid sequence, a HC CDR2 amino acid sequence, and a HC CDR3 amino acid sequence set forth in Table A1 and at least 1 or 2 of the LC CDR amino acid sequences set forth in Table A1.

[00129] In various embodiments, the antigen-binding protein comprises at least 3, 4, or 5 of the amino acid sequences designated by the SEQ ID NOs: in a single row of Table A1. In various embodiments, the antigen-binding protein comprises each of the LC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A1 and at least 1 or 2 of the HC CDR amino acid sequences designated by the SEQ ID NOs: in of a single row of Table A1. In various embodiments, the antigen-binding protein comprises each of the HC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A1 and at least 1 or 2 of the LC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A1. In various embodiments, the antigen-binding protein comprises all 6 of the CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A1. In various embodiments, the antigen-binding protein comprises six CDR amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 449-453 and 475; (b) SEQ ID NOs: 476-477, 454-457; (c) SEQ ID NOs: 458-463; (d) SEQ ID NOs: 57, 58, 464-467; (e) SEQ ID NOs: 68-71 and 468-469; and (f) SEQ ID NOs: 112, and 470-474.

[00130] In various instances, the amino acid sequences of Table A1 are separated by at least one or more (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) intervening amino acid(s). In various instances, there are about 10 to about 20 amino acids between the sequences of the LC CDR1 and the LC CDR2 and about 25 to about 40 amino acids between the sequences of the LC CDR2 and the LC CDR3. In various instances, there are about 14 to about 16 amino acids between the sequences of the LC CDR1 and the LC CDR2 and about 30 to about 35 amino acids between the sequences of LC CDR2 and the LC CDR3. In

various instances, there are about 10 to about 20 amino acids between the sequences of the HC CDR1 and HC CDR2 and about 25 to about 40 amino acids between the sequences of the HC CDR2 and the HC CDR3. In various instances, there are about 14 to about 16 amino acids between the sequences of the HC CDR1 and HC CDR2 and about 30 to about 35 amino acids between the sequences of the HC CDR2 and HC CDR3.

[00131] In various embodiments, the antigen-binding protein comprises (a) a heavy chain variable region amino acid sequence set forth in in Table B1 or a sequence selected from the group consisting of: SEQ ID NO: 478, 480, 482, 484, 486, and 488, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70%(e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; or (b) a light chain variable region amino acid sequence set forth in Table B1 or a sequence selected from the group consisting of: SEQ ID NO: 479, 481, 483, 485, 487, and 489, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity; or (c) both (a) and (b).

TABLE B1

	HC variable	LC variable
AB1*	478	479
AB3*	480	481
AB4*	482	483
AB9*	488	489
AB11*	486	487
AB18*	484	485

[00132] In various embodiments, the antigen-binding protein comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NO: 478 and 479; (b) SEQ ID NO: 480 and 481; (c) SEQ ID NO: 482 and 483; (d) SEQ ID NO: 484 and 485; (e) SEQ ID NO: 486 and 487; and (f) SEQ ID NO: 488 and 489. In various aspects, the antigen-binding protein comprises a variant sequence of a sequence having a SEQ ID NO: listed in Table B1 which differs by only one or two amino acids or which has at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity, wherein the different amino acid(s) occur(s) at the positions described below in “Humanized Antibodies”.

[00133] *Humanized Antibodies*

[00134] In various aspects, the antigen-binding protein is a humanized version of an antigen binding protein described in Table A, Table A1, Table B, or Table B1.

[00135] *Humanized AB1*

[00136] In various aspects, the antigen-binding protein is a humanized version of AB1 as set forth in Table B or B1 with one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) amino acid substitutions in the heavy chain variable region at one or more of the following positions: 5, 8, 11, 12, 13, 20, 31, 33, 35, 38, 40, 48, 50, 55, 57, 59, 61, 65, 66, 67, 68, 70, 72, 74, 76, 79, 80, 82, 87, 90, 91, 98, 101, and 116. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 428. In various aspects, the antigen-binding protein is a humanized version of AB1 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) of the following positions: 20, 31, 35, 48, 50, 59, 67, 70, 74, 79, 98, 101. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 429. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
5	Q, V	8	A, G	11	L,V
12	A, K	13	R, K	20	M, V
31	S, T, V, D	33	Y, T	35	H, N, S
38	K, R	40	R, A	48	I, M
50	F, V, T, Y, I	55	G, S	57	S, Y
59	D, E, N, S	61	N, A	65	K, Q
66	D, G	67	R, Q, N, K	68	T, V
70	L, M	72	R, A	74	K, T
		79	V, D, S, A	82	Q, E
87	T, R	91	S, T	98	N, Q, H, D, R
101	Y	76	ST	116	A, S

[00137] In various aspects, the antigen-binding protein is a humanized version of AB1 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41) of the following positions: 1, 3, 4, 9, 10, 11, 15, 17, 21, 24, 27, 29, 32, 34, 35, 43, 44, 48, 51, 52, 53, 54, 55, 56, 61, 67, 71, 72, 73, 79, 80, 81, 84, 90, 92, 93, 94, 95, 96, 101, 107. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 430. In various aspects, the antigen-binding protein is a humanized version of AB1 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13) of the following positions: 4, 21, 32, 34, 48, 51, 53, 61, 67, 79, 84, 91, and 93. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 431. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
1	Q, D	3	V, Q	4	L, M
9	A, S	10	I, S	11	M, L
15	L, V	17	E, D	21	M, I
24	T, R	27	S, Q	32	T, V, F, D, S
34	F, L	35	H, S, Y, Q, N	43	S, K
44	S, A	48	W, L	51	S, T, Q, A
52	T, A	53	S, T, D, Q	54	N, S
		56	A, Q	61	R, Q, S, D,
67	A, S, T, G	71	S, D	72	Y, F
73	S, T	79	M, L	80	E, Q
81	A, P	84	A, F	90	H, Q
91	Q, H, S	93	H, Q, S, Y	94	R, S
97	L, P	101	A, Q	107	L, I
29	V, I	92	Y, S	95	S, T

[00138] *Humanized AB3*

[00139] In various aspects, the antigen-binding protein is a humanized version of AB3 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33) of the following positions: 3, 5, 18, 19, 23, 31, 33, 35, 40, 42, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 61, 64, 76, 79, 80, 81, 87, 94, 95, 99, 106, 112, 114. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 432. In various aspects, the antigen-binding protein is a humanized version of AB3 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) of the following positions: 31, 35, 50, 55, 79, 99, 106. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 433. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
3	K, Q	5	E, L	18	M, L
19	K, R	23	V, A	31	N, S, R
33	W, A	35	N, S, H	40	S, A
42	E, G	49	A, S	50	Q, S, N, H, A
		52	R, S	53	L, G
54	K, S	55	S, N, T, A, G	56	D, G
				59	A, S
61	H, Y	64	E, D	76	D, N
79	R, N, Q, D, S	80	S, T	81	V, L
87	N, S	94	G, A	95	T, V, I
99	N, D, T, K, A	106	C, Y, A, S, T	112	T, L
114	I, T				

[00140] In various aspects, the antigen-binding protein is a humanized version of AB3 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) of the following positions: 9, 17, 18, 25, 27, 28, 30, 34, 40, 43, 45, 48, 50, 52, 53, 55, 56, 70, 72, 74, 76, 84, 85, 90, 91, 93, 94, 97, and 100. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 434. In various aspects, the antigen-binding protein is a humanized version of AB3 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) of the following positions: 25, 34, 48, 53, 55, 84, 85, 90, and 93. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 435. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
9	A, S	17	E, D	18	T, R
25	I, V, L, T, A	34	A, S, N	40	Q, P
43	S, A	45	Q, K	48	V, I
53	I, V, L, T, S	55	V, T, L, A, Q	70	Q, D
72	S, T	74	K, T	76	N, S
84	G, A	85	N, Q, S, T	90	H, Q, S, T
93	T, S, N, G	100	G, Q	27	E, Q
28	N, S	30	Y, S	50	N, A
52	K, S	56	E, S	91	H, S
94	V, T	97	T, P		

[00141] *Humanized AB4*

[00142] In various aspects, the antigen-binding protein is a humanized version of AB4 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 of the following positions: 5, 11, 12, 13, 20, 29, 31, 33, 37, 38, 40, 45, 48, 50, 55, 56, 57, 59, 61, 62, 65, 66,

67, 68, 70, 72, 74, 76, 79, 82, 84, 87, 91, 97, 101, 117. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 436. In various aspects, the antigen-binding protein is a humanized version of AB4 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19) of the following positions: 20, 29, 31, 37, 45, 48, 56, 59, 61, 62, 65, 66, 68, 70, 74, 79, 84, 97, and 101. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 437. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
5	Q, V	11	L, V	12	A, K
13	R, K	20	M, V	33	T, Y
37	I, V, F, Y	38	K, R	40	R, A
45	Q, L, V, T, N	48	I, M	50	Y, I
55	S, G	56	T, G, S, V, D	57	Y, S
59	H, K, S, Q, N	61	I, A, N, F, Y, V	62	K, Q
65	K, Q	66	D, G	67	K, R
68	A, V	70	L, M	72	A, R
74	T, K	76	S, T	79	A, V
82	Q, E	84	R, S, Q, D	87	T, R
91	S, T	97	S, A, T, V	101	L, V, F
117	A, S	29	F, Y, S, T	31	S, T, Y, D

[00143] In various aspects, the antigen-binding protein is a humanized version of AB4 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) of the following positions: 7, 14, 17, 18, 31, 33, 39, 41, 42, 44, 50, 51, 55, 57, 60, 81, 88, 92, 94, 95, 96, 99, 100, 105. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 438. In various aspects, the antigen-binding protein is a humanized version of AB4 as set forth in Table B or B1

with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) of the following positions: 33, 39, 55, 57, 81, 95, and 96. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 439. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
7	T, S	14	S, T	17	D, Q
18	Q, P	31	Y, H	33	D, N, E, Q
39	H, N, Q, D	41	F, Y	42	L, Q
44	K, R	50	K, R	51	R, L
55	K, R, Q	57	S, T, V	60	D, F
81	R, S, N, D	88	L, V	92	F, Y
94	M, S	95	Q, H , T	96	S, T, G, D
99	W, V	105	G, Q		

[00144] *Humanized AB18*

[00145] In various aspects, the antigen-binding protein is a humanized version of AB18 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) of the following positions: 5, 9, 11, 12, 20, 38, 40, 41, 43, 44, 48, 61, 65, 67, 68, 70, 72, 74, 76, 79, 82, 84, 87, 91, and 116, optionally, one or more (e.g., 1, 2, 3, 4, or 5) of the following positions: 20, 48, 68, 70, 79. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 440 or 441. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
5	K, V	9	P, A	11	L, V
12	E, K	20	I, V	38	K, R
40	S, A	41	N, P	43	K, Q
44	S, G	48	I, V, M	61	N, A

65	T, Q	67	K, R	68	A, V
70	L, M	72	V, R	74	K, T
76	S, T	79	A, V	82	Q, E
84	K, S	87	T, R	91	S, T
116	S, L				

[00146] In various aspects, the antigen-binding protein is a humanized version of AB18 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) of the following positions: 1, 3, 9, 15, 18, 19, 21, 22, 49, 51, 69, 93, 84, 78, 105, and 111, optionally, one or more (e.g., 1, 2, or 3) of the following positions: 19, 21, or 84. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 442 or 443. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
1	N, D	3	M, V	9	S, D
15	A, L	18	K, R	19	V, A
21	M, I	22	S, N	49	S, P
51	R, K	69	T, S	83	N, S
84	V, L	89	L, V	105	A, Q
111	L, I				

[00147] *Humanized AB9*

[00148] In various aspects, the antigen-binding protein is a humanized version of AB9 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) of the following positions: 1, 5, 9, 11, 12, 20, 38, 40, 41, 43, 44, 48, 61, 63, 65, 67, 69, 70, 72, 73, 74, 76, 79, 84, 87, 91, 93, 112, and 113. In various instances, the antigen-binding protein comprises an amino acid sequence of

SEQ ID NO: 444. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
1	E, Q	5	Q, V	9	P, A
11	L, V	12	V, K	20	M, V
38	K R,	40	S, A	41	H, P
43	K Q	44	S, G	48	I, M
61	N, A	63	N, K	65	K, Q
67	K, R	69	A, V	70	L, M
72	V, R	73	N, D	74	K, T
76	S, T	79	A, V	84	R, S
87	T, R	91	S, T	93	A, V
112	T, L	113	L, V		

[00149] In various aspects, the antigen-binding protein is a humanized version of AB9 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) of the following positions: 9, 11, 15, 17, 18, 43, 45, 70, 72, 73, 74, 80, 84, 85, and 100. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 445. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
9	A, S	11	Q, L	15	L, V
17	E, D	18	S, R	43	S, A
45	Q, K	70	R, D	72	S, T
73	F, L	74	K, R	80	A, P
84	V, A	85	S, T	100	G, Q

[00150] *Humanized AB11*

[00151] In various aspects, the antigen-binding protein is a humanized version of AB11 as set forth in Table B or B1 with one or more amino acid substitutions in the heavy chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) of the following positions: 1, 15, 18, 19, 42, 49, 63, 75, 76, 78, 80, 84, 88, and 93. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 446. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
1	D, E	15	R, G	18	R, L
19	K, R	42	E, G	49	A, S
63	T, S	75	P, A	76	T, K
78	T, S	80	F, Y	84	T, N
88	S, A	93	M, V		

[00152] In various aspects, the antigen-binding protein is a humanized version of AB11 as set forth in Table B or B1 with one or more amino acid substitutions in the light chain variable region at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) of the following positions: 4, 9, 17, 22, 64, 78, 80, 81, 82, 83, 84, 87, 89, 104, and 110, optionally, one or more of the following positions: 4, 82, 110. In various instances, the antigen-binding protein comprises an amino acid sequence of SEQ ID NO: 447 or 448. In various aspects, the amino acids at the above-recited positions are selected from the amino acids according to the table below:

Position	*Amino acids*	*Position*	*Amino acids*	*Position*	*Amino acids*
4	L, M	9	A, D	17	Q, E
22	S, N	64	A, D	78	N, T
80	H, S	81	P, S	82	V, L
83	E, Q	84	E, A	87	A, V
89	T, V	104	A, Q	110	L, I

[00153] In various embodiments, the antigen-binding protein comprises (a) a heavy chain variable region amino acid sequence set forth in in Table C or a sequence selected from the group consisting of: 376-379, 384-387, 391-396, 403-408, 412, 413, 416-419, and 422-427 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70%, or about 80%, or about 85%, or about 90%, or about 95% sequence identity; or (b) a light chain variable region amino acid sequence set forth in Table C or a sequence selected from the group consisting of: 380-383, 388-390, 397-402, 409-411, 414, 415, 420, and 421 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70%, or about 80%, or about 85%, or about 90%, or about 95% sequence identity; or (c) both (a) and (b).

TABLE C

	Humanized Light Chain Variable Region	Humanized Heavy Chain Variable Region
AB1	380, 381, 382,383	376, 377, 378, 379
AB3	388, 389, 390	384, 385, 386, 387, 422
AB4	397, 398, 399, 400, 401, 402	391, 392, 392, 394, 395, 396, 423, 424, 425, 426, 427
AB9	409, 410, 411,	403, 404, 405, 406, 407, 408
AB11	414, 415	412, 413
AB18	420, 421	416, 417, 418, 419

[00154] In various embodiments, the humanized antigen-binding protein comprises a pair of amino acid sequences as shown in Table D.

TABLE D

Humanized AB	HC	LC
1-1	376	380
1-2	377	380
1-3	377	381
1-4	377	382
1-5	377	383
1-6	378	381
1-7	378	382
1-8	378	383
1-9	379	381
1-10	379	382
1-11	379	383
3-1	384	388
3-2	385	388
3-3	385	389
3-4	386	388
3-5	386	389
3-6	387	388
3-7	387	389
3-9	422	389
4-1	391	397
4-2	392	397
4-3	392	398
4-4	393	398
4-5	394	398
4-6	395	398
4-7	396	398

Humanized AB	HC	LC
4-8	423	398
4-9	424	398
4-10	425	398
4-11	426	398
4-12	427	398
9-1	403	409
9-2	404	409
9-3	405	410
9-4	405	411
9-5	406	410
9-6	406	411
9-7	407	410
9-8	407	411
9-9	408	410
9-10	408	411
11-1	412	414
11-2	413	414
11-3	413	415
18-1	416	420
18-2	417	420
18-3	417	420
18-4	417	421
18-5	418	420
18-6	418	421
18-7	419	420
18-8	419	421

[00155] In various embodiments, the antigen-binding protein comprises a pair of variant sequences, each having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to a SEQ ID NO listed in Table C. In various embodiments, the antigen-binding protein comprises a pair of sequences: one sequence selected from a SEQ ID NO: listed in Table C and another sequence which is a variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to a sequence having a SEQ ID NO: listed in Table D a sequence having a SEQ ID NO: listed in Table C.

[00156] In various embodiments, the antigen-binding protein comprises a pair of sequences: one sequence selected from a SEQ ID NO: listed in Table D, and another sequence which is a variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to a sequence having a SEQ ID NO: listed in Table D. For instance, in various aspects, the antigen-binding protein comprises a sequences of SEQ ID NO: 419 and the antigen-binding protein further comprises a variant sequence having at least or about 70% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%) sequence identity to SEQ ID NO 421.

[00157] In various instances, the antigen-binding protein is a humanized antigen-binding protein as set forth in Table D with one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) amino acid substitutions in the heavy chain (HC) variable region or in the light chain (LC) variable region, or in both. In exemplary aspects, the antigen-binding protein is a humanized antigen-binding protein of AB1-11 with one or more amino acid substitutions in the HC variable region, the LC variable region, or both. In exemplary aspects, the antigen-binding protein comprises a HC of SEQ ID NO: 379 with 1, 2, 3, 4, or 5 amino acid substitutions. In exemplary aspects, the antigen-binding protein comprises a HC CDR1 of SEQ ID NO: 504, a HC CDR2 of SEQ ID NO: 505, a HC CDR3 of SEQ ID NO: 506, or a combination thereof. In exemplary instances, the antigen-binding protein comprises a HC of SEQ ID NO: 503. In some aspects, the antigen-binding protein comprises a HC of any one of SEQ ID NOs: 496-501. In some aspects, the antigen-binding protein comprises a HC sequence labeled as S7-S12 in FIG. 22. In various instances, the light chain variable region comprises a LC CDR1 of SEQ ID NO: 449, a LC CDR2 of SEQ ID NO: 450, a LC CDR3

of SEQ ID NO: 451, or a combination thereof. In some aspects, the antigen-binding protein comprises a LC of any one of SEQ ID NOs: 380-383, and 479. In exemplary instances, the antigen-binding protein comprises a LC of SEQ ID NO: 383. In some aspects, the antigen-binding protein comprises a LC sequence labeled as S7-S12 in FIG. 22. In exemplary aspects, the antigen-binding protein is a humanized antigen-binding protein of AB3-7 with one or more amino acid substitutions in the HC variable region, the LC variable region, or both. In exemplary aspects, the antigen-binding protein comprises a HC of SEQ ID NO: 387 with 1, 2, 3, 4, 5, or 6 amino acid substitutions. In exemplary aspects, the antigen-binding protein comprises a HC CDR1 of SEQ ID NO: 507, a HC CDR2 of SEQ ID NO: 508, a HC CDR3 of SEQ ID NO: 509, or a combination thereof. In exemplary instances, the antigen-binding protein comprises a HC of SEQ ID NO: 502. In some aspects, the antigen-binding protein comprises a HC of any one of SEQ ID NOs: 490-495. In some aspects, the antigen-binding protein comprises a HC sequence labeled as S1-S6 in FIG. 22. In various instances, the light chain variable region comprises a LC CDR1 of SEQ ID NO: 476, a LC CDR2 of SEQ ID NO: 477, a LC CDR3 of SEQ ID NO: 454, or a combination thereof. In some aspects, the antigen-binding protein comprises a LC of any one of SEQ ID NOs: 388-390, and 481. In exemplary instances, the antigen-binding protein comprises a LC of SEQ ID NO: 389. In some aspects, the antigen-binding protein comprises a LC sequence labeled as S1-S6 in FIG. 22. In exemplary aspects, the antigen-binding protein is a humanized antigen-binding protein of AB3 with one or more amino acid substitutions in the HC variable region, the LC variable region, or both. In exemplary aspects, the antigen-binding protein comprises a HC of SEQ ID NO: 139 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the antigen-binding protein comprises a HC of any one of SEQ ID NOs: 510. In some aspects, the antigen-binding protein comprises a HC sequence of SEQ ID NO: 510 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 23. In exemplary aspects, the antigen-binding protein comprises a HC of SEQ ID NO: 138 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the antigen-binding protein comprises a HC of any one of SEQ ID NOs: 511. In some aspects, the antigen-binding protein comprises a HC sequence of SEQ ID NO: 511 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 24. In exemplary aspects, the antigen-binding protein is a humanized antigen-binding protein of AB1 with one or more amino acid substitutions in the HC variable region, the LC variable region, or both. In exemplary aspects, the antigen-binding protein comprises a HC of SEQ ID NO: 135 with

1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the antigen-binding protein comprises a HC of any one of SEQ ID NOs: 513. In some aspects, the antigen-binding protein comprises a HC sequence of SEQ ID NO: 513 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 25. In exemplary aspects, the antigen-binding protein comprises a HC of SEQ ID NO: 134 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the antigen-binding protein comprises a HC of any one of SEQ ID NOs: 512. In some aspects, the antigen-binding protein comprises a HC sequence of SEQ ID NO: 512 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 26.

[00158] *Afucosylated antibodies*

[00159] Many secreted proteins undergo post-translational glycosylation, a process by which sugar moieties (e.g., glycans, saccharides) are covalently attached to specific amino acids of a protein. In eukaryotic cells, two types of glycosylation reactions occur: (1) N-linked glycosylation, in which glycans are attached to the asparagine of the recognition sequence Asn-X-Thr/Ser, where "X" is any amino acid except proline, and (2) O-linked glycosylation in which glycans are attached to serine or threonine. Regardless of the glycosylation type (N-linked or O-linked), microheterogeneity of protein glycoforms exists due to the large range of glycan structures associated with each site (O or N).

[00160] All N-glycans have a common core sugar sequence: Manα1–6(Manα1–3)Manβ1–4GlcNAcβ1–4GlcNAcβ1-Asn-X-Ser/Thr ($Man_3GlcNAc_2Asn$) and are categorized into one of three types: (A) a high mannose (HM) or oligomannose (OM) type, which consists of two N-acetylglucosamine (GalNAc) moieties and a large number (e.g., 5, 6, 7, 8 or 9) of mannose (Man) residues (B) a complex type, which comprises more than two GlcNAc moieties and any number of other sugar types or (C) a hybrid type, which comprises a Man residue on one side of the branch and GlcNAc at the base of a complex branch. FIG. 1A (taken from Stanley et al., Chapter 8: N-Glycans, Essentials of Glycobiology, 2nd ed., Cold Spring Harbor Laboratory Press; 2009) shows the three types of N-glycans.

[00161] N-linked glycans typically comprise one or more monosaccharides of galactose (Gal), N-acetylgalactosamine (GalNAc), galactosamine (GalN), glucose (GLc), N-acetylglucoasamine (ClcNAc), glucoasamine (GlcN), mannose (Man), N-Acetylmannosamine (ManNAc), Mannosamine (ManN), xylose (Xyl),

N0Acetylneuraminic acid (Neu5Ac), N-Glycolylneuraminic acid (Neu5Gc), 2-keto-3-doxynononic acid (Kdn), fucose (Fuc), Glucuronic acid (GLcA), Iduronic acid (IdoA), Galacturonic acid (Gal A), mannuronic acid (Man A). The commonly used symbols for such saccharides are shown in FIG. 29A.

[00162] N-linked glycosylation begins in the endoplasmic reticulum (ER), where a complex set of reactions result in the attachment of a core glycan structure made essentially of two GlcNAc residues and three Man residues. The glycan complex formed in the ER is modified by action of enzymes in the Golgi apparatus. If the saccharide is relatively inaccessible to the enzymes, it typically stays in the original HM form. If enzymes can access the saccharide, then many of the Man residues are cleaved off and the saccharide is further modified, resulting in the complex type N-glycans structure. For example, mannosidase-1 located in the cis-Golgi, can cleave or hydrolyze a HM glycan, while fucosyltransferase FUT-8, located in the medial-Golgi, fucosylates the glycan (Hanrue Imai- Nishiya (2007), BMC Biotechnology, 7:84).

[00163] Accordingly, the sugar composition and the structural configuration of a glycan structure varies, depending on the glycosylation machinery in the ER and the Golgi apparatus, the accessibility of the machinery enzymes to the glycan structure, the order of action of each enzyme and the stage at which the protein is released from the glycosylation machinery, among other factors.

[00164] In exemplary embodiments of the present disclosure, the antigen-binding proteins comprise an Fc polypeptide. The term “Fc polypeptide” as used herein includes native and mutein forms of polypeptides derived from the Fc region of an antibody. In exemplary aspects, the Fc polypeptide of the presently disclosed antigen-binding protein comprises a glycan. In various instances, the glycan lacks fucose or is afucosylated. In exemplary aspects, the antigen-binding protein comprises an afucosylated glycan. As used herein, the term "afucosylated glycan" or “afuco glycan” or “afucosylated glycoform” or “Afuc” refers to glycoforms which lack a core fucose, e.g., an α1,6-linked fucose on the GlcNAc residue involved in the amide bond with the Asn of the N-glycosylation site. Afucosylated glycoforms include, but are not limited to, A1G0, A2G0, A2G1a, A2G1b, A2G2, and A1G1M5. Additional afucosylated glycans include, e.g., A1G1a, G0[H3N4], G0[H4N4], G0[H5N4], FO-N[H3N3]. See, e.g., Reusch and Tejada, Glycobiology 25(12): 1325-1334 (2015).

[00165] The present disclosure also provides a composition, e.g., a pharmaceutical composition, comprising an antigen binding protein comprising an Fc polypeptide comprising an afucosylated glycan. In exemplary aspects, at least or about 25% of the antigen-binding proteins present in the composition are antigen-binding proteins comprising an Fc polypeptide comprising an afucosylated glycan. In exemplary aspects, at least or about 25% of the antigen-binding proteins present in the composition are afucosylated. Optionally, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the antigen-binding proteins present in the composition are afucosylated. Methods of producing compositions comprising antigen-binding proteins of a particular glycoprofile are known in the art. In exemplary embodiments, the antigen binding proteins are recombinant produced in cells that are genetically modified to alter the activity of an enzyme of the de novo pathway or the salvage pathway. These two pathways of fucose metabolism are shown in FIG. 29B. In exemplary embodiments, the cells are genetically modified to alter the activity of any one or more of: a fucosyl-transferase (FUT, e.g.,FUT1, FUT2, FUT3, FUT4, FUT5, FUT6, FUT7, FUT8, FUT9), a fucose kinase, a GDP-fucose pyrophosphorylase, GDP-D-mannose-4,6-dehydratase (GMD), and GDP-keto-6-deoxymannose-3,5-epimerase, 4-reductase (FX). In exemplary embodiments, the cells are genetically modified to knock-out a gene encoding FX. See, e.g., International Patent Publication No. WO2017/079165 A1; Kanda et al., J Biotechnol 130, 2007, 300-310, Yamane-Ohunuki et al., Biotechnol Bioeng 87, 2004, 614-622, Malphettes et al., Biotechnol Bioeng 106, 2010, 774-783.

[00166] *Nucleic acids*

[00167] The present disclosure further provides nucleic acids comprising a nucleotide sequence encoding an antigen-binding protein of the present disclosure. By "nucleic acid" as used herein includes "polynucleotide," "oligonucleotide," and "nucleic acid molecule," and generally means a polymer of DNA or RNA, or modified forms thereof, which can be single-stranded or double- stranded, synthesized or obtained (e.g., isolated and/or purified) from natural sources, which can contain natural, non-natural or altered nucleotides, and which can contain a natural, non-natural or altered inter-nucleotide linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide. The nucleic acid can comprise any nucleotide sequence which encodes any of the antigen-binding proteins of the

present disclosure. In various aspects, the nucleic acid comprises a nucleotide sequence which encodes an antigen-binding protein comprising (a) a heavy chain (HC) complementarity-determining region (CDR) 1 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 11, 17, 23, 29, 35, 41, 47, 53, 59, 65, 71, 77, 83, 89, 95, 101, 107, 113, 119, 125, 131, 452, 455, 461, 465, and 472, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%) sequence identity; (b) an HC CDR2 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 86, 102, 108, 114, 120, 126, 132, 475, 456, 462, 466, 468, and 473;, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%) sequence identity; (c) an HC CDR3 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, 133, 453, 457, 463, 467, 469, and 474;, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%) sequence identity; (d) a light chain (LC) CDR1 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 8, 14, 20, 32, 38, 44, 50, 56, 62, 68, 74, 80, 86, 92, 98, 104, 110, 116, 122, 128, 449, 476, 458, 464, and 470; or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%) sequence identity; (e) an LC CDR2 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81, 87, 93, 99, 105, 111, 117, 123, 129, 450, 477, 459, and 471; or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%) sequence identity; (f) an LC CDR3 amino acid sequence set forth in Table A or a sequence selected from the group consisting of: SEQ ID NOs: 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76, 82, 88, 94, 100, 106, 112, 118, 124, 130, 451, 454, and 460, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 80%, at least or about 85%,

at least or about 90%, at least or about 95%) sequence identity; or (g) a combination of any two or more of (a)-(f). In various aspects, the nucleic acid comprises a nucleotide sequence encoding an antigen-binding protein comprising a LC CDR1 amino acid sequence, a LC CDR2 amino acid sequence, and a LC CDR3 amino acid sequence set forth in Table A or A1 and at least 1 or 2 of the HC CDR amino acid sequences set forth in Table A or A1. In various aspects, the nucleic acid comprises a nucleotide sequence encoding an antigen-binding protein comprising a HC CDR1 amino acid sequence, a HC CDR2 amino acid sequence, and a HC CDR3 amino acid sequence set forth in Table A or A1 and at least 1 or 2 of the LC CDR amino acid sequences set forth in Table A or A1. In various embodiments, the nucleic acid comprises a nucleotide sequence encoding an antigen-binding protein comprising (a) at least 3, 4, or 5 of the amino acid sequences designated by the SEQ ID NOs: in a single row of Table A or A1, (b) each of the LC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A or A1 and at least 1 or 2 of the HC CDR amino acid sequences designated by the SEQ ID NOs: in of a single row of Table A or A1, (c) each of the HC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A or A1 and at least 1 or 2 of the LC CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A or A1, (d) all 6 of the CDR amino acid sequences designated by the SEQ ID NOs: of a single row of Table A, and/or (e) six CDR amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 74-79; (b) SEQ ID NOs: 50-55; (c) SEQ ID NOs: 122-127; (d) SEQ ID NOs: 26-31; (e) SEQ ID NOs: 128-133; (f) SEQ ID NOs: 38-43; (g) SEQ ID NOs: 62-67; (h) SEQ ID NOs: 80-85; (i) SEQ ID NOs: 44-49; (j) SEQ ID NOs: 86-91; (k) SEQ ID NOs: 104-109; (l) SEQ ID NOs: 56-61; (m) SEQ ID NOs: 32-37; (n) SEQ ID NOs: 110-115; (o) SEQ ID NOs: 98-103; (p) SEQ ID NOs: 92-97; (q) SEQ ID NOs: 116-121; (r) SEQ ID NOs: 8-13; (s) SEQ ID NOs: 68-73; (t) SEQ ID NOs: 14-19; (u) SEQ ID NOs: 20-25, (v) SEQ ID NOs: 449-453 and 475; (w) SEQ ID NOs: 476-477, 454-457; (x) SEQ ID NOs: 458-463; (y) SEQ ID NOs: 57, 58, 464-467; (z) SEQ ID NOs: 68-71 and 468-469; and (aa) SEQ ID NOs: 112, and 470-474. In various embodiments, the nucleic acid comprises a nucleotide sequence encoding an antigen-binding protein comprising (a) a heavy chain variable region amino acid sequence set forth in in Table B or B1 or a sequence selected from the group consisting of: 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 478, 480, 482, 484, 486 and 488, or a variant sequence thereof which differs by only one or two amino acids or which has at least or

about 70% (e.g., at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%) sequence identity; or (b) a light chain variable region amino acid sequence set forth in Table B or B1 or a sequence selected from the group consisting of: 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 479, 481, 483, 485, 487, and 489 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%) sequence identity; or (c) both (a) and (b). In various embodiments, the nucleic acid comprises a nucleotide sequence encoding an antigen-binding protein comprising a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 156 and 157; (b) SEQ ID NOs: 148 and 149; (c) SEQ ID NOs: 172 and 173; (d) SEQ ID NOs: 140 and 141; (e) SEQ ID NOs: 174 and 175; (f) SEQ ID NOs: 144 and 145; (g) SEQ ID NOs: 152 and 153; (h) SEQ ID NOs: 158 and 159; (i) SEQ ID NOs: 146 and 147; (j) SEQ ID NOs: 160 and 161; (k) SEQ ID NOs: 166 and 167; (l) SEQ ID NOs: 150 and 151; (m) SEQ ID NOs: 142 and 143; (n) SEQ ID NOs: 168 and 169; (o) SEQ ID NOs: 164 and 165; (p) SEQ ID NOs: 162 and 163; (q) SEQ ID NOs: 170 and 171; (r) SEQ ID NOs: 134 and 135; (s) SEQ ID NOs: 154 and 155; (t) SEQ ID NOs: 136 and 137; and (u) SEQ ID NOs: 138 and 139. In various embodiments, the nucleic acid comprises a nucleotide sequence encoding an antigen-binding protein comprising a pair of amino acid sequences selected from the group consisting of the pairs listed in Table D. In various aspects, the nucleic acid comprises a nucleotide sequence comprising a sequence of any one or more of SEQ ID NOs: 208-375. In some embodiments, the nucleic acid does not comprise any insertions, deletions, inversions, and/or substitutions. In other embodiments, the nucleic acid comprises one or more insertions, deletions, inversions, and/or substitutions.

[00168] In various aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein which is a humanized antigen-binding protein as set forth in Table D with one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) amino acid substitutions in the heavy chain (HC) variable region or in the light chain (LC) variable region, or in both. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein which is a humanized antigen-binding protein of AB1-11 with one or more amino acid substitutions in the HC variable region, the LC

variable region, or both. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 379 with 1, 2, 3, 4, or 5 amino acid substitutions. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC CDR1 of SEQ ID NO: 504, a HC CDR2 of SEQ ID NO: 505, a HC CDR3 of SEQ ID NO: 506, or a combination thereof. In exemplary instances, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 503. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of any one of SEQ ID NOs: 496-501. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC sequence labeled as S7-S12 in FIG. 22. In various instances, the nucleic acid comprises a nucleotide sequence which encodes the light chain variable region comprising a LC CDR1 of SEQ ID NO: 449, a LC CDR2 of SEQ ID NO: 450, a LC CDR3 of SEQ ID NO: 451, or a combination thereof. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a LC of any one of SEQ ID NOs: 380-383, and 479. In exemplary instances, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a LC of SEQ ID NO: 383. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a LC sequence labeled as S7-S12 in FIG. 22. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein which is a humanized antigen-binding protein of AB3-7 with one or more amino acid substitutions in the HC variable region, the LC variable region, or both. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 387 with 1, 2, 3, 4, 5, or 6 amino acid substitutions. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC CDR1 of SEQ ID NO: 507, a HC CDR2 of SEQ ID NO: 508, a HC CDR3 of SEQ ID NO: 509, or a combination thereof. In exemplary instances, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 502. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of any one of SEQ ID NOs: 490-495. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC sequence labeled as

S1-S6 in FIG. 22. In various instances, the nucleic acid comprises a nucleotide sequence which encodes the light chain variable region comprising a LC CDR1 of SEQ ID NO: 476, a LC CDR2 of SEQ ID NO: 477, a LC CDR3 of SEQ ID NO: 454, or a combination thereof. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a LC of any one of SEQ ID NOs: 388-390, and 481. In exemplary instances, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a LC of SEQ ID NO: 389. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a LC sequence labeled as S1-S6 in FIG. 22.

[00169] In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein which is a humanized antigen-binding protein of AB3 with one or more amino acid substitutions in the HC variable region, the LC variable region, or both. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 139 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of any one of SEQ ID NOs: 510. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC sequence of SEQ ID NO: 510 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 23. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 138 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of any one of SEQ ID NOs: 511. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC sequence of SEQ ID NO: 511 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 24. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein which is a humanized antigen-binding protein of AB1 with one or more amino acid substitutions in the HC variable region, the LC variable region, or both. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 135 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the nucleic acid comprises a nucleotide sequence which

encodes the antigen-binding protein comprising a HC of any one of SEQ ID NOs: 513. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC sequence of SEQ ID NO: 513 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 25. In exemplary aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of SEQ ID NO: 134 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC of any one of SEQ ID NOs: 512. In some aspects, the nucleic acid comprises a nucleotide sequence which encodes the antigen-binding protein comprising a HC sequence of SEQ ID NO: 512 with 1, 2, 3, 4, or 5 (or more) amino acid substitutions as shown in FIG. 26. In some embodiments, the nucleic acid does not comprise any insertions, deletions, inversions, and/or substitutions. In other embodiments, the nucleic acid comprises one or more insertions, deletions, inversions, and/or substitutions.

[00170] In some aspects, the nucleic acids of the present disclosure are recombinant. As used herein, the term "recombinant" refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments to nucleic acid molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above. For purposes herein, the replication can be in vitro replication or in vivo replication.

[00171] The nucleic acids in some aspects are constructed based on chemical synthesis and/or enzymatic ligation reactions using procedures known in the art. See, for example, Sambrook et al., *supra*; and Ausubel et al., *supra*. For example, a nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed upon hybridization (e.g., phosphorothioate derivatives and acridine substituted nucleotides). Examples of modified nucleotides that can be used to generate the nucleic acids include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chIorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5- carboxymethylaminomethyl-2-thiouridme, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N^6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-

methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N -substituted adenine, 7-methylguanine, 5-methylammomethyluracil, 5- methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'- methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N^6-isopentenyladenine, uracil- 5-oxyacetic acid (v), wybutoxosine, pseudouratil, queosine, 2-thiocytosine, 5-methyl-2- thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3- (3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine. Alternatively, one or more of the nucleic acids of the present disclosure can be purchased from companies, such as Macromolecular Resources (Fort Collins, CO) and Synthegen (Houston, TX).

[00172] *Vector*

[00173] The nucleic acids of the present disclosure in some aspects are incorporated into a vector. In this regard, the present disclosure provides vectors comprising any of the presently disclosed nucleic acids. In various aspects, the vector is a recombinant expression vector. For purposes herein, the term "recombinant expression vector" means a genetically-modified oligonucleotide or polynucleotide construct that permits the expression of an mRNA, protein, polypeptide, or peptide by a host cell, when the construct comprises a nucleotide sequence encoding the mRNA, protein, polypeptide, or peptide, and the vector is contacted with the cell under conditions sufficient to have the mRNA, protein, polypeptide, or peptide expressed within the cell. The vectors of the present disclosure are not naturally-occurring as a whole. However, parts of the vectors can be naturally-occurring. The presently disclosed vectors can comprise any type of nucleotides, including, but not limited to DNA and RNA, which can be single- stranded or double-stranded, synthesized or obtained in part from natural sources, and which can contain natural, non-natural or altered nucleotides. The vectors can comprise naturally-occurring or non-naturally-occurring internucleotide linkages, or both types of linkages. In some aspects, the altered nucleotides or non-naturally occurring internucleotide linkages do not hinder the transcription or replication of the vector.

[00174] The vector of the present disclosure can be any suitable vector, and can be used to transduce, transform or transfect any suitable host. Suitable vectors include those designed for propagation and expansion or for expression or both, such as plasmids and viruses. The vector can be a plasmid based expression vector. In various aspects, the vector is selected from the group consisting of the pUC series (Fermentas Life Sciences),

the pBluescript series (Stratagene, LaJoIIa, CA), the pET series (Novagen, Madison, WI), the pGEX series (Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto, CA). Bacteriophage vectors, such as λGTIO, λGTl 1, λZapII (Stratagene), λEMBL4, and λNMl 149, also can be used. Examples of plant expression vectors include pBIOl, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM and pMAMneo (Clontech). In some aspects, the vector is a viral vector, e.g., a retroviral vector. In various aspects, the vector is an adenovirus vector, an adeno-associated virus (AAV) vector, a Herpes Simplex Virus (HSV) vector, a Vesicular stomatitis virus (VSV) vector, vaccinia virus vector, or lentivirus vector. See, e.g., Howarth et al., Cell Biol. Toxicol. 26(1): 1-20 (2010). In various aspects, the vector is a baculovirus vector which infects arthropods, e.g., insects. In various aspects, the baculovirus vector is an Autographacalifornica multiple nuclear virus (AcMNPV) or a Bombyxmorinuclear polyhedrosis (BmNPV). See, e.g., Khan, Adv Pharm Bull 3(2): 257-263 (2013); Miller, Bioessays 11(4): 91-96 (1989); Atkinson et al., Pestic Sci 28: 215-224 (1990).

[00175] The vectors of the present disclosure can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., supra, and Ausubel et al., supra. Constructs of expression vectors, which are circular or linear, can be prepared to contain a replication system functional in a prokaryotic or eukaryotic host cell. Replication systems can be derived, e.g., from CoIEl, 2 μ plasmid, λ, SV40, bovine papilloma virus, and the like.

[00176] In some aspects, the vector comprises regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host (e.g., bacterium, fungus, plant, or animal) into which the vector is to be introduced, as appropriate and taking into consideration whether the vector is DNA- or RNA- based.

[00177] The vector can include one or more marker genes, which allow for selection of transformed or transfected hosts. Marker genes include biocide resistance, e.g., resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy, and the like. Suitable marker genes for the presently disclosed expression vectors include, for instance, neomycin/G418 resistance genes, hygromycin resistance genes, histidinol resistance genes, tetracycline resistance genes, and ampicillin resistance

genes.

[00178] The vector can comprise a native or normative promoter operably linked to the nucleotide sequence encoding the polypeptide (including functional portions and functional variants thereof), or to the nucleotide sequence which is complementary to or which hybridizes to the nucleotide sequence encoding the polypeptide. The selection of promoters, e.g., strong, weak, inducible, tissue-specific and developmental- specific, is within the ordinary skill of the artisan. Similarly, the combining of a nucleotide sequence with a promoter is also within the skill of the artisan. The promoter can be a non-viral promoter or a viral promoter, e.g., a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV promoter, and a promoter found in the long-terminal repeat of the murine stem cell virus.

[00179] *Host cells*

[00180] Provided herein are host cells comprising a nucleic acid or vector of the present disclosure. As used herein, the term "host cell" refers to any type of cell that can contain the presently disclosed vector and is capable of producing an expression product encoded by the nucleic acid (e.g., mRNA, protein). The host cell in some aspects is an adherent cell or a suspended cell, i.e., a cell that grows in suspension. The host cell in various aspects is a cultured cell or a primary cell, i.e., isolated directly from an organism, e.g., a human. The host cell can be of any cell type, can originate from any type of tissue, and can be of any developmental stage.

[00181] In various aspects, the antigen-binding protein is a glycosylated protein and the host cell is a glycosylation-competent cell. In various aspects, the glycosylation-competent cell is an eukaryotic cell, including, but not limited to, a yeast cell, filamentous fungi cell, protozoa cell, algae cell, insect cell, or mammalian cell. Such host cells are described in the art. See, e.g., Frenzel, et al., *Front Immunol* 4: 217 (2013). In various aspects, the eukaryotic cells are mammalian cells. In various aspects, the mammalian cells are non-human mammalian cells. In some aspects, the cells are Chinese Hamster Ovary (CHO) cells and derivatives thereof (e.g., CHO-K1, CHO pro-3), mouse myeloma cells (e.g., NS0, GS-NS0, Sp2/0), cells engineered to be deficient in dihydrofolatereductase (DHFR) activity (e.g., DUKX-X11, DG44), human embryonic kidney 293 (HEK293) cells or derivatives thereof (e.g., HEK293T, HEK293-EBNA), green African monkey kidney cells (e.g., COS cells, VERO cells), human cervical cancer cells (e.g., HeLa), human bone osteosarcoma epithelial cells U2-OS, adenocarcinomic human alveolar basal epithelial cells A549, human

fibrosarcoma cells HT1080, mouse brain tumor cells CAD, embryonic carcinoma cells P19, mouse embryo fibroblast cells NIH 3T3, mouse fibroblast cells L929, mouse neuroblastoma cells N2a, human breast cancer cells MCF-7, retinoblastoma cells Y79, human retinoblastoma cells SO-Rb50, human liver cancer cells Hep G2, mouse B myeloma cells J558L, or baby hamster kidney (BHK) cells (Gaillet et al. 2007; Khan, Adv Pharm Bull 3(2): 257-263 (2013)).

[00182] For purposes of amplifying or replicating the vector, the host cell is in some aspects is a prokaryotic cell, e.g., a bacterial cell.

[00183] Also provided by the present disclosure is a population of cells comprising at least one host cell described herein. The population of cells in some aspects is a heterogeneous population comprising the host cell comprising vectors described, in addition to at least one other cell, which does not comprise any of the vectors. Alternatively, in some aspects, the population of cells is a substantially homogeneous population, in which the population comprises mainly host cells (e.g., consisting essentially of) comprising the vector. The population in some aspects is a clonal population of cells, in which all cells of the population are clones of a single host cell comprising a vector, such that all cells of the population comprise the vector. In various embodiments of the present disclosure, the population of cells is a clonal population comprising host cells comprising a vector as described herein.

[00184] *Manufacture methods*

[00185] Also provided herein are methods of producing an antigen-binding protein which binds to CLDN6. In various embodiments, the method comprises culturing a host cell comprising a nucleic acid comprising a nucleotide sequence encoding the antigen-binding protein as described herein in a cell culture medium and harvesting the antigen-binding protein from the cell culture medium. The host cell can be any of the host cells described herein. In various aspects, the host cell is selected from the group consisting of: CHO cells, NS0 cells, COS cells, VERO cells, and BHK cells. In various aspects, the step of culturing a host cell comprises culturing the host cell in a growth medium to support the growth and expansion of the host cell. In various aspects, the growth medium increases cell density, culture viability and productivity in a timely manner. In various aspects, the growth medium comprises amino acids, vitamins, inorganic salts, glucose, and serum as a source of growth factors, hormones, and attachment factors. In various aspects, the growth medium

is a fully chemically defined media consisting of amino acids, vitamins, trace elements, inorganic salts, lipids and insulin or insulin-like growth factors. In addition to nutrients, the growth medium also helps maintain pH and osmolality. Several growth media are commercially available and are described in the art. See, e.g., Arora, "Cell Culture Media: A Review" MATER METHODS 3:175 (2013).

[00186] In various aspects, the method comprises culturing the host cell in a feed medium. In various aspects, the method comprises culturing in a feed medium in a fed-batch mode. Methods of recombinant protein production are known in the art. See, e.g., Li et al., "Cell culture processes for monoclonal antibody production" MAbs 2(5): 466–477 (2010).

[00187] The method making an antigen-binding protein can comprise one or more steps for purifying the protein from a cell culture or the supernatant thereof and preferably recovering the purified protein. In various aspects, the method comprises one or more chromatography steps, e.g., affinity chromatography (e.g., protein A affinity chromatography), ion exchange chromatography, hydrophobic interaction chromatography. In various aspects, the method comprises purifying the protein using a Protein A affinity chromatography resin.

[00188] In various embodiments, the method further comprises steps for formulating the purified protein, etc., thereby obtaining a formulation comprising the purified protein. Such steps are described in Formulation and Process Development Strategies for Manufacturing, eds. Jameel and Hershenson, John Wiley & Sons, Inc. (Hoboken, NJ), 2010.

[00189] In various aspects, the antigen-binding protein linked to a polypeptide and the antigen-binding protein is part of a fusion protein. Thus, the present disclosure further provides methods of producing a fusion protein comprising an antigen-binding protein which binds to CLDN6. In various embodiments, the method comprises culturing a host cell comprising a nucleic acid comprising a nucleotide sequence encoding the fusion protein as described herein in a cell culture medium and harvesting the fusion protein from the cell culture medium.

[00190] *Conjugates*

[00191] The present disclosure also provides antigen-binding proteins attached, linked or conjugated to a second moiety (e.g., a heterologous moiety, a conjugate moiety).

Accordingly, the present disclosure provides a conjugate comprising an antigen-binding protein and a heterologous moiety. As used herein, the term "heterologous moiety" is synonymous with "conjugate moiety" and refers to any molecule (chemical or biochemical, naturally-occurring or non-coded) which is different from the antigen-binding proteins of the present disclosure. Various heterologous moieties include, but are not limited to, a polymer, a carbohydrate, a lipid, a nucleic acid, an oligonucleotide, a DNA or RNA, an amino acid, peptide, polypeptide, protein, therapeutic agent, (e.g., a cytotoxic agent, cytokine), or a diagnostic agent.

[00192] In some embodiments, the heterologous moiety is a polymer. The polymer can be branched or unbranched. The polymer can be of any molecular weight. The polymer in some embodiments has an average molecular weight of between about 2 kDa to about 100 kDa (the term "about" indicating that in preparations of a water soluble polymer, some molecules will weigh more, some less, than the stated molecular weight). The average molecular weight of the polymer is in some aspect between about 5 kDa and about 50 kDa, between about 12 kDa to about 40 kDa or between about 20 kDa to about 35 kDa.

[00193] In some embodiments, the polymer is modified to have a single reactive group, such as an active ester for acylation or an aldehyde for alkylation, so that the degree of polymerization can be controlled. The polymer in some embodiments is water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. In some embodiments, when, for example, the composition is used for therapeutic use, the polymer is pharmaceutically acceptable. Additionally, in some aspects, the polymer is a mixture of polymers, e.g., a co-polymer, a block co-polymer.

[00194] In some embodiments, the polymer is selected from the group consisting of: polyamides, polycarbonates, polyalkylenes and derivatives thereof including, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polymers of acrylic and methacrylic esters, including poly(methyl methacrylate), poly(ethyl methacrylate), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate), polyvinyl polymers including polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, poly(vinyl acetate), and polyvinylpyrrolidone, polyglycolides,

polysiloxanes, polyurethanes and co-polymers thereof, celluloses including alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, and cellulose sulphate sodium salt, polypropylene, polyethylenes including poly(ethylene glycol), poly(ethylene oxide), and poly(ethylene terephthalate), and polystyrene.

[00195] A particularly preferred water-soluble polymer for use herein is polyethylene glycol (PEG). As used herein, polyethylene glycol is meant to encompass any of the forms of PEG that can be used to derivatize other proteins, such as mono-(C1-C10) alkoxy- or aryloxy-polyethylene glycol. PEG is a linear or branched neutral polyether, available in a broad range of molecular weights, and is soluble in water and most organic solvents.

[00196] In some embodiments, the heterologous moiety is a carbohydrate. In some embodiments, the carbohydrate is a monosaccharide (e.g., glucose, galactose, fructose), a disaccharide (e.g., sucrose, lactose, maltose), an oligosaccharide (e.g., raffinose, stachyose), a polysaccharide (a starch, amylase, amylopectin, cellulose, chitin, callose, laminarin, xylan, mannan, fucoidan, galactomannan.

[00197] In some embodiments, the heterologous moiety is a lipid. The lipid, in some embodiments, is a fatty acid, eicosanoid, prostaglandin, leukotriene, thromboxane, N-acyl ethanolamine), glycerolipid (e.g., mono-, di-, tri-substituted glycerols), glycerophospholipid (e.g., phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine), sphingolipid (e.g., sphingosine, ceramide), sterol lipid (e.g., steroid, cholesterol), prenol lipid, saccharolipid, or a polyketide, oil, wax, cholesterol, sterol, fat-soluble vitamin, monoglyceride, diglyceride, triglyceride, a phospholipid.

[00198] In some embodiments, the heterologous moiety is a therapeutic agent. The therapeutic agent can be any of those known in the art. Examples of therapeutic agents that are contemplated herein include, but are not limited to, natural enzymes, proteins derived from natural sources, recombinant proteins, natural peptides, synthetic peptides, cyclic peptides, antibodies, receptor agonists, cytotoxic agents, immunoglobins, beta-adrenergic blocking agents, calcium channel blockers, coronary vasodilators, cardiac glycosides, antiarrhythmics, cardiac sympathomemetics, angiotensin converting enzyme (ACE) inhibitors, diuretics, inotropes, cholesterol and triglyceride reducers, bile acid sequestrants,

fibrates, 3-hydroxy-3-methylgluteryl (HMG)-CoA reductase inhibitors, niacin derivatives, antiadrenergic agents, alpha-adrenergic blocking agents, centrally acting antiadrenergic agents, vasodilators, potassium-sparing agents, thiazides and related agents, angiotensin II receptor antagonists, peripheral vasodilators, antiandrogens, estrogens, antibiotics, retinoids, insulins and analogs, alpha-glucosidase inhibitors, biguanides, meglitinides, sulfonylureas, thizaolidinediones, androgens, progestogens, bone metabolism regulators, anterior pituitary hormones, hypothalamic hormones, posterior pituitary hormones, gonadotropins, gonadotropin-releasing hormone antagonists, ovulation stimulants, selective estrogen receptor modulators, antithyroid agents, thyroid hormones, bulk forming agents, laxatives, antiperistaltics, flora modifiers, intestinal adsorbents, intestinal anti-infectives, antianorexic, anticachexic, antibulimics, appetite suppressants, antiobesity agents, antacids, upper gastrointestinal tract agents, anticholinergic agents, aminosalicylic acid derivatives, biological response modifiers, corticosteroids, antispasmodics, 5-HT_4 partial agonists, antihistamines, cannabinoids, dopamine antagonists, serotonin antagonists, cytoprotectives, histamine H2-receptor antagonists, mucosal protective agent, proton pump inhibitors, H. pylori eradication therapy, erythropoieses stimulants, hematopoietic agents, anemia agents, heparins, antifibrinolytics, hemostatics, blood coagulation factors, adenosine diphosphate inhibitors, glycoprotein receptor inhibitors, fibrinogen-platelet binding inhibitors, thromboxane-A_2 inhibitors, plasminogen activators, antithrombotic agents, glucocorticoids, mineralcorticoids, corticosteroids, selective immunosuppressive agents, antifungals, drugs involved in prophylactic therapy, AIDS-associated infections, cytomegalovirus, non-nucleoside reverse transcriptase inhibitors, nucleoside analog reverse transcriptse inhibitors, protease inhibitors, anemia, Kaposi's sarcoma, aminoglycosides, carbapenems, cephalosporins, glycopoptides, lincosamides, macrolies, oxazolidinones, penicillins, streptogramins, sulfonamides, trimethoprim and derivatives, tetracyclines, anthelmintics, amebicies, biguanides, cinchona alkaloids, folic acid antagonists, quinoline derivatives, Pneumocystis carinii therapy, hydrazides, imidazoles, triazoles, nitroimidzaoles, cyclic amines, neuraminidase inhibitors, nucleosides, phosphate binders, cholinesterase inhibitors, adjunctive therapy, barbiturates and derivatives, benzodiazepines, gamma aminobutyric acid derivatives, hydantoin derivatives, iminostilbene derivatives, succinimide derivatives, anticonvulsants, ergot alkaloids, antimigrane preparations, biological response modifiers, carbamic acid eaters, tricyclic derivatives, depolarizing agents, nondepolarizing agents, neuromuscular paralytic agents, CNS stimulants, dopaminergic reagents, monoamine

oxidase inhibitors, COMT inhibitors, alkyl sulphonates, ethylenimines, imidazotetrazines, nitrogen mustard analogs, nitrosoureas, platinum-containing compounds, antimetabolites, purine analogs, pyrimidine analogs, urea derivatives, antracyclines, actinomycinds, camptothecin derivatives, epipodophyllotoxins, taxanes, vinca alkaloids and analogs, antiandrogens, antiestrogens, nonsteroidal aromatase inhibitors, protein kinase inhibitor antineoplastics, azaspirodecanedione derivatives, anxiolytics, stimulants, monoamind reuptake inhibitors, selective serotonin reuptake inhibitors, antidepressants, benzisooxazole derivatives, butyrophenone derivatives, dibenzodiazepine derivatives, dibenzothiazepine derivatives, diphenylbutylpiperidine derivatives, phenothiazines, thienobenzodiazepine derivatives, thioxanthene derivatives, allergenic extracts, nonsteroidal agents, leukotriene receptor antagonists, xanthines, endothelin receptor antagonist, prostaglandins, lung surfactants, mucolytics, antimitotics, uricosurics, xanthine oxidase inhibitors, phosphodiesterase inhibitors, metheamine salts, nitrofuran derivatives, quinolones, smooth muscle relaxants, parasympathomimetic agents, halogenated hydrocarbons, esters of amino benzoic acid, amides (e.g. lidocaine, articaine hydrochloride, bupivacaine hydrochloride), antipyretics, hynotics and sedatives, cyclopyrrolones, pyrazolopyrimidines, nonsteroidal anti-inflammatory drugs, opioids, para-aminophenol derivatives, alcohol dehydrogenase inhibitor, heparin antagonists, adsorbents, emetics, opoid antagonists, cholinesterase reactivators, nicotine replacement therapy, vitamin A analogs and antagonists, vitamin B analogs and antagonists, vitamin C analogs and antagonists, vitamin D analogs and antagonists, vitamin E analogs and antagonists, vitamin K analogs and antagonists.

[00199] The antigen-binding proteins of the present disclosure can be conjugated to one or more cytokines and growth factors that are effective in inhibiting tumor metastasis, and wherein the cytokine or growth factor has been shown to have an antiproliferative effect on at least one cell population. Such cytokines, lymphokines, growth factors, or other hematopoietic factors include, but are not limited to: M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IFN, TNFα, TNF1, TNF2, G-CSF, Meg-CSF, GM-CSF, thrombopoietin, stem cell factor, and erythropoietin. Additional growth factors for use herein include angiogenin, bone morphogenic protein-1, bone morphogenic protein-2, bone morphogenic protein-3, bone morphogenic protein-4, bone morphogenic protein-5, bone morphogenic protein-6, bone morphogenic protein-7, bone morphogenic protein-8, bone morphogenic protein-9, bone morphogenic protein-10, bone morphogenic protein-11, bone morphogenic protein-

12, bone morphogenic protein-13, bone morphogenic protein-14, bone morphogenic protein-15, bone morphogenic protein receptor IA, bone morphogenic protein receptor IB, brain derived neurotrophic factor, ciliary neutrophic factor, ciliary neutrophic factor receptor α, cytokine-induced neutrophil chemotactic factor 1, cytokine-induced neutrophil, chemotactic factor 2 α, cytokine-induced neutrophil chemotactic factor 2 β, β endothelial cell growth factor, endothelin 1, epithelial-derived neutrophil attractant, glial cell line-derived neutrophic factor receptor α 1, glial cell line-derived neutrophic factor receptor α 2, growth related protein, growth related protein α, growth related protein β, growth related protein γ, heparin binding epidermal growth factor, hepatocyte growth factor, hepatocyte growth factor receptor, insulin-like growth factor I, insulin-like growth factor receptor, insulin-like growth factor II, insulin-like growth factor binding protein, keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor α, nerve growth factor nerve growth factor receptor, neurotrophin-3, neurotrophin-4, pre-B cell growth stimulating factor, stem cell factor, stem cell factor receptor, transforming growth factor α, transforming growth factor β, transforming growth factor β1, transforming growth factor β1.2, transforming growth factor β2, transforming growth factor β3, transforming growth factor β5, latent transforming growth factor β1, transforming growth factor β binding protein I, transforming growth factor β binding protein II, transforming growth factor β binding protein III, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, urokinase-type plasminogen activator receptor, and chimeric proteins and biologically or immunologically active fragments thereof.

[00200] In some embodiments, the conjugate comprises a compound as described herein and a cytotoxic agent. The cytotoxic agent is any molecule (chemical or biochemical) which is toxic to a cell. In some aspects, when a cytotoxic agent is conjugated to a compound of the invention, the results obtained are synergistic. That is to say, the effectiveness of the combination therapy of a compound and the cytotoxic agent is synergistic, i.e., the effectiveness is greater than the effectiveness expected from the additive individual effects of each. Therefore, the dosage of the cytotoxic agent can be reduced and thus, the risk of the toxicity problems and other side effects is concomitantly reduced. In some embodiments, the cytotoxic agent is a chemotherapeutic agent. Chemotherapeutic agents are known in the art and include, but not limited to, platinum coordination compounds, topoisomerase inhibitors, antibiotics, antimitotic alkaloids and difluoronucleosides, as described in U.S. Pat. No. 6,630,124.

[00201] In some embodiments, the chemotherapeutic agent is a platinum coordination compound. The term "platinum coordination compound" refers to any tumor cell growth inhibiting platinum coordination compound that provides the platinum in the form of an ion. In some embodiments, the platinum coordination compound is cis-diamminediaquoplatinum (II)-ion; chloro(diethylenetriamine)-platinum(II)chloride; dichloro(ethylenediamine)-platinum(II), diammine(1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin); spiroplatin; iproplatin; diammine(2-ethylmalonato)-platinum(II); ethylenediaminemalonatoplatinum(II); aqua(1,2-diaminodyclohexane)-sulfatoplatinum(II); (1,2-diaminocyclohexane)malonatoplatinum(II); (4-caroxyphthalato)(1,2-diaminocyclohexane)platinum(II); (1,2-diaminocyclohexane)-(isocitrato)platinum(II); (1,2-diaminocyclohexane)cis(pyruvato)platinum(II); (1,2-diaminocyclohexane)oxalatoplatinum(II); ormaplatin; and tetraplatin.

[00202] In some embodiments, cisplatin is the platinum coordination compound employed in the compositions and methods of the present invention. Cisplatin is commercially available under the name PLATINOL™ from Bristol Myers-Squibb Corporation and is available as a powder for constitution with water, sterile saline or other suitable vehicle. Other platinum coordination compounds suitable for use in the present invention are known and are available commercially and/or can be prepared by conventional techniques. Cisplatin, or cis-dichlorodiammineplatinum II, has been used successfully for many years as a chemotherapeutic agent in the treatment of various human solid malignant tumors. More recently, other diamino-platinum complexes have also shown efficacy as chemotherapeutic agents in the treatment of various human solid malignant tumors. Such diamino-platinum complexes include, but are not limited to, spiroplatinum and carboplatinum. Although cisplatin and other diamino-platinum complexes have been widely used as chemotherapeutic agents in humans, they have had to be delivered at high dosage levels that can lead to toxicity problems such as kidney damage.

[00203] In some embodiments, the chemotherapeutic agent is a topoisomerase inhibitor. Topoisomerases are enzymes that are capable of altering DNA topology in eukaryotic cells. They are critical for cellular functions and cell proliferation. Generally, there are two classes of topoisomerases in eukaryotic cells, type I and type II. Topoisomerase I is a monomeric enzyme of approximately 100,000 molecular weight. The enzyme binds to DNA and introduces a transient single-strand break, unwinds the double helix (or allows it


to unwind), and subsequently reseals the break before dissociating from the DNA strand. Various topoisomerase inhibitors have recently shown clinical efficacy in the treatment of humans afflicted with ovarian, cancer, esophageal cancer or non-small cell lung carcinoma.

[00204] In some aspects, the topoisomerase inhibitor is camptothecin or a camptothecin analog. Camptothecin is a water-insoluble, cytotoxic alkaloid produced by Camptotheca accuminata trees indigenous to China and Nothapodytes foetida trees indigenous to India. Camptothecin exhibits tumor cell growth inhibiting activity against a number of tumor cells. Compounds of the camptothecin analog class are typically specific inhibitors of DNA topoisomerase I. By the term "inhibitor of topoisomerase" is meant any tumor cell growth inhibiting compound that is structurally related to camptothecin. Compounds of the camptothecin analog class include, but are not limited to; topotecan, irinotecan and 9-amino-camptothecin.


[00205] In additional embodiments, the cytotoxic agent is any tumor cell growth inhibiting camptothecin analog claimed or described in: U.S. Pat. No. 5,004,758, issued on Apr. 2, 1991 and European Patent Application Number 88311366.4, published on Jun. 21, 1989 as 20' Publication Number EP 0 321 122; U.S. Pat. No. 4,604,463, issued on Aug. 5, 1986 and European Patent Application Publication Number EP 0 137 145, published on Apr. 17, 1985; U.S. Pat. No. 4,473,692, issued on Sep. 25, 1984 and European Patent Application Publication Number EP 0 074 256, published on Mar. 16, 1983; U.S. Pat. No. 4,545,880, issued on Oct. 8, 1985 and European Patent Application Publication Number EP 0 074 256, published on Mar. 16, 1983; European Patent Application Publication Number EP 0 088 642, published on Sep. 14, 1983; Wani et al., J. Med. Chem., 29, 2358-2363 (1986); Nitta et al., Proc. 14th International Congr. Chemotherapy, Kyoto, 1985, Tokyo Press, Anticancer Section 1, p. 28-30, especially a compound called CPT-11. CPT-11 is a camptothecin analog with a 4-(piperidino)-piperidine side chain joined through a carbamate linkage at C-10 of 10-hydroxy-7-ethyl camptothecin. CPT-11 is currently undergoing human clinical trials and is also referred to as irinotecan; Wani et al, J. Med. Chem., 23, 554 (1980); Wani et. al., J. Med. Chem., 30, 1774 (1987); U.S. Pat. No. 4,342,776, issued on Aug. 3, 1982; U.S. patent application Ser. No. 581,916, filed on Sep. 13, 1990 and European Patent Application Publication Number EP 418 099, published on Mar. 20, 1991; U.S. Pat. No. 4,513,138, issued on Apr. 23, 1985 and European Patent Application Publication Number EP 0 074 770, published on Mar. 23, 1983; U.S. Pat. No. 4,399,276,

issued on Aug. 16, 1983 and European Patent Application Publication Number 0 056 692, published on Jul. 28, 1982; the entire disclosure of each of which is hereby incorporated by reference. All of the above-listed compounds of the camptothecin analog class are available commercially and/or can be prepared by conventional techniques including those described in the above-listed references. The topoisomerase inhibitor may be selected from the group consisting of topotecan, irinotecan and 9-aminocamptothecin.

[00206] In some embodiments, the camptothecin analog is an active metabolite of irinotecan (CPT-11). In some such embodiments, the camptothecin analog is 7-ethyl-10-hydroxycamptothecin (SN-38). As a metabolite, SN-38 is formed by hydrolysis of irinotecan by carboxylesterases. In some embodiments, SN-38 has one of the following structures:




or



SN-38 has been described in U.S. patent application Ser. No. 7,999,083; U.S. patent application Ser. No. 8,080,250; U.S. patent application Ser. No. 8,759,496; U.S. patent application Ser. No. 8,999,344; U.S. patent application Ser. No. 10,195,288; and U.S. patent application Ser. No. 9,808,537.

[00207] In some embodiments, the camptothecin analog is exatecan methanesulfonate. Exatecan methanesulfonate is a water-soluble camptothecin (CPT) that exhibits more potent topoisomerase I inhibitory activity and antitumor activity than other CPT analogs. In addition, exatecan is effective against p-glycoprotein (P-gp)-mediated multi-drug resistant cells.

[00208] In some embodiments, the camptothecin analog is deruxtecan (Dxd), a potent derivative of exatecan, which has 10-fold higher topoisomerase I inhibitory potency than SN-38. In some embodiments, Dxd has the following structure:



Dxd has been described in U.S. patent application Ser. No. 6,407,115; U.S. patent application Ser. No. 10,195,288; U.S. patent application Ser. No. 9,808,537; and U.S. patent application Ser. No. 6,407,115.

[00209] The preparation of numerous compounds of the camptothecin analog class (including pharmaceutically acceptable salts, hydrates and solvates thereof) as well as the preparation of oral and parenteral pharmaceutical compositions comprising such a compounds of the camptothecin analog class and an inert, pharmaceutically acceptable carrier or diluent, is extensively described in U.S. Pat. No. 5,004,758, issued on Apr. 2, 1991 and European Patent Application Number 88311366.4, published on Jun. 21, 1989 as Publication Number EP 0 321 122, the teachings of which are incorporated herein by reference.


[00210] In still yet other embodiments of the invention, the chemotherapeutic agent is an antibiotic compound. Suitable antibiotic include, but are not limited to, doxorubicin, mitomycin, bleomycin, daunorubicin and streptozocin.

[00211] In some embodiments, the chemotherapeutic agent is an antimitotic alkaloid. In general, antimitotic alkaloids can be extracted from Cantharanthus roseus, and have been shown to be efficacious as anticancer chemotherapy agents. A great number of semi-synthetic derivatives have been studied both chemically and pharmacologically (see, O. Van Tellingen et al, Anticancer Research, 12, 1699-1716 (1992)). The antimitotic alkaloids of the present invention include, but are not limited to, vinblastine, vincristine, vindesine, Taxol and vinorelbine. The latter two antimitotic alkaloids are commercially available from Eli Lilly and Company, and Pierre Fabre Laboratories, respectively (see, U.S. Pat. No. 5,620,985). In one embodiment, the antimitotic alkaloid is vinorelbine.

[00212] In other embodiments of the invention, the chemotherapeutic agent is a difluoronucleoside. 2'-deoxy-2',2'-difluoronucleosides are known in the art as having antiviral activity. Such compounds are disclosed and taught in U.S. Pat. Nos. 4,526,988 and 4,808614. European Patent Application Publication 184,365 discloses that these same difluoronucleosides have oncolytic activity. In certain aspects, the 2'-deoxy-2',2'-difluoronucleoside used in the compositions and methods of the present invention is 2'-deoxy-2',2'-difluorocytidine hydrochloride, also known as gemcitabine hydrochloride. Gemcitabine is commercially available or can be synthesized in a multi-step process as


disclosed and taught in U.S. Pat. Nos. 4,526,988, 4,808,614 and 5,223,608, the teachings of which are incorporated herein by reference.

[00213] In various aspects, the chemotherapeutic agent is an anti-mitotic agent which inhibits cell division by blocking tubulin polymerization, destabilizing microtubules, or altering microtubule dynamics, *e.g.,* maytansinoid or a derivative thereof (*e.g.,* DM1 or DM4), auristatin or a derivative thereof. In various instances, the chemotherapeutic agent is an auristatin. For instance, the auristatin is in some aspects, dolastatin, Monomethyl auristatin E (MMAE), Monomethyl auristatin E (MMAE), or PF-06380101. Auristatins are described in the art. See, e.g., Maderna, A.; *et al.*, Mol Pharmaceutics 12(6): 1798-1812 (2015). In various aspects, the conjugate comprises an antibody of the present disclosure in combination with MMAE. Optionally, the conjugate comprises a linker. In some aspects, the linker comprises a cleavable linking moiety. In various instances, the conjugate comprises an antibody of the present disclosure linked to an attachment group which is linked to a cathepsin-cleavable linker, which in turn is linked to a spacer which is linked to MMAE. In aspects, the attachment group is attached to the antibody via a Cys residue of the Fc region of the antibody. In exemplary aspects, the attachment group comprises the structure of Formula I:




[Formula I]

In exemplary aspects, the cathepsin cleavable linker comprises the structure of Formula II:




[Formula II].

In exemplary aspects, the spacer comprises the structure of Formula III:



[Formula III].

[00214] In some embodiments, MMAE has the following structure:



[00215] The present disclosure also provides conjugates comprising an antigen-binding protein of the present disclosure linked to a polypeptide, such that the conjugate is a fusion protein. Therefore, the present disclosure provides fusion proteins comprising an antigen-binding protein of the present disclosure linked to a polypeptide. In various embodiments, the polypeptide is a diagnostic label, e.g., a fluorescent protein, such as green fluorescent protein, or other tag, e.g., Myc tag. In various aspects, the polypeptide is one of the cytokines, lymphokines, growth factors, or other hematopoietic factors listed above.

[00216] *Linkers*

[00217] In some embodiments, the conjugate is directly linked to the heterologous moiety. In alternative embodiments, the conjugate comprises a linker that joins the compound of the present disclosure to the heterologous moiety. In some aspects, the linker comprises a chain of atoms from 1 to about 60, or 1 to 30 atoms or longer, 2 to 5 atoms, 2 to 10 atoms, 5 to 10 atoms, or 10 to 20 atoms long. In some embodiments, the chain atoms are all carbon atoms. In some embodiments, the chain atoms in the backbone of the linker are selected from the group consisting of C, O, N, and S. Chain atoms and linkers can be selected according to their expected solubility (hydrophilicity) so as to provide a more soluble conjugate. In some embodiments, the linker provides a functional group that is subject to cleavage by an enzyme or other catalyst or hydrolytic conditions found in the target tissue or organ or cell. In some embodiments, the length of the linker is long enough to reduce the potential for steric hindrance. In some embodiments, the linker is an amino acid or a peptidyl linker. Such peptidyl linkers can be any length. Various linkers are from about 1 to 50 amino acids in length, 5 to 50, 3 to 5, 5 to 10, 5 to 15, or 10 to 30 amino acids in length.


[00218] A variety of suitable linkers are known in the art. The linker can be cleavable (a cleavable linker), e.g., under physiological conditions, e.g., under intracellular conditions, such that cleavage of the linker releases the drug in the intracellular environment. Alternatively, the linker can be cleavable under extracellular conditions, *e.g.,* outside the tumor cells or in the vicinity of the tumor mass, such that cleavage of the linker releases the drug that permeates preferentially inside the tumor cells. In other embodiments, the linker is not cleavable (a non-cleavable linker), and the drug is released, for example, by antibody degradation.

[00219] The linker can be bonded to a chemically reactive group on the antibody moiety, e.g., to a free amino, imino, hydroxyl, thiol, or carboxyl group (e.g., to the N- or C-terminus, to the epsilon amino group of one or more lysine residues, to the free carboxylic acid group of one or more glutamic acid or aspartic acid residues, to the sulfhydryl group of one or more cysteinyl residues, or to the hydroxyl group of one or more serine or threonine residues). The site to which the linker is bound can be a natural residue in the amino acid sequence of the antibody moiety, or it can be introduced into the antibody moiety, e.g., by DNA recombinant technology (e.g., by introducing a cysteine or protease cleavage site in

the amino acid sequence) or by protein biochemistry (e.g., reduction, pH adjustment, or proteolysis). The site to which the linker is bound can also be a non-natural amino acids. The site to which the linker is bound can also be a glycan on the antibody.


[00220] Typically, the linker is substantially inert under conditions for which the two groups it is connecting are linked. The term "bifunctional crosslinking agent," "bifunctional linker" or "crosslinking agent" refers to a modifying agent that possess two reactive groups at each end of the linker, such that one reactive group can be first reacted with the cytotoxic compound to provide a compound bearing the linker moiety and a second reactive group, which can then react with the antibody. Alternatively, one end of the bifunctional crosslinking agent can be first reacted with the antibody to provide an antibody bearing a linker moiety and a second reactive group, which can then react with the cytotoxic compound. The linking moiety may contain a chemical bond that allows for the release of the cytotoxic moiety at a particular site. Suitable chemical bonds are well known in the art and include disulfide bonds, thioether bonds, acid labile bonds, photolabile bonds, protease/peptidase labile bonds, and esterase labile bonds. See, for example, U.S. Patent Nos. 5,208,020; 5,475,092; 6,441,163; 6,716,821; 6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and 7,414,073. In some embodiments, the bonds are disulfide bonds, thioether, and/or protease/peptidase labile bonds. Other linkers that can be used in the present invention include non-cleavable linkers, such as those described in detail in US 20050169933, charged linkers, or hydrophilic linkers, such as those described in US 2009/0274713, US 2010/0129314, and WO 2009/134976, each of which is expressly incorporated herein by reference.

[00221] In some embodiments, the linker is a hydrophilic linker that confers hydrophilicity to the conjugate. In some embodiments, the hydrophilic linker comprises polyethylene glycol (PEG). In some embodiments, the hydrophilic linker is CLA2. In some embodiments, the CLA2 linker has the following structure:



CLA2 has been described in U.S. Patent Nos. 8,080,250; 8,759,496; and 10,195,288.


[00222] In some embodiments, the hydrophilic linker is CL2E. In some embodiments, the CL2E has the following structure:



CL2E has been described in U.S. Patent Nos. 8,080,250; 8,759,496; and 10,195,288.


[00223] In some embodiments, the linker is cleavable by a cleaving agent that is present in the intracellular environment (e.g., within a lysosome or endosome or caveolea). The linker can be, e.g., a peptide linker that is cleaved by an intracellular or extracellular peptidase or protease enzyme, including, but not limited to, a lysosomal or endosomal protease. In some embodiments, the peptide linker comprises at least two, at least three, at least four, or at least five amino acids long.

[00224] In some embodiments, the peptide linker is MC-VC-PAB, comprising valine and citruline residues. In some embodiments, the MC-VC-PAB linker has the following structure:



MC-VC-PAB has been described in U.S. Patent Nos. 7,659,241; 7,829,531; 6,884,869; 6,214,345; and 6,214,345.

[00225] In some embodiments, the peptide linker is maleimidocaproyl glycine-glycine-phenylalanine-glycine (MC-GGFG). In some embodiments, the MC-GGFG linker has the following structure:



MC-GGFG has been described in U.S. Patent Nos. 9,808,537 and 10,195,288.

[00226] In other embodiments, the cleavable linker is pH-sensitive, i.e., sensitive to hydrolysis at certain pH values. In some embodiments, the pH-sensitive linker is hydrolyzable under acidic conditions. For example, an acid-labile linker that is hydrolyzable in the lysosome (e.g., a hydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetal, ketal, or the like) can be used (see, e.g., US Patent Nos. 5,122,368; 5,824,805; 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al, 1989, Biol. Chem. 264: 14653-14661). Such linkers are relatively stable under neutral pH conditions, such as those in the blood, but are unstable at below pH 5.5 or 5.0, the approximate pH of the lysosome. In certain embodiments, the hydrolyzable linker is a thioether linker (such as, e.g., a thioether attached to the therapeutic agent via an acylhydrazone bond (see, e.g., US Patent No. 5,622,929).

[00227] In other embodiments, the linker is cleavable under reducing conditions (e.g., a disulfide linker). Bifunctional crosslinking agents that enable the linkage of an antibody with cytotoxic compounds via disulfide bonds include, but are not limited to, N-succinimidyl-4-(4-nitropyridyl-2-dithio)butanoate, N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio)-2-sulfo butanoate (sulfo-SPDB). Sulfo-SPDB is described, e.g., in US Patent 8,236,319, incorporated herein by reference. Alternatively, crosslinking agents that introduce thiol groups such as 2-iminothiolane, homocysteine thiolactone, or S-acetylsuccinic anhydride can be used. In other embodiments, the linker may contain a combination of one or more of the peptide, pH-sensitive, or disulfide linkers described previously.

[00228] "Heterobifunctional crosslinking agents" are bifunctional crosslinking agents having two different reactive groups. Heterobifunctional crosslinking agents containing both an amine-reactive N-hydroxysuccinimide group (NHS group) and a carbonyl-reactive hydrazine group can also be used to link cytotoxic compounds with an antibody. Examples of such commercially available heterobifunctional crosslinking agents include succinimidyl 6-hydrazinonicotinamide acetone hydrazone (SANH), succinimidyl 4-

hydrazidoterephthalate hydrochloride (SHTH) and succinimidyl hydrazinium nicotinate hydrochloride (SHNH). Conjugates bearing an acid-labile linkage can also be prepared using a hydrazine-bearing benzodiazepine derivative of the present invention. Examples of bifunctional crosslinking agents that can be used include succinimidyl-p-formyl benzoate (SFB) and succinimidyl-p-formylphenoxyacetate (SFPA).

[00229] The linkers described herein may be used in any combination with the heterologous moiety described herein. All of the above-listed linkers and heterologous moiety described herein are available commercially and/or can be prepared by conventional techniques including those described in the above-listed references.

[00230] *Conjugation*

[00231] The heterologous moiety-to-antigen-binding protein ratio (HAR) represents the number of a heterologous moiety linked per antigen-binding molecule. In some embodiments, the HAR ranges from 1 to 15, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, the HAR ranges from 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4 or 2 to 3. In other embodiments, the HAR is about 2, about 2.5, about 3, about 4, about 5, or about 6. In some embodiments, the HAR ranges from about 2 to about 4. The HAR may be characterized by conventional means such as mass spectrometry, UV/Vis spectroscopy, ELISA assay, and/or HPLC.

[00232] In some embodiments, the conjugates are heterogeneous conjugates (also referred to as "conventional"), wherein the antigen-binding proteins are conjugated to a different number of the heterologous moiety. In some embodiments, the heterogeneous conjugates follow a Gaussian distribution or quasi-Gaussian distribution of the conjugates, wherein the distribution centers on the average heterologous moiety loading value with some antigen-binding proteins conjugated with higher than average and some antigen-binding proteins conjugated with lower than the average.

[00233] In some embodiments, the conjugates are homogeneous conjugates, wherein the substantial percentage of the antigen-binding proteins are conjugated to a defined number of the heterologous moiety. In some embodiments, the homogeneous conjugates comprise the HAR of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the homogeneous conjugates comprise the HAR of 2, 4, 6, or 8. In preferred embodiments, the homogeneous conjugates comprise the HAR of 4. In other preferred embodiments, the homogeneous conjugates comprise the HAR of 2. In some embodiments, the homogeneous conjugates

comprise greater than or equal to 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent conjugates with the defined HAR. In some embodiments, the homogeneous conjugates comprise about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent conjugates with the defined HAR. In some embodiments, the homogeneous conjugates comprise at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent conjugates with the defined HAR. In some embodiments, the homogeneous conjugates comprise the HAR distribution that is not Gaussian or quasi-Gaussian distribution. In some embodiments, the homogeneity of the homogeneous conjugates is determined by a chromatogram, *e.g.,* HPLC or any suitable chromatography. In some embodiments, the chromatogram is a HIC chromatogram. The homogeneous conjugate may be generated by a site-specific conjugation.

[00234] In some embodiments, the heterologous moiety is conjugated to the antigen-binding protein (e.g., antibody) in a site-specific manner. Various site-specific conjugation methods are known in the art, e.g., thiomab or TDC or conjugation at an unpaired cysteine residue (Junutula *et al.* (2008) *Nat. Biotechnol.* 26:925-932; Dimasi *et al.* (2017) *Mol. Pharm.* 14:1501-1516; Shen *et al.* (2012) *Nat. Biotechnol.* 30:184-9); thiol bridge linker (Behrens *et al.* (2015) *Mol. Pharm.* 12:3986-98); conjugation at glutamine using a transglutaminase (Dennler *et al.* (2013) *Methods Mol. Bio.* 1045:205-15; Dennler *et al.* (2014) *Bioconjug Chem.* 25:569-78); conjugation at engineered unnatural amino acid residues (Axup *et al.* (2012) *Proc Natl Acad Sci U.S.A.* 104-16101-6; Tian *et al.* (2014) *Proc Natl Acad Sci U.S.A.* 111:1766-71; VanBrunt *et al.* (2015) *Bioconjug Chem* 26:2249-60; Zimmerman *et al.* (2014) *Bioconjug Chem* 25:351-61); selenocysteine conjugation (Li *et al.* (2017) *Cell Chem Biol* 24:433-442); glycan-mediated conjugation (Okeley *et al.* (2013) *Bioconjug Chem* 24:1650-5); conjugation at galactose or GalNAc analogues (Ramakrishnan and Qasba (2002) *J Biol Chem* 277:20833-9; van Geel *et al.* (2015) *Bioconjug Chem* 26:2233-42); via glycan engineering (Zhou *et al.* (2014) *Bioconjug Chem* 25:510-20; Tang *et al.* (2017) *Nat Protoc* 12:1702-1721); via a short peptide tag, such as engineering a glutamine tag or sortase A-mediated transpeptidation (Strop *et al.* (2013) *Chem Biol* 20:161-7; Beerli *et al.* (2015) *PLoS One* 10:e0131177); and via an aldehyde tag (Wu *et al.* (2009) *Proc Natl Acad Sci U.S.A.* 106:3000-5).

[00235] *Unpredictability of conjugate (e.g., ADC)*

[00236] It is not possible to predict in advance, simply based on an antibody profile, or a drug payload profile, which antibody-drug conjugates will be sufficiently safe and effective for clinical applications. For example, a particular drug payload may function perfectly well when conjugated to an antibody directed to one target, but it may not work nearly as well when conjugated to an antibody directed to a different target, or even to a different antibody directed to the same target. Why different antibody-drug conjugates display different anti-tumor activity in vivo is not sufficiently well understood to allow accurate predictions in the design of new antibody-drug conjugates. It is speculated that an unpredictable interplay of many factors play a role. These factors may include, for example, the binding affinity of an antibody-drug conjugate to a target antigen, the ability of the conjugate to penetrate solid tumors, as well as the half-life in circulation for proper exposure to tumors without causing toxicity.

[00237] The complexity and unpredictability is well demonstrated by antibody affinity alone. Antibodies or antibody-drug conjugates with high affinity track with better cellular uptake, which leads to a higher level of the cytotoxic payloads released inside the cells. Higher affinity is also known to enhance the antibody-dependent cellular cytotoxicity (ADCC). All these attributes favor the cell killing property of antibody-drug conjugates. However, it is also known that high affinity of an antibody or antibody-drug conjugate can prevent efficient tumor penetration via an "antigen barrier effect," suggesting that in order to achieve a strong anti-tumor activity in vivo, affinity of the antibody-drug conjugate has to be just right: not too high or not too low. To date, it is not known how to predict what will be the most efficient or effective level of affinity for an antibody-drug conjugate.

[00238] In addition, *in vivo* anti-tumor activity cannot be predicted by the mechanism of linkers and payloads alone. For example, O. Ab et al, *Mol. Cancer Ther*. 14(&):1605-1613 (2015) demonstrated that, when tested in pre-clinical cancer models, the same antibody conjugated to the same anti-tubulin toxin via different linkers exhibited dramatically different anti-tumor activity. This example is particularly surprising because the chemical structures of the two linkers are very similar. Moreover, the linker present in the superior conjugate contained a hydrophilic moiety. Hydrophilic metabolites are generally less membrane-permeable, and are thought to be slower in efflux from the lysosomes (the site of conjugate degradation), leading to a delay in the anti-tubulin activity of the released

payload. This finding argues for an "ideal" kinetics of payload delivery, but to date, there is no insight into what constitutes such kinetics. Adding to this complexity is the open question of whether ideal kinetics of payload delivery, even if defined for a particular cell type, would apply to all cell types. Thus, it is not possible to predict the most effective *in vivo* anti-tumor activity merely from the chemical composition of the linker or payload.

[00239] *Compositions, Pharmaceutical Compositions and Formulations*

[00240] Compositions comprising an antigen-binding protein, a nucleic acid, a vector, a host cell, or a conjugate as presently disclosed are provided herein. The compositions in some aspects comprise the antigen-binding proteins in isolated and/or purified form. In some aspects, the composition comprises a single type (e.g., structure) of an antigen-binding protein of the present disclosure or comprises a combination of two or more antigen-binding proteins of the present disclosure, wherein the combination comprises two or more antigen-binding proteins of different types (e.g., structures).

[00241] In some aspects, the composition comprises agents which enhance the chemico-physico features of the antigen-binding protein, e.g., via stabilizing the antigen-binding protein at certain temperatures, e.g., room temperature, increasing shelf life, reducing degradation, e.g., oxidation protease mediated degradation, increasing half-life of the antigen-binding protein, etc. In some aspects, the composition comprises any of the agents disclosed herein as a heterologous moiety or conjugate moiety, optionally in admixture with the antigen-binding proteins of the present disclosure or conjugated to the antigen-binding proteins.

[00242] In various aspects of the present disclosure, the composition additionally comprises a pharmaceutically acceptable carrier, diluents, or excipient. In some embodiments, the antigen-binding protein, a nucleic acid, a vector, a host cell, or a conjugate as presently disclosed (hereinafter referred to as "active agents") is formulated into a pharmaceutical composition comprising the active agent, along with a pharmaceutically acceptable carrier, diluent, or excipient. In this regard, the present disclosure further provides pharmaceutical compositions comprising an active agent which is intended for administration to a subject, e.g., a mammal.

[00243] In some embodiments, the active agent is present in the pharmaceutical composition at a purity level suitable for administration to a patient. In some embodiments, the active agent has a purity level of at least about 90%, about 91%, about 92%, about 93%,

about 94%, about 95%, about 96%, about 97%, about 98% or about 99%, and a pharmaceutically acceptable diluent, carrier or excipient. In some embodiments, the compositions contain an active agent at a concentration of about 0.001 to about 30.0 mg/ml.

[00244] In various aspects, the pharmaceutical compositions comprise a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.

[00245] The pharmaceutical composition can comprise any pharmaceutically acceptable ingredients, including, for example, acidifying agents, additives, adsorbents, aerosol propellants, air displacement agents, alkalizing agents, anticaking agents, anticoagulants, antimicrobial preservatives, antioxidants, antiseptics, bases, binders, buffering agents, chelating agents, coating agents, coloring agents, desiccants, detergents, diluents, disinfectants, disintegrants, dispersing agents, dissolution enhancing agents, dyes, emollients, emulsifying agents, emulsion stabilizers, fillers, film forming agents, flavor enhancers, flavoring agents, flow enhancers, gelling agents, granulating agents, humectants, lubricants, mucoadhesives, ointment bases, ointments, oleaginous vehicles, organic bases, pastille bases, pigments, plasticizers, polishing agents, preservatives, sequestering agents, skin penetrants, solubilizing agents, solvents, stabilizing agents, suppository bases, surface active agents, surfactants, suspending agents, sweetening agents, therapeutic agents, thickening agents, tonicity agents, toxicity agents, viscosity-increasing agents, water-absorbing agents, water-miscible cosolvents, water softeners, or wetting agents. *See, e.g.*, the *Handbook of Pharmaceutical Excipients*, Third Edition, A. H. Kibbe (Pharmaceutical Press, London, UK, 2000), which is incorporated by reference in its entirety. *Remington's Pharmaceutical Sciences*, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), which is incorporated by reference in its entirety.

[00246] In various aspects, the pharmaceutical composition comprises formulation materials that are nontoxic to recipients at the dosages and concentrations employed. In specific embodiments, pharmaceutical compositions comprising an active agent and one or more pharmaceutically acceptable salts; polyols; surfactants; osmotic balancing agents;

tonicity agents; anti-oxidants; antibiotics; antimycotics; bulking agents; lyoprotectants; anti-foaming agents; chelating agents; preservatives; colorants; analgesics; or additional pharmaceutical agents. In various aspects, the pharmaceutical composition comprises one or more polyols and/or one or more surfactants, optionally, in addition to one or more excipients, including but not limited to, pharmaceutically acceptable salts; osmotic balancing agents (tonicity agents); anti-oxidants; antibiotics; antimycotics; bulking agents; lyoprotectants; anti-foaming agents; chelating agents; preservatives; colorants; and analgesics.

[00247] In certain embodiments, the pharmaceutical composition can contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (such as sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. See, REMINGTON'S PHARMACEUTICAL SCIENCES, 18″ Edition, (A. R. Genrmo, ed.), 1990, Mack Publishing Company.

[00248] The pharmaceutical compositions can be formulated to achieve a physiologically compatible pH. In some embodiments, the pH of the pharmaceutical composition can be for example between about 4 or about 5 and about 8.0 or about 4.5 and about 7.5 or about 5.0 to about 7.5. In various embodiments, the pH of the pharmaceutical composition is between 5.5 and 7.5.

[00249] The present disclosure provides methods of producing a pharmaceutical composition. In various aspects, the method comprises combining the antigen-binding protein, conjugate, fusion protein, nucleic acid, vector, host cell, or a combination thereof, with a pharmaceutically acceptable carrier, diluent, or excipient.

[00250] *Routes of Administration*

[00251] With regard to the present disclosure, the active agent, or pharmaceutical composition comprising the same, can be administered to the subject via any suitable route of administration. For example, the active agent can be administered to a subject via parenteral, nasal, oral, pulmonary, topical, vaginal, or rectal administration. The following discussion on routes of administration is merely provided to illustrate various embodiments and should not be construed as limiting the scope in any way.

[00252] Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The term, "parenteral" means not through the alimentary canal but by some other route such as subcutaneous, intramuscular, intraspinal, or intravenous. The active agent of the present disclosure can be administered with a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol, a glycol, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol, ketals such as 2,2- dimethyl-l53-dioxolane-4-methanol, ethers, poly(ethyleneglycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose,

hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.

[00253] Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.

[00254] Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-β-aminopropionates, and 2-alkyl -imidazoline quaternary ammonium salts, and (e) mixtures thereof.

[00255] The parenteral formulations in some embodiments contain from about 0.5% to about 25% by weight of the active agent of the present disclosure in solution. Preservatives and buffers can be used. In order to minimize or eliminate irritation at the site of injection, such compositions can contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations in some aspects are presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions in some aspects are prepared from sterile powders, granules, and tablets of the kind previously described.

[00256] Injectable formulations are in accordance with the present disclosure. The requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., *Pharmaceutics and Pharmacy Practice*, J. B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and *ASHP Handbook on Injectable Drugs*, Toissel, 4th ed., pages 622-630 (1986)).

[00257] *Dosages*

[00258] The active agents of the disclosure are believed to be useful in methods of inhibiting tumor growth, as well as other methods, as further described herein, including methods of treating or preventing cancer. For purposes of the disclosure, the amount or dose of the active agent administered should be sufficient to effect, e.g., a therapeutic or prophylactic response, in the subject or animal over a reasonable time frame. For example, the dose of the active agent of the present disclosure should be sufficient to treat cancer as described herein in a period of from about 1 to 4 minutes, 1 to 4 hours or 1 to 4 weeks or longer, e.g., 5 to 20 or more weeks, from the time of administration. In certain embodiments, the time period could be even longer. The dose will be determined by the efficacy of the particular active agent and the condition of the animal (e.g., human), as well as the body weight of the animal (e.g., human) to be treated.

[00259] Many assays for determining an administered dose are known in the art. For purposes herein, an assay, which comprises comparing the extent to which cancer is treated upon administration of a given dose of the active agent of the present disclosure to a mammal among a set of mammals, each set of which is given a different dose of the active agent, could be used to determine a starting dose to be administered to a mammal. The extent to which cancer is treated upon administration of a certain dose can be represented by, for example, the extent of tumor regression achieved with the active agent in a mouse xenograft model. Methods of assaying tumor regression are known in the art and described herein in EXAMPLES.

[00260] The dose of the active agent of the present disclosure also will be determined by the existence, nature and extent of any adverse side effects that might accompany the administration of a particular active agent of the present disclosure. Typically, the attending physician will decide the dosage of the active agent of the present disclosure with which to treat each individual patient, taking into consideration a variety of factors, such as

age, body weight, general health, diet, sex, active agent of the present disclosure to be administered, route of administration, and the severity of the condition being treated. By way of example and not intending to limit the present disclosure, the dose of the active agent of the present disclosure can be about 0.0001 to about 1 g/kg body weight of the subject being treated/day, from about 0.0001 to about 0.001 g/kg body weight/day, or about 0.01 mg to about 1 g/kg body weight/day.

[00261] *Controlled Release Formulations*

[00262] In some embodiments, the active agents described herein can be modified into a depot form, such that the manner in which the active agent of the present disclosure is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Patent No. 4,450,150). Depot forms of active agents of the present disclosure can be, for example, an implantable composition comprising the active agents and a porous or non-porous material, such as a polymer, wherein the active agent is encapsulated by or diffused throughout the material and/or degradation of the non-porous material. The depot is then implanted into the desired location within the body of the subject and the active agent is released from the implant at a predetermined rate.

[00263] The pharmaceutical composition comprising the active agent in certain aspects is modified to have any type of *in vivo* release profile. In some aspects, the pharmaceutical composition is an immediate release, controlled release, sustained release, extended release, delayed release, or bi-phasic release formulation. Methods of formulating peptides for controlled release are known in the art. See, for example, Qian et al., *J Pharm* 374: 46-52 (2009) and International Patent Application Publication Nos. WO 2008/130158, WO2004/033036; WO2000/032218; and WO 1999/040942.

[00264] The instant compositions can further comprise, for example, micelles or liposomes, or some other encapsulated form, or can be administered in an extended release form to provide a prolonged storage and/or delivery effect.

[00265] *Use*

[00266] The antigen-binding proteins of the present disclosure are useful for inhibiting tumor growth. Without being bound to a particular theory, the inhibiting action of the

antigen-binding proteins provided herein allow such entities to be useful in methods of treating cancer.

[00267] Accordingly, provided herein are methods of inhibiting tumor growth in a subject and methods of reducing tumor size in a subject. In various embodiments, the methods comprise administering to the subject the pharmaceutical composition of the present disclosure in an amount effective for inhibiting tumor growth or reducing tumor size in the subject. In various aspects, the growth of an ovarian tumor, melanoma tumor, bladder tumor, or endometrial tumor is inhibited. In various aspects, the size of an ovarian tumor, melanoma tumor, bladder tumor, or endometrial tumor is reduced.

[00268] As used herein, the term "inhibit" or "reduce" and words stemming therefrom may not be a 100% or complete inhibition or reduction. Rather, there are varying degrees of inhibition or reduction of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the antigen-binding proteins of the present disclosure may inhibit tumor growth or reduce tumor size to any amount or level. In various embodiments, the inhibition provided by the methods of the present disclosure is at least or about a 10% inhibition (e.g., at least or about a 20% inhibition, at least or about a 30% inhibition, at least or about a 40% inhibition, at least or about a 50% inhibition, at least or about a 60% inhibition, at least or about a 70% inhibition, at least or about a 80% inhibition, at least or about a 90% inhibition, at least or about a 95% inhibition, at least or about a 98% inhibition). In various embodiments, the reduction provided by the methods of the present disclosure is at least or about a 10% reduction (e.g., at least or about a 20% reduction, at least or about a 30% reduction, at least or about a 40% reduction, at least or about a 50% reduction, at least or about a 60% reduction, at least or about a 70% reduction, at least or about a 80% reduction, at least or about a 90% reduction, at least or about a 95% reduction, at least or about a 98% reduction).

[00269] Additionally provided herein are methods of treating a subject with cancer, e.g., CLDN6-expressing cancer. In various embodiments, the method comprises administering to the subject the pharmaceutical composition of the present disclosure in an amount effective for treating the cancer in the subject.

[00270] For purposes herein, the cancer of the methods disclosed herein can be any cancer, e.g., any malignant growth or tumor caused by abnormal and uncontrolled cell division that may spread to other parts of the body through the lymphatic system or the

blood stream. The cancer in some aspects is one selected from the group consisting of acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer (e.g., renal cell carcinoma (RCC)), small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, and urinary bladder cancer. In particular aspects, the cancer is selected from the group consisting of: head and neck, ovarian, cervical, bladder and oesophageal cancers, pancreatic, gastrointestinal cancer, gastric, breast, endometrial and colorectal cancers, hepatocellular carcinoma, glioblastoma, bladder, lung cancer, e.g., non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma. In various aspects, the cancer is ovarian cancer, melanoma, bladder cancer, lung cancer, liver cancer, endometrial cancer. In various aspects, the cancer is any cancer characterized by moderate to high expression of CLDN6. See, e.g., FIG. 1-FIG. 3. In various aspects, the cancer is acute myeloid leukemia, large B-cell lymphoma, stomach cancer, prostate cancer, melanoma, colon cancer, rectal cancer, bladder cancer, cervical cancer, liver cancer, breast cancer, kidney clear cell carcinoma, head and neck cancer, sarcoma, kidney chromophobe cancer, lower grade glioma, adrenocortical cancer, glioblastoma, kidney papillary cell carcinoma, lung squamous cell carcinoma, thyroid cancer, lung adenocarcinoma, pancreatic cancer, endometroid cancer, uterine carcinsarcoma, or ovarian cancer. In various aspects, the cancer is selected from ovarian cancer, endometrioid cancer, uterine cancer, lung cancer, gastric cancer, breast cancer Head and Neck Squamous Cell Carcinoma (HNSCC) cancer, cervical cancer, and bladder.

[00271] As used herein, the term "treat," as well as words related thereto, do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the methods of treating cancer of the present disclosure

can provide any amount or any level of treatment. Furthermore, the treatment provided by the method of the present disclosure can include treatment of one or more conditions or symptoms or signs of the cancer being treated. Also, the treatment provided by the methods of the present disclosure can encompass slowing the progression of the cancer. For example, the methods can treat cancer by virtue of enhancing the T cell activity or an immune response against the cancer, reducing tumor or cancer growth, reducing metastasis of tumor cells, increasing cell death of tumor or cancer cells, and the like. In various aspects, the methods treat by way of delaying the onset or recurrence of the cancer by at least 1 day, 2 days, 4 days, 6 days, 8 days, 10 days, 15 days, 30 days, two months, 3 months, 4 months, 6 months, 1 year, 2 years, 3 years, 4 years, or more. In various aspects, the methods treat by way increasing the survival of the subject.

[00272] The antigen binding proteins of the present disclosure also may be used to detect CLDN6 in a sample or diagnose a CLDN6-positive cancer. Therefore, the present disclosure provides methods of detecting Claudin6 (CLDN6) in a sample. In various embodiments, the method comprises contacting the sample with an antigen-binding protein, a conjugate, or a fusion protein, as described herein, and assaying for an immunocomplex comprising the antigen-binding protein, conjugate or fusion protein bound to CLDN6. The present disclosure also provides methods of diagnosing a Claudin6 (CLDN6)-positive cancer in a subject. In various embodiments, the method comprises contacting a biological sample comprising cells or tissue obtained from the subject with an antigen-binding protein, a conjugate, or a fusion protein, as described herein, and assaying for an immunocomplex comprising the antigen-binding protein, conjugate or fusion protein bound to CLDN6.

[00273] *Subjects*

[00274] In some embodiments of the present disclosure, the subject is a mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits, mammals from the order Carnivora, including Felines (cats) and Canines (dogs), mammals from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). In some aspects, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). In some aspects, the mammal is a human.

[00275] *Kits*

[00276] In some embodiments, the antigen-binding proteins of the present disclosure are provided in a kit. In various aspects, the kit comprises the antigen-binding protein(s) as a unit dose. For purposes herein "unit dose" refers to a discrete amount dispersed in a suitable carrier. In various aspects, the unit dose is the amount sufficient to provide a subject with a desired effect, e.g., inhibition of tumor growth, reduction of tumor size, treatment of cancer. Accordingly, provided herein are kits comprising an antigen-binding protein of the present disclosure optionally provided in unit doses. In various aspects, the kit comprises several unit doses, e.g., a week or month supply of unit doses, optionally, each of which is individually packaged or otherwise separated from other unit doses. In some embodiments, the components of the kit/unit dose are packaged with instructions for administration to a patient. In some embodiments, the kit comprises one or more devices for administration to a patient, e.g., a needle and syringe, and the like. In some aspects, the antigen-binding protein of the present disclosure, a pharmaceutically acceptable salt thereof, a conjugate comprising the antigen-binding protein, or a multimer or dimer comprising the antigen-binding protein, is pre-packaged in a ready to use form, e.g., a syringe, an intravenous bag, etc. In some aspects, the kit further comprises other therapeutic or diagnostic agents or pharmaceutically acceptable carriers (e.g., solvents, buffers, diluents, etc.), including any of those described herein. In particular aspects, the kit comprises an antigen-binding protein of the present disclosure, along with an agent, e.g., a therapeutic agent, used in chemotherapy or radiation therapy.

[00277] *Various embodiments*

[00278] In various embodiments of the present disclosure, the antigen-binding protein binds to a human Claudin6 (CLDN6) protein (SEQ ID NO: 200), wherein (a) the antigen-binding protein binds *to* Extracellular Loop 2 (EL2) of an extracellular domain (ECD) of CLDN6 and does not bind to Extracellular Loop 1 (EL1) of the ECD of CLDN6; or (b) does not bind to any of Claudin3 (CLDN3), Claudin4 (CLDN4), and Claudin9 (CLDN9) and inhibits binding of a reference antibody to CLDN6 endogenously expressed by OVCA429 cells with less than about 1200 nM; or (c) a combination thereof. In various instances, the antigen- binding protein binds to an epitope within the amino acid sequence of WTAHAIIRDFYNPLVAEAQKREL (SEQ ID NO: 2), or binds to the amino acid sequence of TAHAIIRDFYNPL (SEQ ID NO: 3) or LVAEAQKREL (SEQ ID NO: 4) of

CLDN 6. In various aspects, the antigen-binding protein does not bind to any one or more of Claudin3 (CLDN3), Claudin4 (CLDN4), and Claudin9 (CLDN9). In various instances, the antigen-binding protein does not bind to CLDN3. In various instances, the antigen-binding protein binds to CLDN6, CLDN4, and CLDN9 but does not bind to CLDN3. In various instances, the antigen-binding protein binds to CLDN6 and CLDN4 but does not bind to CLDN3 or CLDN9. In various aspects, the antigen-binding protein binds to CLDN6 and CLDN9 but does not bind to CLDN3 or CLDN4.

[00279] In various instances, the antigen-binding protein of the present disclosure inhibits binding of a reference antibody to CLDN6 endogenously expressed by OVCA429 cells with less than about 1200 nM and the reference antibody comprises a light chain variable sequence of SEQ ID NO: 181 and a heavy chain variable sequence of SEQ ID NO: 182 or a light chain variable sequence of SEQ ID NO: 185 and a heavy chain variable sequence of SEQ ID NO: 186. In various aspects, the antigen-binding protein of the present disclosure inhibits binding of a reference antibody to CLDN6 endogenously expressed by OVCA429 cells with less than about 1000 nM or less than 750 nM (e.g., less than about 500 nM, less than about 250 nM, less than aobut 100 nM) and the reference antibody comprises a light chain variable sequence of SEQ ID NO: 181 and a heavy chain variable sequence of SEQ ID NO: 182 or a light chain variable sequence of SEQ ID NO: 185 and a heavy chain variable sequence of SEQ ID NO: 186.

[00280] In various embodiments, the antigen-binding protein comprises (a) a heavy chain CDR1 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 11, 17, 23, 29, 35, 41, 47, 53, 59, 65, 71, 77, 83, 89, 95, 101, 107, 113, 119, 125, 131, 452, 455, 461, 465, and 472, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; (b) a heavy chain CDR2 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 86, 102, 108, 114, 120, 126, 132, 475, 456, 462, 466, 468, and 473, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; (c) a heavy chain CDR3 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103,

109, 115, 121, 127, 133, 453, 457, 463, 467, 469, and 474, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; (d) a light chain CDR1 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 8, 14, 20, 32, 38, 44, 50, 56, 62, 68, 74, 80, 86, 92, 98, 104, 110, 116, 122, 128, 449, 476, 458, 464, and 470, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; (e) a light chain CDR2 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81, 87, 93, 99, 105, 111, 117, 123, 129, 450, 477, 459, and 471, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; (f) a light chain CDR3 amino acid sequence set forth in Table A or A1 or a sequence selected from the group consisting of: SEQ ID NOs: 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76, 82, 88, 94, 100, 106, 112, 118, 124, 130, 451, 454, and 460, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; (g) a combination of any two or more of (a)-(f).

[00281] In various aspects, the antigen-binding protein comprises a light chain CDR1 amino acid sequence, a light chain CDR2 amino acid sequence, and a light chain CDR3 amino acid sequence set forth in Table A or A1 and 1 or 2 of the heavy chain CDR amino acid sequences set forth in Table A or A1. In some instances, the antigen-binding protein comprises a heavy chain CDR1 amino acid sequence, a heavy chain CDR2 amino acid sequence, and a heavy chain CDR3 amino acid sequence set forth in Table A or A1 and 1 or 2 of the light chain CDR amino acid sequences set forth in Table A or A1. In various aspects, the antigen-binding protein comprises six CDR amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 74-79; (b) SEQ ID NOs: 50-55; (c) SEQ ID NOs: 122-127; (d) SEQ ID NOs: 26-31; (e) SEQ ID NOs: 128-133; (f) SEQ ID NOs: 38-43; (g) SEQ ID NOs: 62-67; (h) SEQ ID NOs: 80-85; (i) SEQ ID NOs: 44-49; (j) SEQ ID NOs: 86-91; (k) SEQ ID NOs: 104-109; (l) SEQ ID NOs: 56-61; (m) SEQ ID NOs: 32-37; (n) SEQ ID NOs: 110-115; (o) SEQ ID NOs: 98-103; (p) SEQ ID NOs: 92-97; (q) SEQ ID NOs: 116-121; (r) SEQ ID NOs: 8-13; (t) SEQ ID NOs: 68-73; (u) SEQ ID NOs: 14-19; (v) SEQ ID NOs: 20-25, (v) SEQ I D NOs: 449-453 and 475; (w) SEQ ID NOs: 476-477, 454-

457, (x) SEQ ID NOs: 458-463; (y) SEQ ID NOs: 57, 58, 464-467; (z) SEQ ID NOs: 68-71 and 468-469; and (aa) SEQ ID NOs: 112, and 470-474. In various aspects, the antigen-binding protein of comprises (a) a heavy chain variable region amino acid sequence set forth in in Table B or a sequence selected from the group consisting of: SEQ ID NOs: 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, and 175, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; or (b) a light chain variable region amino acid sequence set forth in in Table B or a sequence selected from the group consisting of: SEQ ID NOs: 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, and 176, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% (e.g., at least or about 85%, at least or about 90%) sequence identity; or both (a) and (b). In various aspects, the antigen-binding protein comprises a pair of amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 156 and 157; (b) SEQ ID NOs: 148 and 149; (c) SEQ ID NOs: 172 and 173; (d) SEQ ID NOs: 140 and 141; (e) SEQ ID NOs: 174 and 175; (f) SEQ ID NOs: 144 and 145; (g) SEQ ID NOs: 152 and 153; (h) SEQ ID NOs: 158 and 159; (i) SEQ ID NOs: 146 and 147; (j) SEQ ID NOs: 160 and 161; (k) SEQ ID NOs: 166 and 167; (l) SEQ ID NOs: 150 and 151; (m) SEQ ID NOs: 142 and 143; (n) SEQ ID NOs: 168 and 169; (o) SEQ ID NOs: 164 and 165; (p) SEQ ID NOs: 162 and 163; (q) SEQ ID NOs: 170 and 171; (r) SEQ ID NOs: 134 and 135; (s) SEQ ID NOs: 154 and 155; (t) SEQ ID NOs: 136 and 137; and (u) SEQ ID NOs: 138 and 139.

[00282] In various embodiments, the antigen-binding protein comprises (a) a heavy chain variable region amino acid sequence set forth in in Table B1 or C or a sequence selected from the group consisting of: SEQ ID NOs: 376-379, 384-387, 391-396, 403-408, 412, 413, 416-419, 422-427, 478, 480, 482, 484, 486, and 488 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70%, or about 80%, or about 90%, or about 95% sequence identity; or (b) a light chain variable region amino acid sequence set forth in Table B1 or C or a sequence selected from the group consisting of: SEQ ID NOs: 380-383, 388-390, 397-402, 409-411, 414, 415, 420, 421, and 479, 481, 483, 485, 487, and 489 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70%, or about 80%, or about 90%, or about 95% sequence identity; or (c) both (a) and (b). In various aspects, the antigen-binding protein comprises a pair of amino acid sequences as listed in Table D.

[00283] The present disclosure provides an antigen-binding protein comprising: (A) an HC CDR1 comprising the amino acid sequence of YTFTXYT, wherein X is T, V, D, or S (SEQ ID NO: 452), optionally, comprising the amino acid sequence of YTFTTYT (SEQ ID NO: 11); (B) an HC CDR2 comprising the amino acid sequence of IXPSSGYT, wherein X is Q, S, A, or N (SEQ ID NO: 475), optionally, comprising the amino acid sequence of INPSSGYT (SEQ ID NO: 12); (C) an HC CDR3 comprising the amino acid sequence of AXGDYYVAY, wherein X is N, Q, H, or D (SEQ ID NO: 453), optionally, comprising the amino acid sequence of ANGDYYVAY (SEQ ID NO:13); (D) an LC CDR1 comprising the amino acid sequence of SSVSSXY, wherein X is T, V, F, or D (SEQ ID NO: 449), optionally, comprising the amino acid sequence of SSVSSTY (SEQ ID NO: 8); (E) an LC CDR2 comprising the amino acid sequence of XTX, wherein X at position 1 is S, T, Q, or A and X at position 3 is S, T, D, or Q (SEQ ID NO: 450), optionally, comprising the amino acid sequence of STS (SEQ ID NO: 9); and (F) an LC CDR3 comprising the amino acid sequence of HXYXRSPLT, wherein X at position 2 is Q, H, or S and X at position 4 is H, Y, Q, or S (SEQ ID NO: 451), optionally, comprising the amino acid sequence of HQYHRSPLT (SEQ ID NO: 10).

[00284] An antigen-binding protein comprising: (A) an HC CDR1 comprising the amino acid sequence of FTFSXYX, wherein X at position 5 is N, S, R, Q, or A and X at position 7 is W, H, Y, F (SEQ ID NO: 455), optionally, comprising the amino acid sequence of FTFSNYW (SEQ ID NO: 23); (B) an HC CDR2 comprising the amino acid sequence of IRLKXDXYAT, wherein X at position 5 is S, N, A, or T and X at position 7 is Q, S, A, N (SEQ ID NO: 456), optionally, comprising the amino acid sequence of IRLKSDNYAT (SEQ ID NO: 24); (C) an HC CDR3 comprising the amino acid sequence of XDGPPSGX, wherein X at position 1 is N, D, or T and X at position 8 is S, T, A, C, or Y (SEQ ID NO: 457), optionally, comprising the amino acid sequence of NDGPPSGC (SEQ ID NO: 25); (D) an LC CDR1 comprising the amino acid sequence of EXIYSY, wherein X is Q, S, A, D, or N (SEQ ID NO: 476), optionally, comprising the amino acid sequence of ENIYSY (SEQ ID NO: 20); (E) an LC CDR2 comprising the amino acid sequence of XAK, wherein X at position 1 is Q, S, A, D, or N (SEQ ID NO: 477), optionally, comprising the amino acid sequence of NAK (SEQ ID NO: 21); and (F) an LC CDR3 comprising the amino acid sequence of QXHYXVPWT, wherein X at position 2 is H, Q, S, or T and X at position 5 is T, S, N, or G (SEQ ID NO: 454), optionally, comprising the amino acid sequence of QHHYTVPWT (SEQ ID NO: 22).

[00285] An antigen-binding protein comprising: (A) an HC CDR1 comprising the amino acid sequence of YTXTXYT, wherein X at position 3 is F, Y, S, or T and X at position 5 is S, T, Y, or D (SEQ ID NO: 461), optionally, comprising the amino acid sequence of YTFTSYT (SEQ ID NO: 29); (B) an HC CDR2 comprising the amino acid sequence of IXPSSXYT, wherein X at position 2 is Q, S, A, or N and X at position 6 is T, S, V, D, or G (SEQ ID NO: 462), optionally, comprising the amino acid sequence of INPSSTYT (SEQ ID NO: 30); (C) an HC CDR3 comprising the amino acid sequence of XRGEXGGFAY, wherein X at position 1 is S, A, T, or V and X at position 5 is L, V, or F (SEQ ID NO: 463), optionally, comprising the amino acid sequence of SRGELGGFAY (SEQ ID NO: 31); (D) an LC CDR1 comprising the amino acid sequence of QSLVHSXGXTY, wherein X at position 7 is D, N, E, Q, S, or A and X at position 9 is Q, S, A, D, or N (SEQ ID NO: 458), optionally, comprising the amino acid sequence of QSLVHSDGNTY (SEQ ID NO: 26); (E) an LC CDR2 comprising the amino acid sequence of XVX, wherein X at position 1 is K, Q, or R and X at position 3 is S, T, or V (SEQ ID NO: 459), optionally, comprising the amino acid sequence of KVS (SEQ ID NO: 27); and (F) an LC CDR3 comprising the amino acid sequence of SXXTHVPYT, wherein X at position 2 is Q, H, or T and X at position 3 is S, G, T, or D (SEQ ID NO: 460), optionally, comprising the amino acid sequence of SQSTHVPYT (SEQ ID NO: 28).

[00286] In various embodiments, the antigen-binding protein comprises:

(a) a heavy chain CDR1 amino acid sequence of: SEQ ID NO: 504 or SEQ ID NO: 507, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;

(b) a heavy chain CDR2 amino acid sequence of: SEQ ID NOs: 505 or SEQ ID NO: 508, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;

(c) a heavy chain CDR3 amino acid sequence of: SEQ ID NO: 506 or SEQ ID NO: 509, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;

(d) a light chain CDR1 amino acid sequence of: SEQ ID NO: 449 or SEQ ID NO: 476, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;

(e) a light chain CDR2 amino acid sequence of: SEQ ID NO: 450 or SEQ ID NO: 477, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
(f) a light chain CDR3 amino acid sequence of: SEQ ID NO: 451 or SEQ ID NO: 454, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
(g) a combination of any two or more of (a)-(f).

[00287] Optionally, the variant sequence has at least about 80%, at least or about 85%, at least or about 90% or at least or about 95% sequence identity.

[00288] In exemplary aspects, the antigen-binding protein comprises a light chain CDR1 amino acid sequence of SEQ ID NO: 449, a light chain CDR2 amino acid sequence or SEQ ID NO: 450, and a light chain CDR3 amino acid sequence or SEQ ID NO: 451 and one or two of a heavy chain CDR1 amino acid sequence of SEQ ID NO: 504, a heavy chain CDR2 amino acid sequence or SEQ ID NO: 505, and a heavy chain CDR3 amino acid sequence or SEQ ID NO: 506. In various instances, the antigen-binding protein comprises a light chain CDR1 amino acid sequence of SEQ ID NO: 476, a light chain CDR2 amino acid sequence or SEQ ID NO: 477, and a light chain CDR3 amino acid sequence or SEQ ID NO: 454 and one or two of a heavy chain CDR1 amino acid sequence of SEQ ID NO: 507, a heavy chain CDR2 amino acid sequence or SEQ ID NO: 508, and a heavy chain CDR3 amino acid sequence or SEQ ID NO: 509. Optionally, the antigen-binding protein of comprises six CDR amino acid sequences selected from the group consisting of: SEQ ID NOs: 449-451 and 504-506; and SEQ ID NOs: 476, 477, 454 and 507-509.

[00289] In exemplary aspects, the antigen-binding protein comprises: (a) a heavy chain variable region amino acid sequence of any one of SEQ ID NOs: 490-503, or a heavy chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or (b) a light chain variable region amino acid sequence of any one of SEQ ID NOs: 380-383, 388-390, 479, and 481, or a light chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or (c) both (a) and (b). In some aspects, the variant sequence has at least about 80% or at least about 85%

sequence identity, or the variant sequence has at least about 90% or at least about 95% sequence identity.

[00290] In exemplary instances, the antigen-binding protein comprises a pair of amino acid sequences:

SEQ ID NOs: 389 and 490;
SEQ ID NOs: 389 and 491;
SEQ ID NOs: 389 and 492;
SEQ ID NOs: 389 and 493;
SEQ ID NOs: 389 and 494;
SEQ ID NOs: 389 and 495;
SEQ ID NOs: 383 and 496;
SEQ ID NOs: 383 and 497;
SEQ ID NOs: 383 and 498;
SEQ ID NOs: 383 and 499;
SEQ ID NOs: 383 and 500;
SEQ ID NOs: 383 and 501;
SEQ ID NOs: 383 and 503;
SEQ ID NOs: 389 and 502;
the heavy chain variable region sequence labeled as S1 in FIG. 22 and the light chain variable region sequence labeled as S1 in FIG. 22;
the heavy chain variable region sequence labeled as S2 in FIG. 22 and the light chain variable region sequence labeled as S2 in FIG. 22;
the heavy chain variable region sequence labeled as S3 in FIG. 22 and the light chain variable region sequence labeled as S3 in FIG. 22;
the heavy chain variable region sequence labeled as S4 in FIG. 22 and the light chain variable region sequence labeled as S4 in FIG. 22;
the heavy chain variable region sequence labeled as S5 in FIG. 22 and the light chain variable region sequence labeled as S5 in FIG. 22;
the heavy chain variable region sequence labeled as S6 in FIG. 22 and the light chain variable region sequence labeled as S6 in FIG. 22;
the heavy chain variable region sequence labeled as S7 in FIG. 22 and the light chain variable region sequence labeled as S7 in FIG. 22;

the heavy chain variable region sequence labeled as S78 in FIG. 22 and the light chain variable region sequence labeled as S8 in FIG. 22;
the heavy chain variable region sequence labeled as S89 in FIG. 22 and the light chain variable region sequence labeled as S9 in FIG. 22;
the heavy chain variable region sequence labeled as S910 in FIG. 22 and the light chain variable region sequence labeled as S10 in FIG. 22;
the heavy chain variable region sequence labeled as S11 in FIG. 22 and the light chain variable region sequence labeled as S11 in FIG. 22; or
the heavy chain variable region sequence labeled as S12 in FIG. 22 and the light chain variable region sequence labeled as S12 in FIG. 22.

[00291] In some aspects, the antigen-binding protein is an antibody, e.g., monoclonal antibody. In various aspects, antibody is an IgG. Optionally, the antigen-binding protein inhibits at least about 50% colony growth in a soft agar 3D proliferation assays, inhibits tumor growth in xenograft mice injected with human cancer cells, inhibits tumor growth of in xenograft mice injected with ovarian cancer cells, melanoma cancer cells, bladder cancer cells, or endometrial cancer cells, or inhibits at least 50% tumor growth in xenograft mice injected with ovarian cancer cells, bladder cancer cells, or endometrial cancer cells.

[00292] Accordingly, the various embodiments, the present disclosure provides an antigen-binding protein comprising

(a) a heavy chain CDR1 amino acid sequence of: SEQ ID NO: 504 or SEQ ID NO: 507, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
(b) a heavy chain CDR2 amino acid sequence of: SEQ ID NOs: 505 or SEQ ID NO: 508, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
(c) a heavy chain CDR3 amino acid sequence of: SEQ ID NO: 506 or SEQ ID NO: 509, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
(d) a light chain CDR1 amino acid sequence of: SEQ ID NO: 449 or SEQ ID NO: 476, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;

(e) a light chain CDR2 amino acid sequence of: SEQ ID NO: 450 or SEQ ID NO: 477, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;

(f) a light chain CDR3 amino acid sequence of: SEQ ID NO: 451 or SEQ ID NO: 454, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or

(g) a combination of any two or more of (a)-(f).

[00293] Also provided is an antigen-binding protein comprising six CDR amino acid sequences selected from the group consisting of: SEQ ID NOs: 449-451 and 504-506; and SEQ ID NOs: 476, 477, 454 and 507-509.

[00294] The present disclosure provides an antigen-binding protein comprising:

(a) a heavy chain variable region amino acid sequence of any one of SEQ ID NOs: 490-503, or a heavy chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or

(b) a light chain variable region amino acid sequence of any one of SEQ ID NOs: 380-383, 388-390, 479, and 481, or a light chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or

(c) both (a) and (b).

[00295] In various aspects, the variant sequence has at least about 85% sequence identity or about 90% or about 95% sequence identity.

[00296] The present disclosure also provides an antigen-binding protein comprising a pair of amino acid sequences selected from the group consisting of:

SEQ ID NOs: 389 and 490;

SEQ ID NOs: 389 and 491;

SEQ ID NOs: 389 and 492;

SEQ ID NOs: 389 and 493;

SEQ ID NOs: 389 and 494;

SEQ ID NOs: 389 and 495;

SEQ ID NOs: 383 and 496;

SEQ ID NOs: 383 and 497;

SEQ ID NOs: 383 and 498;

SEQ ID NOs: 383 and 499;

SEQ ID NOs: 383 and 500;

SEQ ID NOs: 383 and 501;

SEQ ID NOs: 383 and 503;

SEQ ID NOs: 389 and 502;

the heavy chain variable region sequence labeled as S1 in FIG. 22 and the light chain variable region sequence labeled as S1 in FIG. 22;

the heavy chain variable region sequence labeled as S2 in FIG. 22 and the light chain variable region sequence labeled as S2 in FIG. 22;

the heavy chain variable region sequence labeled as S3 in FIG. 22 and the light chain variable region sequence labeled as S3 in FIG. 22;

the heavy chain variable region sequence labeled as S4 in FIG. 22 and the light chain variable region sequence labeled as S4 in FIG. 22;

the heavy chain variable region sequence labeled as S5 in FIG. 22 and the light chain variable region sequence labeled as S5 in FIG. 22;

the heavy chain variable region sequence labeled as S6 in FIG. 22 and the light chain variable region sequence labeled as S6 in FIG. 22;

the heavy chain variable region sequence labeled as S7 in FIG. 22 and the light chain variable region sequence labeled as S7 in FIG. 22;

the heavy chain variable region sequence labeled as S78 in FIG. 22 and the light chain variable region sequence labeled as S8 in FIG. 22;

the heavy chain variable region sequence labeled as S89 in FIG. 22 and the light chain variable region sequence labeled as S9 in FIG. 22;

the heavy chain variable region sequence labeled as S910 in FIG. 22 and the light chain variable region sequence labeled as S10 in FIG. 22;

the heavy chain variable region sequence labeled as S11 in FIG. 22 and the light chain variable region sequence labeled as S11 in FIG. 22; or

the heavy chain variable region sequence labeled as S12 in FIG. 22 and the light chain variable region sequence labeled as S12 in FIG. 22.

[00297] Provided herein is an antigen-binding protein comprising:

(a) a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 510 or 513 or in FIG. 23 or FIG. 25, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or

(b) a light chain variable region amino acid sequence set forth as SEQ ID NO: 511 or 512 or in FIG. 24 or FIG. 26, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or

(c) both (a) and (b).

[00298] The present disclosure also provides an antigen-binding protein comprising a pair of amino acid sequences wherein the pair comprises

(a) a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 510 and a light chain variable region amino acid sequence set forth as SEQ ID NO: 511, or a variant sequence thereof which differs by only 1-5 amino acids or which has at least or about 70% sequence identity; optionally, wherein the 1-5 amino acids which differ are as shown in FIG. 23 for the heavy chain or FIG. 24 for the light chain, or

(b) a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 513 and a light chain variable region amino acid sequence set forth as SEQ ID NO: 512, or a variant sequence thereof which differs by only 1-5 amino acids or which has at least or about 70% sequence identity; or optionally, wherein the 1-5 amino acids which differ are as shown in FIG. 25 for the heavy chain or FIG. 26 for the light chain.

[00299] In various aspects, the presently disclosed antigen-binding protein comprises an Fc polypeptide comprising an afucosylated glycan.

[00300] In various aspects, the antigen-binding protein of the present disclosure is an antibody, e.g., a monoclonal antibody. In various instances, the antigen-binding protein is an IgG. In various aspects, the antigen-binding protein inhibits at least about 50% colony growth in a soft agar 3D proliferation assays or inhibits tumor growth in xenograft mice injected with human cancer cells. In various aspects, the antigen-binding protein inhibits tumor growth of in xenograft mice injected with ovarian cancer cells, melanoma cancer cells, bladder cancer cells, or endometrial cancer cells. In various instances, the antigen-

binding protein inhibits at least 50% tumor growth in xenograft mice injected with ovarian cancer cells, bladder cancer cells, or endometrial cancer cells.

[00301] The present disclosure provides a conjugate comprising an antigen-binding protein described herein and a heterologous moiety. In exemplary aspects, the conjugate comprises a cytotoxic agent or a chemotherapeutic agent, such as, for example, any of those described herein. The chemotherapeutic agent in various aspects is an anti-mitotic agent which inhibits cell division by blocking tubulin polymerization. In some instances, the anti-mitotic agent is an auristatin, optionally, MMAE.

[00302] The present disclosure also provides a fusion protein comprising an antigen-binding protein described herein. The present disclosure further provides a nucleic acid comprising a nucleotide sequence encoding an antigen binding protein, a conjugate, or a fusion protein, of the present disclosure. The present disclosure provides a vector comprising the nucleic acid comprising a nucleotide sequence encoding an antigen binding protein, a conjugate, or a fusion protein, of the present disclosure. The present disclosure additionally provides a host cell comprising the nucleic acid or the vector of the present disclosure.

[00303] The present disclosure provides a method of producing an antigen-binding protein that binds to a Claudin6 (CLDN6) protein, comprising (i) culturing the host cell of the present disclosure in a cell culture medium, wherein the host cell comprises a nucleic acid comprising a nucleotide sequence encoding an antigen binding protein of any one of the previous claims, and (ii) harvesting the antigen-binding protein from the cell culture medium. Also, provided is a method of producing a fusion protein comprising an antigen-binding protein that binds to a Claudin6 (CLDN6) protein, comprising (i) culturing the host cell of the present disclosure in a cell culture medium, wherein the host cell comprises a nucleic acid comprising a nucleotide sequence encoding a fusion protein of the present disclosure, and (ii) harvesting the fusion protein from the cell culture medium.

[00304] The present disclosure furthermore provides a method of producing a pharmaceutical composition comprising combining an antigen-binding protein, a conjugate, a fusion protein, a nucleic acid, a vector, a host cell, of the present disclosure, or a combination thereof, and a pharmaceutically acceptable carrier, diluent or excipient. Also provided are pharmaceutical compositions comprising antigen-binding protein, a conjugate,

a fusion protein, a nucleic acid, a vector, a host cell, of the present disclosure, or a combination thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

[00305] Provided herein is a method of treating a subject with a CLDN6-expressing cancer comprising administering to the subject a pharmaceutical composition described herein in an amount effective to treat the cancer. Also provided is a method of inhibiting tumor growth in a subject, comprising administering to the subject a pharmaceutical composition described herein in an amount effective to inhibit tumor growth. The present disclosure provides a method of reducing tumor size in a subject, comprising administering to the subject a pharmaceutical composition described herein in an amount effective to reduce tumor size. Further provided is a method of preventing the recurrence of cancer in a subject, comprising administering to the subject a pharmaceutical composition described herein in an amount effective to prevent the recurrence of cancer.

[00306] The present disclosure provides a method of detecting Claudin6 (CLDN6) in a sample, comprising contacting the sample with an antigen-binding protein, a conjugate, or a fusion protein, of the present disclosure, and assaying for an immunocomplex comprising the antigen-binding protein, conjugate or fusion protein bound to CLDN6. Also provided herein is a method of diagnosing a Claudin6 (CLDN6)-positive cancer in a subject, comprising contacting a biological sample comprising cells or tissue obtained from the subject with an antigen-binding protein, a conjugate, or a fusion protein, of the present disclosure, and assaying for an immunocomplex comprising the antigen-binding protein, conjugate or fusion protein bound to CLDN6.

[00307] The present disclosure also provides a method of treating cancer in a subject diagnosed to be a low over-expresser of CLDN6. In various embodiments, the method comprises administering to the subject a presently disclosed pharmaceutical composition in an amount effective to prevent the recurrence of cancer. In some aspects, the administering induces apoptosis in tumor cells, optionally, the administering induces apoptosis in cells expressing CLDN6. In various aspects, the subject has a tumor and the tumor is semi-quantitatively categorized into one of four groups: high expressers, moderate expressers, low expressers, and non-expressers. In various instances, high expressers are defined as CLDN6 RNA greater than 12 log Fragments Per Kilobase Million (FPKM), wherein the CLDN6 RNA is measured by RNASeq, or CLDN6 protein levels are greater than 3+ as measured by immunohistochemistry (IHC). In various instances, moderate expressers are

defined as CLDN6 RNA greater than 10 log FPKM, wherein the CLDN6 RNA is measured by RNASeq, or CLDN6 protein levels are greater than 2+ as measured by IHC. In various instances, low expressers are defined as CLDN6 RNA greater than 6 log FPKM, wherein the CLDN6 RNA is measured by RNASeq, or CLDN6 protein levels are greater than 1+ as measured by IHC. In various instances, non-expressers are defined as CLDN6 RNA less than than 6 log FPKM, wherein the CLDN6 RNA is measured by RNASeq, or CLDN6 protein levels are below IHC detection limits. In various aspects, the subject having said tumor is likewise described as a high expresser, moderate expresser, low expresser, or non-expresser of CLDN6.

[00308] The following examples are given merely to illustrate the present disclosure and not in any way to limit its scope.

EXAMPLES

EXAMPLE 1

[00309] This example demonstrates an analysis of CLDN6 RNA levels in different cell and tissue sources.

[00310] In order to establish a baseline for expression of CLDN6 in different source materials, expression levels of CLDN6 expression in patient samples, normal tissue and cell lines created by the Translational Oncology Research laboratory (TORL) were assayed.

[00311] Levels of CLDN6 RNA in patient samples were measured using information contained in The Cancer Genome Atlas (TCGA) database managed by the National Cancer Institute (NCI). CLDN6 levels in normal tissue were measured using information in the Genotype-Tissue Expression (GTEX) database maintained by the Common Fund. The analysis of tissues from the GTEX database showed that CLDN6 is detectable in various sites, including the brain, pituitary, pancreas, kidney, lung, thyroid, and cervix, among other tissues (FIG. 1).

[00312] CLDN6 expression levels were measured in TORL cancer cell lines using Agilent 44K microarrays (4x44K array chip, Agilent Technologies, Santa Clara, CA) and RNA sequencing (RNA-Seq) assays. RNASeq was performed by BGI Americas (Cambridge, MA) using their "RNASeq for quantification" service. As shown in FIG. 2 and FIG. 3, ovarian, head and neck, lung, and bladder cancer cells expressed the highest

levels of CLDN6, though CLDN6 expression levels were detectable in breast, kidney, colon, sarcoma and liver cancer cells.

EXAMPLE 2

[00313] This example demonstrates the production of cells engineered to overexpress CLDN6.

[00314] Models engineered to overexpress CLDN6 were generated. These models were used to determine the efficacy of CLDN6 antibodies described in Example 5. Briefly, a nucleotide sequence encoding CLDN6 was engineered into a bicistronic vector having a CMV promoter and an attenuated Internal ribosome entry site (IRES) of encephalomyocarditis virus (EMCV). The IRES was located between the Gene of Interest (GOI) cDNA (CLDN6) and puromycin cDNA. A woodchuck posttranscriptional regulatory element (WPRE) was located downstream of the puromycin cDNA. The vector also expressed either a GFP marker sequence or a MycDDK tag. The sequence of the expression vector containing GFP is provided herein as SEQ ID NO: 189.

[00315] The expression vector was virally transduced into HEK293T cells (for screening purposes) and NIH3T3 cells (for immunizations). Positively transduced cells were selected based on survival in medium containing puromycin (1 μg/ml). The positive cells were subcloned to obtain a stable, uniform, clonal population of CLDN6 overexpressing cells.

[00316] Subclone CLDN6 expression was confirmed by flow cytometry using a reference CLDN6 monoclonal antibody (mAb) on a BD Biosciences Accuri™ flow cytometer (San Jose, CA). Secondary antibody and conjugate: Alexa Fluor® 647 Goat anti-mouse IgG (minimal x-reactivity) antibody (Biolegend, San Diego, CA; Cat#405322) was used to detect binding activity between the reference CLDN6 mAb and the CLDN6 expressed by subclone.

[00317] Cellular localization of CLDN6 was determined by fluorescence microscopy using the Cellavista® imaging system (Synentec (Mountain View, CA) with cells expressing a CLDN6-green fluorescence protein (GFP) fusion protein. As shown in FIG. 4, fluorescence of the GFP was detected in the cell membrane, evidencing that CLDN6 localizes to the cell membrane.

EXAMPLE 3

[00318] This example demonstrates the production of reference and control antibodies.

[00319] Benchmark (reference) CLDN6-specific antibodies and control antibodies were made by cloning the antibody heavy and light chain variable regions into the ExpiCHO™ expression system (ThermoFisher Scientific, Waltham, MA) to produce recombinant mouse IgG2A chimeric antibodies. These antibodies were tested alongside newly generated CLDN6 specific antibodies described in Example 5.

[00320] Briefly, plasmids containing the control and benchmark antibody sequences were transfected using the ExpiCHO™ Expression System (Catalog Number: A29133, ThermoFisher Scientific, USA) according to the manufacturer's protocol. The cells were cultured at 37° C and 8% CO_2 at day 1 and then at 32° C and 5% CO_2 post-transfection in media provided in the kit. Antibodies were purified by clarifying the ExpiCHO™ culture medium by centrifugation at 1,000g for 10 min followed by 5,000g for 30 min. The supernatant was then filtered using a 0.45μm filter followed by a 0.22μm filter. Subsequently, the supernatant was subjected to affinity purification using protein A/G resins (Life Technologies, Carlsbad, CA; Catalog# 20424) according to the manufacturer's protocol. Prior to ELISA purification, antibody titer in the culture medium was roughly determined to ensure the amount of medium loaded occupied less than 80% of the resin binding capacity. After incubation, the resins were washed with PBS and eluted with Elution Buffer (Life Technologies, Catalog# 21004). The elution fractions were immediately adjusted to physiologic pH by adding Tris Buffer, pH8.0. The purified antibodies were subsequently subjected to buffer exchange and protein concentration using Amicon Ultra-15 Centrifugal Filter Unit (Life Technologies, Catalog# UFC900324) in PBS buffer. Antibody concentration was determined by BCA Protein Assay. SDS-PAGE and Coomassie-staining were carried out to test the antibody purity. The purified protein was aliquoted and stored at -80°C for long time storage or kept at 4°C for immediate use.

[00321] The integrity of the antibody was validated by SDS-PAGE followed by Coomassie staining under non-reducing vs reducing conditions; under non-reducing condition, one dominating band around 150 kDa, whereas under reducing conditions, two bands were observed, 50 kDa and 25 kDa.

[00322] Antibodies specific for other CLDN family members having sequence similarity (FIG. 5), namely, CLDN3, CLDN4, and CLDN9 were produced in essentially the same manner, except that the antibody sequences contained in the plasmids were antibody sequences specific to CLDN3, CLDN4, or CLDN9.

EXAMPLE 4

[00323] This example demonstrates the characterization of cell lines with high endogenous CLDN6 expression.

[00324] A panel of cancer cell lines was analyzed for their endogenous expression of CLDN6 by FACS and Western blot. Briefly, the binding of antibodies to targets were validated by FACS using cells overexpressing CLDN6 (e.g., HEK293T cells overexpressing CLDN6, described in Example 2), and cell lines that endogenously express CLDN6 at high or low levels, as determined in Example 1. The CLDN6-expressing cells were incubated with reference or control antibodies (described in Example 3) for 30 min on ice, and, after washing, incubated with Alexa Fluor® 647 conjugated Goat anti-mouseIgG (minimal x-reactivity) antibody, Biolegend cat#405322 for 30 min on ice. Fluorescence was read by a BD Biosciences Accuri™ flow cytometer (San Jose, CA).

[00325] Western blots were carried out on nitrocellulose with reference and control antibodies. Briefly, samples from cell lysates were boiled to denature protein content. SDS-PAGE (SDS-polyacrylamide gel electrophoresis) was used to separate the denatured proteins by the length of the polypeptide. Separated proteins were then transferred from the acrylamide gel to a nitrocellulose membrane. A 2% Bovine Serum Albumin (BSA) solution was used to block the membrane, minimizing non-specific antibody binding. The membrane was incubated with reference or control antibodies. The membrane was stained with a horseradish peroxidase (HRP)-conjugated secondary antibody that recognizes the reference or control antibodies and detection of secondary antibody was via chemiluminescence.

[00326] The overexpressed lines were used to validate the control and reference antibodies, and, once validated, the control and reference antibodies were used to characterize the endogenous cell lines. The cells overexpressing CLDN6 were included as positive controls in these assays.

[00327] The FACS assays showed that four ovarian cancer cell lines, in addition to an endometrial cancer cell line, bladder cancer cell line, lung cancer cell line, and upper GI cancer cell line, express CLDN6 on the surface at high levels. The high levels of CLDN6 expression was also detected by Western blot. An additional two ovarian cancer cell lines, an additional liver cancer cell line, additional lung cancer cell line, and additional upper GI cancer cell line were shown to express CLDN6 to a moderate level on the surface, as

detected by Western blot. Endometrial tumor cells and bladder tumor cells also expressed high levels of CLDN6 as xenografts *in vivo*. Endogenous expression levels of CLDN6 by the tested cancer cells lines are summarized in Table 2.

TABLE 2

Cell_Line_Name	Primary Histology	CLDN6 RNASeq	Group	Surface Expression by FACS	Protein Expression by WB (Cell Lines)	Protein Expression by WB (xenograft)	Tumorigenic Sub Q	Tumorigenic IP (Nude)	Tumorigenic IP (SCID)
OVCA429	Ovarian	393.99	Pos Con	++++	++++		No	Slow	TBD
ARK2	Endometrial	335.06	Pos Con	++++	++++	+++	Yes		
OAW28	Ovarian	273.78	Pos Con	++++	++++		No	TBD	TBD
UMUC-4	Bladder	242.93	Pos Con	++++	++++	++	Yes	Slow	TBD
PEO14	Ovarian	196.63	Pos Con	++++	+++		No	TBD	TBD
OV177	Ovarian	195.53	Pos Con	++++	+		No	TBD	TBD
H1693	Lung	184.12	Pos Con	++++	+++		TBD		
MKN7	Upper GI	118.6	Pos Con	+++	++		TBD		
OV-90	Ovarian	108.23	Pos Con	++	++	+	Yes		
HUH-7	Liver	93.52	Pos Con	++	+		Yes		
JHOS-4	Ovarian	69.3	Pos Con	++	+		No	TBD	TBD
H1435	Lung	42.8	Pos Con	++	+/-		TBD		
NUGC 3	Upper GI	41.11	Pos Con	++	++	+	Yes		
RMG-1	Ovarian	0.63	Neg Con	-	-	-	Yes	TBD	TBD
COLO704	Ovarian	0.44	Neg Con	-	-	-	Yes	TBD	TBD
MCF-7	Breast	0	Neg Con	-	-	-	Yes		
LS513	Colon	0	Neg Con	-	-	-	Yes		
M202	Melanoma	0	Neg Con	-	-	-	Yes		
M275	Melanoma	0	Neg Con	-	-		Yes		
KOC-7C	Ovarian	0	Neg Con	-	-	-	Yes	Yes	TBD

EXAMPLE 5

[00328] This example demonstrates the immunization of mice for the production of CLDN6 specific antibodies.

[00329] CLDN6-specific antibodies were produced by immunizing Balb/c and CD1 mice with a mixture of three different peptide immunogens following techniques of the Fred Hutchinson Cancer Research Center. The three peptides spanned the second loop in the

CLDN6 extracellular domain (i.e., EL2). The peptides include the full length of EL2, a peptide spanning the first (N-terminal) half of EL2, and a peptide spanning the second (C-terminal) half of EL2. Table 3 provides the sequences of the three peptides.

TABLE 3

Peptide Immunogen	EL2	SEQ ID NO:
Ac-CWTAHAIIRDFYNPLVAEAQKREL-amide	Full length EL2	2
Ac-CTAHAIIRDFYNPL-amide	N-terminal half	3
Ac-LVAEAQKRELGC-amide	C-terminal half	4

[00330] Mice also were immunized with 3T3 cells overexpressing full length CLDN6 using a plasmid comprising a human CLDN6-myc-DDK expression vector.

[00331] Splenocytes were harvested from the immunized mice and fused with myeloma lines by BTX Electrofusion (BTX, Holliston, MA) to generate hydridomas. 7680 primary hybridoma cultures were generated and cultured in 384-well plates. The ability of the antibodies to bind peptide was assessed by bead array using beads expressing the three different peptides targets. 1920 potential positive antibodies were re-arrayed into 96 well plates further screened by flow cytometry against endogenous and artificial cell line models.

[00332] Positive hybridoma supernatants were then counter-screened by flow cytometry against endogenous and artificial models of proteins that have sequence similarity to the target region (e.g., other CLDN proteins). From the secondary screen and counterscreen, ~20 CLDN6-specfic antibodies were chosen for additional study. These antibodies were subcloned and the variable heavy and light chain sequences were determined. See Table B and sequence listing.

[00333] CLDN6 antibodies were formatted as full-length IgG antibodies using ExpiCHO™ expression. The heavy and light chain variable regions of the antibodies were cloned into an antibody expression vector which was engineered in the lab based on a pcDNA™3.4-TOPO® vector (Catalog Number: A14697, ThermoFisher Scientific, USA) and transfected into CHO cells by (According to protocol provided in the kit (ExpiCHO™ Expression System, Catalog Number: A29133, ThermoFisher Scientific, USA)). Antibodies were purified and cell surface binding of the antibodies to CLDN6 and the

antibody IC50 were determined by FACS in which CLDN6 antibodies were directly conjugated with Alexa Fluor® 647 NHS Ester (Succinimidyl Ester), Cat# A20106 (ThermoFisher Scientific) following the manufacturer's protocol. CLDN6 antibodies were tested from 0.32nM to 1000 nM (serial dilution 1:5, 6 points) in a 50µl volume with 150,000 cells system.

[00334] CLDN6-expressing cells were used in FACS assays to determine the CLDN6 antibody's ability to bind to CLDN6 on the surface of cells and to cross-react with other CLDN family members. HEK293 T cells engineered to express human CLDN6 fused to GFP, mouse CLDN6 fused to GFP, CLDN9-GFP, CLDN4-GFP, or CLDN3-GFP, or GFP alone (without CLDN6) were used as artificial models of CLDN6 expression. ARK2, OVCA429, LS513 and MCF7 cells were used as endogenous models of CLDN6 expression, as well as models for CLDN3/4 expression.

[00335] For each type of cell tested and for each mAb, cells were detached from the surface of the culture flasks by EDTA (instead of trypsin) in order to protect the cell surface proteins. The detached cells were then incubated with Alexa Fluor®-labeled CLDN6 mAbs for 30 min in the dark on ice at a pre-determined concentration. The CLDN6 mAbs were directly labeled with Alexa Fluor® 647 NHS Ester (Succinimidyl Ester). After washing, the cells were read by a BD Accuri™ Flow Cytometer C6 to detect antibody-antigen protein binding in channel FL4H. Each antibody was tested at varied concentrations to establish a dose-fluorescence curve. The EC50/IC50 of the antibodies (the concentration of the antibody at which half the max value were calculated based on the values of FL4H (gated in viable singlet cells) using the Very Simple IC50 Tool kit available online which allows biological dose-response data to be plotted and fitted to curve types to give the EC50/IC50. The max value was the lowest concentration of the antibody at which fluorescence maxes out. The antibodies were also screened for their ability to cross-react with other CLDN proteins such as CLDN9, CLDN3, and CLDN4. These values were used to determine each antibody's relative affinity among the set of antibodies tested. Cross-reactivity data were obtained using a similar methodology, but with cells having a different expression profile for CLDN6, CLDN3, CLDN4 and CLDN9.

[00336] Relative affinity data and cross-reactivity data as determined in this manner are set out in Tables 4 and 5.

TABLE 4

AB#	Rank	HEK293T-CLDN6-mGFP Artificial CLDN6+	HEK293T-CLDN6-mGFP Artificial CLDN6+ (mouse)	HEK293T CLDN9-mGFP Artificial CLDN9+	HEK293T CLDN4-mGFP Artificial CLDN4+	HEK293T CLDN3-mGFP Artificial CLDN3+	HEK293T-mGFP Parental
1	1	109	72	2765	5000	5000	5000
2	2	182	5000	5000	5000	5000	5000
3	3	604	2487	5000	5000	5000	5000
4	4	17	5000	1860	739	5000	5000
5	5	10	11	25	5000	5000	5000
6	6	1427	2222	2769	26	5000	5000
7	7	579	1548	1938	2088	5000	5000
8	8	1918	5000	2769	5000	5000	5000
9	9	2671	5000	5000	5000	5000	5000
10	10	2757	5000	246	5000	5000	5000
11	11	1696.29	2375	5000	2238	5000	5000
12	Neg	5000	5000	2468	2087	5000	5000
13	Neg	5000	5000	5000	5000	5000	5000
14	Neg	5000	5000	5000	5000	5000	5000
16	Neg	5000	5000	5000	5000	5000	5000
17	Neg	2,645.95	5000	5000	5000	5000	5000
18	Neg	5000	5000	5000	5000	5000	5000
15	Neg	5000	5000	5000	5000	5000	5000
19	Neg	5000	5000	5000	5000	5000	5000
Reference Ab2	0	122	46	5000	5000	5000	5000
Reference Ab1	0	57	651	2943	5000	5000	5000

AB# corresponds to AB# listed in Tables A and B.

TABLE 5

AB#	ARK2 Endogenous CLDN6+	OVCA429 Endogenous CLDN6+	LS513 Endogenous CLDN3/4+	MCF7 Endogenous CLDN3/4+
1	105	84	5000	5000
2	1365	912	5000	5000
3	1653	1096	5000	5000
4	48	168	730	653
5	8	5	781	1485
6	765	394	133	1135
7	353	531	635	979
8	1136	1090	1126	1063
9	1140	1165	1040	5000
10	2143	2473	1947	5000
11	362.81	834.65	492.567	427.031
12	1297	2294	2266	5000
13	1147	2287	1594	5000
14	1304	1661	1161	546
16	5000	5000	5000	5000
17	5000	5000	5000	5000
18	1,354.80	2,435.18	5000	5000
15	5000	5000	5000	5000
19	5000	5000	5000	5000
Reference Ab2	1115	1283	2222	5000
Reference Ab1	162	62	5000	5000

AB# corresponds to AB# listed in Tables A and B.

EXAMPLE 6

[00337] This example demonstrates the characterization of chimeric mouse IgG mAbs.

[00338] Soft agar 3D proliferation assays and xenograft binding assays were carried out to further characterize mAbs described in Example 5. Briefly, a 250 µL top layer mixture containing 10,000 cells in 0.6% SeaPlaque agarose in 1x RPMI medium was plated on top of a solidified 250uL bottom layer of 0.6% SeaPlaque agarose in 1x RPMI medium for each well of a 48-well plate. A 250uL liquid feeder layer containing 1x RPMI medium was placed above the solidified top layer. All three layers of the soft agar assay were prepared with or without Trastuzumab, Cldn6 mAbs, or mouse IgG2a control starting at 150ng/mL (1uM) and ending at 1.5ng/mL, diluting 1:10. Each test condition was performed in duplicates. Cells were allowed to form colonies for 3 weeks before staining with 0.05% neutral red, and imaged on the EVOS XL inverted light microscope. Cell lines with a ≥20% decrease in colony number in treated versus control were considered sensitive.

[00339] As shown in Table 6, many of cell lines exhibited a decrease in colony number when treated with the indicated antibody.

TABLE 6

	Activity in vitro 3D
Reference Ab1**	70%
Reference Ab2**	50%
AB1	50%
AB2	50%
AB3	50%
AB4	70%
AB5	70%
AB6	70%
AB7	50%
AB8	0%
AB9	0%
AB10	50%
AB11	50%
AB12	0%
AB13	50%
AB14	0%
AB19	50%
AB16	25%
AB17	0%
AB18	0%
AB19	0%

[00340] *In vivo* binding studies were carried out in xenograft mice injected with human cancer cell lines. Briefly, xenograft models of human cancer cell lines were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories). The following conditions were followed for subcutaneous injection of each cell line: ARK2 0.75×10^7, UMUC4 1.0×10^7, OV90 1.0×10^7 and M202 0.5×10^7 cells all with 50% matrigel (BD Biosciences). Sufficient numbers of mice were injected to achieve 8 mice per treatment arm. When tumors reached an average size of 150 to 300 mm^3, mice were randomized into treatment groups. For treatment, each therapeutic antibody (AB3, AB2, Reference Ab1, Reference Ab2, Reference Ab 3 (trastuzumab) and non-targeting IgG2-control were diluted in sterile saline to a working concentration of 1mg/ml for intravenous tail vein (IV) injection. For the M202 study, trametinib (DMSO-solvate, MedChem Express) was dosed

at 1.0mg/kg (10% Cremaphor, 10% PEG400) by PO on a 5 days on, 2 days off schedule for the first weekly cycle, followed by reduction to 0.5mg/kg for the remaining two weeks of dosing. Tumor xenografts were measured with calipers thrice a week, and tumor volume in mm^3 was determined by multiplying height × width × length. Mice were treated for 2-7 weeks. At the end of study, animals were euthanized and tumor tissue was excised and divided to be stored as snap-frozen or formalin fixed paraffin embedded (FFPE) tissue for biomarker analysis. All animal work was carried out under a protocol approved by IACUC and the University of California at Los Angeles Animal Research Committee. Data was analyzed using StudyLog software from StudyDirector (San Francisco, CA). Results are presented as mean volumes for each group. Error bars represent the standard error (SE) of the mean.

[00341] The results of the xenograft assays are shown in FIG. 6-FIG. 10. As shown in FIG. 6A and FIG. 6B, each of AB2 and AB3 caused a substantial mean change in tumor volume at Day 14, relative to control IgG2 antibody, in mice bearing endometrial tumors. As shown in FIG. 7A and FIG. 7B, AB3 caused a substantial mean change in tumor volume at Day 35, relative to control IgG2 antibody, in mice bearing bladder tumors. FIG. 8A and FIG. 8B show that each of AB2 and AB3 caused a substantial mean change in tumor volume at Day 20, relative to control IgG2 antibody, in mice bearing ovarian tumors. FIG. 9A and FIG. 9B demonstrates that AB3 functions in a CLDN-specific manner, since the model used in FIG. 9A and FIG. 9B did not express any of CLDN6, CLDN3, CLDN4, and CLDN9 and was, therefore, used as a negative control. The data of FIG. 9A and FIG. 9B also suggests that AB3 has less off-target activity than Reference Ab1 and Reference Ab2. FIG. 10A summarizes the results of FIG. 6-FIG. 9. As shown in FIG. 10A, AB3 significantly reduced tumor growth in mice bearing endometrial, bladder, and ovarian tumors, each of which express CLDN6, but did not reduce tumor growth in mice bearing melanoma tumors, which did not express CLDN6 (FIG. 10B). As shown in FIG. 11, the mean chain in mouse body weight during treatment did not substantially change, suggesting the safety of the treatment.

[00342] A second set of experiments were carried out in xenograft models of a human ovarian cancer cell line, OV90. Mice were injected with one of 10 mAbs described in Example 5 or with a control antibody (mouse IgG2a antibody, reference CLDN6 ab) or with a PBS vehicle control. There were 8 mice per group and each animal was

intravenously injected with 10 mg/kg antibody every 4 days. As shown in FIG. 12A and FIG. 12B, several antibodies described in Example 5 reduced tumor volume in mice bearing ovarian tumors. Among the best performers were AB3, AB4, AB7, and AB10, though all antibodies tested reduced tumor volume, relative to vehicle control. As shown in FIG. 13, the body weight of the animals treated with AB3, AB4, AB7, or AB10 did not significantly change, suggesting their safety.

EXAMPLE 7

[00343] This example demonstrates the further characterization of chimeric mouse IgG mAbs.

[00344] Internalization quantification assays were carried out. Briefly, the study of CLDN6 protein internalization triggered by Reference Ab1, AB3, or AB4 binding was performed with a positive control, ubiquitously expressed Transferrin Receptor (TfR) which is a known cell surface receptor that is internalized after antibody binding.

[00345] TfR and CLDN6 antibodies were labeled with Texas Red™-X, Succinimidyl Ester, mixed isomers, cat# T6134 (ThermoFisher Scientific). Cells were seeded in a μ-Slide 8 Well chamber (Cat# 80826, ibidi Cells In Focus Inc.) one day before the antibody treatment to allow cells to attach and grow. Cells were incubated with labeled antibodies for 30 min in dark on ice. Then the chamber containing CLDN6 or TfR labeled cells were read by Echo lab fluorescence microscope to collect images before internalization. The chamber was then incubated at 37°C for 40min to allow internalization process and images were collected again by the Echo lab fluorescence microscope. AB3 and AB4 caused a greater degree of CLDN6 internalization, compared to that caused by Reference Ab1 (Data not shown).

EXAMPLE 8

[00346] This example demonstrates the further characterization of chimeric mouse IgG mAbs.

[00347] Two-dimensional (2D) proliferation assays were carried out with select antibodies described in Example 5 as follows: Cells were seeded in duplicate at 5,000 to 20,000 cells per well in a 24-well plate. On the following day, cells were treated with six 1-5 dilutions of mAb (starting at 100 nM of either Trastuzumab, Cldn6 mAbs, or mouse IgG2A control) and a fixed concentration of 1ng/μL Monomethyl auristatin E (MMAE) -

conjugated anti-mouse secondary (Moradec, LLC) to generate dose response curves. Untreated wells of cells were quantified on Day 1, the day of antibody treatment, and later on Day 6 to determine the range of cell growth. Wells treated with mAbs were quantified on Day 6 and a growth in each treatment condition was determined as a normalized percent ratio against the growth of untreated cells. Quantification was performed on the Z1 Particle Counter (Beckman Coulter, Inc).

[00348] The results are shown in FIG. 14. AB2, AB3, AB4, and AB5 demonstrated the greatest efficacy at inhibiting proliferation. The IC50 for each of these antibodies was between 0.1 nM and 1 nM. Each of AB7, AB10, AB11, and AB15 also demonstrated the ability to inhibit proliferation in this assay, though to a lesser extent than AB2, AB3, AB4, and AB5.

EXAMPLE 9

[00349] This example demonstrates the humanization of antibodies of the present disclosures.

[00350] A subset of antibodies listed in Table A were selected for humanization analysis. The heavy chain variable (VH) and light chain variable (VL) sequences of AB1, AB3, AB4, AB9, AB11, and AB18 antibodies were compared to a library of known human germline sequences from human VH genes and human VLkappa genes (IMGT® the international ImMunoGeneTics information system® www.imgt.org; founder and director: Marie-Paule Lefranc, Montpellier, France).; the databases used were IMGT human VH genes (F+ORF, 273 germline sequences) and IMGT human VLkappa genes (F+ORF, 74 germline sequences). The acceptor human germline was chosen from those closest in sequence to the parental antibody.

[00351] Table 7 provides, for each VH and VL of each antibody, information on the human germline sequences chosen as the acceptor sequence and the human heavy chain joining region (J gene) chosen. The joining region (J gene) was chosen from human joining region sequences compiled at *IMGT® the international ImMunoGeneTics information system®* www.imgt.org *(founder and director: Marie-Paule Lefranc, Montpellier, France)*

.

TABLE 7

	Human HC germline	Human HC joining region (J gene)	Human LC germline	Human LC joining region (J gene)
AB1	IGHV1-46(allele 1)	IGHJ4(allele 1)	IGLV1-39(allele 1)	IGKJ2(allele 1)
AB3	IGHV3-23(allele 1)	IGHJ4(allele 1)	IGLV1-39(allele 1)	IGKJ2(allele 1)
AB4	IGHV1-46(allele 1)	IGHJ4(allele 1)	IGLV2-30(allele 1)	IGKJ2(allele 1)
AB9	IGHV1-46(allele 1)	IGHJ4(allele 1)	IGLV1-39(allele 1)	IGKJ2(allele 1)
AB11	IGHV3-48(allele 1)	IGHJ4(allele 1)	IGLV4-1(allele 1)	IGKJ2(allele 1)
AB18	IGHV1-46(allele 1)	IGHJ4(allele 1)	IGLV4-1(allele 1)	IGKJ2(allele 1)

[00352] CDRs were defined according to the AbM definition (see the website of Dr. Andrew C. R. Martin www.bioinf.org.uk/abs/ for a table comparing CDR definitions).

[00353] Alteration of human germline framework (i.e., non-CDR residues in VH and VL) positions to corresponding parental murine sequence might be required to optimize binding of the humanized antibody. The sequences for versions of humanized antibodies are provided as SEQ ID NOs: 376-421.

[00354] For AB1, each of Asn52 (sequential numbering) of CDR2 of the HC and Asn54 of CDR2 in the LC was determined to have a low potential for deamidation based on sequence and conformation.

[00355] For AB3, each of Asn31 (sequential numbering) of CDR1 of the HC, Asn57 of CDR2 of the HC, Asn 28 of CDR1 of LC, and Asn50 of CDR2 of the LC was determined to have a low potential for deamidation based on sequence and conformation. Trp33 of CDR1 of the HC was determined as likely solvent-exposed and to have potential for oxidation, especially under stress conditions. In CDR3 of the HC it was determined that there is a free Cys106 within the CDR that could be problematic when manufacturing the

antibody, as it is likely solvent-exposed. This Cys residue was recommended for alteration to Tyr, Ser or Ala. The maintenance of binding of these altered antibodies are tested. Ile53 of CDR2 of the LC was determined to be solvent-exposed and could lead to non-specific binding. It was suggested that this Ile residue be altered to Ser. The maintenance of binding of this altered antibody is tested.

[00356] For AB4, each of Asn52 (sequential numbering) of the CDR2 of HC and Asn58 of CDR2 of the LC was determined to have a low potential for deamidation based on sequence and conformation. The sequence DGNT in the CDR1 of the LC was determined as problematic, as it was determined to have a high potential for isoaspartate formation (at the sequence DG) as well as a potential for deamidation (at the sequence NT). This sequence was recommended for alteration.

[00357] For AB9, Asn33 (sequential numbering) in CDR1 of HC, and Asn52 and Asn59 in CDR2 of HC were determined to have a low potential for deamidation based on sequence and conformation. Asn54 was determined to have a medium potential for deamidation based on sequence and conformation. The NGG sequence in CDR2 of the HC was determined to have a high/ medium potential for deamidation followed by isoaspartate formation. Thus, it was recommended that this amino acid sequence is altered. A free Cys106 in CDR3 of the HC may be problematic when manufacturing the antibody, as it is determined as likely solvent-exposed. This Cys residue is suggested for alteration to Tyr, Ser or Ala. The maintenance of binding of these altered antibodies is tested. Arg28 in CDR1 of HC is not often found in human antibodies. This residue is altered to Thr and the maintenance of binding tested. For AB 9, Trp32 (sequential numbering) in CDR1 of the LC was determined as likely solvent-exposed and could undergo oxidation, especially under stress conditions. Leu24 of the same CDR is not often found in human antibodies. This residue is altered to Arg and maintenance of binding is tested.

[00358] For AB11, Asp54-Ser55 (sequential numbering) in CDR2 of the HC was determined as having a low potential for isoaspartate formation. Asn57 in CDR2 of the LC was determined as having a low potential for deamidation based on sequence and conformation.

[00359] For AB18, Asn33 and CDR-H2 Asn50 (sequential numbering) in CDR1 of the HC was determined as having a low potential for deamidation based on sequence and conformation. In CDR2 of the HC, the Asp-Pro (DP) sequence was determined as having a

potential for undergoing fragmentation under acidic conditions. In the VL domain, Asn34 and Asn37 in the CDR1 of the LC was determined as having a low potential for deamidation based on sequence and conformation. In CDR3 of the LC, Trp56 was determined as likely solvent-exposed and could undergo oxidation, especially under stress conditions.

[00360] Table 8 shows a scheme for combining the humanized VH and VL. If none of the humanized versions is equivalent to the chimeric mAb. Preferred pairs are shown in bold underlined text.

TABLE 8

Parental	Humanized Ab #	VH (SEQ ID NO:)	VL (SEQ ID NO:)
AB1	AB1-1	376	380
	AB1-2	377	380
	AB1-3	377	**381**
	AB1-4	377	**382**
	AB1-5	377	**383**
	AB1-6	**378**	**381**
AB3	AB3-1	384	h21G5-L1 (optional)
	AB3-2	**385**	**388**
	AB3-3	**385**	**389**
	AB3-4	**386**	**388**
	AB3-5	**386**	**389**
	AB3-6	387	388
	AB3-7 (also referred to as AB23)	387	389
AB4	AB4-1	391	397
	AB4-2	392	397
	AB4-3	**392**	**398**
	AB4-4	**393**	**398**
	AB4-5	**394**	**398**
	AB4-6	395	**398**
	AB4-7	396	**398**
AB9	AB9-1	403	409
	AB9-2	404	409
	AB9-3	**405**	**410**
	AB9-4	**405**	**411**

	AB9-5	406	410
	AB9-6	406	411
	AB9-7	407	410
	AB9-8	407	411
	AB9-9	408	410
	AB9-10	408	411
AB11	AB11-1	412	414
	AB11-2	**413**	**414**
	AB11-3	**413**	**415**
AB18	AB18-1	416	420
	AB18-2	417	420
	AB18-3	417	420
	AB18-4	417	421
	AB18-5	418	420
	AB18-6	418	421
	AB18-7	419	420

[00361] Humanized antibodies described in Table 8 were constructed and expressed as essentially described in Example 5. FACS assays were carried out as essentially described in Example 5 to determine relative antigen binding strengths of the humanized antibodies. Two doses (1.5 µg or 0.3 µg) of the humanized antibodies were tested for binding to either human CLDN6 or murine CLDN6 which proteins were expressed by engineered 293T clones. The results of the assays are provided in Table 9.

TABLE 9

Humanized Ab Designation	Human CLDN6 (1.5µg Ab)	Human CLDN6 (0.3µg Ab)	Mouse CLDN6
2nd Ab only	768.07	768.07	1061.72
64A-chim	224297.77	124463.44	170906.13
h64A	233932.53	93415.06	188577.77
SC27-108-chim	320381.33	150854.98	284326.77
AB1-Chim	364416.49	311923.02	513665.18
AB1-3	142182.2	141773.57	89292.21
AB1-4	197142.08	101763.71	75860.6
AB1-5	213233.57	137828.05	128498.45
AB1-6	227152.34	119699.97	77561.34
AB1-7	207009.91	79207.94	99740.72
AB1-8	209971.67	98785.97	121717.49
AB1-11	112923.25	64892.04	101386.62

AB3-chim	459373.03	267327.83	67927.47
AB3-2	395813.97	309318.89	31741.02
AB3-3	339510.79	250519.45	23038.44
AB3-4	55845.14	11641.7	1521.79
AB3-5	48550.83	13335.93	783.28
AB3-7	169209.42	105881.93	56071.82
AB3-8	151519.51	108419.64	21509.63
AB4-chim	326603.58	176289.63	3639.29
AB4-3	47760.08	14309.78	671.08
AB4-4	48975.26	14081.47	741.03
AB4-5	43385.34	16765.44	2003.95
AB4-6	29243.78	10841.68	14205.6
AB4-7	33342.17	19215.28	6635.91
AB4-8	77642.77	49310.15	4703.98
AB4-9	56854.11	37231.13	1778.41
AB4-10	77159.9	50809.2	2647.29
AB4-11	61204.92	37798.69	1227.86
AB4-12	86189.87	71121.12	1133.16
AB18-chim	135142.76	73775.39	57373.94
AB18-3	58948.59	30357.27	2512.77
AB18-4	54378.24	32424.7	4294.94
AB18-5	51871.17	29448.66	8191.13
AB18-6	58464.54	26883.47	3680.42
AB9-chim	72036.29	46694.71	6745.58
AB9-3	24649.43	9504.6	3175.17
AB9-4	34309.83	15331.51	1709.25
AB11-chim	3491.4	1671.35	5490.52
AB11-2	2557.3	1289.17	7160.15
AB11-3	2364.44	1009.7	5521.52

[00362] FACS assays were also carried out to determine relative antigen binding strengths of the humanized antibodies (at either 1.5 µg or 0.3 µg) for binding to CLDN6 as expressed by the indicated cancer cell lines. The results of the assays are provided in Table 10. 2nd Ab only was used as a negative control. 64A-chim, h64A, and SC27-108-chim were used as reference antibodies Corresponding Parental antibodies (antibodies prior to humanization) were used as controls and designated with "chim".

TABLE 10

Humanized Ab Designation	OVCA429 1.5µg	ARK2 1.5µg	ARK2 0.3µg	M202 1.5µg	M202 0.3µg
2nd Ab only	885.77	1351.21	1351.21	638.83	638.83
64A-chim	140378.55	80449.93	66518.52	1456.2	628.72
h64A	161168.87	69118.48	90346.66	3093.69	2467.63
SC27-108-chim	54987.78	25522.86	62410.85	2293.1	742.74
AB1-Chim	176836.16	51913.52	58762.01	23377.33	9426.64
AB1-3	27535.69	10776.6	2829.25	1225.78	694.08
AB1-4	34551.99	10039.46	3641.11	970.7	697.98
AB1-5	54331.07	22353.67	7494.86	869.06	684.3
AB1-6	29949.91	7743.19	2816.15	880.4	1423.53
AB1-7	44711.89	11224.28	4443.54	876.24	611.15
AB1-8	65974.83	17642.9	5805.35	583.54	1886.84
AB1-11	untested	97659.62	53926.71	5079.26	978.76
AB3-chim	138190.1	29114.68	17055.33	1120.39	843.5
AB3-2	85941.69	33618.84	14656.49	1483.17	727.98
AB3-3	88679.61	54901.39	1156.25	801.56	749.95
AB3-4	2955.8	1459.46	1315.36	839.75	563.41
AB3-5	2951.18	2909.74	1275.51	713.46	611.66
AB3-7	untested	90420.04	35995.73	7841	1742.34
AB3-8	untested	23259.52	11856.48	1903.05	952.71
AB4-chim	64796.15	38447.83	19142.38	1343.31	1007.71
AB4-3	1155.95	1522.98	1192.96	708.25	984.95
AB4-4	1203.16	1398.82	1048.05	899.25	618.43
AB4-5	1351.27	1198.66	966.62	1203.98	653.41
AB4-6	untested	9842.52	3303.34	2520.88	1281.68
AB4-7	untested	7563.59	2765.93	3322.65	1444.19
AB4-8	untested	7313.46	3118.74	1495.74	974.83
AB4-9	untested	7787.35	3058.96	1179.5	825.33
AB4-10	untested	20227.28	7212.1	1392.45	546.63
AB4-11	untested	9167.61	6392.04	895.77	549.19
AB4-12	untested	24221.65	9690.02	2015.4	1506.93
AB18-chim	25521.37	9149.19	3442.7	1048.6	895.4
AB18-3	2703.41	1210.4	1079.32	684.33	592.8
AB18-4	3220.08	1379.11	1134.22	1231.31	762.51
AB18-5	4273.83	1330.44	1313.83	1001.99	594.43
AB18-6	6753.92	1936.48	1393.53	914.2	865.43
AB9-chim	3569.69	4487.55	3508.75	1331.44	680.03
AB9-3	1257.3	1471.97	1139.54	1659.76	1111.31
AB9-4	1110.93	1553.6	1116.78	1149.55	625.38
AB11-chim	2440.63	1260.97	1315.28	973.48	610.05
AB11-2	2694.81	1937.51	1400.43	1766.07	872.68
AB11-3	2201.32	1541.47	1320.38	1134.3	940.92

"chim" is pre-humanized form of antibody.

[00363] Based on the *in vitro* antigen binding data, three humanized antibodies were selected for further testing and development. The antibodies were derived from AB1, AB3, and AB4.

[00364] *In vivo* binding studies of the humanized versions of AB1, AB3, and AB4 were carried out in xenograft mice injected with bladder cancer cell lines UMUC4, as essentially described in Example 6. Briefly, xenograft models of UMUC4 were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories). After tumors reached an average size of 150 to 300 mm^3, mice were randomized into treatment groups. Humanized antibodies were diluted in sterile saline to a working concentration of 1mg/ml for intravenous tail vein (IV) injection. Tumor xenografts were measured with calipers thrice a week, and tumor volume in mm^3 was determined by multiplying height × width × length. Mice were treated for 2-7 weeks. At the end of study, animals were euthanized and tumor tissue was excised and divided to be stored as snap-frozen or formalin fixed paraffin embedded (FFPE) tissue for biomarker analysis.

[00365] The results of the xenograft assays are shown in FIG. 15-FIG. 21. FIG. 15 shows the xenograft assay results for two versions of humanized AB3 (AB3-2 and AB3-4), wherein treatment involved 10 mg/kg administered Q4D. Controls included vehicle control (PBS), human IgG (10 mg/kg Q4D), and the murine version of AB3 (10 mg/kg Q4D). As shown in this figure, humanized AB3-4 demonstrated a decrease in tumor volume over the 35 day treatment period. FIG. 16 shows the xenograft assay results for the same treatments as the experiments shown in FIG. 15, except that two additional controls (64A MSE and a chimeric version thereof (64A-CHIM)) were carried out. As in FIG. 15, FIG. 16 shows a marked decrease in tumor volume upon treatment with humanized AB3-4.

[00366] FIG. 17 shows the xenograft assay results for humanized AB1-5. Controls included vehicle control (PBS), human IgG (10 mg/kg Q4D), and the murine version of AB1 (10 mg/kg Q4D). As shown in FIG. 17, mice treated with humanized AB1-5 demonstrated a marked decrease in tumor volume.

[00367] FIG. 18 shows the xenograft assay results for humanized AB4-3. Controls included vehicle control (PBS), human IgG (10 mg/kg Q4D), and the murine version of AB4 (10 mg/kg Q4D). Mice treated with humanized AB4-3 did not demonstrate a marked decrease in tumor volume.

[00368] FIG. 19-FIG. 21 demonstrate the results of a xenograft assay wherein all 4 humanized antibodies of FIG. 15-FIG. 18 were tested. Mouse and Chimeric versions of reference CLDN6 antibodies were used as controls. As shown in FIG. 19, mice treated with humanized AB3-4 and AB1-5 demonstrated decreases in tumor volume. FIG. 20 demonstrates tumor volume over the course of time to Day 55. The body weights of mice in the assay are shown in FIG. 21.

EXAMPLE 10

[00369] An *in silico* analysis was carried out with different sequences of AB1, AB3, and AB4. In particular, the sequences for (a) the original parental clone, (b) the closest mouse germline sequence, (c) the closest human germline sequence, and (d) the humanized sequence, for each antibody, were aligned. Amino acids believed to have undergone affinity maturation are marked with an asterisk while amino acids that differ from amino acids at that position according to antibody database information are marked with a hashtag. CDRs for each sequence are boxed. Based on this analysis, several humanized antibodies will be made having a sequence listed in TABLE 10.

TABLE 10

Parent Clone	Consensus Sequence HC	Consensus Sequence LC
AB1	422	423
AB3	424	425
AB4	426	427

[00370] Multiples antibodies having a sequence as defined by these consensus sequences are made as essentially described in Example 5 and tested *in vitro* for antigen binding via FACS (as essentially described in Example 5) and *in vivo* for the ability to decrease tumor volume in mice (as essentially described in Example 6).

EXAMPLE 11

[00371] This example describes a Next-Generation Sequencing (NGS) analysis of CLDN6 antibodies of the present disclosure.

[00372] The sequences of AB1 and AB3 were subjected to NGS analysis to identify somatic hypermutation (SHM) related variants of the heavy chain and light chain for each antibody. The NGS analysis identified points of SHM in both the heavy and light chain sequences for each antibody. The analysis revealed 1452 different heavy chain sequences and 326 different light chain sequences for AB3 and 372 different heavy chain sequences and 3081 different light chain sequences for AB1. Example results are shown in FIG. 23-FIG. 26. FIG. 23 and FIG. 24 show identified changes to heavy and light chains of a variant AB3, respectively, while FIG. 25 and FIG. 26 show identified changes to heavy and light chains of a variant AB1, respectively. Mutations in Chothia numbering are provided at the bottom of each figure.

[00373] Antibodies with NGS-identified SHM in the heavy chain were selected based on likelihood for binding involvement. Six antibodies were manufactured based on humanized AB3-7 (AB S1-S6) and six antibodies were made based on humanized AB1-11 (AB S7-S12) and subsequently evaluated for phenotype. FIG. 22 is a listing of the parental and 12 variant heavy chain sequences paired with light chain sequences. FACS binding studies of the 12 antibodies (AB S1-S12) were carried out as essentially described herein and the results are shown in FIG. 27.

[00374] FACS binding assays were also carried out with different amounts of AB S1-S12. The antibody concentrations tested in this limiting dilution assay were 0.32 nM, 1.6 nM, 8 nM, 40 nM, 200 nM, and 1000 nM and different cell lines expression CLDN6 were used. The results are shown in FIG. 28.

[00375] These data support that the newly identified antibodies (S1-S12) demonstrated increased binding over the corresponding parental humanized antibody.

EXAMPLE 12

[00376] This example demonstrates *in vivo* analysis of humanized antibodies described herein.

[00377] *In vivo* studies were carried out in xenograft mice injected with human cancer cell lines as essentially described in Example 6. In this study, cells of the UMUC4 cell line, a bladder cancer cell line strongly expressing CLDN6, and of the OV-90 cell line, an ovarian cancer cell line expressing CLDN6, were used. Both cell lines are tumorigenic when administered to mice subcutaneously. Briefly, xenograft models of human cancer cell

lines were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories). The following conditions were followed for subcutaneous injection of each cell line: UMUC4 1.0×10^7 and OV90 1.0×10^7 all with 50% matrigel (BD Biosciences). CD-1 nude mice (8 mice per group) were subcutaneously injected in the right flank with the UMUC4 or OV-90 cell line. When tumors reached an average size of 150 to 300 mm^3, mice were randomized into treatment groups. For treatment, each therapeutic antibody (humanized AB1-11, humaninzed AB3-7) and a human IgG control antibody were diluted in sterile saline and administered via intravenous tail vein (IV) injection at 10 mg/kg once every 4 days daily (Q4D – FIG. 30) or once weekly (QW – FIG. 31). Tumor xenografts were measured with calipers thrice a week, and tumor volume in mm^3 was determined by multiplying height × width × length. Mice were treated for 21-36 days At the end of study, animals were euthanized and tumor tissue was excised and divided to be stored as snap-frozen or formalin fixed paraffin embedded (FFPE) tissue for biomarker analysis. All animal work was carried out under a protocol approved by IACUC and the University of California at Los Angeles Animal Research Committee. Data was analyzed using StudyLog software from StudyDirector (San Francisco, CA). Results are presented as mean volumes for each group. Error bars represent the standard error (SE) of the mean.

[00378] The results of the xenograft assays are shown in FIG. 30 and FIG. 31. As shown in FIG. 30, Q4D treatment with AB1-11 or AB3-7 led to remarkable decreases in tumor volumes or UMUC4 tumors relative to control treated mice. Both humanized antibodies achieved a 60% decrease in tumor volume relative to control mice by the end of the study period.

[00379] As shown in FIG. 31, the OV-90 tumor volumes of mice treated with either humanized antibody were less than the tumor volume of control treated mice. By the end of the study, AB1-11 achieved a 33% decrease in tumor volume relative to control mice while AB3-7 achieved a 16% decrease.

[00380] These data support that the humanized antibodies maintain the therapeutic efficacy first observed with the corresponding mouse antibodies.

EXAMPLE 13

[00381] This example demonstrates an antibody drug conjugate tested in vivo.

[00382] An conjugate comprising MMAE and humanized AB1-11 was made and tested in vivo using xenograft mice injected with OV-90 ovarian cancer cell lines expression CLDN6 as essentially described in Example 6. In this experiment, CD-1 nude mice (8 mice per group) were subcutaneously injected into the right flank with OV-90 cells. When tumors reached an average size of 150 to 300 mm^3, mice were randomized into treatment groups. For treatment, mice were administered once weekly by tail vein injection (1) 10 mg/kg humanized AB1-11 antibody, (2) 10 mg/kg a human IgG control antibody, (3) 5 mg/kg untargeted conjugate comprising MMAE without AB1-11, and (4) 10 mg/kg targeted antibody drug conjugate (ADC) comprising MMAE and AB1-11. The untargeted conjugate comprised MMAE conjugated to a non-targeting human IgG control antibody. Tumor xenografts were measured with calipers thrice a week, and tumor volume in mm^3 was determined by multiplying height × width × length. Mice were treated for 20-36 days At the end of study, animals were euthanized and tumor tissue was excised and divided to be stored as snap-frozen or formalin fixed paraffin embedded (FFPE) tissue for biomarker analysis. All animal work was carried out under a protocol approved by IACUC and the University of California at Los Angeles Animal Research Committee. Data was analyzed using StudyLog software from StudyDirector (San Francisco, CA). Results are presented as mean volumes for each group. Error bars represent the standard error (SE) of the mean.

[00383] As shown in FIG. 32, the administration of the targeted ADC led to a substantial decrease in tumor volume. By the end of the study, the tumor volume of mice treated with the targeted ADC exhibited a greater than 70% decrease relative to control treated mice.

[00384] The same in vivo analysis was carried out with mice subcutaneously injected with UMUC4 bladder cancer cells instead of OV-90 cells and the treatments were administered once weekly by tail vein injection (1) 10 mg/kg humanized AB1-11 antibody, (2) 10 mg/kg a human IgG control antibody, (3) 5 mg/kg untargeted conjugate comprising MMAE without AB1-11, and (4) 10 mg/kg targeted antibody drug conjugate (ADC) comprising MMAE and AB1-11. The untargeted conjugate comprised MMAE conjugated to a non-targeting human IgG control antibody. The targeted conjugate was given a total of 3 times, whereas the other treatments were administered once weekly 5 times in total. Tumor volume measurements were made as described above, though measurements for the targeted ADC treated mice were measured for up to 80 days.

[00385] As shown in FIG. 33, the administration of the targeted ADC demonstrates tumor volumes decreasing from almost 200 mm^3 to almost 0 mm^3. The effect carried on to 80 days of the study or more than about 60 days after the last ADC treatment.

[00386] These data support that an antibody drug conjugate comprising an antibody of the present disclosure is effective to reduce tumor size and to treat cancer.

EXAMPLE 14

[00387] This Example demonstrates the *in vitro* characterization of the CLDN6 ADCs.

[00388] ADCs comprising various linker-drug combinations were made with a humanized AB3-7 antibody (also referred to as AB23, see *e.g.,* Table 8): (a) VC-PAB-MMAE, (b) GGFG-MMAE, (c) CL2A-SN38, (d) GGFG-Dxd, and (e) VC-PAB-Dxd. The ADCs were prepared at WuXi Biologics (Shanghai, China).

[00389] FIG. 34A-FIG. 34H show the biochemical characterization of the CLDN6 ADCs comprising AB3-7. FIG. 34A is a table summarizing the biochemical properties of the seven CLDN6 ADCs comprising AB3-7. The ADCs that are labeled as D4 refers to substantially homogenous conjugates that comprise a significant number of antibodies being conjugated to 4 drugs per antibody (D4 technology, a technology of WuXi Biologics). The ADCs that are labeled as CTRL refers to conventional heterogeneous conjugates (conventional) that comprise the Gaussian distribution of the number of drugs per antibody. The ADCs comprised a low percentage of unconjugated antibody, high-molecular-weight (HMWs) species, and unconjugated free drugs. The ADCs also comprised a low level of endotoxin, rendering them suitable for *in vivo* studies. FIG. 34B-FIG. 34H represent the HIC-HPLC chromatograms that show the relative abundance of the antibody conjugated to different numbers of drugs for each ADC. For example, the peak area under D0 indicates the relative abundance of the unconjugated AB3-7. Similarly, the peak area under D1, D2, D3…D8 indicates the relative abundance of AB3-7 antibody conjugated to 1, 2, 3…8 drugs per antibody.

[00390] FIG. 35 shows that the molecular integrity of the CLDN6 ADCs comprising AB3-7 was not altered by conjugation. The molecular integrity of the CLDN6 ADCs and unconjugated AB3-7 antibody was assessed by NativePAGE (NativePAGE 4-16% Bis-Tris Protein Gels (Cat.# BN1002BOX, ThermoFisher). Native PAGE separates proteins according to the net charge, size, and shape of their native structure. Under the native

condition, all seven CLDN6 ADCs remain structurally intact and did exhibit any indication of degradation compared with the unconjugated AB3-7 antibody. Thus, conjugation does not alter the molecular integrity of the AB3-7 antibody.

[00391] FIG. 36 shows that conjugation does not affect the binding affinity of the AB3-7 antibody. Flow cytometry shows that the CLDN6 ADCs comprising AB3-7 retained the specific and high binding affinity for CLDN6. The ADC binding activity was analyzed by flow cytometry for three cell lines: (a) UMUC4 bladder cancer cell line (natively expressing CLDN6), (b) HEK293T CLDN6-mGFP A11 (engineered to artificially overexpress (OE) CLDN6), and (c) M202 melanoma cell line (CLDN6-negative cells). Specifically, the ADCs were incubated with ~150,000 cells in 50µl 2% FBS/PBS at 4°C for 30mins followed by washing with 2% FBS/PBS. The ADCs were then incubated with Alexa Fluor® 647 anti-human IgG Fc Antibody from Biolegend (409320) at 4°C for 30mins. The binding was measured by BD Accuri™ C6 Flow Cytometer. Seven different CLDN6 ADCs showed similar binding affinity by flow cytometry compared with their unconjugated antibody AB3-7 to CLDN6-positive cell lines (UMUC4 cells and HEK293T CLDN6-mGFP A11), while showing no binding for a CLDN6-negative cell line (M202).

[00392] FIG. 37 further shows that conjugation does not affect the binding affinity of the AB3-7 antibody. Measurements of the dissociation constant (KD) demonstrated that the CLDN6 ADCs comprising AB3-7 retained the specific and high binding affinity for CLDN6. The cell-based antibody affinity (KD) of the CLDN6 ADCs was measured by KinExA 4000 (Sapidyne Instrument, Boise, Idaho). Briefly, HEK293T CLDN6-mGFP A11 cells were detached using versene and equilibrated with either 500pM or 10nM antibody in 2% FBS/DMEM at 4°C overnight. The cell concentration started at $5x10^6$ cells/ml and 2-fold serial dilutions were performed up to 10 points. The next day, the cells were centrifuged at 1500 rpm for 10 min and the supernatants were saved. The PMMA beads (Sapidye Instrument, Cat.# 440176) were pre-coated with goat-anti-human IgG (Jackson ImmunoResearch Labs (Cat.# 109-005-003) at 30 µg/ml. Fluorescent secondary antibody Alexa Fluor® 647 AffiniPure Goat Anti-Human IgG (Jackson ImmunoResearch Labs, Cat.# 109-605-088) was diluted in 1% BSA/PBS at 0.5 µg/ml. The antibody solution only (Signal 100%) and nonspecific binding (NSB, buffer only) controls were also included in the measurements. The KD was calculated using two antibody curves analyzed by the n-curve analysis. As demonstrated in FIG. 37, the binding affinity (KD) is

similar across all ADCs and unconjugated AB3-7. Thus, conjugation to various linker-drug combinations did not alter the antibody binding affinity for CLDN6 expressed on the HEK293T CLDN6-mGFP A11 cells.

[00393] FIG. 38 shows that the CLDN6 ADCs comprising AB3-7 are internalized efficiently by cancer cells, an important step in the activation of ADCs. Specifically, ARK2 cells (uterine carcinosarcoma expressing CLDN6) were stained with nucleus (blue), lysosome (green) and the CLDN6 ADCs (red). Images on the top panels were taken at an early stage (within 30min after the ADC/antibody staining), and those on the lower panels were taken at a later stage (between 5-6 hours after the ADC/antibody staining) to show the internalization of CLDN6 complexed with ADC or unconjugated antibody. As demonstrated in FIG. 38, conjugation did not change the antibody internalization rates in comparison with those of its unconjugated antibody AB3-7.

EXAMPLE 15

[00394] This Example demonstrates the *in vitro* anti-cancer activity of CLDN6 ADCs against cancer cells.

[00395] FIG. 39A-FIG. 39G show the 2D anti-proliferative effect of different CLDN6 ADCs comprising AB3-7 on cancer cells. The anti-proliferative activity of the CLDN6 ADCs were tested against four cancer cell lines; CLDN6-positive cell lines (UMUC4, OV90) and CLDN6-negative cell lines (MCF7, M202). Each cell line was seeded uniformly into wells of 48-well plates, ranging from 300-1000 cells per well. After 48hrs, a baseline measurement of the number of cells per well per cell line was measured. The remaining wells of cells were treated with a 1:5 serial dilution of 6 drug concentrations, resulting in a final treatment concentration ranging from 200nM (30ng/mL) to 0.064nm (0.0096ng/mL). After 7 days, the anti-proliferative activity was assessed by comparing the counts of cells in the treated versus control untreated.

[00396] As demonstrated in FIG. 39A-FIG. 39G, the CLDN6 ADCs comprising MC-VC-PAB-MMAE (conventional) and MC-VC-PAB-MMAE (D4 technology) were comparable in exhibiting the greatest anti-proliferative potency and specificity against the CLDN6-positive cells (UMUC4). The CLDN6 ADCs comprising CL2A-SN38 (conventional) and CL2A-SN38 (D4 technology) exhibited equally similar anti-proliferative potency but was nonspecific, killing indiscriminately between the CLDN6-positive cells and CLDN6-negative cells. The CLDN6 ADCs comprising MC-GGFG-

MMAE showed low anti-proliferative potency with specificity against the CLDN6-positive cells (UMUC4). The CLDN6 ADCs comprising MC-GGFG-DXD and MC-VC-PAB-DXD show no anti-proliferative effect against any cell line.

[00397] FIG. 39H-FIG. 39N show the 2D anti-proliferative effect of the CLDN6 comprising AB1-11 conjugated to VC-PAB-MMAE (ADC-11) against various cell lines. Specifically, four cell lines were tested: CLDN6-positive cell lines (ARK2, OVCA429, H841, OV90, H1693) and CLDN6-negative cell lines (MCF7, M202). Each cell line was seeded uniformly into wells of 48-well plates, ranging from 300-1000 cells per well. After 48hrs, a baseline measurement of the number of cells per well per cell line was measured. The remaining wells of cells were treated with 1:5 serial dilutions of (a) CLDN6-targeting ADC-11, (b) a control ADC (a non-targeting IgG conjugated to VC-PAB-MMAE), (c) an unconjugated non-targeting IgG, and (d) unconjugated AB1-11, resulting in the final treatment concentration ranging from 1000 nM (150 ng/mL) to 0.32 nM (0.0048 ng/mL). After 7 days, the anti-proliferative activity was assessed by comparing the counts of cells in the treated versus untreated control.

[00398] As demonstrated in FIG. 39H-FIG. 39N, ADC-11 exhibited robust anti-proliferative activity against CLDN6-positive cell lines (ARK2, OVCA429, H841, OV90, H1693) with no activity against the CLDN6-negative cell lines (M202 and MCF7).

EXAMPLE 16

[00399] This Example shows the *in vivo* anti-cancer efficacy of CLDN6 ADCs against cancer cell line xenografts.

[00400] For all *in vivo* experiments, tumor xenografts were measured with calipers 3 times/week, and the tumor volume in mm^3 was determined by multiplying height x width x length. All animal work was carried out under a protocol approved by IACUC and the UCLA Animal Research Committee. Data were analyzed using the StudyLog software from StudyDirector (San Francisco, CA).

[00401] FIG. 40 shows the anti-cancer efficacy of a CLDN6 ADC against CLDN6-positive ovarian cancer cell line (OV90) xenografts. The CLDN6 ADC tested herein comprises a humanized AB1-11 conjugated to VC-PAB-MMAE (ADC-11; conventional). The OV90 ovarian cancer cell line xenografts were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories) by subcutaneous injection of 1.0×10^7

cells with 50% matrigel (BD Biosciences) into the right rear flank of the animal. When tumors reached an average size of 100-200mm^3, mice (n=8) were randomized into treatment groups of either 1) non-targeting human IgG1 control antibody at 10mg/kg QW IV 4 weeks, 2) humanized CLDN6-AB1-11 (HU-11) at 10mg/kg QW IV (intravenous injection) for 4 weeks, 3) ADC-11 at 5mg/kg QW IV for 3 weeks, and 4) non-targeting control ADC 5mg/kg QW IV for 3 weeks. Xenografts were followed post-dosing until tumor progression. Treatment with the CLDN6 ADC resulted in xenograft tumor regression. The activity of the CLDN6 ADC is superior to that observed with the unconjugated CLDN6 mAb or non-targeting control ADC.

[00402] FIG. 41A-FIG. 41B show no anti-cancer activity of CLDN6 ADC-11 (conventional) against CLDN6-negative melanoma cancer cell line (M202) xenografts. ADC-11 did not show any anti-cancer activity in M202 cell line xenografts that do not express CLDN6. The M202 melanoma cancer cell line xenografts were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories) by subcutaneous injection of 1.0×10^7 cells with 50% matrigel (BD Biosciences) into the right rear flank of the animal. When tumors reached an average size of 100-300mm^3, mice (n=8) were randomized into treatment groups of either 1) non-targeting human IgG1 control antibody at 10mg/kg QW IV 4 weeks or 2) ADC-11 at 5mg/kg QW IV for 3 weeks. The lack of anti-cancer activity of the CLDN6 ADC against CLDN6-negative xenografts demonstrates the specificity of the CLDN6 ADC activity.

[00403] FIG. 42A-FIG. 42B show the *in vivo* anti-cancer efficacy of CLDN6 ADC-23 against cancer cell line xenografts. The CLDN6 ADC tested herein comprises humanized AB3-7 conjugated to VC-PAB-MMAE (ADC-23; conventional). FIG. 42A shows that CLDN6 ADC-23 is efficacious against CLDN6-positive bladder cell line (UMUC4) xenografts. Specifically, the UMUC4 bladder cancer cell line xenografts were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories) by subcutaneous injection of 1.0×10^7 cells with 50% matrigel (BD Biosciences) into the right rear flank of the animal. When tumors reached an average size of 100-200mm^3, mice (n=8) were randomized into treatment groups of either 1) non-targeting human IgG1 (Hu-IgG1) control antibody at 10mg/kg once per week (QW IV) for 4 weeks, 2) humanized CLDN6 AB3-7 antibody (Hu23) at 10mg/kg QW IV for 4 weeks, 3) ADC-23 at 5mg/kg QW IV for 3 weeks. Xenografts were followed post-dosing until tumor progression or 60 days post

initiation of the treatment. FIG. 42B shows Haemotoxylin and Eosin (H&E) stain of the xenograft tissues collected at the indicated time points post-treatment with either Hu-IgG1 control antibody or 5mg/kg ADC-23. Histopathological analysis of the xenograft tissue collected during the study showed that epithelial-tumor cell content was lost in ADC-23-treated mice (FIG. 42B).

[00404] Treatment with the CLDN6 ADC-23 resulted in xenograft tumor regressions in the UMUC4 CLDN6-positive cell line xenografts. The data presented in FIG. 42A-FIG. 42B and those presented above demonstrate that both CLDN6 ADCs (ADC-11 and ADC-23) are effective in targeting CLDN6-positive cell line xenografts.

EXAMPLE 17

[00405] This Example shows the *in vivo* anti-cancer activity of CLDN6 ADC-23 against patient-derived xenografts (PDX).

[00406] FIG. 43A-FIG. 43E show the *in vivo* anti-cancer efficacy of CLDN6 ADC-23 (conventional) against ovarian cancer PDX models. Specifically, a panel of ovarian PDX samples was screened for CLDN6 protein expression by the Western blot analysis (FIG. 43A). Two CLDN6-positive (DF189 & DF181) and one CLDN6-negative (DF20) samples were selected for the study. Ovarian cancer cells from each PDX were transfected with the luciferase enzyme before injection into the intraperitoneal space of immunocompromised mice (NSG) (FIG. 43B). FIG. 43C-FIG. 43E show the luciferase activity output that was measured once per week in mice treated with (1) non-targeting Hu-IgG1 control antibody at 10 mg/kg QW IV 4 weeks, (2) humanized CLDN6 AB3-7 at 10mg/kg QW IV for 4 weeks, or (3) ADC-23 at 5mg/kg QW IV for 3 weeks. The mice treated with Hu-IgG1 control or CLDN6 AB3-7 mAb showed a continuous increase in tumor burden in the intraperitoneal space until the mice had to be euthanized at approximately 50 days post-implantation of the cancer cells for each of the PDX models tested. However, mice treated with ADC-23 showed a significant reduction in tumor burden and a significant improvement in overall survival. These responses were limited to mice injected with the CLDN6-positive ovarian cancer cells (FIG. 43C and FIG. 43D). The DF20 CLDN6 negative model showed only a limited benefit to treatment with no impact on overall survival (FIG. 43E).

EXAMPLE 18

[00407] This Example shows the dose-dependent activity of CLDN6 ADC-23.

[00408] FIG. 44A-FIG. 44C show the dose-dependent anti-cancer activity of CLDN6 ADC-23 (D4 technology) against the CLDN6-positive ovarian cancer cell line (OV90) xenografts. The OV90 ovarian cancer cell line xenografts were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories) by subcutaneous injection of 1.0×10^7 cells with 50% matrigel (BD Biosciences) into the right rear flank of the animal. When tumors reached an average size of ~200mm^3, mice (n=6) were randomized into treatment groups. Mice with OV90 xenografts were treated with various doses ranging from 0.1 mg/kg to 2.5 mg/kg IV QW for 3 weeks. A reduction in anti-tumor activity was observed as the dosing concentration was decreased. Treatment with 2.5 mg/kg of CLDN6 ADC-23 induced uniform xenograft regressions (FIG. 44A and FIG. 44B). No impact on mouse body weight was observed in response to the treatment with CLDN6 ADC-23 at any dose given (FIG. 44C). Thus, the selective and dose-dependent activity of the novel CLDN6 ADC-23 was confirmed in the CLDN6-positive ovarian cancer cell line xenografts.

[00409] FIG. 45A-FIG. 45C show that there is no off-target activity of the CLDN6 ADC-23 (D4 technology) in the CLDN6-negative melanoma cancer cell line (M202) xenografts. The M202 melanoma cancer cell line xenografts were established in six-week-old CD-1 athymic nude mice (Charles River Laboratories) by subcutaneous injection of 1.0×10^7 cells with 50% matrigel (BD Biosciences) into the right rear flank of the animal. When tumors reached an average size of ~200mm^3, mice (n=6) were randomized into treatment groups. Mice bearing the M202 melanoma xenografts were treated with various doses ranging from 0.1 mg/kg to 2.5 mg/kg IV QW for 3 weeks. No anti-cancer activity of the CLDN6 ADC against CLDN6-negative M202 xenografts was observed at any dose given (FIG. 45A-FIG. 45B). No impact on mouse body weight was observed in response to the treatment with CLDN6 ADC at any dose given (FIG. 45C).

[00410] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[00411] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and

"containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted.

[00412] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range and each endpoint, unless otherwise indicated herein, and each separate value and endpoint is incorporated into the specification as if it were individually recited herein.

[00413] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or various language (e.g., "such as") provided herein, is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.

[00414] Preferred embodiments of this disclosure are described herein, including the best mode known to the inventors for carrying out the disclosure. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the disclosure to be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.

WHAT IS CLAIMED IS:

1. An antigen-binding protein comprising:
    a. a heavy chain CDR1 amino acid sequence of: SEQ ID NO: 504 or SEQ ID NO: 507, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
    b. a heavy chain CDR2 amino acid sequence of: SEQ ID NOs: 505 or SEQ ID NO: 508, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
    c. a heavy chain CDR3 amino acid sequence of: SEQ ID NO: 506 or SEQ ID NO: 509, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
    d. a light chain CDR1 amino acid sequence of: SEQ ID NO: 449 or SEQ ID NO: 476, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
    e. a light chain CDR2 amino acid sequence of: SEQ ID NO: 450 or SEQ ID NO: 477, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
    f. a light chain CDR3 amino acid sequence of: SEQ ID NO: 451 or SEQ ID NO: 454, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; and/or
    g. a combination of any two or more of (a)-(f).

2. The antigen-binding protein of claim 1, wherein the variant sequence has at least about 80% or at least or about 85% sequence identity.

3. The antigen-binding protein of claim 2, wherein the variant sequence has at least about 90% sequence identity or at least or about 95% sequence identity.

4. The antigen-binding protein of claim of any one of claims 1-3, wherein:
    a. the antigen-binding protein binds to a human Claudin6 (CLDN6) protein (SEQ ID NO: 200);
    b. the antigen-binding protein binds to Extracellular Loop 2 (EL2) of an extracellular domain (ECD) of CLDN6 and does not bind to Extracellular Loop 1 (EL1) of the ECD of CLDN6;

c. does not bind to any of Claudin3 (CLDN3), Claudin4 (CLDN4), and Claudin9 (CLDN9) and inhibits binding of a reference antibody to CLDN6 endogenously expressed by OVCA429 cells with less than about 1200 nM; or

d. a combination thereof.

5. The antigen- binding protein of any one of claims 1-4, which binds to an epitope within the amino acid sequence of WTAHAIIRDFYNPLVAEAQKREL (SEQ ID NO: 2).

6. The antigen-binding protein of claim 5, which binds to the amino acid sequence of TAHAIIRDFYNPL (SEQ ID NO: 3) or LVAEAQKREL (SEQ ID NO: 4) of CLDN 6.

7. The antigen-binding protein of any one of claims 1 to 6, which does not bind to any one or more of Claudin3 (CLDN3), Claudin4 (CLDN4), and Claudin9 (CLDN9).

8. The antigen-binding protein of claim 7, which does not bind to CLDN3.

9. The antigen-binding protein of claim 8, which binds to CLDN6, CLDN4, and CLDN9.

10. The antigen-binding protein of claim 8, which does not bind to CLDN9.

11. The antigen-binding protein of claim 10, which binds to CLDN6 and CLDN4.

12. The antigen-binding protein of claim 8, which does not bind to CLDN4.

13. The antigen-binding protein of claim 12, which binds to CLDN6 and CLDN9.

14. The antigen-binding protein of any one of the previous claims, comprising a light chain CDR1 amino acid sequence of SEQ ID NO: 449, a light chain CDR2 amino acid sequence or SEQ ID NO: 450, and a light chain CDR3 amino acid sequence or SEQ ID NO: 451 and one or two of a heavy chain CDR1 amino acid sequence of SEQ ID NO: 504, a heavy chain CDR2 amino acid sequence or SEQ ID NO: 505, and a heavy chain CDR3 amino acid sequence or SEQ ID NO: 506.

15. The antigen-binding protein of claim any one of the previous claims, comprising a light chain CDR1 amino acid sequence of SEQ ID NO: 476, a light chain CDR2 amino acid sequence or SEQ ID NO: 477, and a light chain CDR3 amino acid sequence or SEQ ID NO: 454 and one or two of a heavy chain CDR1 amino acid sequence of SEQ ID NO: 507, a heavy chain CDR2 amino acid sequence or SEQ ID NO: 508, and a heavy chain CDR3 amino acid sequence or SEQ ID NO: 509.

16. The antigen-binding protein of any one of claims 11-15, comprising six CDR amino acid sequences selected from the group consisting of:
    a. SEQ ID NOs: 449-451 and 504-506; and
    b. SEQ ID NOs: 476, 477, 454 and 507-509.

17. The antigen-binding protein of any one of claims 11-16, comprising:
    a. a heavy chain variable region amino acid sequence of any one of SEQ ID NOs: 490-503, or a heavy chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or
    b. a light chain variable region amino acid sequence of any one of SEQ ID NOs: 380-383, 388-390, 479, and 481, or a light chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or
    c. both (a) and (b).

18. The antigen-binding protein of claim 17, wherein the variant sequence has at least about 80% or at least about 85% sequence identity.

19. The antigen-binding protein of claim 18, wherein the variant sequence has at least about 90% or at least about 95% sequence identity.

20. The antigen-binding protein of any one of claims 17-19, comprising a pair of amino acid sequences:
    a. SEQ ID NOs: 389 and 490;
    b. SEQ ID NOs: 389 and 491;

c. SEQ ID NOs: 389 and 492;
d. SEQ ID NOs: 389 and 493;
e. SEQ ID NOs: 389 and 494;
f. SEQ ID NOs: 389 and 495;
g. SEQ ID NOs: 383 and 496;
h. SEQ ID NOs: 383 and 497;
i. SEQ ID NOs: 383 and 498;
j. SEQ ID NOs: 383 and 499;
k. SEQ ID NOs: 383 and 500;
l. SEQ ID NOs: 383 and 501;
m. SEQ ID NOs: 383 and 503;
n. SEQ ID NOs: 389 and 502;
o. the heavy chain variable region sequence labeled as S1 in FIG. 22 and the light chain variable region sequence labeled as S1 in FIG. 22;
p. the heavy chain variable region sequence labeled as S2 in FIG. 22 and the light chain variable region sequence labeled as S2 in FIG. 22;
q. the heavy chain variable region sequence labeled as S3 in FIG. 22 and the light chain variable region sequence labeled as S3 in FIG. 22;
r. the heavy chain variable region sequence labeled as S4 in FIG. 22 and the light chain variable region sequence labeled as S4 in FIG. 22;
s. the heavy chain variable region sequence labeled as S5 in FIG. 22 and the light chain variable region sequence labeled as S5 in FIG. 22;
t. the heavy chain variable region sequence labeled as S6 in FIG. 22 and the light chain variable region sequence labeled as S6 in FIG. 22;
u. the heavy chain variable region sequence labeled as S7 in FIG. 22 and the light chain variable region sequence labeled as S7 in FIG. 22;
v. the heavy chain variable region sequence labeled as S78 in FIG. 22 and the light chain variable region sequence labeled as S8 in FIG. 22;
w. the heavy chain variable region sequence labeled as S89 in FIG. 22 and the light chain variable region sequence labeled as S9 in FIG. 22;
x. the heavy chain variable region sequence labeled as S910 in FIG. 22 and the light chain variable region sequence labeled as S10 in FIG. 22;

y. the heavy chain variable region sequence labeled as S11 in FIG. 22 and the light chain variable region sequence labeled as S11 in FIG. 22; or
z. the heavy chain variable region sequence labeled as S12 in FIG. 22 and the light chain variable region sequence labeled as S12 in FIG. 22.

21. The antigen-binding protein of any one of the previous claims, which is an antibody.

22. The antigen-binding protein of claim 21, which is a monoclonal antibody.

23. The antigen-binding protein of claim 21 or 22, which is an IgG.

24. The antigen-binding protein of any one of the previous claims, which inhibits at least about 50% colony growth in a soft agar 3D proliferation assays.

25. The antigen-binding protein of any one of the previous claims, which inhibits tumor growth in xenograft mice injected with human cancer cells.

26. The antigen-binding protein of claim 25, which inhibits tumor growth of in xenograft mice injected with ovarian cancer cells, melanoma cancer cells, bladder cancer cells, or endometrial cancer cells.

27. The antigen-binding protein of claim 26, which inhibits at least 50% tumor growth in xenograft mice injected with ovarian cancer cells, bladder cancer cells, or endometrial cancer cells.

28. An antigen-binding protein comprising
a. a heavy chain CDR1 amino acid sequence of: SEQ ID NO: 504 or SEQ ID NO: 507, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
b. a heavy chain CDR2 amino acid sequence of: SEQ ID NOs: 505 or SEQ ID NO: 508, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
c. a heavy chain CDR3 amino acid sequence of: SEQ ID NO: 506 or SEQ ID NO: 509, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;

d. a light chain CDR1 amino acid sequence of: SEQ ID NO: 449 or SEQ ID NO: 476, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
e. a light chain CDR2 amino acid sequence of: SEQ ID NO: 450 or SEQ ID NO: 477, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity;
f. a light chain CDR3 amino acid sequence of: SEQ ID NO: 451 or SEQ ID NO: 454, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or
g. a combination of any two or more of (a)-(f).

29. An antigen-binding protein comprising six CDR amino acid sequences selected from the group consisting of:
a. SEQ ID NOs: 449-451 and 504-506; and
b. SEQ ID NOs: 476, 477, 454 and 507-509.

30. An antigen-binding protein comprising:
a. a heavy chain variable region amino acid sequence of any one of SEQ ID NOs: 490-503, or a heavy chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or
b. a light chain variable region amino acid sequence of any one of SEQ ID NOs: 380-383, 388-390, 479, and 481, or a light chain variable region amino acid sequence labeled as S1-S12 in FIG. 22, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or
c. both (a) and (b).

31. The antigen-binding protein of claim 30, wherein the variant sequence has at least about 85% sequence identity or about 90% or about 95% sequence identity.

32. An antigen-binding protein comprising a pair of amino acid sequences selected from the group consisting of:
a. SEQ ID NOs: 389 and 490;

b. SEQ ID NOs: 389 and 491;
c. SEQ ID NOs: 389 and 492;
d. SEQ ID NOs: 389 and 493;
e. SEQ ID NOs: 389 and 494;
f. SEQ ID NOs: 389 and 495;
g. SEQ ID NOs: 383 and 496;
h. SEQ ID NOs: 383 and 497;
i. SEQ ID NOs: 383 and 498;
j. SEQ ID NOs: 383 and 499;
k. SEQ ID NOs: 383 and 500;
l. SEQ ID NOs: 383 and 501;
m. SEQ ID NOs: 383 and 503;
n. SEQ ID NOs: 389 and 502;
o. the heavy chain variable region sequence labeled as S1 in FIG. 22 and the light chain variable region sequence labeled as S1 in FIG. 22;
p. the heavy chain variable region sequence labeled as S2 in FIG. 22 and the light chain variable region sequence labeled as S2 in FIG. 22;
q. the heavy chain variable region sequence labeled as S3 in FIG. 22 and the light chain variable region sequence labeled as S3 in FIG. 22;
r. the heavy chain variable region sequence labeled as S4 in FIG. 22 and the light chain variable region sequence labeled as S4 in FIG. 22;
s. the heavy chain variable region sequence labeled as S5 in FIG. 22 and the light chain variable region sequence labeled as S5 in FIG. 22;
t. the heavy chain variable region sequence labeled as S6 in FIG. 22 and the light chain variable region sequence labeled as S6 in FIG. 22;
u. the heavy chain variable region sequence labeled as S7 in FIG. 22 and the light chain variable region sequence labeled as S7 in FIG. 22;
v. the heavy chain variable region sequence labeled as S78 in FIG. 22 and the light chain variable region sequence labeled as S8 in FIG. 22;
w. the heavy chain variable region sequence labeled as S89 in FIG. 22 and the light chain variable region sequence labeled as S9 in FIG. 22;
x. the heavy chain variable region sequence labeled as S910 in FIG. 22 and the light chain variable region sequence labeled as S10 in FIG. 22;

y. the heavy chain variable region sequence labeled as S11 in FIG. 22 and the light chain variable region sequence labeled as S11 in FIG. 22; or
z. the heavy chain variable region sequence labeled as S12 in FIG. 22 and the light chain variable region sequence labeled as S12 in FIG. 22.

33. An antigen-binding protein comprising:
a. a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 510 or 513 or in FIG. 23 or FIG. 25, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or
b. a light chain variable region amino acid sequence set forth as SEQ ID NO: 511 or 512 or in FIG. 24 or FIG. 26, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or
c. both (a) and (b).

34. The antigen-binding protein of claim 33, wherein the variant sequence has at least about 85% sequence identity.

35. The antigen-binding protein of claim 34, wherein the variant sequence has at least about 90% or about 95% sequence identity.

36. An antigen-binding protein comprising a pair of amino acid sequences wherein the pair comprises
a. a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 510 and a light chain variable region amino acid sequence set forth as SEQ ID NO: 511, or a variant sequence thereof which differs by only 1-5 amino acids or which has at least or about 70% sequence identity; optionally, wherein the 1-5 amino acids which differ are as shown in FIG. 23 for the heavy chain or FIG. 24 for the light chain, or
b. a heavy chain variable region amino acid sequence set forth as SEQ ID NO: 513 and a light chain variable region amino acid sequence set forth as SEQ ID NO: 512, or a variant sequence thereof which differs by only 1-5 amino acids or which has at least or about 70% sequence identity; or optionally,

wherein the 1-5 amino acids which differ are as shown in FIG. 25 for the heavy chain or FIG. 26 for the light chain.

37. The antigen-binding protein of any one of the previous claims, comprising a Fc polypeptide comprising an afucosylated glycan.

38. A conjugate comprising an antigen-binding protein of any one of the previous claims or described herein.

39. The conjugate of claim 38, wherein the antigen-binding protein comprises the amino acid sequence set forth in SEQ ID NO: 387 and SEQ ID NO: 389.

40. The conjugate of claim 38, wherein the antigen-binding protein comprises the amino acid sequence set forth in SEQ ID NO: 379 and SEQ ID NO: 383.

41. The conjugate of any one of claims 38-40 comprising a cytotoxic agent or a chemotherapeutic agent.

42. The conjugate of claim 41, wherein the chemotherapeutic agent is an anti-mitotic agent which inhibits cell division by blocking tubulin polymerization.

43. The conjugate of claim 42, wherein the anti-mitotic agent is an auristatin.

44. The conjugate of claim 43, wherein the auristatin is MMAE.

45. The conjugate of any one of claims 38-44, wherein the agent is conjugated to the antigen-binding protein via a cleavable linker.

46. The conjugate of claim 45, wherein the cleavable linker is VC-PAB-MMAE.

47. The conjugate of any one of claims 38-46, wherein the antigen-binding protein is an antibody,

48. The conjugate of claim 47, wherein the antibody is a monoclonal antibody, optionally wherein the monoclonal antibody is an IgG antibody.

49. The conjugate of claim 47 or 48, wherein the antibody is a human antibody, humanized antibody, or a chimeric antibody.

50. The conjugate of any one of claims 38-49, wherein an average number of units of the agent conjugated per antibody is in a range of 1 to 8, preferably wherein the average number of units of the agent conjugated per antibody is in a range of 3-8.

51. The conjugate of any one of claims 38-50, wherein the conjugate is a heterogeneous conjugate.

52. The conjugate of any one of claims 38-50, wherein the conjugate is a homogeneous conjugate.

53. The conjugate of any one of claims 38-50 and 52, wherein the agent is conjugated at a specific site of the antigen-binding protein.

54. The conjugate of claim 53, wherein the specific site is an unpaired cysteine residue.

55. The conjugate of any one of claims 47-54, wherein the conjugate comprises a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 387 and SEQ ID NO: 389 conjugated to MC-VC-PAB-MMAE.

56. The conjugate of any one of claims 47-54, wherein the conjugate comprises a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 379 and SEQ ID NO: 383 conjugated to MC-VC-PAB-MMAE.

57. A fusion protein comprising an antigen-binding protein of any one of the previous claims.

58. A nucleic acid comprising a nucleotide sequence encoding an antigen binding protein of any one of the previous claims, a conjugate of claim 38-56, or a fusion protein of claim 57.

59. A vector comprising the nucleic acid of claim 58.

60. A host cell comprising the nucleic acid of claim 58 or the vector of claim 59.

61. A method of producing an antigen-binding protein that binds to a Claudin6 (CLDN6) protein, comprising (i) culturing the host cell of claim 60 in a cell culture medium, wherein the host cell comprises a nucleic acid comprising a nucleotide

sequence encoding an antigen binding protein of any one of the previous claims, and (ii) harvesting the antigen-binding protein from the cell culture medium.

62. A method of producing a fusion protein comprising an antigen-binding protein that binds to a Claudin6 (CLDN6) protein, comprising (i) culturing the host cell of claim 60 in a cell culture medium, wherein the host cell comprises a nucleic acid comprising a nucleotide sequence encoding a fusion protein of claim 43, and (ii) harvesting the fusion protein from the cell culture medium.

63. A method of producing a pharmaceutical composition comprising combining an antigen-binding protein of any one of claims 1 to 37, a conjugate of any one of claims 38-56, a fusion protein of claim 57, a nucleic acid of claim 58, a vector of claim 59, a host cell of claim 60, or a combination thereof, and a pharmaceutically acceptable carrier, diluent or excipient

64. A pharmaceutical composition comprising an antigen-binding protein of any one of claims 1 to 37, a conjugate of any one of claims 38-56, a fusion protein of claim 57, a nucleic acid of claim 58, a vector of claim 59, a host cell of claim 60, and a pharmaceutically acceptable carrier, diluent or excipient.

65. A method of treating a subject with a CLDN6-expressing cancer comprising administering to the subject a pharmaceutical composition of claim 64 in an amount effective to treat the cancer.

66. A method of inhibiting tumor growth in a subject, comprising administering to the subject a pharmaceutical composition of claim 64 in an amount effective to inhibit tumor growth.

67. A method of reducing tumor size in a subject, comprising administering to the subject a pharmaceutical composition of claim 64 in an amount effective to reduce tumor size.

68. A method of preventing the recurrence of cancer in a subject, comprising administering to the subject a pharmaceutical composition of claim 64 in an amount effective to prevent the recurrence of cancer.

69. A method of treating cancer in a subject diagnosed to be a low over-expresser of CLDN6, comprising administering to the subject a pharmaceutical composition of claim 64 in an amount effective to prevent the recurrence of cancer

70. The method of any one of claims 65-69 wherein the administering induces apoptosis in tumor cells.

71. The method of any one of claims 65-69 wherein the administering induces apoptosis in cells expressing CLDN6

72. A method of detecting Claudin6 (CLDN6) in a sample, comprising contacting the sample with an antigen-binding protein of any one of claims 1 to 37, a conjugate of any one of claims 38-56, or a fusion protein of claim 57, and assaying for an immunocomplex comprising the antigen-binding protein, conjugate or fusion protein bound to CLDN6.

73. A method of diagnosing a Claudin6 (CLDN6)-positive cancer in a subject, comprising contacting a biological sample comprising cells or tissue obtained from the subject with an antigen-binding protein of any one of claims 1 to 37, a conjugate of any one of claims 38-56, or a fusion protein of claim 57, and assaying for an immunocomplex comprising the antigen-binding protein, conjugate or fusion protein bound to CLDN6.



CLDN6 Gene Express on
Log10(RPKM)
0.5
0.5
-0.5
-1.0
-1.5
Colon - Transverse
Adipose - Subcutaneous
Vagina
Adrenal - Gland
Artery - Coronary
Artery - Tibial
Bladder
Uterus
Stomach
Spleen
Small Intestine - Terminal Ileum
Skin - Sun Exposed (Lower leg)
Skin - Not Sun Exposed (Suprapubic)
Prostate
Ovary
Nerve - Tibial
Muscle - Skeletal
Liver
Heart - Left Ventricle
Heart - Atrial Appendage
Fallopian Tissue
Esophagus - Mucosa
Esophagus - Mammary
Cervix - Ectocervix
Esophagus - Muscularis
Colon - Sigmoid
Breast - Mammary Tissue
Adipose - Visceral (Omentum)
Esophagus - Gastroesophageal Junction
Cells - EBV-transformed lymphocytes
Whole Blood
Artery - Aorta
Artery - Tibial
Cells - Transformed fibroblasts
Cervix - Endocervix
Brain - Substantia nigra
Kidney - Cortex
Brain - Amygdala
Brain - Cortex (BA24)
Brain - Anterior cingulate cortex (BA9)
Brain - Frontal Cortex (BA9)
Brain - Hypothalamus
Pancreas
Pituitary
Brain - Nucleus accumbens (basal ganglia)
Brain - Caudate (basal ganglia)
Brain - Putamen (basal ganglia)
Brain - Cerebellum
Brain - Cerebellar Hemisphere
Testis
Cells - Cultured fibroblasts
Brain - Hippocampus
Lung
Thyroid
Salivary Gland
Minor Salivary Gland
Brain - Spinal cord (cervical c-1)

FIG. 1



CLDN6: Log(FKPM) Distribution By Cancer Type
Log(FKPM)
10
9
8
7
6
5
4
3
2
1
0
Melanoma (N = 46)
Myeloma (N = 22)
lymphoma (N = 48)
Colon (N = 30)
Kidney (N = 30)
Breast (N = 48)
Prostate (N = 5)
Sarcoma (N = 59)
Head and Neck (N = 30)
Pancreas (N = 29)
Lung (N = 68)
Liver (N = 18)
Bladder (N = 29)
Upper GI (N = 25)
Endometrial (N = 20)
Ovarian (N = 42)
Primary Site

FIG. 2



Log(FKPM)
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Primary Site
Acute Myeloid leukemia (N = 173)
large B-cell lymphoma (N = 28)
Stomach Cancer (N = 68)
Prostate Cancer (N = 301)
Melanoma (N = 357)
Colon Cancer (N = 284)
Rectal Cancer (N = 97)
Bladder Cancer (N = 231)
Cervical Cancer (N = 162)
Liver Cancer (N = 197)
Breast Cancer (N = 1115)
Kidney Clear Cell Carcinoma (N = 581)
Head and Neck Cancer (N = 467)
Sarcoma (N = 107)
Kidney Chromophobe (N = 91)
lower Grade Glioma (N = 306)
Adrenocortical Cancer (N = 79)
Glioblastoma (N = 167)
Kidney Papillary Cell Carcinoma (N = 200)
Lung Squamous Cell Carcinoma (N = 534)
Thyroid Cancer (N = 562)
Lung Adenocarcinoma (N = 548)
Pancreatic Cancer (N = 59)
Endometrioid Cancer (N = 166)
Uterine Carcinosarcoma (N = 56)
Ovarian Cancer (N = 266)

FIG. 3



HEK293T-CLDN6-mGF
HEK293T-CLDN6v-mGFP
HEK293T-CLDN9-mGFP
HEK293T-CLDN4-mGFP
HEK293T-CLDN3-

FIG. 4

FIG. 5



CLUSTAL O(1.2.1) multiple sequence alignment
SP|P56747|CLD6_HUMAN MASAGMQILGVVLTLLGWVNGLVSCALPMWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTG 60
SP|O15551|CLD3_HUMAN -MSNGLEITGTALAVLGWLGTIVCCALPMWRVSAFIGSNIITSQNIWEGLWMNCVVQSTG 59
SP|O14493|CLD4_HUMAN MASMGLQVMGIALAVLGWLAVMLCCALPMWRVTAFIGSNIVTSQTIWEGLWMNCVVQSTG 60
SP|O95484|CLD9_HUMAN MASTGLELLGMTLAVLGWLGTLVSCALPLWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTG 60
SP|Q92262|CLD6_MOUSE MASTGLQILGIVLTLLGWVNALVSCALPMWKVTAFIGNSIVVAQMVWEGLWMSCVVQSTG 60
QMQCKVYDSLLALPQDLQAARALCVIALLVALPGLLVYLAGARCTTCVEEKDSKARLVLT 120
SP|O15551|CLD3_HUMAN QMQCKVYDSLLALPQDLQAARALIVVAILLAAPGLLVALVGAQCTNCVQDDTAKAKITIV 119
SP|O14493|CLD4_HUMAN QMQCKVYDSLLALPQDLQAARALVIISIIVAALGVLLSVVGGKCTNCLEDESAKAKTMIV 120
SP|O95484|CLD9_HUMAN QMQCKVYDSLLALPQDLQAARALCVIALLLALLGLLVAITGAQCTTCVEDEGAKARIVLT 120
SP|Q92262|CLD6_MOUSE QMQCKVYDSLLALPQDLQAARALCVVTLLIVLLGLLVYLAGAKCTTCVEDRNSKSRLVLI 120
SP|P56747|CLD6_HUMAN SGIVFVISGVLTLIPVCWTAHAIIQDFYNPLVAEAQKREMGASLYLGWAASGLLLLGGGL 180
SP|O15551|CLD3_HUMAN AGVLFLLAALLTLVPVSWSANTIIRDFYNPVVPEAQKREMGAGLYVGWAAAALQLLGGAL 179
SP|O14493|CLD4_HUMAN AGVVFLLAGLMVIVPVSWTAHNIIQDFYNPLVASGQKREMGASLYVGWAASGLLLLGGGL 180
SP|O95484|CLD9_HUMAN AGVILLLAGILVLIPVCWTAHAIIQDFYNPLVAEALKRELGASLYLGWAAAALLMLGGGL 180
SP|Q92262|CLD6_MOUSE SGIIFVISGVLTLIPVCWTAHSIIQDFYNPLVADAQKRELGASLYLGWAASGLLLLGGGL 180
SP|P56747|CLD6_HUMAN LCCTCPSGGSQGPSHYMARYSTSAPA--ISRGPSEYPTKNYV 220
SP|O15551|CLD3_HUMAN LCCSCPPREKK-YTATKVVYSAPRSTGPGASLGTGYDRRDYV 220
SP|O14493|CLD4_HUMAN LCCNCPPRTDK-PYSAK--YSAARSAAASN----------YV 209
SP|O95484|CLD9_HUMAN LCCTCPPPQVERPRGPRLGYSIPS------RSGASGLDKRDYV 217
SP|Q92262|CLD6_MOUSE LCCACSSGGTQGPRHYMACYSTSVPH---SRGPSEYPTKNYV 219
ECD Loop 1
ECD Loop 2
SEQ ID NO:177
SEQ ID NO:2
CLD6_HUMAN=SEQ ID NO:1
CLD3_HUMAN=SEQ ID NO:5
CLD4_HUMAN=SEQ ID NO:6
CLD9_HUMAN=SEQ ID NO:7
CLD6_MOUSE=SEQ ID NO:176

FIG. 6A



Tumor Volume mm3
700
600
500
400
300
200
100
0
0
2
4
6
8
10
12
14
Days
Dose
Control IgG2, 10 mg/kg
AB2, 10 mg/kg
AB3, 10 mg/kg
Reference Ab1, 10 mg/kg
Reference Ab2, 10 mg/kg
Reference Ab3 (trastuzumab), 10 mg/kg

FIG. 6B



Mean Δ in Tumor Volume mm3
700
600
500
400
300
200
100
0
Control IgG2, 10 mg/kg
AB2, 10 mg/kg
AB3, 10 mg/kg
Reference Ab1, 10 mg/kg
Reference Ab2, 10 mg/kg
Reference Ab3, 10 mg/kg

FIG. 7A



Tumor Volume mm3
450
400
350
300
250
200
150
100
50
0
0
5
10
15
20
25
30
35
Days
Q4D Dosing
Control IgG2, 10 mg/kg
Reference Ab1, 10 mg/kg
Reference Ab2, 10 mg/kg
AB3, 10 mg/kg

FIG. 7B



Mean Δ in Tumor Volume mm3
350
300
250
200
150
100
50
0
-50
Control IgG2, 10 mg/kg
Reference Ab1, 10 mg/kg
Reference Ab2, 10 mg/kg
AB3, 10 mg/kg

FIG. 8A





Tumor Volume mm3
1,600
1,400
1,200
1,000
800
600
400
200
0
0
4
8
12
16
20
Days
Q3D Dosing
Control IgG2, 10 mg/kg
Reference Ab1, 10 mg/kg
AB2, 10 mg/kg
AB3, 10 mg/kg

FIG. 8B


Mean Δ in Tumor Volume mm3
1,400
1,200
1,000
800
600
400
200
0
Control IgG2, 10 mg/kg
Reference Ab1, 10 mg/kg
AB3, 10 mg/kg
AB2, 10 mg/kg


FIG. 9A
Tumor Volume mm3
1,000
900
800
700
600
500
400
300
200
100
0
0
3
6
9
12
15
18
21
Days
Q4D Dosing
Control IgG2, 10 mg/kg
Reference Ab1, 10 mg/kg
Trametinib 1mg/kg
Reference Ab2, 10 mg/kg
AB3, 10 mg/kg



FIG. 9B
Mean Δ in Tumor Volume mm3
800
700
600
500
400
300
200
100
0
Control IgG2, 10 mg/kg
Reference Ab2, 10 mg/kg
Reference Ab1, 10 mg/kg
AB3, 10 mg/kg
Trametinib, 1 mg/kg

FIG. 10A




FIG. 10B





FIG. 11


10.00%
5.00%
0.00%
-5.00%
-10.00%
-15.00%
-20.00%
% Change in Body Weight
0
2
4
6
8
10
12
14
16
18
1
2
3
4
5
6
1 Vehicle (PBS)
2 AB3, 10 mg/kg Q4D IV
3 Control IgG2, 10 mg/kg Q4D IV
4 Reference Ab1, 10 mg/kg Q4D IV
5 Reference Ab2, 10 mg/kg Q4D IV
6 Reference Ab3 (trastuzumab), 10 mg/kg Q4D IV



Vehicle Control
Control IgG2
Reference Ab1
AB2
AB3
AB10
AB7
AB5
AB13
AB15
AB11
Tumor Volume mm3
1,500
1,400
1,300
1,200
1,100
1,000
900
800
700
600
500
400
300
200
100
0
4
8
12
16
20
24
28
Days
Dosing 10 mg/kg, Q4D, IV

FIG. 12A

FIG. 12B



Δ in Tumor Volume mm3
1,200
1,000
800
600
400
200
0
Vehicle Control
Control IgG2
Reference Ab1
AB2
AB3
AB10
AB7
AB5
AB13
AB15
AB11
AB4
AB6

FIG. 13






8.00%
6.00%
4.00%
2.00%
0.00%
-1
-2.00%
-4.00%
-6.00%
-8.00%
-10.00%
% Body Weight
1 Vehicle control
2 Control IgG2
3 Reference Ab1
4 AB2
5 AB3
6 AB10
7 AB7
8 AB5
9 AB13
10 AB15
11 AB11
12 AB4
13 AB6
14

FIG. 14


Dose response curves for CLDN mAb primary - MMAE linked secondary
% Inhibition
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
0.0001
0.001
0.01
0.1
1
10
100
Antibody Concentration (nM)
AB10
AB15
AB11
AB7
AB3
AB2
AB4
AB6
AB13
Mouse IgG
Reference Ab2
MMAE only
AB5
Reference Ab1


FIG. 15B
Δ in Tumor Volume mm3
450
400
350
300
250
200
150
100
50
0
-50
Vehicle control PBS
Human IgG 10mg/kg Q4D
AB3-2 10mg/kg Q4D
AB3-4 10mg/kg Q4D
AB3-MOUSE 10mg/kg Q4D


FIG. 15A
Tumor Volume mm3
600
550
500
450
400
350
300
250
200
150
100
-5
5
15
25
35
Days
Dose
Vehicle control PBS
Human IgG 10mg/kg Q4D
AB3-2 10mg/kg Q4D
AB3-4 10mg/kg Q4D
AB3-MOUSE 10mg/kg Q4D



FIG. 16A
Tumor Volume mm3
600
550
500
450
400
350
300
250
200
150
100
-5
5
15
25
35
Days
Dose
Vehicle control PBS
Human IgG 10mg/kg Q4D
AB3-2 10mg/kg Q4D
AB3-4 10mg/kg Q4D
AB3-MOUSE 10mg/kg Q4D
64A-MSE 10mg/kg Q4D
64A-CHIM 10mg/kg Q4D
FIG. 16B
Δ in Tumor Volume mm3
450
400
350
300
250
200
150
100
50
0
-50
Vehicle control PBS
Human IgG 10mg/kg Q4D
AB3-2 10mg/kg Q4D
AB3-4 10mg/kg Q4D
AB3-MOUSE 10mg/kg Q4D
64A-MSE 10mg/kg Q4D
64A-CHIM 10mg/kg Q4D

FIG. 17A




FIG. 17B




FIG. 18A




FIGURE 18A

FIG. 18B




FIGURE 18B




FIGURE 19B




FIGURE 19A

FIG. 20




FIGURE 20




FIG. 21

FIGURE 21

FIG. 22





Heavy Chain Variable Region (VH)
Light Chain Variable Region (VL)
hAB3
EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAQIRLKSDNYATH
YADSVKGRFTISRDDSKRTVYLQMNSLRAEDTGVYYCNDGFPSGSWGQGTLLTVSS
DIQMTQSPSSLSASVGDRVTITCRISENIYSYLAWYQQKPGKAPKLLVYNAKIL
VEGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHHYTVPWTFGQGTKLEIK
hAB3
S1
EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWIAQIRLKSDNYATH
YTDSVKGRFTISRDDSKRIVYLQMNSLRAEDTGIYYCSDGFPSGSWGQGTLLTVSS
DIQMTQSPSSLSASVGDRVTITCRISENIYSYLAWYQQKPGKAPKLLVYNAKIL
VEGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHHYTVPWTFGQGTKLEIK
S1
S2
EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWIAQIRLKSDNYATH
YADSVKGRFTISRDDGKRTVYLQMNSLRAEDTGTYYCSDGFPSGSWGQGTLLTVSS
DIQMTQSPSSLSASVGDRVTITCRISENIYSYLAWYQQKPGKAPKLLVYNAKIL
VSGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHHYTVPWTFGQGTKLEIK
S2
S3
EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWIAQIRLKSDRYVTH
YTDSVKGRFTISRDDGKRTVYLQMNSLRASDTGIYYCSDGFPSGSWGQGTLLTVSS
DIQMTQSPSSLSASVGDRVTITCRISENIYSYLAWYQQKPGKAPKLLVYNAKIL
VSGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHHYTVPWTFGQGTKLEIK
S3
S4
EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWIAQIRLKSDWYATH
YTDSVKGRFTISRDDSKSTVYLQMNSLRAEDTGIYYCNDGFPSGSWGQGTLLTVSS
DIQMTQSPSSLSASVGDRVTITCRISENIYSYLAWYQQKPGKAPKLLVYNAKIL
VEGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHEYTVPWTFGQGTKLEIK
S4
S5
EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWLAQIRLKSDWYATH
YTDSVKGRFTISRDDSKRTVYLQMNSLRAEDTGIYYCSDGFPSGSWGQGTLLTVSS
DIQMTQSPSSLSASVGDRVTITCRIPERIYSYLAWYQQKPGKAPKLLVYNAKIL
VEGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHRYTVPWTFGQGTKLEIK
S5
S6
EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWLAQIRLKSDNYVTH
YADSVKGRFTISRDDSKRTVYLQMNSLRAEDTGTYYCNDGFPSGSWGQGTLLTVSS
DIQMTQSPSSLSASVGDRVTITCRIPERIYSYLAWYQQKPGKAPKLLVYNAKIL
VEGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHRYTVPWTFGQGTKLEIK
S6
hAB1
QVQLVQSGAEVKKPGASVKMSCKASGYTFTTYTMHWVRQAPGQGLEWIGFINPSSGYTDYA
QKFQGRVTLTADKSTSTVYMELSSLRSEDTAVYYCANGDYYVAYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTMTCTASSSVSSTYFHWYQQKPGKAPKLWIYSTSN
LASGVPSRFSGSGSGTDYTLTISSMQPEDAATYYCHQYHRSPLTFGQGTKLEIK
hAB1
S7
QVQLVQSGAEVKKPGASVKMSCKASGYTFTTYTIHWVRQAPGQGLEWIGFINPSSGYTEYA
QKFQGRVTLTADKSTSTVYMELSSLRSEDTAVYFCANGDYYVAYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTMTCTASSSVSSTYFHWYQQKPGKAPKLWIYSTSN
LASGVPSRFSGSGSGTDYTLTISSMQPEDAATYYCHQYHRSPLTFGQGTKLEIK
S7
S8
QVQLVQSGAEVKKPGASVKMSCKASGYTFTTYTMHWVRQAPGQGLEWIGVINPSSGYTEYA
QKFQGRVTLTADKSTSTVYMELSSLRSEDTAVYFCANGDYYVGYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTMTCTASSSVSSTYFHWYQQKPGKAPKLWIYSTSN
LASGVPSRFSGSGSGTDYTLTISSMQPEDAATYYCHQYHRSPLTFGQGTKLEIK
S8
S9
QVQLVQSGAEVKKPGASVKMSCKASGYTFTTYTIHWVRQAPGQGLEWIGVINPSSGYTDYA
QKFQGRVTLTADKSTSTVYMELSSLKSEDTAVYFCANGDYYVGYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTMTCTASSSVSSTYFHWYQQKPGKAPKLWIYSTSN
LASGVPSRFSGSGSGTDYTLTISSMQPEDAATYYCHQYHRSPLTFGQGTKLEIK
S9
S10
QVQLVQSGAEVKKPGASVKMSCKASGYTFTTYTMHWVRQAPGQGLEWIGFINPSSGYTEYA
QKFQGRVTLTADKSTSTVYMELSSLRSEDTAVYYCANGDYYVGYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTMTCTASSSVSSTYFHWYQQKPGKAPKLWIYSTSN
LASGVPSRFSGSGSGTDYTLTISSMQPEDAATYYCHQYHRSPLTFGQGTKLEIK
S10
S11
QVQLVQSGAEVKKPGASVKMSCKASGYTFTTYTIHWVRQAPGQGLEWIGVINPSSGYTEYA
QKFQGRVTLTADKSTSTVYMELSSLRSEDTAVYFCANGDYYVAYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTMTCTASSSVSSTYFHWYQQKPGKAPKLWIYSTSN
LASGVPSRFSGSGSGTDYTLTISSMQPEDAATYYCHQYHRSPLTFGQGTKLEIK
S11
S12
QVQLVQSGAEVKKPGASVKMSCKASGYTFTTYTMHWVRQAPGQGLEWIGFINPSSGYTEYA
QKFQGRVTLTADKSTSTVYMELSSLRSEDTAVYFCANGDYYVGYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTMTCTASSSVSSTYFHWYQQKPGKAPKLWIYSTSN
LASGVPSRFSGSGSGTDYTLTISSMQPEDAATYYCHQYHRSPLTFGQGTKLEIK
S12

FIG. 23




AB3 Heavy Chain: A(H24)SV, G(H26)V, N(H31)D, V(H48)IL, A(H56)V, A(H60)T, S(N76)RK, A(H84)T, I(H89)T, Y(H91)F, A(H93)S, C(H102)W

FIG. 24




AB3 LightChain: A(L25)IVL, T(L53)I, V(L55)A, S(L85)TNR,

FIG. 25



AB1 Heavy Chain: S(H31)T, M(H34)IL, Y(H50)FV, T(H57)S, D(H58)E, K(H62)N, D(H72)G, K(H73)R, A(H78)V, S(H82a)N, Y(H98)F, A(H101)G

FIG. 26



AB1 Light Chain: S(L31)TIN, L(L33)FM, A(H60)RVPT, N(H53)TK

FIG. 27

	D	E	F	G	H	I	J	K	L	N	O	P	Q
1	Concentration (mg/ml)	PuritySDS-PAGE(%)	Adjusted concentration (mg/ml)	4.5ug antibody (µl)	PBS to make 45ul	HEK293T parental 1.0ug	HEK293T CLDN6 Clone A11 1.0ug	MJ02-1.0ug	AE4-2-1.0ug	HEK293T parental 1.0ug GFP	HEK293T CLDN6 Clone A11 1.0ug GFP	MJ02-1.0ug GFP	AE4-2-1.0ug GFP
2	4.04	95	3.84	1.17	43.83	790.77	159,670.25	1,577.77	26,871.38	1,987.72	269,609.72	3,129.07	2,547.29
3	4.86	95	4.62	0.97	44.03	775.16	162,035.52	1,031.60	38,481.74	2,000.32	255,311.20	3,132.12	3,039.45
4	4.19	90	3.77	1.19	43.81	1,012.63	179,393.08	1,766.40	40,340.11	2,035.44	268,949.57	3,125.73	3,264.88
5	4.04	90	3.64	1.24	43.76	871.63	103,300.51	1,126.11	13,041.68	2,099.52	256,942.66	3,199.44	3,037.91
6	4.6	90	4.14	1.09	43.91	1,182.99	172,763.22	1,619.41	45,508.76	2,247.94	218,014.63	3,097.02	3,138.87
7	3.87	90	3.48	1.29	43.71	1,776.60	137,752.47	1,911.32	30,006.33	2,313.18	247,752.35	3,077.88	2,883.57
8	10	100	10.00	0.45	44.55	588.33	107,697.75	711.13	11,164.56	2,342.33	231,265.77	3,195.62	3,260.58
9	7.57	95	7.19	0.63	44.37	760.56	140,464.50	859.31	30,749.09	2,641.52	444,449.47	2,500.27	3,185.14
10	9.03	95	8.58	0.52	44.48	1,032.63	142,124.71	4,291.82	157,421.48	2,865.74	454,865.34	4,413.56	2,906.09
11	3.56	95	3.38	1.33	43.67	996.33	168,768.81	1,359.04	133,707.53	2,806.37	460,890.24	2,415.04	3,467.41
12	9.27	90	8.34	0.54	44.46	731.67	148,025.10	1,122.48	81,039.93	2,882.36	466,422.96	2,450.33	2,685.77
13	3.82	95	3.63	1.24	43.76	738.75	141,975.03	813.74	109,817.51	2,637.38	459,943.61	2,514.71	2,695.76
14	1.58	95	1.50	3.00	42.00	979.19	157,476.89	1,208.61	110,696.17	2,814.89	448,763.93	2,551.39	3,612.99
15	10	100	10.00	0.45	44.55	1,049.34	158,381.29	4,056.15	61,308.34	2,877.20	443,566.10	4,653.58	2,849.07

Row 1: AB-S1
Row 2: AB-S2
Row 3: AB-S3
Row 4: AB-S4
Row 5: AB-S5
Row 6: AB-S6
Row 8: humanized AB3-7
Row 9: AB-S7
Row 10: AB-S8
Row 11: AB-S9
Row 12: AB-S10
Row 13: AB-S11
Row 14: AB-S12
Row 15: humanized AB1-11

Column L: cell line artificially overexpressing CLDN6
Column K: cell line with no CLDN6 expression
Column L: cell line with high endogenous expression of CLDN6

FIG. 28

OV90

nM	AB3-7	AB-S1	AB-S2	AB-S3	AB-S4	AB-S5	AB-S6	AB1-11	AB-S7	AB-S8	AB-S9	AB-S10	AB-S11	AB-S12
1000	9,389.47	100,508.46	107,583.14	117,618.48	41,952.41	152,671.44	76,606.87	72,082.35	53,936.15	236,772.66	241,453.66	126,164.17	152,526.36	83,366.67
200	2,333.88	43,482.65	53,386.01	63,076.33	15,902.41	73,314.68	38,596.51	32,455.99	24,011.58	166,575.11	181,477.29	87,858.12	85,582.87	38,509.78
40	1,140.44	10,526.93	18,070.76	19,511.47	4,594.96	22,485.01	12,605.56	7,824.04	9,568.44	85,915.42	116,775.96	50,429.98	44,913.69	14,607.92
8	565.19	2,354.72	3,954.59	4,470.79	1,359.68	5,219.16	2,954.23	2,146.37	4,496.10	26,639.71	46,479.21	16,284.66	14,736.67	4,631.10
1.6	566.87	667.93	1,510.81	1,044.49	514.67	1,041.22	790.82	782.7	1,912.08	6,407.08	13,986.99	4,685.86	4,949.98	1,262.03
0.32	393.29	474.6	536.69	482.04	431.92	557.96	466.55	451.73	586.44	834.48	2,938.23	861.52	1,456.35	637.98


ARK2

nM	AB3-7	AB-S1	AB-S2	AB-S3	AB-S4	AB-S5	AB-S6	AB1-11	AB-S7	AB-S8	AB-S9	AB-S10	AB-S11	AB-S12
1000	11,368.22	130,296.91	133,590.43	126,711.61	62,464.84	140,706.27	104,178.29	50,496.68	76,677.97	249,374.07	255,448.66	159,906.22	149,284.66	119,570.23
200	3,056.92	62,480.67	83,339.84	83,601.27	31,634.82	79,817.38	54,104.45	16,448.77	46,995.00	216,273.24	241,564.12	124,517.63	137,991.27	62,341.09
40	1,636.26	25,787.60	21,029.91	24,569.08	6,352.34	25,677.71	14,613.41	3,462.10	15,969.78	105,970.32	136,679.79	68,155.49	59,411.70	22,940.15
8	991.01	3,849.71	4,942.46	4,828.11	1,717.35	5,558.19	3,200.96	2,286.95	6,294.39	42,563.87	54,575.38	27,535.46	20,101.53	8,853.51
1.6	538.72	1,383.77	955.93	932.37	438.42	996.98	765.41	636.75	2,354.82	10,396.67	16,443.66	7,686.98	6,085.07	2,062.83
0.32	402.37	466.3	608.48	371.86	354.47	372.11	447.6	377.07	876.2	1,536.34	2,993.63	2,082.26	2,134.09	1,313.75

UMUC4

nM	AB3-7	AB-S1	AB-S2	AB-S3	AB-S4	AB-S5	AB-S6	AB1-11	AB-S7	AB-S8	AB-S9	AB-S10	AB-S11	AB-S12
1000	9,837.80	41,530.55	56,705.72	49,256.69	35,012.80	47,248.78	42,259.10	27,177.86	37,333.06	40,515.64	69,054.34	35,094.89	33,385.97	48,557.38
200	2,112.03	18,694.04	20,045.12	20,752.72	13,455.55	19,044.48	12,538.34	15,700.59	16,749.15	32,938.87	35,578.77	22,232.27	19,859.43	37,530.08
40	1,115.88	6,678.95	6,965.68	7,782.50	4,121.95	7,079.11	4,120.12	4,158.48	7,974.52	16,552.19	23,910.57	9,941.51	12,811.06	14,751.85
8	724.24	2,333.28	2,256.97	1,963.06	1,238.77	2,342.93	3,300.30	1,605.67	3,939.26	7,200.07	19,833.21	6,651.23	6,556.29	5,035.45
1.6	569.69	766.79	745.16	646.96	651.25	884.61	1,685.97	839.48	1,791.21	6,216.09	11,603.22	2,538.59	2,765.67	1,913.10
0.32	604.17	639.23	506.04	532.85	518.11	491.4	1,318.59	617.87	1,441.28	719.98	1,910.36	873.75	2,346.83	947.24

FIG. 29A






FIG. 29B

FIG. 30



Hu-IgG Control 10mg/kg IV Q4D
Humanized AB1-11 (10 mg/kg: Q4D: IV)
Humanized AB3-7 (10 mg/kg: Q4D: IV)
Tumor Volume mm3
550
500
450
400
350
300
250
200
150
100
0
3
6
9
12
15
18
21
24
27
30
33
36
Dose
Days

FIG. 31



Human IgG Control (10 mg/kg: QW: IV)
Humanized AB1-11 (10 mg/kg: QW: IV)
Humanized AB3-7 (10 mg/kg: QW: IV)
Tumor Volume mm3
600
550
500
450
400
350
300
250
200
150
100
0
3
6
9
12
15
18
21
Days
Dose

FIG. 32




Control human IgG ab (10 mg/kg: QW: IV)
Humanized AB1-11 (10 mg/kg: QW: IV)
Untargeted ADC with control ab (5 mg/kg: QW: IV)
Targeted ADC with AB1-11 (5 mg/kg: QW: IV)
Tumor Volume mm3
600
550
500
450
400
350
300
250
200
150
100
0
5
10
15
20
Days
Dose

FIG. 33


Control human IgG1 ab (10 mg/kg: QW: IV)
Humanized AB1-11 (10 mg/kg: QW: IV)
Targeted ADC with AB1-11 (5 mg/kg: QW: IV)
Untargeted ADC with control ab (5 mg/kg: QW: IV)
Tumor Volume mm3
1,200
1,000
800
600
400
200
0
0
10
20
30
40
50
60
70
80
90
Days
ADCDose
mAb Dose

Summary table

FIG. 34A

WuXi Biologics

Lot#	HIC-DAR	SEC-DAR	D4 (%)	Un-conjugated (%)	Conc. (mg/ml)	Purity (%)	HMWs (%)	Free drug (%)	Endotoxin (EU/mg)	Yield (mg)
WBP2227-20191210-23-7-MC-vc-PAB-MMAE-CTRL	3.92	-	33.0	6.0	5.21	97.8	2.2	1.1	0.1	65
WBP2227-20200102-23-7-MC-vc-PAB-MMAE-D4	4.06	-	74.9	2.4	4.15	96.8	3.2	< 0.2	0.2	64
WBP2227-20200109-23-7-MC-GGFG-MMAE-D4	3.91	-	71.6	3.0	3.90	96.2	1.8	0.4[c]	0.4[d]	55
WBP2227-20191211-23-7-CL2A-SN38-CTRL[a]	-	4.02	-	13.0	2.85	96.7	3.3	< 1[c]	0.1[d]	52
WBP2227-20200113-23-7-CL2A-SN38-D4[b]	-	4.26	73.1	6.0	4.37	97.1	2.9	< 1[c]	0.1[d]	62
WBP2227-20200107-23-7-MC-GGFG-Dxd	3.90	-	64.1	6.2	3.22	97.1	2.9	0.4	0.1[d]	65
WBP2227-20200113-23-7-MC-vc-PAB-Dxd[b]	3.90	-	61.4	10.3	4.25	97.9	2.1	1.87	0.2	66

Confidential Information

- Storage buffer and temperature: 20 mM L-Histidine, pH 5.5; -80 ° C;
- DAR and Unconjugated mAb determined by HIC-HPLC
- Concentration determined by Nanodrop One;
- Purity and aggregation determined by SEC-HPLC;
- Free drug determined by RP-HPLC with C18 column;
- Endotoxin level determined by endosafe-PTS 9547.

a. Storage buffer and temperature: 20 mM Succinic Acid, pH 6.0; -80 ° C;

b. Storage buffer and temperature: 20 mM L-Histidine, pH 6.0; -80 ° C;

c. Free drug determined by RP-HPLC-Mass Spectrum with C4 column;

d. Endotoxin level determined by kinetic turbidimetric limulus tests.



WuXi Biologics
Product HIC-HPLC
23-7-MC-vc-PAB-MMAE-CTRL
FIG. 34B
23-7-CL2A-SN38-CTRL
FIG. 34E
23-7-MC-vc-PAB-MMAE-D4
FIG. 34C
23-7-CL2A-SN38-D4
FIG. 34F
23-7-MC-GGFG-MMAE-D4
FIG. 34D
23-7-MC-GGFG-DXd-D4
FIG. 34G
23-7-MC-vc-PAB-DXd-D4
FIG. 34H
Confidential Information

FIG. 35



1-MC-vc-PAB-MMAE-CTRL
2-MC-vc-PAB-MMAE-D4
3-MC-GGFG-MMAE-D4
4-CL2A-SN38-CTRL
5-CL2A-SN38-D4
6-MC-GGFG-Dxd
7-MC-vc-PAB-Dxd
23-7 naked Ab

FIG. 36

	CLDN6-ADCs	Label in Flow	0.1μg Ab/Sample			1μg Ab/Sample		
			Positive Cell Line	Positive Artificial OE Cell Line	Negative Cell Line	Positive Cell Line	Positive Artificial OE Cell Line	Negative Cell Line
			UMUC4	HEK293T CLDN6-mGFP A11	M202	UMUC4	HEK293T CLDN6-mGFP A11	M202
1	WBP2227-20191219-23-7-MC-vc-PAB-MMAE-CTRL	23-7-ADC1	8,919.55	128,083.32	927.12	28,820.18	204,123.83	862.54
2	WBP2227-20200102-23-7-MC-vc-PAB-MMAE-D4	23-7-ADC2	9,446.99	126,605.73	893.31	26,899.61	242,085.63	913.31
3	WBP2227-20200109-23-7-MC-GGFG-MMAE-D4	23-7-ADC3	8,789.80	135,063.24	769.02	31,565.36	274,145.07	726.01
4	WBP2227-20191231-23-7-CL2A-SN38-CTRL	23-7-ADC4	9,986.85	125,873.13	730.25	33,821.28	257,400.13	914.24
5	WBP2227-20200113-23-7-CL2A-SN38-D4	23-7-ADC5	9,138.96	134,515.99	831.15	34,593.90	212,790.01	796.68
6	WBP2227-20200107-23-7-MC-GGFG-Dxd	23-7-ADC6	10,489.23	120,680.42	854.62	32,801.26	196,185.70	823.43
7	WBP2227-20200113-23-7-MC-vc-PAB-Dxd	23-7-ADC7	10,793.44	110,404.22	741.90	32,637.46	194,003.99	939.83
8	CLDN6 #23-7 Naked Ab (the Same Batch)	23-7	8,823.06	107,267.03	744.69	27,278.44	232,045.32	833.69
9	2nd Ab only	2nd Ab only	1,114.73	1,242.89	778.99	1,114.73	1,242.89	778.99

FIG. 37

CLDN6 ADCs	KD			Expression Level		Equilibrium Curves	Cell Model	Cells Detached by
	KD (nM)	Error%	95% Confidence Interval (CI)	Expression Level	95% Confidence Interval (CI)			
WBP2227-20191219-23-7-MC-vc-PAB-MMAE-CTRL	6.68	3.59	3.41nM - 14.99nM	9.843E+05	5.714E+05 - 2.220E+06	500pM, 10nM	HEK293T CLDN6-mGFP A11	Versene
WBP2227-20200102-23-7-MC-vc-PAB-MMAE-D4	5.34	4.89	1.49nM - 17.05nM	4.324E+05	1.112E+05 - 1.447E+06	500pM, 10nM		
WBP2227-20200109-23-7-MC-GGFG-MMAE-D4	1.01	2.84	0.56nM - 1.66nM	6.769E+05	5.015E+05 - 9.045E+05	500pM, 10nM		
WBP2227-20191231-23-7-CL2A-SN38-CTRL	1.91	3.45	1.05nM - 3.38nM	9.892E+05	7.024E+05 - 1.456E+06	500pM, 10nM		
WBP2227-20200113-23-7-CL2A-SN38-D4	2.87	4.65	1.07nM - 7.74nM	9.535E+05	4.935E+05 - 2.206E+06	500pM, 10nM		
WBP2227-20200107-23-7-MC-GGFG-Dxd	3.01	3.05	1.46nM - 6.47nM	9.922E+05	6.106E+05 - 1.822E+06	500pM, 10nM		
WBP2227-20200113-23-7-MC-vc-PAB-Dxd	3.42	2.52	2.10nM - 5.42nM	5.176E+05	3.440E+05 - 7.643E+05	500pM, 10nM		
CLDN6 Ab #23-7 (Naked Ab)	1.13	2.57	0.53nM - 2.03nM	4.821E+05	3.155E+05 - 6.993E+05	500pM, 10nM		

FIG. 38



h23-7-ADC#1
23-7-MC-vc-PAB-MMAE
Conventional conjugation method
h23-7-ADC#2
23-7-MC-vc-PAB-MMAE
High D4 technology
h23-7-ADC#3
23-7-GGFG-MMAE
High D4 technology
h23-7-ADC#4
23-7-CL2A-SN38
Conventional conjugation method
h23-7-ADC#5
23-7-CL2A-SN38
High D4 technology
h23-7-ADC#6
23-7-MC-GGFG-DXd
High D4 technology
h23-7-ADC#7
23-7-MC-vc-PAB-DXd
High D4 technology
h23-7 naked
Same batch as we sent to Wuxi

FIG. 39A




FIG. 39B




FIG. 39C




FIG. 39D




FIG. 39E




FIG. 39F




FIG. 39G




FIG. 39H




FIG. 39I




FIG. 39J




FIG. 39K




FIG. 39L




FIG. 39M




FIG. 39N




FIG. 40



Hu-IgG 10mg/kg IV QW
hu11 10mg/kg IV QW
Non-TarGeting ADC Control 5mg/kg IV QW
ADC -11 5mg/kg 10mg/kg IV QW
600
500
400
300
200
100
0
0
5
10
15
20
25
30
Days

FIG. 41A




FIG. 41B




FIG. 42A




FIG. 42B




FIG. 43A





FIG. 43B





FIG. 43C
DF149 Survival
DF149 IgG
DF149 CLDN6 Hu23
DF149 CLDN6 ADC
Percent survival
Days
FIG. 43D
DF181 Survival
DF181 IgG
DF181 CLDN6 Hu23
DF181 CLDN6 ADC
Percent survival
Days
FIG. 43E
DF20 Survival
DF20 IgG
DF20 CLDN6 Hu23
DF20 CLDN6 ADC
Percent survival
Days

FIG. 44A




FIG. 44B




FIG. 44C

FIG. 45A




FIG. 45B




FIG. 45C

SEQUENCE LISTING

<110> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

<120> CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES

<130> 32424/54086P1

<160> 513

<170> PatentIn version 3.5

<210> 1
<211> 220
<212> PRT
<213> Homo sapiens

<300>
<308> NCBI / NP_067018.2
<309> 2017-06-04
<313> (1)..(220)

<400> 1

```
Met Ala Ser Ala Gly Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu
1               5                  10                  15


Gly Trp Val Asn Gly Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val
            20                  25                  30


Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Val Val Trp Glu
        35                  40                  45


Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
    50                  55                  60


Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65                  70                  75                  80


Arg Ala Leu Cys Val Ile Ala Leu Leu Val Ala Leu Phe Gly Leu Leu
                85                  90                  95


Val Tyr Leu Ala Gly Ala Lys Cys Thr Thr Cys Val Glu Glu Lys Asp
            100                 105                 110
```

```
Ser Lys Ala Arg Leu Val Leu Thr Ser Gly Ile Val Phe Val Ile Ser
        115                 120                 125


Gly Val Leu Thr Leu Ile Pro Val Cys Trp Thr Ala His Ala Ile Ile
    130                 135                 140


Arg Asp Phe Tyr Asn Pro Leu Val Ala Glu Ala Gln Lys Arg Glu Leu
145                 150                 155                 160


Gly Ala Ser Leu Tyr Leu Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
                165                 170                 175


Gly Gly Gly Leu Leu Cys Cys Thr Cys Pro Ser Gly Gly Ser Gln Gly
            180                 185                 190


Pro Ser His Tyr Met Ala Arg Tyr Ser Thr Ser Ala Pro Ala Ile Ser
        195                 200                 205


Arg Gly Pro Ser Glu Tyr Pro Thr Lys Asn Tyr Val
    210                 215                 220


<210>  2
<211>  23
<212>  PRT
<213>  Homo sapiens

<400>  2

Trp Thr Ala His Ala Ile Ile Arg Asp Phe Tyr Asn Pro Leu Val Ala
1               5                   10                  15


Glu Ala Gln Lys Arg Glu Leu
            20


<210>  3
<211>  13
<212>  PRT
<213>  Homo sapiens
```

<400> 3

Thr Ala His Ala Ile Ile Arg Asp Phe Tyr Asn Pro Leu
1   5   10

<210> 4
<211> 10
<212> PRT
<213> Homo sapiens

<400> 4

Leu Val Ala Glu Ala Gln Lys Arg Glu Leu
1   5   10

<210> 5
<211> 220
<212> PRT
<213> Homo sapiens

<300>
<308> NCBI / NP_001297.1
<309> 2017-07-10
<313> (1)..(220)

<400> 5

Met Ser Met Gly Leu Glu Ile Thr Gly Thr Ala Leu Ala Val Leu Gly
1   5   10   15

Trp Leu Gly Thr Ile Val Cys Cys Ala Leu Pro Met Trp Arg Val Ser
            20   25   30

Ala Phe Ile Gly Ser Asn Ile Ile Thr Ser Gln Asn Ile Trp Glu Gly
        35   40   45

Leu Trp Met Asn Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys Lys
    50   55   60

Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala Arg
65   70   75   80

Ala Leu Ile Val Val Ala Ile Leu Leu Ala Ala Phe Gly Leu Leu Val

```
                85                  90                  95

Ala Leu Val Gly Ala Gln Cys Thr Asn Cys Val Gln Asp Asp Thr Ala
            100                 105                 110

Lys Ala Lys Ile Thr Ile Val Ala Gly Val Leu Phe Leu Leu Ala Ala
        115                 120                 125

Leu Leu Thr Leu Val Pro Val Ser Trp Ser Ala Asn Thr Ile Ile Arg
    130                 135                 140

Asp Phe Tyr Asn Pro Val Val Pro Glu Ala Gln Lys Arg Glu Met Gly
145                 150                 155                 160

Ala Gly Leu Tyr Val Gly Trp Ala Ala Ala Ala Leu Gln Leu Leu Gly
                165                 170                 175

Gly Ala Leu Leu Cys Cys Ser Cys Pro Pro Arg Glu Lys Lys Tyr Thr
            180                 185                 190

Ala Thr Lys Val Val Tyr Ser Ala Pro Arg Ser Thr Gly Pro Gly Ala
        195                 200                 205

Ser Leu Gly Thr Gly Tyr Asp Arg Lys Asp Tyr Val
    210                 215                 220


<210>  6
<211>  209
<212>  PRT
<213>  Homo sapiens

<300>
<308>  NCBI / NP_001296.1
<309>  2017-07-10
<313>  (1)..(209)

<400>  6

Met Ala Ser Met Gly Leu Gln Val Met Gly Ile Ala Leu Ala Val Leu
1               5                   10                  15
```

```
Gly Trp Leu Ala Val Met Leu Cys Cys Ala Leu Pro Met Trp Arg Val
            20                  25                  30

Thr Ala Phe Ile Gly Ser Asn Ile Val Thr Ser Gln Thr Ile Trp Glu
        35                  40                  45

Gly Leu Trp Met Asn Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
    50                  55                  60

Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65                  70                  75                  80

Arg Ala Leu Val Ile Ile Ser Ile Ile Val Ala Ala Leu Gly Val Leu
                85                  90                  95

Leu Ser Val Val Gly Gly Lys Cys Thr Asn Cys Leu Glu Asp Glu Ser
            100                 105                 110

Ala Lys Ala Lys Thr Met Ile Val Ala Gly Val Val Phe Leu Leu Ala
        115                 120                 125

Gly Leu Met Val Ile Val Pro Val Ser Trp Thr Ala His Asn Ile Ile
    130                 135                 140

Gln Asp Phe Tyr Asn Pro Leu Val Ala Ser Gly Gln Lys Arg Glu Met
145                 150                 155                 160

Gly Ala Ser Leu Tyr Val Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
                165                 170                 175

Gly Gly Gly Leu Leu Cys Cys Asn Cys Pro Pro Arg Thr Asp Lys Pro
            180                 185                 190

Tyr Ser Ala Lys Tyr Ser Ala Ala Arg Ser Ala Ala Ala Ser Asn Tyr
        195                 200                 205

Val
```

<210> 7
<211> 217
<212> PRT
<213> Homo sapiens

<300>
<308> NCBI / NP_066192.1
<309> 2017-04-15
<313> (1)..(217)

<400> 7

```
Met Ala Ser Thr Gly Leu Glu Leu Leu Gly Met Thr Leu Ala Val Leu
1               5                   10                  15


Gly Trp Leu Gly Thr Leu Val Ser Cys Ala Leu Pro Leu Trp Lys Val
            20                  25                  30


Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Val Val Trp Glu
        35                  40                  45


Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
    50                  55                  60


Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65                  70                  75                  80


Arg Ala Leu Cys Val Ile Ala Leu Leu Leu Ala Leu Leu Gly Leu Leu
                85                  90                  95


Val Ala Ile Thr Gly Ala Gln Cys Thr Thr Cys Val Glu Asp Glu Gly
            100                 105                 110


Ala Lys Ala Arg Ile Val Leu Thr Ala Gly Val Ile Leu Leu Leu Ala
        115                 120                 125


Gly Ile Leu Val Leu Ile Pro Val Cys Trp Thr Ala His Ala Ile Ile
    130                 135                 140
```

```
Gln Asp Phe Tyr Asn Pro Leu Val Ala Glu Ala Leu Lys Arg Glu Leu
145                 150                 155                 160


Gly Ala Ser Leu Tyr Leu Gly Trp Ala Ala Ala Ala Leu Leu Met Leu
                165                 170                 175


Gly Gly Gly Leu Leu Cys Cys Thr Cys Pro Pro Pro Gln Val Glu Arg
            180                 185                 190


Pro Arg Gly Pro Arg Leu Gly Tyr Ser Ile Pro Ser Arg Ser Gly Ala
        195                 200                 205


Ser Gly Leu Asp Lys Arg Asp Tyr Val
    210                 215


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  8

Ser Ser Val Ser Ser Thr Tyr
1               5


<210>  9
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  9

Ser Thr Ser
1


<210>  10
```

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 10

His Gln Tyr His Arg Ser Pro Leu Thr
1 5

<210> 11
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 11

Gly Tyr Thr Phe Thr Thr Tyr Thr
1 5

<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 12

Ile Asn Pro Ser Ser Gly Tyr Thr
1 5

<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 13

Ala Asn Gly Asp Tyr Tyr Val Ala Tyr
1 5

<210> 14
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 14

Glu Asn Ile Tyr Ser Tyr
1 5

<210> 15
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 15

Asn Ala Lys
1

<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 16

Gln His His Tyr Thr Val Pro Trp Thr
1 5

<210> 17
<211> 8
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 17

Gly Phe Thr Phe Ser Asp Tyr Trp
1 5

<210> 18
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 18

Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr
1 5 10

<210> 19
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 19

Asn Asp Gly Pro Pro Ser Gly Cys
1 5

<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 20

Glu Asn Ile Tyr Ser Tyr

1 5

<210> 21
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 21

Asn Ala Lys
1

<210> 22
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 22

Gln His His Tyr Thr Val Pro Trp Thr
1 5

<210> 23
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 23

Gly Phe Thr Phe Ser Asn Tyr Trp
1 5

<210> 24
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 24

Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr
1   5   10

<210> 25
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 25

Asn Asp Gly Pro Pro Ser Gly Cys
1   5

<210> 26
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 26

Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr
1   5   10

<210> 27
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 27

Lys Val Ser
1

<210> 28
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 28

Ser Gln Ser Thr His Val Pro Tyr Thr
1   5

<210> 29
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 29

Gly Tyr Thr Phe Thr Ser Tyr Thr
1   5

<210> 30
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 30

Ile Asn Pro Ser Ser Thr Tyr Thr
1   5

<210> 31
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 31

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr
1 5 10

<210> 32
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 32

Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr
1 5 10

<210> 33
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 33

Lys Val Ser
1

<210> 34
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 34

Phe Gln Gly Ser His Val Pro Phe Thr
1 5

<210> 35

<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 35

Gly Tyr Ile Phe Thr His Tyr Ile
1 5

<210> 36
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 36

Ile Asn Pro Tyr Asn Asp Gly Thr
1 5

<210> 37
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 37

Ala Arg Tyr Tyr Gly Tyr Pro Tyr Tyr Ser Met Asp Tyr
1 5 10

<210> 38
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 38

Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Asn Tyr
1 5 10

<210> 39
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 39

Trp Ala Ser
1

<210> 40
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 40

Lys Gln Ser Tyr Tyr Leu Tyr Thr
1 5

<210> 41
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 41

Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr
1 5

<210> 42
<211> 7
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 42

Ile Ser Tyr Asp Gly Gly Ile
1 5

<210> 43
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 43

Ala Arg Phe Gly Lys Gly Ala Met Asp Tyr
1 5 10

<210> 44
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 44

Ser Ser Val Ser Ser Ser Tyr
1 5

<210> 45
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 45

Ser Thr Ser

1

<210> 46
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 46

His Gln Tyr His Arg Ser Pro Pro Thr
1 5

<210> 47
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 47

Gly Tyr Ser Phe Thr Gly Tyr Thr
1 5

<210> 48
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 48

Ile Asn Pro Tyr Asn Gly Gly Thr
1 5

<210> 49
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 49

Ala Arg Gly Val Tyr Asp Tyr Asp Gly Phe Thr Tyr
1   5   10

<210> 50
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 50

Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr
1   5   10

<210> 51
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 51

Lys Val Ser
1

<210> 52
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 52

Ser Gln Ser Thr His Val Pro Tyr Thr
1   5

<210> 53
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 53

Gly Tyr Thr Phe Thr Thr Tyr Thr
1 5

<210> 54
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 54

Ile Asn Pro Arg Ser Gly Tyr Ser
1 5

<210> 55
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 55

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr
1 5 10

<210> 56
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 56

Gln Thr Ile Gly Thr Trp
1 5

<210> 57
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 57

Ala Ala Ala
1

<210> 58
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 58

Gln Gln Leu Tyr Ser Ile Pro Arg Thr
1 5

<210> 59
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 59

Gly Tyr Arg Phe Thr Asp Tyr Asn
1 5

<210> 60

<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 60

Ile Asn Pro Asn Asn Gly Gly Thr
1 5

<210> 61
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 61

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys
1 5 10

<210> 62
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 62

Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr
1 5 10

<210> 63
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 63

Lys Val Ser
1

<210> 64
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 64

Ser Gln Ile Thr His Val Pro Tyr Thr
1 5

<210> 65
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 65

Gly Tyr Thr Phe Thr Asp Tyr Ser
1 5

<210> 66
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 66

Ile Ser Thr Glu Thr Gly Glu Pro
1 5

<210> 67
<211> 10
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 67

Thr Arg Gly Leu Trp Ser Ser Phe Ala Tyr
1 5 10

<210> 68
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 68

Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
1 5 10

<210> 69
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 69

Leu Ala Ser
1

<210> 70
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 70

Gln His Ser Arg Glu Leu Pro Leu Thr

1 5

<210> 71
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 71

Gly Phe Thr Phe Ser Ser Phe Gly
1 5

<210> 72
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 72

Ile Ser Ser Asp Ser Arg Thr Ile
1 5

<210> 73
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 73

Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr
1 5 10

<210> 74
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 74

Gln Asp Ile Gly Gly Asn
1   5

<210> 75
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 75

Ser Thr Ser
1

<210> 76
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 76

Leu Gln Arg Asn Ala Tyr Pro Leu Thr
1   5

<210> 77
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 77

Gly Phe Thr Phe Ser Ser Tyr Ala
1   5

<210> 78
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 78

Ile Arg Ser Gly Gly Thr Thr
1 5

<210> 79
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 79

Ala Lys Val Gly Gly Asn Pro Tyr Pro Met Asp Tyr
1 5 10

<210> 80
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 80

Ser Ser Ile Ser Ser Asn Tyr
1 5

<210> 81
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 81

Arg Thr Ser
1

<210> 82
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 82

Gln Gln Gly Ser Ser Ile Pro Leu Thr
1 5

<210> 83
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 83

Gly Tyr Ala Phe Ser Asn Tyr Leu
1 5

<210> 84
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 84

Ile Asn Pro Gly Ser Gly Gly Thr
1 5

<210> 85

<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 85

Ala Arg Ser Tyr Phe Gly Arg Ser Tyr Pro Tyr Thr Met Asp Tyr
1 5 10 15

<210> 86
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 86

Gln Ser Val Asp Tyr Asp Gly Asp Asn Tyr
1 5 10

<210> 87
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 87

Ala Ala Ser
1

<210> 88
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 88

Gln Gln Ser Asn Glu Asp Pro Phe Thr
1 5

<210> 89
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 89

Gly Tyr Thr Phe Thr Asp Tyr Ala
1 5

<210> 90
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 90

Ile Ser Thr Tyr Ser Gly Asn Thr
1 5

<210> 91
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 91

Ala Arg Arg Gly Asp Tyr Ser Leu Tyr Ala Met Asp Tyr
1 5 10

<210> 92
<211> 12
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 92

Gln Ser Val Leu Phe Ser Ser Asn Gln Lys Asn Tyr
1 5 10

<210> 93
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 93

Trp Ala Ser
1

<210> 94
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 94

His Gln Tyr Leu Ser Ser Arg Thr
1 5

<210> 95
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 95

Gly Phe Thr Phe Ser Ser Phe Gly

1 5

<210> 96
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 96

Ile Ser Ser Asp Ser Arg Thr Ile
1 5

<210> 97
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 97

Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr
1 5 10

<210> 98
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 98

Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe
1 5 10

<210> 99
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 99

Ala Ala Ser
1

<210> 100
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 100

Gln Gln Ser Lys Glu Val Pro Leu Thr
1   5

<210> 101
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 101

Gly Phe Pro Phe Ser Ser Ser Ala
1   5

<210> 102
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 102

Ile Asn Ser Asp Gly Asn Thr
1   5

<210> 103
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 103

Thr Arg Asn Gly Asp Tyr Arg Tyr Asp Glu Phe Ala Tyr
1   5   10

<210> 104
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 104

Ser Ser Val Ser Ser Ser Tyr
1   5

<210> 105
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 105

Ser Thr Ser
1

<210> 106
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 106

His Gln Tyr His Arg Ser Pro Pro Thr
1 5

<210> 107
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 107

Gly Tyr Thr Phe Thr Gly Tyr Trp
1 5

<210> 108
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 108

Ile Asn Pro Ser Thr Gly Tyr Thr
1 5

<210> 109
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 109

Ala Arg Glu Gly Ile Thr Thr Val Leu Val Asp Tyr
1 5 10

<210> 110

<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 110

Gln Ser Val Leu Phe Ser Ser Asn Gln Lys Asn Tyr
1 5 10

<210> 111
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 111

Trp Ala Ser
1

<210> 112
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 112

His Gln Tyr Leu Ser Ser Arg Thr
1 5

<210> 113
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 113

Gly Tyr Ser Phe Thr Gly Tyr Asn
1 5

<210> 114
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 114

Ile Asp Pro Tyr Tyr Gly Gly Ser
1 5

<210> 115
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 115

Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr
1 5 10

<210> 116
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 116

Gln Ser Val Leu Phe Ser Ser Asn Gln Lys Asn Tyr
1 5 10

<210> 117
<211> 3
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 117

Trp Ala Ser
1

<210> 118
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 118

His Gln Tyr Leu Ser Ser Arg Thr
1 5

<210> 119
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 119

Gly Tyr Ser Phe Thr Gly Tyr Thr
1 5

<210> 120
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 120

Ile Asn Pro Tyr Asn Gly Val Thr

1 5

<210> 121
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 121

Thr Arg Asp Pro Leu Tyr Tyr Gly Tyr Arg Asp Ser Thr Met Asp Tyr
1 5 10 15

<210> 122
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 122

Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr
1 5 10

<210> 123
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 123

Lys Val Ser
1

<210> 124
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 124

Ser Gln Ser Thr His Val Pro Tyr Thr
1   5

<210> 125
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 125

Gly Tyr Thr Phe Thr Ser Tyr Thr
1   5

<210> 126
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 126

Ile Asn Pro Ser Ser Thr Tyr Thr
1   5

<210> 127
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 127

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr
1   5   10

<210> 128
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 128

Gln Gly Ile Arg Gly Asn
1   5

<210> 129
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 129

Ser Thr Ser
1

<210> 130
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 130

Leu Gln Arg Asn Ala Tyr Pro Leu Thr
1   5

<210> 131
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 131

Gly Phe Thr Phe Ser Ser Phe Ala
1 5

<210> 132
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 132

Ile Arg Ser Gly Gly Ile Thr
1 5

<210> 133
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 133

Ala Arg Val Ser Thr Ala Thr Tyr Tyr Gly Met Asp Tyr
1 5 10

<210> 134
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 134

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
1 5 10 15

Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Thr

```
            20                  25                  30

Tyr Phe His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
        35                  40                  45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Arg Arg Phe Ser
    50                  55                  60

Gly Ser Ala Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65                  70                  75                  80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                85                  90                  95

Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
            100                 105


<210>  135
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  135

Gln Val Gln Leu Gln Gln Ser Ala Ala Glu Leu Ala Arg Pro Gly Ala
1               5                   10                  15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20                  25                  30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Asp Tyr Asn Gln Lys Phe
    50                  55                  60

Lys Asp Arg Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Val Tyr
```

65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Asn Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ala
115

<210> 136
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 136

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Glu Thr Val Thr Ile Thr Cys Arg Ile Ser Glu Asn Ile Tyr Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
35 40 45

Tyr Asn Ala Lys Ile Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Gly Asn Tyr Tyr Cys Gln His His Tyr Thr Val Pro Trp
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 137
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 137

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr
85 90 95

Tyr Cys Asn Asp Gly Pro Pro Ser Gly Cys Trp Gly Gln Gly Thr Thr
100 105 110

Leu Ile Val Ser Ser
115

<210> 138
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 138

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1   5   10   15

Glu Thr Val Thr Ile Thr Cys Arg Ile Ser Glu Asn Ile Tyr Ser Tyr
            20   25   30

Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
        35   40   45

Tyr Asn Ala Lys Ile Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
    50   55   60

Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro
65   70   75   80

Glu Asp Phe Gly Asn Tyr Tyr Cys Gln His His Tyr Thr Val Pro Trp
                85   90   95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100   105

<210> 139
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 139

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20   25   30

```
Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu
    50                  55                  60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Ser
65                  70                  75                  80

Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Thr Tyr
                85                  90                  95

Tyr Cys Asn Asp Gly Pro Pro Ser Gly Cys Trp Gly Gln Gly Thr Thr
            100                 105                 110

Leu Ile Val Ser Ser
        115
```

<210> 140
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 140

```
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1               5                   10                  15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20                  25                  30

Asp Gly Asn Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50                  55                  60
```

```
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80


Arg Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
                85                  90                  95


Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110
```

<210> 141
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 141

```
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1               5                   10                  15


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30


Thr Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Gln Glu Trp Ile
        35                  40                  45


Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ile Lys Lys Phe
    50                  55                  60


Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Gln Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95


Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110
```

Val Thr Val Ser Ala
        115

<210> 142
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 142

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1   5   10   15

Asp Gln Pro Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser
            20   25   30

Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35   40   45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
                85   90   95

Ser His Val Pro Phe Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
            100   105   110

<210> 143
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 143

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr His Tyr
            20   25   30

Ile Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Cys Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
    50   55   60

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85   90   95

Ala Arg Tyr Tyr Gly Tyr Pro Tyr Tyr Ser Met Asp Tyr Trp Gly Gln
            100   105   110

Gly Thr Ser Val Thr Val Ser Ser
        115   120

<210> 144
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 144

Ala Ile Val Met Phe Gln Ser Pro Ser Ser Leu Val Val Ser Ala Gly
1   5   10   15

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser

```
            20                  25                  30

Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
        35                  40                  45

Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
    50                  55                  60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65                  70                  75                  80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln
                85                  90                  95

Ser Tyr Tyr Leu Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110
```

<210> 145
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 145

```
Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Ser Ser Gln
1               5                   10                  15

Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
            20                  25                  30

Tyr Tyr Trp Lys Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
        35                  40                  45

Met Gly Tyr Ile Ser Tyr Asp Gly Gly Ile Asn Tyr Asn Pro Ser Leu
    50                  55                  60

Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
```

65 70 75 80

Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Lys Tyr Tyr Cys
85 90 95

Ala Arg Phe Gly Lys Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
100 105 110

Val Thr Val Ser Ser
115

<210> 146
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 146

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
1 5 10 15

Asp Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser
20 25 30

Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
85 90 95

Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 147
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 147

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30

Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile
35 40 45

Gly Leu Ile Asn Pro Tyr Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Val Tyr Asp Tyr Asp Gly Phe Thr Tyr Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ala
115

<210> 148
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 148

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1   5   10   15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20   25   30

Asp Gly Asn Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35   40   45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
                85   90   95

Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 149
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 149

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20   25   30

```
Thr Met His Trp Leu Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45


Gly Tyr Ile Asn Pro Arg Ser Gly Tyr Ser Asn Tyr Asn Gln Lys Phe
    50                  55                  60


Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr
65                  70                  75                  80


Met Gln Leu Asn Thr Leu Thr Ser Glu Asp Ser Lys Val Tyr Tyr Cys
                85                  90                  95


Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110


Val Thr Val Ser Ala
        115


<210>  150
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  150

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly
1               5                   10                  15


Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp
            20                  25                  30


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile
        35                  40                  45


Tyr Ala Ala Ala Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
```

```
Ser Gly Ser Gly Thr Arg Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala
65                  70                  75                  80


Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Ser Ile Pro Arg
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105
```

<210> 151
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 151

```
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr
            20                  25                  30


Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Asn Phe
    50                  55                  60


Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Ala Tyr Tyr Cys
                85                  90                  95


Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Thr
            100                 105                 110
```

Leu Thr Val Ser Ser
        115

<210> 152
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 152

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1   5   10   15

Asp Gln Ala Ser Ile Ser Cys Arg Ala Ser Gln Ser Leu Val His Ser
            20   25   30

Asn Gly Asn Thr Tyr Leu His Trp Phe Leu Gln Lys Pro Gly Gln Ser
        35   40   45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ile
                85   90   95

Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 153
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 153

```
Gln Ile Gln Leu Val Gln Ser Gly Pro Ala Leu Lys Lys Pro Gly Glu
1               5                   10                  15


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30


Ser Met His Trp Ile Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
        35                  40                  45


Gly Trp Ile Ser Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Gly Phe
    50                  55                  60


Lys Gly Arg Phe Asp Phe Ser Leu Glu Thr Ser Ala Asp Thr Ala Tyr
65                  70                  75                  80


Leu Ser Ile Asn Asn Leu Thr Asn Glu Asp Thr Ala Thr Tyr Phe Cys
                85                  90                  95


Thr Arg Gly Leu Trp Ser Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110


Val Thr Val Ser Ala
        115
```

<210> 154
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 154

```
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1               5                   10                  15


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
```

```
            20                  25                  30

Gly Tyr Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
        35                  40                  45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
    50                  55                  60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65                  70                  75                  80

Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
                85                  90                  95

Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
            100                 105                 110
```

<210> 155
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 155

```
Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Arg Gly
1               5                   10                  15

Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
            20                  25                  30

Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Tyr Ile Ser Ser Asp Ser Arg Thr Ile Tyr Tyr Ala Asp Thr Val
    50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Thr Asn Thr Leu Phe
```

65 70 75 80

Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ala
115

<210> 156
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 156

Asp Ile Gln Met Ile Gln Ser Pro Ser Ser Met Phe Ala Ser Leu Gly
1 5 10 15

Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Asp Ile Gly Gly Asn
20 25 30

Leu Asp Trp Tyr Gln Gln Lys Pro Gly Gly Thr Ile Lys Leu Leu Ile
35 40 45

Tyr Ser Thr Ser Asn Leu Asn Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Thr Ser Leu Glu Ser
65 70 75 80

Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Arg Asn Ala Tyr Pro Leu
85 90 95

Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys

100 105

<210> 157
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 157

Glu Val Lys Leu Met Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
35 40 45

Ala Ser Ile Arg Ser Gly Gly Thr Thr Tyr Tyr Pro Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ile Leu Tyr Leu
65 70 75 80

Arg Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95

Lys Val Gly Gly Asn Pro Tyr Pro Met Asp Tyr Trp Gly Gln Gly Thr
100 105 110

Ser Val Thr Val Ser Ser
115

<210> 158
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 158

Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly
1   5   10   15

Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn
            20   25   30

Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu
        35   40   45

Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
    50   55   60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu
65   70   75   80

Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile Pro
                85   90   95

Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
            100   105

<210> 159
<211> 122
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 159

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr
1   5   10   15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asn Tyr
            20   25   30

```
Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe
    50                  55                  60

Lys Gly Lys Ala Thr Met Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80

Met His Leu Ser Asn Leu Thr Ser Glu Asp Ser Val Val Tyr Phe Cys
                85                  90                  95

Ala Arg Ser Tyr Phe Gly Arg Ser Tyr Pro Tyr Thr Met Asp Tyr Trp
            100                 105                 110

Gly Gln Gly Thr Ser Val Thr Val Ser Ser
        115                 120
```

<210> 160
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 160

```
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1               5                   10                  15

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
            20                  25                  30

Gly Asp Asn Tyr Val Asn Trp Tyr Gln Gln Lys Val Gly Gln Pro Pro
        35                  40                  45

Lys Leu Leu Ile Ser Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
    50                  55                  60
```

```
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65                  70                  75                  80


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                85                  90                  95


Glu Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110


<210>  161
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  161

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Val
1               5                   10                  15


Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30


Ala Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Val Ile Ser Thr Tyr Ser Gly Asn Thr Asn Tyr Asn Gln Lys Phe
    50                  55                  60


Gln Asp Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Ala Leu Ala Arg Leu Thr Ser Asp Asp Ser Ala Ile Tyr Tyr Cys
                85                  90                  95


Ala Arg Arg Gly Asp Tyr Ser Leu Tyr Ala Met Asp Tyr Trp Gly Gln
            100                 105                 110
```

Gly Thr Ser Val Thr Val Ser Ser
        115   120

<210> 162
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 162

Asn Ile Met Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1   5   10   15

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
            20   25   30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
        35   40   45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
    50   55   60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65   70   75   80

Ile Ser Asn Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys His Gln
                85   90   95

Tyr Leu Ser Ser Arg Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
            100   105   110

<210> 163
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 163

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Arg Gly
1   5   10   15

Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
            20   25   30

Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val
        35   40   45

Ala Tyr Ile Ser Ser Asp Ser Arg Thr Ile Tyr Tyr Ala Asp Thr Val
    50   55   60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Thr Asn Thr Leu Phe
65   70   75   80

Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                85   90   95

Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr Trp Gly Gln Gly Thr
            100   105   110

Leu Val Thr Val Ser Ala
        115

<210> 164
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 164

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Leu Ser Leu Gly
1   5   10   15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr

20 25 30

Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His
65 70 75 80

Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser Lys
85 90 95

Glu Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 165
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 165

Glu Val Arg Leu Val Glu Ser Gly Gly Gly Leu Met Gln Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Pro Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Ser
20 25 30

Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
35 40 45

Ala Ser Ile Asn Ser Asp Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Arg Asn Ile Leu Tyr Leu

65 70 75 80

Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Thr
85 90 95

Arg Asn Gly Asp Tyr Arg Tyr Asp Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ala
115

<210> 166
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 166

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
1 5 10 15

Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser
20 25 30

Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
85 90 95

Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys

100 105

<210> 167
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 167

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45

Gly Tyr Ile Asn Pro Ser Thr Gly Tyr Thr Glu Ser Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr
65 70 75 80

Met Gln Leu Arg Ser Leu Thr Pro Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Ile Thr Thr Val Leu Val Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Thr Leu Thr Val Ser Ser
115

<210> 168
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 168

Asn Ile Met Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1   5   10   15

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
            20   25   30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
        35   40   45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
    50   55   60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65   70   75   80

Ile Ser Asn Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys His Gln
                85   90   95

Tyr Leu Ser Ser Arg Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
            100   105   110

<210> 169
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 169

Gln Val Gln Leu Lys Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
            20   25   30

```
Asn Met Asn Trp Val Lys Gln Ser Asn Gly Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Ser Thr Tyr Asn Gln Lys Phe
    50                  55                  60


Thr Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Ser Val Thr Val Ser Ser
        115                 120
```

<210> 170
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 170

```
Asn Ile Met Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1               5                   10                  15


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
            20                  25                  30


Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
        35                  40                  45


Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
    50                  55                  60
```

```
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65                  70                  75                  80


Ile Ser Asn Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys His Gln
                85                  90                  95


Tyr Leu Ser Ser Arg Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
            100                 105                 110
```

<210> 171
<211> 123
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 171

```
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Gly
1               5                   10                  15


Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
            20                  25                  30


Thr Met Asn Trp Val Lys Arg Ser His Gly Lys Asn Leu Glu Trp Ile
        35                  40                  45


Gly Leu Ile Asn Pro Tyr Asn Gly Val Thr Thr Tyr Asn Gln Asn Phe
    50                  55                  60


Lys Gly Lys Ala Thr Leu Ala Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Leu Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95


Thr Arg Asp Pro Leu Tyr Tyr Gly Tyr Arg Asp Ser Thr Met Asp Tyr
            100                 105                 110
```

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
        115   120

<210> 172
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 172

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1   5   10   15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20   25   30

Asp Gly Asn Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35   40   45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Arg Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
                85   90   95

Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 173
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 173

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20   25   30

Thr Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Gln Glu Trp Ile
        35   40   45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ile Lys Lys Phe
    50   55   60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65   70   75   80

Met Gln Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85   90   95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100   105   110

Val Thr Val Ser Ala
        115

<210> 174
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 174

Asp Ile Gln Met Ile Gln Ser Pro Ser Ser Met Phe Ala Ser Leu Gly
1   5   10   15

Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Gly Ile Arg Gly Asn

```
            20                  25                  30

Leu Asp Trp Tyr Gln Gln Lys Pro Gly Gly Thr Ile Lys Leu Leu Ile
        35                  40                  45

Tyr Ser Thr Ser Ile Leu Asn Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60

Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Thr Ser Leu Glu Ser
65                  70                  75                  80

Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Arg Asn Ala Tyr Pro Leu
                85                  90                  95

Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys
            100                 105
```

<210> 175
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 175

```
Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Met Lys Pro Gly Gly
1               5                   10                  15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
            20                  25                  30

Ala Leu Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
        35                  40                  45

Ala Ser Ile Arg Ser Gly Gly Ile Thr Tyr His Ala Asp Ser Val Lys
    50                  55                  60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gly Asn Ile Leu Tyr Leu
```

65 70 75 80

Gln Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Phe Cys Ala
85 90 95

Arg Val Ser Thr Ala Thr Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 176
<211> 219
<212> PRT
<213> Mus musculus

<300>
<308> NCBI / NP_061247.1
<309> 2017-08-07
<313> (1)..(219)

<400> 176

Met Ala Ser Thr Gly Leu Gln Ile Leu Gly Ile Val Leu Thr Leu Leu
1 5 10 15

Gly Trp Val Asn Ala Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val
20 25 30

Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Met Val Trp Glu
35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
50 55 60

Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65 70 75 80

Arg Ala Leu Cys Val Val Thr Leu Leu Ile Val Leu Leu Gly Leu Leu
85 90 95

```
Val Tyr Leu Ala Gly Ala Lys Cys Thr Thr Cys Val Glu Asp Arg Asn
            100                 105                 110

Ser Lys Ser Arg Leu Val Leu Ile Ser Gly Ile Ile Phe Val Ile Ser
        115                 120                 125

Gly Val Leu Thr Leu Ile Pro Val Cys Trp Thr Ala His Ser Ile Ile
    130                 135                 140

Gln Asp Phe Tyr Asn Pro Leu Val Ala Asp Ala Gln Lys Arg Glu Leu
145                 150                 155                 160

Gly Ala Ser Leu Tyr Leu Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
                165                 170                 175

Gly Gly Gly Leu Leu Cys Cys Ala Cys Ser Ser Gly Gly Thr Gln Gly
            180                 185                 190

Pro Arg His Tyr Met Ala Cys Tyr Ser Thr Ser Val Pro His Ser Arg
        195                 200                 205

Gly Pro Ser Glu Tyr Pro Thr Lys Asn Tyr Val
    210                 215
```

<210> 177
<211> 80
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 177

```
Met Ala Ser Ala Gly Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu
1               5                   10                  15

Gly Trp Val Asn Gly Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val
            20                  25                  30
```

Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Val Val Trp Glu
        35   40   45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
    50   55   60

Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65   70   75   80

<210> 178
<211> 220
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 178

Met Ala Ser Ala Gly Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu
1   5   10   15

Gly Trp Val Asn Gly Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val
            20   25   30

Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Val Val Trp Glu
        35   40   45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
    50   55   60

Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65   70   75   80

Arg Ala Leu Cys Val Ile Ala Leu Leu Val Ala Leu Phe Gly Leu Leu
                85   90   95

Val Tyr Leu Ala Gly Ala Lys Cys Thr Thr Cys Val Glu Glu Lys Asp
            100   105   110

```
Ser Lys Ala Arg Leu Val Leu Thr Ser Gly Ile Val Phe Val Ile Ser
        115                 120                 125


Gly Val Leu Thr Leu Ile Pro Val Cys Trp Thr Ala His Ala Val Ile
    130                 135                 140


Arg Asp Phe Tyr Asn Pro Leu Val Ala Glu Ala Gln Lys Arg Glu Leu
145                 150                 155                 160


Gly Ala Ser Leu Tyr Leu Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
                165                 170                 175


Gly Gly Gly Leu Leu Cys Cys Thr Cys Pro Ser Gly Gly Ser Gln Gly
            180                 185                 190


Pro Ser His Tyr Met Ala Arg Tyr Ser Thr Ser Ala Pro Ala Ile Ser
        195                 200                 205


Arg Gly Pro Ser Glu Tyr Pro Thr Lys Asn Tyr Val
    210                 215                 220


<210>  179
<211>  322
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  179

Cys Ala Gly Ala Thr Cys Gly Thr Gly Cys Thr Gly Ala Cys Thr Cys
1               5                   10                  15


Ala Gly Ala Gly Thr Cys Cys Thr Thr Cys Ala Ala Thr Thr Ala Thr
            20                  25                  30


Gly Thr Cys Cys Gly Thr Gly Ala Gly Cys Cys Cys Ala Gly Gly Cys
        35                  40                  45
```

```
Gly Ala Gly Ala Ala Gly Gly Thr Cys Ala Cys Cys Ala Thr Cys Ala
    50                  55                  60

Cys Ala Thr Gly Cys Ala Gly Thr Gly Cys Cys Thr Cys Cys Ala Gly
65                  70                  75                  80

Cys Thr Cys Thr Gly Thr Cys Thr Cys Ala Thr Ala Cys Ala Thr Gly
                85                  90                  95

Cys Ala Cys Thr Gly Gly Thr Thr Cys Cys Ala Gly Cys Ala Gly Ala
            100                 105                 110

Ala Gly Cys Cys Ala Gly Gly Gly Ala Cys Cys Ala Gly Thr Cys Cys
        115                 120                 125

Cys Ala Ala Gly Cys Thr Gly Thr Gly Cys Ala Thr Cys Thr Ala Cys
    130                 135                 140

Thr Cys Thr Ala Cys Ala Thr Cys Gly Ala Ala Cys Cys Thr Gly Gly
145                 150                 155                 160

Cys Cys Thr Cys Cys Gly Gly Ala Gly Thr Gly Cys Cys Cys Gly Cys
                165                 170                 175

Ala Ala Gly Gly Thr Thr Thr Ala Gly Cys Gly Gly Thr Cys Gly Gly
            180                 185                 190

Gly Gly Cys Thr Cys Thr Gly Gly Ala Ala Cys Thr Thr Cys Ala Thr
        195                 200                 205

Ala Cys Thr Cys Cys Cys Thr Gly Ala Cys Cys Ala Thr Cys Thr Cys
    210                 215                 220

Gly Cys Gly Gly Gly Thr Gly Gly Cys Cys Gly Cys Thr Gly Ala Gly
225                 230                 235                 240

Gly Ala Thr Gly Cys Ala Gly Cys Ala Ala Cys Ala Thr Ala Cys Thr
```

```
                245                 250                 255

Ala Thr Thr Gly Cys Cys Ala Gly Cys Ala Gly Ala Gly Gly Thr Cys
            260                 265                 270

Cys Ala Ala Thr Thr Ala Thr Cys Cys Cys Cys Cys Thr Thr Gly Gly
        275                 280                 285

Ala Cys Ala Thr Thr Cys Gly Gly Cys Gly Gly Ala Gly Gly Thr Ala
    290                 295                 300

Cys Cys Ala Ala Ala Cys Thr Cys Gly Ala Gly Ala Thr Thr Ala Ala
305                 310                 315                 320

Gly Cys
```

<210> 180
<211> 351
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 180

```
Gly Ala Ala Gly Thr Cys Cys Ala Gly Cys Thr Gly Cys Ala Gly Cys
1               5                   10                  15

Ala Gly Thr Cys Thr Gly Gly Cys Cys Cys Thr Gly Ala Ala Cys Thr
            20                  25                  30

Gly Gly Thr Gly Ala Ala Gly Cys Cys Thr Gly Gly Cys Gly Cys Cys
        35                  40                  45

Ala Gly Cys Ala Thr Gly Ala Ala Gly Ala Thr Cys Thr Cys Cys Thr
    50                  55                  60

Gly Cys Ala Ala Gly Gly Cys Cys Ala Gly Cys Gly Gly Cys Thr Ala
```

```
65                  70                  75                  80

Cys Thr Cys Cys Thr Thr Cys Ala Cys Cys Gly Gly Cys Thr Ala Thr
                85                  90                  95

Ala Cys Ala Ala Thr Gly Ala Ala Cys Thr Gly Gly Gly Thr Gly Ala
            100                 105                 110

Ala Gly Cys Ala Gly Thr Cys Cys Cys Ala Cys Gly Gly Cys Ala Ala
        115                 120                 125

Gly Ala Ala Thr Cys Thr Gly Gly Ala Gly Thr Gly Gly Ala Thr Cys
    130                 135                 140

Gly Gly Cys Cys Thr Gly Ala Thr Cys Ala Ala Cys Cys Cys Ala Thr
145                 150                 155                 160

Ala Cys Ala Ala Thr Gly Gly Cys Gly Gly Cys Ala Cys Cys Ala Thr
                165                 170                 175

Cys Thr Ala Cys Ala Ala Cys Cys Ala Gly Ala Ala Gly Thr Thr Thr
            180                 185                 190

Ala Ala Gly Gly Gly Cys Ala Ala Gly Gly Cys Cys Ala Cys Cys Cys
        195                 200                 205

Thr Gly Ala Cys Ala Gly Thr Gly Gly Ala Cys Ala Ala Gly Ala Gly
    210                 215                 220

Cys Thr Cys Cys Thr Cys Thr Ala Cys Cys Gly Cys Cys Thr Ala Cys
225                 230                 235                 240

Ala Thr Gly Gly Ala Gly Cys Thr Gly Cys Thr Gly Thr Cys Thr Cys
                245                 250                 255

Thr Gly Ala Cys Ala Ala Gly Cys Gly Ala Gly Gly Ala Cys Thr Cys
            260                 265                 270
```

```
Cys Gly Cys Cys Gly Thr Gly Thr Ala Cys Thr Ala Thr Thr Gly Cys
        275                 280                 285


Gly Cys Cys Cys Gly Gly Gly Ala Cys Thr Ala Cys Gly Gly Cys Thr
    290                 295                 300


Thr Cys Gly Thr Gly Cys Thr Gly Gly Ala Cys Thr Ala Thr Thr Gly
305                 310                 315                 320


Gly Gly Gly Cys Cys Ala Gly Gly Gly Cys Ala Cys Cys Ala Cys Ala
                325                 330                 335


Cys Thr Gly Ala Cys Ala Gly Thr Gly Ala Gly Cys Thr Cys Cys
            340                 345                 350


<210>  181
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  181

Gln Ile Val Leu Thr Gln Ser Pro Ser Ile Met Ser Val Ser Pro Gly
1               5                   10                  15


Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
            20                  25                  30


His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Cys Ile Tyr
        35                  40                  45


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Arg
    50                  55                  60


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Ala Ala Glu
65                  70                  75                  80
```

```
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Asn Tyr Pro Pro Trp
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  182
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  182

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1               5                   10                  15


Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
            20                  25                  30


Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile
        35                  40                  45


Gly Leu Ile Asn Pro Tyr Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe
    50                  55                  60


Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Asp Tyr Gly Phe Val Leu Asp Tyr Trp Gly Gln Gly Thr Thr
            100                 105                 110


Leu Thr Val Ser Ser
        115
```

<210> 183
<211> 324
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 183
gaaattgtgc tcacccagtc tccagcactc atggctgcat ctccagggga gaaggtcacc 60

atcacctgca gtgtcagctc aagtataagt tccagcaact tgcactggta ccagcagaag 120

tcaggaacct cccccaaact ctggatttat ggcacatcca acctggcttc tggagtccct 180

gttcgcttca gtggcagtgg atctgggacc tcttattctc tcacaatcag caacatggag 240

gctgaagatg ctgccactta ttactgtcaa cagtggagta gttacccaca cacgttcgga 300

gggggggacca agctggaaat aaaa 324

<210> 184
<211> 378
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 184
caggtccaaa tgcagcagtc tggagctgag ctggtaaggc ctgggacttc agtgaaggtg 60

tcctgcaagg cttctggata cgccttcact aattacttga tagagtgggt aaagcagagg 120

cctggacagg gccttgagtg gattggactg attaatcctg gaagtggtgg tactaattac 180

aatgagaagt tcaagggcaa ggcaacactg actgcagaca aatcctccac cactgcctac 240

atgcagctca gcagcctgac atctgatgac tctgcggttt atttctgtgc aagacggtcc 300

cctctaggga gttggatcta ctatgcttac gacggtgttg cttactgggg ccaagggact 360

ctggtcactg tctctgca 378

<210> 185
<211> 108
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 185

Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ala Ala Ser Pro Gly
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Val Ser Ser Ser Ile Ser Ser Ser
20 25 30

Asn Leu His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Trp
35 40 45

Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Asn Met Glu
65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro
85 90 95

His Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 186
<211> 126
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 186

Gln Val Gln Met Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr

```
            20                  25                  30

Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Leu Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe
    50                  55                  60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr
65                  70                  75                  80

Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys
                85                  90                  95

Ala Arg Arg Ser Pro Leu Gly Ser Trp Ile Tyr Tyr Ala Tyr Asp Gly
            100                 105                 110

Val Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
        115                 120                 125
```

<210> 187
<211> 645
<212> DNA
<213> Mus musculus

<400> 187

```
gatattgtgc taactcagtc tccagccacc ctgtctgtga ctccaggaaa tagcgtcagt       60

ctttcctgca gggccagcca aagtattggc ggtaacctac actggtatca acaaaaatca      120

catgagtctc caaggcttct catcaagtat gcttcccagt ccatctctgg gatcccctcc      180

aggttcagtg gcagtggatc agggacagat ttcactctca gtatcaacag tgtggagact      240

gaagattttg gaatgtattt ctgtcaacag agtaacagct ggccttacac gttcggaggg      300

gggaccaagc tggaaataaa acgggcagat gctgcaccaa ctgtatccat cttcccacca      360

tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac      420

cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg      480

aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg      540
```

ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 600

tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttag 645

<210> 188
<211> 1335
<212> DNA
<213> Mus musculus

<400> 188
gacgtgcagc ttcaggagtc aggacctagc ctcgtgaaac cttctcagac tctgtccctc 60

acctgttctg tcactggcga ctccatcacc agtgattact ggagctggat ccggaaattc 120

ccagggaata gacttgagta catggggtac gtaagctaca gtggtagcac ttactacaat 180

ccatctctca aaagtcgaat ctccatcacc cgagacacat ccaagaacca gtactacctg 240

gatttgaatt ctgtgactac tgaggacaca gccacatatt actgtgcaaa ctgggacggt 300

gattactggg gccaagggac tctggtcact gtctcttcag cagctaaaac aacagcccca 360

tcggtctatc cactggcccc tgtgtgtgga gatacaactg gctcctcggt gactctagga 420

tgcctggtca agggttattt ccctgagcca gtgaccttga cctggaactc tggatccctg 480

tccagtggtg tgcacacctt cccagctgtc ctgcagtctg acctctacac cctcagcagc 540

tcagtgactg taacctcgag cacctggccc agccagtcca tcacctgcaa tgtggcccac 600

ccggcaagca gcaccaaggt ggacaagaaa attgagccca gagggcccac aatcaagccc 660

tgtcctccat gcaaatgccc agcacctaac ctcttgggtg gaccatccgt cttcatcttc 720

cctccaaaga tcaaggatgt actcatgatc tccctgagcc ccatagtcac atgtgtggtg 780

gtggatgtga gcgaggatga cccagatgtc cagatcagct ggtttgtgaa caacgtggaa 840

gtacacacag ctcagacaca aacccataga gaggattaca acagtactct ccgggtggtc 900

agtgccctcc ccatccagca ccaggactgg atgagtggca aggagttcaa atgcaaggtc 960

aacaacaaag acctcccagc gcccatcgag agaaccatct caaaacccaa agggtcagta 1020

agagctccac aggtatatgt cttgcctcca ccagaagaag agatgactaa gaaacaggtc 1080

actctgacct gcatggtcac agacttcatg cctgaagaca tttacgtgga gtggaccaac 1140

aacgggaaaa cagagctaaa ctacaagaac actgaaccag tcctggactc tgatggttct 1200

tacttcatgt acagcaagct gagagtggaa aagaagaact gggtggaaag aaatagctac 1260

tcctgttcag tggtccacga gggtctgcac aatcaccaca cgactaagag cttctcccgg 1320

actccgggta aatga 1335

<210> 189
<211> 8806
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 189
aatgtagtct tatgcaatac tcttgtagtc ttgcaacatg gtaacgatga gttagcaaca 60

tgccttacaa ggagagaaaa agcaccgtgc atgccgattg gtggaagtaa ggtggtacga 120

tcgtgcctta ttaggaaggc aacagacggg tctgacatgg attggacgaa ccactgaatt 180

gccgcattgc agagatattg tatttaagtg cctagctcga tacataaacg ggtctctctg 240

gttagaccag atctgagcct gggagctctc tggctaacta gggaacccac tgcttaagcc 300

tcaataaagc ttgccttgag tgcttcaagt agtgtgtgcc cgtctgttgt gtgactctgg 360

taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca gtggcgcccg 420

aacagggact tgaaagcgaa agggaaacca gaggagctct ctcgacgcag gactcggctt 480

gctgaagcgc gcacggcaag aggcgagggg cggcgactgg tgagtacgcc aaaaattttg 540

actagcggag gctagaagga gagagatggg tgcgagagcg tcagtattaa gcgggggaga 600

attagatcgc gatgggaaaa aattcggtta aggccagggg gaaagaaaaa atataaatta 660

aaacatatag tatgggcaag cagggagcta gaacgattcg cagttaatcc tggcctgtta 720

gaaacatcag aaggctgtag acaaatactg ggacagctac aaccatccct tcagacagga 780

tcagaagaac ttagatcatt atataataca gtagcaaccc tctattgtgt gcatcaaagg 840

atagagataa aagacaccaa ggaagcttta gacaagatag aggaagagca aaacaaaagt 900

aagaccaccg cacagcaagc ggccgctgat cttcagacct ggaggaggag atatgaggga 960

caattggaga agtgaattat ataaatataa agtagtaaaa attgaaccat taggagtagc 1020

acccaccaag gcaaagagaa gagtggtgca gagagaaaaa agagcagtgg gaataggagc 1080

tttgttcctt gggttcttgg gagcagcagg aagcactatg ggcgcagcgt caatgacgct 1140

gacggtacag gccagacaat tattgtctgg tatagtgcag cagcagaaca atttgctgag 1200

ggctattgag gcgcaacagc atctgttgca actcacagtc tggggcatca agcagctcca 1260

ggcaagaatc ctggctgtgg aaagatacct aaaggatcaa cagctcctgg ggatttgggg 1320

ttgctctgga aaactcattt gcaccactgc tgtgccttgg aatgctagtt ggagtaataa 1380

atctctggaa cagatttgga atcacacgac ctggatggag tgggacagag aaattaacaa 1440

ttacacaagc ttaatacact ccttaattga agaatcgcaa aaccagcaag aaaagaatga 1500

acaagaatta ttggaattag ataaatgggc aagtttgtgg aattggttta acataacaaa 1560

ttggctgtgg tatataaaat tattcataat gatagtagga ggcttggtag gtttaagaat 1620

agtttttgct gtactttcta tagtgaatag agttaggcag ggatattcac cattatcgtt 1680

tcagacccac ctcccaaccc cgaggggacc cgacaggccc gaaggaatag aagaagaagg 1740

tggagagaga gacagagaca gatccattcg attagtgaac ggatctcgac ggtatcggtt 1800

aacttttaaa agaaaagggg ggattggggg gtacagtgca ggggaaagaa tagtagacat 1860

aatagcaaca gacatacaaa ctaaagaatt acaaaaacaa attacaaaaa ttcaaaattt 1920

tccgataagc ttgggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac 1980

cgcccaacga cccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgccaa 2040

tagggacttt ccattgacgt caatgggtgg agtatttacg gtaaactgcc cacttggcag 2100

tacatcaagt gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaatggc 2160

ccgcctggca ttatgcccag tacatgacct tatgggactt tcctacttgg cagtacatct 2220

acgtattagt catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg 2280

gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc aatgggagtt 2340

tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc gccccattga 2400

cgcaaatggg cggtaggcgt gtacggtggg aggtctatat aagcagagct cgtttagtga 2460

accgtcagat cgcctggaga cgccatccac gctgttttga cctccataga agacaccgac 2520

tctagaacta gtggatcccc cgggctgcag gaattcgtcg actggatccg gtaccgagga 2580

gatctgccgc cgcgatcgcc ggcgcgccag atctcaagct taactagtta gcggaccgac 2640

gcgtacgcgg ccgctcgaga tgagcggggg cgaggagctg ttcgccggca tcgtgcccgt 2700

gctgatcgag ctggacggcg acgtgcacgg ccacaagttc agcgtgcgcg gcgagggcga 2760

gggcgacgcc gactacggca agctggagat caagttcatc tgcaccaccg gcaagctgcc 2820

cgtgccctgg cccaccctgg tgaccaccct ctgctacggc atccagtgct tcgcccgcta 2880

ccccgagcac atgaagatga acgacttctt caagagcgcc atgcccgagg gctacatcca 2940

ggagcgcacc atccagttcc aggacgacgg caagtacaag acccgcggcg aggtgaagtt 3000

cgagggcgac accctggtga accgcatcga gctgaagggc aaggacttca aggaggacgg 3060

caacatcctg ggccacaagc tggagtacag cttcaacagc cacaacgtgt acatccgccc 3120

cgacaaggcc aacaacggcc tggaggctaa cttcaagacc cgccacaaca tcgagggcgg 3180

cggcgtgcag ctggccgacc actaccagac caacgtgccc ctgggcgacg gccccgtgct 3240

gatccccatc aaccactacc tgagcactca gaccaagatc agcaaggacc gcaacgaggc 3300

ccgcgaccac atggtgctcc tggagtcctt cagcgcctgc tgccacaccc acggcatgga 3360

cgagctgtac aggtccggac tcagataagt ttaaacccga tatcatcatc tagggcggcc 3420

aattccgccc ctctcccccc ccctaacgtt actggccgaa gccgcttgga ataaggccgg 3480

tgtgcgtttg tctatatgtt attttccacc atattgccgt cttttggcaa tgtgagggcc 3540

cggaaacctg gccctgtctt cttgacgagc attcctaggg gtctttcccc tctcgccaaa 3600

ggaatgcaag gtctgttgaa tgtcgtgaag gaagcagttc ctctggaagc ttcttgaaga 3660

caaacaacgt ctgtagcgac cctttgcagg cagcggaacc ccccacctgg cgacaggtgc 3720

ctctgcggcc aaaagccacg tgtataagat acacctgcaa aggcggcaca accccagtgc 3780

cacgttgtga gttggatagt tgtggaaaga gtcaaatggc tctcctcaag cgtattcaac 3840

aaggggctga aggatgccca gaaggtaccc cattgtatgg gatctgatct ggggcctcgg 3900

tgcacatgct ttacatgtgt ttagtcgagg ttaaaaaaac gtctaggccc cccgaaccac 3960

ggggacgtgg ttttcctttg aaaaacacga tgataagctt gccacaaccc acaaggagac 4020

gaccttccat gaccgagtac aagcccacgg tgcgcctcgc cacccgcgac gacgtccccc 4080

gggccgtacg caccctcgcc gccgcgttcg ccgactaccc cgccacgcgc cacaccgtcg 4140

acccggaccg ccacatcgag cgggtcaccg agctgcaaga actcttcctc acgcgcgtcg 4200

ggctcgacat cggcaaggtg tgggtcgcgg acgacggcgc cgcggtggcg gtctggacca 4260

cgccggagag cgtcgaagcg ggggcggtgt tcgccgagat cggcccgcgc atggccgagt 4320

tgagcggttc ccggctggcc gcgcagcaac agatggaagg cctcctggcg ccgcaccggc 4380

ccaaggagcc cgcgtggttc ctggccaccg tcggcgtctc gcccgaccac cagggcaagg 4440

gtctgggcag cgccgtcgtg ctccccggag tggaggcggc cgagcgcgcc ggggtgcccg 4500

ccttcctgga gacctccgcg ccccgcaacc tccccttcta cgagcggctc ggcttcaccg 4560

tcaccgccga cgtcgaggtg cccgaaggac cgcgcacctg gtgcatgacc cgcaagcccg 4620

gtgcctgaaa ttagatcgat accgtcgaca atcaacctct ggattacaaa atttgtgaaa 4680

gattgactgg tattcttaac tatgttgctc cttttacgct atgtggatac gctgctttaa 4740

tgcctttgta tcatgctatt gcttcccgta tggctttcat tttctcctcc ttgtataaat 4800

cctggttgct gtctctttat gaggagttgt ggcccgttgt caggcaacgt ggcgtggtgt 4860

gcactgtgtt tgctgacgca acccccactg gttggggcat tgccaccacc tgtcagctcc 4920

tttccgggac tttcgctttc cccctcccta ttgccacggc ggaactcatc gccgcctgcc 4980

ttgcccgctg ctggacaggg gctcggctgt tgggcactga caattccgtg gtgttgtcgg 5040

ggaagctgac gtcctttcca tggctgctcg cctgtgttgc cacctggatt ctgcgcggga 5100

cgtccttctg ctacgtccct tcggccctca atccagcgga ccttccttcc cgcggcctgc 5160

tgccggctct gcggcctctt ccgcgtcttc gccttcgccc tcagacgagt cggatctccc 5220

tttgggccgc ctccccgcct gaatacgagc tcggtacctt taagaccaat gacttacaag 5280

gcagctgtag atcttagcca ctttttaaaa gaaaaggggg gactggaagg gctaattcac 5340

tcccaacgaa gacaagatct gctttttgct tgtactgggt ctctctggtt agaccagatc 5400

tgagcctggg agctctctgg ctaactaggg aacccactgc ttaagcctca ataaagcttg 5460

ccttgagtgc ttcaagtagt gtgtgcccgt ctgttgtgtg actctggtaa ctagagatcc 5520

ctcagaccct tttagtcagt gtggaaaatc tctagcagta gtagttcatg tcatcttatt 5580

attcagtatt tataacttgc aaagaaatga atatcagaga gtgagaggaa cttgtttatt 5640

gcagcttata atggttacaa ataaagcaat agcatcacaa atttcacaaa taaagcattt 5700

ttttcactgc attctagttg tggtttgtcc aaactcatca atgtatctta tcatgtctgg 5760

ctctagctat cccgccccta actccgccca tcccgcccct aactccgccc agttccgccc 5820

attctccgcc ccatggctga ctaatttttt ttatttatgc agaggccgag gccgcctcgg 5880

cctctgagct attccagaag tagtgaggag gctttttttgg aggcctaggg acgtacccaa 5940

ttcgccctat agtgagtcgt attacgcgcg ctcactggcc gtcgttttac aacgtcgtga 6000

ctgggaaaac cctggcgtta cccaacttaa tcgccttgca gcacatcccc ctttcgccag 6060

ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc gcagcctgaa 6120

tggcgaatgg gacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg 6180

cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc 6240

ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg 6300

gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc 6360

acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 6420

ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc 6480

ttttgattta taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta 6540

acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaatttccc aggtggcact 6600

tttcggggaa atgtgcgcgg aacccctatt tgtttatttt tctaaataca ttcaaatatg 6660

tatccgctca tgagacaata accctgataa atgcttcaat aatattgaaa aaggaagagt 6720

atgagtattc aacatttccg tgtcgcccttt attccctttt ttgcggcatt ttgccttcct 6780

gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca 6840

cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcccc 6900

gaagaacgtt ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc 6960

cgtattgacg ccgggcaaga gcaactcggt cgccgcatac actattctca gaatgacttg 7020

gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta 7080

tgcagtgctg ccataaccat gagtgataac actgcggcca acttacttct gacaacgatc 7140

ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt 7200

gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg 7260

cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct 7320

tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc 7380

tcggcccttc cggctggctg gtttattgct gataaatctg gagccggtga gcgtgggtct 7440

cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac 7500

acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataggtgcc 7560

tcactgatta agcattggta actgtcagac caagtttact catatatact ttagattgat 7620

ttaaaacttc atttttaatt taaaaggatc taggtgaaga tccttttga taatctcatg 7680

accaaaatcc cttaacgtga gttttcgttc cactgagcgt cagaccccgt agaaaagatc 7740

aaaggatctt cttgagatcc ttttttttctg cgcgtaatct gctgcttgca aacaaaaaaa 7800

ccaccgctac cagcggtggt ttgtttgccg gatcaagagc taccaactct ttttccgaag 7860

gtaactggct tcagcagagc gcagatacca aatactgtcc ttctagtgta gccgtagtta 7920

ggccaccact tcaagaactc tgtagcaccg cctacatacc tcgctctgct aatcctgtta 7980

ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg ggttggactc aagacgatag 8040

ttaccggata aggcgcagcg gtcgggctga acgggggggtt cgtgcacaca gcccagcttg 8100

gagcgaacga cctacaccga actgagatac ctacagcgtg agctatgaga aagcgccacg 8160

cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg gcagggtcgg aacaggagag 8220

cgcacgaggg agcttccagg gggaaacgcc tggtatcttt atagtcctgt cgggtttcgc 8280

cacctctgac ttgagcgtcg atttttgtga tgctcgtcag gggggcggag cctatggaaa 8340

aacgccagca acgcggcctt tttacggttc ctggcctttt gctggccttt tgctcacatg 8400

ttctttcctg cgttatcccc tgattctgtg gataaccgta ttaccgcctt tgagtgagct 8460

gataccgctc gccgcagccg aacgaccgag cgcagcgagt cagtgagcga ggaagcggaa 8520

gagcgcccaa tacgcaaacc gcctctcccc gcgcgttggc cgattcatta atgcagctgg 8580

cacgacaggt ttcccgactg gaaagcgggc agtgagcgca acgcaattaa tgtgagttag 8640

ctcactcatt aggcacccca ggctttacac tttatgcttc cggctcgtat gttgtgtgga 8700

attgtgagcg gataacaatt tcacacagga aacagctatg accatgatta cgccaagcgc 8760

gcaattaacc ctcactaaag ggaacaaaag ctggagctgc aagctt 8806

<210> 190
<211> 220
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (143)..(143)
<223> Xaa can be any naturally occurring amino acid

<400> 190

Met Ala Ser Ala Gly Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu
1 5 10 15

Gly Trp Val Asn Gly Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val
20 25 30

Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Val Val Trp Glu
35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
50 55 60

Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65 70 75 80

Arg Ala Leu Cys Val Ile Ala Leu Leu Val Ala Leu Phe Gly Leu Leu

85 90 95

Val Tyr Leu Ala Gly Ala Lys Cys Thr Thr Cys Val Glu Glu Lys Asp
100 105 110

Ser Lys Ala Arg Leu Val Leu Thr Ser Gly Ile Val Phe Val Ile Ser
115 120 125

Gly Val Leu Thr Leu Ile Pro Val Cys Trp Thr Ala His Ala Xaa Ile
130 135 140

Arg Asp Phe Tyr Asn Pro Leu Val Ala Glu Ala Gln Lys Arg Glu Leu
145 150 155 160

Gly Ala Ser Leu Tyr Leu Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
165 170 175

Gly Gly Gly Leu Leu Cys Cys Thr Cys Pro Ser Gly Gly Ser Gln Gly
180 185 190

Pro Ser His Tyr Met Ala Arg Tyr Ser Thr Ser Ala Pro Ala Ile Ser
195 200 205

Arg Gly Pro Ser Glu Tyr Pro Thr Lys Asn Tyr Val
210 215 220

<210> 191
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 191
cagaaactca tctcagaaga ggatctggca gcaaatgata tcctggatta caaggatgac 60

gacgataa 68

<210> 192

<211> 683
<212> DNA
<213> Homo sapiens

<300>
<308> NCBI / NM_021195.4
<309> 2017-06-04
<313> (1)..(683)

<400> 192
ccgcgatcgc catggcctct gccggaatgc agatcctggg agtcgtcctg acactgctgg 60

gctgggtgaa tggcctggtc tcctgtgccc tgcccatgtg gaaggtgacc gctttcatcg 120

gcaacagcat cgtggtggcc caggtggtgt gggagggcct gtggatgtcc tgcgtggtgc 180

agagcaccgg ccagatgcag tgcaaggtgt acgactcact gctggcgctg ccacaggacc 240

tgcaggctgc acgtgccctc tgtgtcatcg ccctccttgt ggccctgttc ggcttgctgg 300

tctaccttgc tggggccaag tgtaccacct gtgtggagga gaaggattcc aaggcccgcc 360

tggtgctcac ctctgggatt gtctttgtca tctcaggggt cctgacgcta atccccgtgt 420

gctggacggc gcatgccgtc atccgggact tctataaccc cctggtggct gaggcccaaa 480

agcgggagct gggggcctcc ctctacttgg gctgggcggc ctcaggcctt ttgttgctgg 540

gtgggggttt gctgtgctgc acttgcccct cgggggggtc ccagggcccc agccattaca 600

tggcccgcta ctcaacatct gcccctgcca tctctcgggg gccctctgag taccctacca 660

agaattacgt cacgcgtacg cgg 683

<210> 193
<211> 677
<212> DNA
<213> Mus musculas

<300>
<308> NCBI / NM_018777.4
<309> 2017-08-07
<313> (1)..(677)

<400> 193
gccgcgatcg ccatggcctc tactggtctg caaatcttgg ggatcgtcct gaccctgctt 60

ggctgggtca acgccctggt gtcctgtgcc ctgcccatgt ggaaggtgac cgccttcatc 120

ggcaacagca tcgtcgtggc ccagatggtg tgggaggggc tgtggatgtc ctgtgtggtt 180

cagagcactg gccagatgca gtgcaaggtg tatgactcac tgttggcgct gccccaggac 240

ctgcaggctg ccagagccct ctgtgttgtc accctcctca ttgtcctgct tggcctgctc 300

gtgtacctgg ctggagccaa gtgcactacc tgtgtggaag ataggaactc caagtctcgt 360

ctggtgctca tctctggcat catctttgtc atttctgggg tcctgacgct cattcctgtc 420

tgctggactg cccactctat catccaggac ttctacaacc ccttggtggc tgatgctcaa 480

aagcgggagc tgggggcctc cctctacctg ggctgggcag cctcaggcct tttgctgctg 540

ggtggagggc tactatgctg cgcctgctct tctggaggga cccagggacc cagacattac 600

atggcctgct attctacatc tgtcccacat tctcggggac cctccgaata tcccaccaag 660

aattatgtga cgcgtac 677

<210> 194
<211> 683
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 194
cgcgatcgcc atggcctctg ccggaatgca gatcctggga gtcgtcctga cactgctggg 60

ctgggtgaat ggcctggtct cctgtgccct gcccatgtgg aaggtgaccg ctttcatcgg 120

caacagcatc gtggtggccc aggtggtgtg ggagggcctg tggatgtcct gcgtggtgca 180

gagcaccggc cagatgcagt gcaaggtgta cgactcactg ctggcgctgc cacaggacct 240

gcaggctgca cgtgccctct gtgtcatcgc cctccttgtg gccctgttcg gcttgctggt 300

ctaccttgct ggggccaagt gtaccacctg tgtggaggag aaggattcca aggcccgcct 360

ggtgctcacc tctgggattg tctttgtcat ctcaggggtc ctgacgctaa tccccgtgtg 420

ctggacggcg catgccatca tccgggactt ctataacccc ctggtggctg aggcccaaaa 480

gcgggagctg ggggcctccc tctacttggg ctgggcggcc tcaggccttt tgttgctggg 540

tgggggggttg ctgtgctgca cttgcccctc gggggggtcc cagggcccca gccattacat 600

ggcccgctac tcaacatctg cccctgccat ctctcggggg ccctctgagt accctaccaa 660

gaattacgtc acgcgtacgc ggc 683

<210> 195
<211> 672
<212> DNA
<213> Homo sapiens

<300>
<308> NCBI / NM_020982.3
<309> 2017-04-15
<313> (1)..(672)

<400> 195
gccgcgatcg ccatggcttc gaccggctta gaactgctgg gcatgaccct ggctgtgctg 60

ggctggctgg ggaccctggt gtcctgcgcc ctgcccctgt ggaaggtgac cgccttcatc 120

ggcaacagca tcgtggtggc ccaggtggtg tgggagggcc tgtggatgtc ctgcgtggtg 180

cagagcacgg gccagatgca gtgcaaggtg tacgactcac tgctggctct gccgcaggac 240

ctgcaggccg cacgtgccct ctgtgtcatt gccctcctgc tggccctgct tggcctcctg 300

gtggccatca caggtgccca gtgtaccacg tgtgtggagg acgaaggtgc caaggcccgt 360

atcgtgctca ccgcgggggt catcctcctc ctcgccggca tcctggtgct catccctgtg 420

tgctggacgg cgcacgccat catccaggac ttctacaacc ccctggtggc tgaggccctc 480

aagcgggagc tgggggcctc cctctacctg ggctgggcgg cggctgcact gcttatgctg 540

ggcgggggggc tcctctgctg cacgtgcccc ccgccccagg tcgagcggcc ccgcggacct 600

cggctgggct actccatccc ctcccgctcg ggtgcatctg gactggacaa gagggactac 660

gtgacgcgta cg 672

<210> 196
<211> 651
<212> DNA
<213> Homo sapiens

<300>
<308> NCBI / NM_001305.4
<309> 2017-07-10
<313> (1)..(651)

<400> 196
ccgcgatcgc catggcctcc atggggctac aggtaatggg catcgcgctg gccgtcctgg 60

gctggctggc cgtcatgctg tgctgcgcgc tgcccatgtg gcgcgtgacg gccttcatcg 120

gcagcaacat tgtcacctcg cagaccatct gggagggcct atggatgaac tgcgtggtgc 180

agagcaccgg ccagatgcag tgcaaggtgt acgactcgct gctggcactg ccgcaggacc 240

tgcaggcggc ccgcgccctc gtcatcatca gcatcatcgt ggctgctctg ggcgtgctgc 300

tgtccgtggt gggggggcaag tgtaccaact gcctggagga tgaaagcgcc aaggccaaga 360

ccatgatcgt ggcgggcgtg gtgttcctgt tggccggcct tatggtgata gtgccggtgt 420

cctggacggc ccacaacatc atccaagact tctacaatcc gctggtggcc tccgggcaga 480

agcgggagat gggtgcctcg ctctacgtcg gctgggccgc ctccggcctg ctgctccttg 540

gcgggggggct gctttgctgc aactgtccac cccgcacaga caagccttac tccgccaagt 600

attctgctgc ccgctctgct gctgccagca actacgtgac gcgtacgcgg c 651

<210> 197
<211> 680
<212> DNA
<213> Homo sapiens

<300>
<308> NCBI / NM_001306.3
<309> 2017-07-10
<313> (1)..(680)

<400> 197
gccgcgatcg ccatgtccat gggcctggag atcacgggca ccgcgctggc cgtgctgggc 60

tggctgggca ccatcgtgtg ctgcgcgttg cccatgtggc gcgtgtcggc cttcatcggc 120

agcaacatca tcacgtcgca gaacatctgg gagggcctgt ggatgaactg cgtggtgcag 180

agcaccggcc agatgcagtg caaggtgtac gactcgctgc tggcactgcc acaggacctt 240

caggcggccc gcgccctcat cgtggtggcc atcctgctgg ccgccttcgg gctgctagtg 300

gcgctggtgg gcgcccagtg caccaactgc gtgcaggacg acacggccaa ggccaagatc 360

accatcgtgg caggcgtgct gttccttctc gccgccctgc tcaccctcgt gccggtgtcc 420

tggtcggcca acaccattat ccgggacttc tacaaccccg tggtgcccga ggcgcagaag 480

cgcgagatgg gcgcgggcct gtacgtgggc tgggcggccg cggcgctgca gctgctgggg 540

ggcgcgctgc tctgctgctc gtgtccccca cgcgagaaga agtacacggc caccaaggtc 600

gtctactccg cgccgcgctc caccggcccg ggagccagcc tgggcacagg ctacgaccgc 660

aaggactacg tcacgcgtac 680

<210> 198
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 198

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
1 5 10 15

Asn Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Gly Asn
20 25 30

Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
35 40 45

Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr
65 70 75 80

Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
100 105 110

Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly

```
        115                 120                 125

Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
    130                 135                 140

Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
145                 150                 155                 160

Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                165                 170                 175

Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
            180                 185                 190

Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
        195                 200                 205

Phe Asn Arg Asn Glu Cys
    210


<210>  199
<211>  444
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  199

Asp Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1               5                   10                  15

Thr Leu Ser Leu Thr Cys Ser Val Thr Gly Asp Ser Ile Thr Ser Asp
            20                  25                  30

Tyr Trp Ser Trp Ile Arg Lys Phe Pro Gly Asn Arg Leu Glu Tyr Met
        35                  40                  45

Gly Tyr Val Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
```

```
    50                  55                  60

Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Tyr Tyr Leu
65                  70                  75                  80

Asp Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala
                85                  90                  95

Asn Trp Asp Gly Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
            100                 105                 110

Ser Ala Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val
        115                 120                 125

Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys
    130                 135                 140

Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu
145                 150                 155                 160

Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr
                165                 170                 175

Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln
            180                 185                 190

Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp
        195                 200                 205

Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys
    210                 215                 220

Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe
225                 230                 235                 240

Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val
                245                 250                 255
```

```
Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile
            260                 265                 270

Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr
        275                 280                 285

His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro
    290                 295                 300

Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val
305                 310                 315                 320

Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro
                325                 330                 335

Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu
            340                 345                 350

Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp
        355                 360                 365

Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr
    370                 375                 380

Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser
385                 390                 395                 400

Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu
                405                 410                 415

Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His
            420                 425                 430

His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
        435                 440
```

<210> 200

<211> 220
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (143)..(143)
<223> Xaa can be any naturally occurring amino acid

<400> 200

Met Ala Ser Ala Gly Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu
1 5 10 15

Gly Trp Val Asn Gly Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val
20 25 30

Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Val Val Trp Glu
35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
50 55 60

Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65 70 75 80

Arg Ala Leu Cys Val Ile Ala Leu Leu Val Ala Leu Phe Gly Leu Leu
85 90 95

Val Tyr Leu Ala Gly Ala Lys Cys Thr Thr Cys Val Glu Glu Lys Asp
100 105 110

Ser Lys Ala Arg Leu Val Leu Thr Ser Gly Ile Val Phe Val Ile Ser
115 120 125

Gly Val Leu Thr Leu Ile Pro Val Cys Trp Thr Ala His Ala Xaa Ile
130 135 140

```
Arg Asp Phe Tyr Asn Pro Leu Val Ala Glu Ala Gln Lys Arg Glu Leu
145                 150                 155                 160


Gly Ala Ser Leu Tyr Leu Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
                165                 170                 175


Gly Gly Gly Leu Leu Cys Cys Thr Cys Pro Ser Gly Gly Ser Gln Gly
            180                 185                 190


Pro Ser His Tyr Met Ala Arg Tyr Ser Thr Ser Ala Pro Ala Ile Ser
        195                 200                 205


Arg Gly Pro Ser Glu Tyr Pro Thr Lys Asn Tyr Val
    210                 215                 220


<210>  201
<211>  220
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  misc_feature
<222>  (143)..(143)
<223>  Xaa can be any naturally occurring amino acid

<400>  201

Met Ala Ser Ala Gly Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu
1               5                   10                  15


Gly Trp Val Asn Gly Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val
            20                  25                  30


Thr Ala Phe Ile Gly Asn Ser Ile Val Val Ala Gln Val Val Trp Glu
        35                  40                  45


Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
```

```
    50                  55                  60

Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
65                  70                  75                  80

Arg Ala Leu Cys Val Ile Ala Leu Leu Val Ala Leu Phe Gly Leu Leu
                85                  90                  95

Val Tyr Leu Ala Gly Ala Lys Cys Thr Thr Cys Val Glu Glu Lys Asp
            100                 105                 110

Ser Lys Ala Arg Leu Val Leu Thr Ser Gly Ile Val Phe Val Ile Ser
        115                 120                 125

Gly Val Leu Thr Leu Ile Pro Val Cys Trp Thr Ala His Ala Xaa Ile
    130                 135                 140

Arg Asp Phe Tyr Asn Pro Leu Val Ala Glu Ala Gln Lys Arg Glu Leu
145                 150                 155                 160

Gly Ala Ser Leu Tyr Leu Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
                165                 170                 175

Gly Gly Gly Leu Leu Cys Cys Thr Cys Pro Ser Gly Gly Ser Gln Gly
            180                 185                 190

Pro Ser His Tyr Met Ala Arg Tyr Ser Thr Ser Ala Pro Ala Ile Ser
        195                 200                 205

Arg Gly Pro Ser Glu Tyr Pro Thr Lys Asn Tyr Val
    210                 215                 220


<210>  202

<400>  202
000

<210>  203
```

<400> 203
000

<210> 204

<400> 204
000

<210> 205

<400> 205
000

<210> 206

<400> 206
000

<210> 207

<400> 207
000

<210> 208
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 208
tccagtgtaa gttccactta c 21

<210> 209
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 209
agcacatcc 9

<210> 210
<211> 27
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 210
caccagtatc atcgttcccc gctcacg 27

<210> 211
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 211
ggctacacct ttactaccta cacg 24

<210> 212
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 212
attaatccta gcagtggata tact 24

<210> 213
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 213
gcaaacgggg attactacgt cgcttac 27

<210> 214
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 214
gagaatattt acagttat 18

<210> 215
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 215
aatgcaaaa 9

<210> 216
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 216
caacatcatt atactgttcc gtggacg 27

<210> 217
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 217
ggtttcactt tcagtgatta ctgg 24

<210> 218
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 218
attagattga aatctgataa ttatgcaaca 30

<210> 219
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 219
aatgatggcc ccccctcggg gtgt 24

<210> 220
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 220
gagaatattt acagttat 18

<210> 221
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 221
aatgcaaaa 9

<210> 222
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 222

caacatcatt atactgttcc gtggacg 27

<210> 223
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 223
ggattcactt tcagtaatta ctgg 24

<210> 224
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 224
attagattga aatctgataa ttatgcaaca 30

<210> 225
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 225
aatgatggcc ccccctcggg gtgt 24

<210> 226
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 226
cagagccttg tacacagtga tggaaacacc tat 33

<210> 227
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 227
aaagtttcc 9

<210> 228
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 228
tctcaaagta cacatgttcc ttacacg 27

<210> 229
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 229
ggctacacct ttactagcta cacg 24

<210> 230
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 230
attaatccta gcagtactta tact 24

<210> 231

<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 231
tcaagagggg aactgggagg gtttgcttac 30

<210> 232
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 232
cagagcattg tacatagtaa tggaaacacc tat 33

<210> 233
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 233
aaagtttcc 9

<210> 234
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 234
tttcaaggtt cacatgttcc attcacg 27

<210> 235
<211> 24
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 235
ggatacatat tcactcacta tatt 24

<210> 236
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 236
attaatcctt acaatgatgg tact 24

<210> 237
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 237
gcaagatact acggctaccc ttactattct atggactac 39

<210> 238
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 238
cagagtctgc tcaacagtag aacccgaaag aactac 36

<210> 239
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 239
tgggcatcc 9

<210> 240
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 240
aagcaatctt attatctgta cacg 24

<210> 241
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 241
ggctactcca tcaccagtgg ttattac 27

<210> 242
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 242
atcagctacg atggtggcat t 21

<210> 243
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 243
gcaagatttg gtaaggggc tatggactac 30

<210> 244
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 244
tcaagtgtaa gttccagtta c 21

<210> 245
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 245
agcacatcc 9

<210> 246
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 246
caccagtatc atcgttcccc acccacg 27

<210> 247
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 247

ggttactcat tcactggcta cacc 24

<210> 248
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 248
attaatcctt acaatggtgg tact 24

<210> 249
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 249
gcaagagggg tctatgatta cgacggattt acttac 36

<210> 250
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 250
cagagccttg tacacagtga tggaaacacc tat 33

<210> 251
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 251
aaagtttcc 9

<210> 252
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 252
tctcaaagta cacatgttcc ttacacg 27

<210> 253
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 253
ggctacacct ttactaccta cacg 24

<210> 254
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 254
attaatcctc gcagtggtta tagt 24

<210> 255
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 255
tcaagagggg aactgggagg gtttgcttac 30

<210> 256

<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 256
cagaccattg gtacatgg 18

<210> 257
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 257
gctgcagcc 9

<210> 258
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 258
caacaacttt acagtattcc tcggacg 27

<210> 259
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 259
ggatacagat tcactgacta caac 24

<210> 260
<211> 24
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 260
attaacccta acaatggtgg tact 24

<210> 261
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 261
gcaagagatt acttgtactt ctttgactgc 30

<210> 262
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 262
cagagccttg tacacagtaa tggaaacacc tat 33

<210> 263
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 263
aaagtttcc 9

<210> 264
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 264
tctcaaatta cacatgttcc gtacacg 27

<210> 265
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 265
ggttatacct tcacagacta ttca 24

<210> 266
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 266
ataagcactg agactggtga gcca 24

<210> 267
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 267
actagaggtc tatggtcctc gtttgcttac 30

<210> 268
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 268
aaaagtgtca gtacatctgg ctatagttat 30

<210> 269
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 269
cttgcatcc 9

<210> 270
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 270
cagcacagta gggagcttcc gctcacg 27

<210> 271
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 271
ggattcactt tcagtagctt tgga 24

<210> 272
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 272

attagtagtg acagtaggac catc 24

<210> 273
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 273
gcaagagact acggtagaac ctacgaggct tac 33

<210> 274
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 274
caggacattg gaggaaat 18

<210> 275
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 275
tccacatcc 9

<210> 276
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 276
ctacagcgta atgcgtatcc gctcact 27

<210> 277
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 277
ggattcactt tcagtagtta tgcc 24

<210> 278
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 278
attagaagtg gtggtaccac c 21

<210> 279
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 279
gcaaaagtgg gcggtaaccc ctatcctatg gactac 36

<210> 280
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 280
tcaagtataa gttccaatta c 21

<210> 281

<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 281
aggacatcc 9

<210> 282
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 282
cagcagggta gtagtatacc gctcacg 27

<210> 283
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 283
ggatacgcct tcagtaatta cttg 24

<210> 284
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 284
attaatcctg gaagtggtgg tact 24

<210> 285
<211> 45
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 285
gcaagatcat acttcggtag aagctacccc tatactatgg actac 45

<210> 286
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 286
caaagtgttg attatgatgg tgataattat 30

<210> 287
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 287
gctgcatcc 9

<210> 288
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 288
cagcaaagta atgaggatcc attcacg 27

<210> 289
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 289
ggctacacat tcactgatta tgct 24

<210> 290
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 290
attagtacat actctggtaa taca 24

<210> 291
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 291
gcaagaaggg gcgattacag cctctatgct atggactac 39

<210> 292
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 292
caaagtgttt tattcagttc aaatcagaaa aactac 36

<210> 293
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 293
tgggcatcc 9

<210> 294
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 294
catcaatacc tctcctcgcg cacg 24

<210> 295
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 295
ggattcactt tcagtagctt tgga 24

<210> 296
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 296
attagtagtg acagtaggac catc 24

<210> 297
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 297

gcaagagact acggtagaac ctacgaggct tac 33

<210> 298
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 298
gaaagtgttg ataattatgg cattagtttt 30

<210> 299
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 299
gctgcatcc 9

<210> 300
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 300
cagcaaagta aggaggttcc gctcacg 27

<210> 301
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 301
ggattccctt tcagtagctc tgcc 24

<210> 302
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 302
attaatagtg atggtaacac c 21

<210> 303
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 303
acaagaaacg gggactatag gtacgacgag tttgcttac 39

<210> 304
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 304
tcaagtgtaa gttccagtta c 21

<210> 305
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 305
agcacatcc 9

<210> 306

<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 306
caccagtatc atcgttcccc acccacg 27

<210> 307
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 307
ggctacacct ttactggcta ctgg 24

<210> 308
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 308
attaatccta gcactggtta tact 24

<210> 309
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 309
gcaagagagg ggattactac tgtgctggtt gactac 36

<210> 310
<211> 36
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 310
caaagtgttt tattcagttc aaatcagaaa aactac 36

<210> 311
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 311
tgggcatcc 9

<210> 312
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 312
catcaatacc tctcctcgcg cacg 24

<210> 313
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 313
ggttactctt tcactggcta caat 24

<210> 314
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 314
attgatcctt actatggtgg ttct 24

<210> 315
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 315
gcaagagaga ggtcgggcta cgttttctct gctatggact ac 42

<210> 316
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 316
caaagtgttt tattcagttc aaatcagaaa aactac 36

<210> 317
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 317
tgggcatcc 9

<210> 318
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 318
catcaatacc tctcctcgcg cacg 24

<210> 319
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 319
ggttactcat tcactggcta cacc 24

<210> 320
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 320
attaatcctt acaatggtgt tact 24

<210> 321
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 321
acaagagatc ccctttacta cggctacagg gactctacta tggactac 48

<210> 322
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 322

cagagccttg tacacagtga tggaaacacc tat 33

<210> 323
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 323
aaagtttcc 9

<210> 324
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 324
tctcaaagta cacatgttcc ttacacg 27

<210> 325
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 325
ggctacacct ttactagcta cacg 24

<210> 326
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 326
attaatccta gcagtacgta tact 24

<210> 327
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 327
tcaagagggg aactgggagg gtttgcttac 30

<210> 328
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 328
cagggcatta gaggtaat 18

<210> 329
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 329
tccacatcc 9

<210> 330
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 330
ctacagcgta atgcgtatcc tctcacg 27

<210> 331

<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 331
ggattcactt tcagtagttt tgcc 24

<210> 332
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 332
attagaagtg gtggtattac c 21

<210> 333
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 333
gcaagagtta gtacggctac gtactatggt atggactac 39

<210> 334
<211> 325
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 334
caaattgttc tcacccagtc tccagcaatc atgtctgcat ctctagggga acgggtcacc 60

atgacctgca ctgccagctc cagtgtaagt tccacttact ttcactggta ccaacagaag 120

ccaggatcct cccccaaact ctggatttat agcacatcca acctggcttc tggagtccca 180

cgtcgcttca gtggcagtgc gtctgggacc tcttactctc tcacaatcag cagcatggag 240

gctgaagatg ctgccactta ttattgccac cagtatcatc gttccccgct cacgttcggt 300

gctgggacca agctggagct gaaac 325

<210> 335
<211> 349
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 335
caggtccagc tgcagcagtc tgcagctgaa ctggcaagac ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacctttact acctacacga tgcactgggt aaaacagagg 120

cctggacagg gtctggaatg gattggattc attaatccta gcagtggata tactgactac 180

aatcagaagt tcaaggacag gaccacattg actgcagaca aatcctccag cacagtctac 240

atgcaactga gtagcctgac atctgaggac tctgcggtct attactgtgc aaacggggat 300

tactacgtcg cttactgggg ccaagggact ctggtcactg tctctgcag 349

<210> 336
<211> 322
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 336
gacatccaga tgactcagtc tccagcctcc ctatctgcat ctgtgggaga aactgtcacc 60

atcacatgtc gaataagcga gaatatttac agttatttag catggtatca gcagaaacag 120

ggaaaatctc ctcagctcct ggtctataat gcaaaaatct tagtagaagg tgtgccatca 180

aggttcagtg gcagtggatc aggcacacag ttttctctga agatcaacag cctgcagcct 240

gaagattttg ggaattatta ctgtcaacat cattatactg ttccgtggac gttcggtgga 300

ggcaccaaac tggaaatcaa ac 322

<210> 337
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 337
gaagtgaagc ttgaggagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc 60

tcctgtgttg cctctggttt cactttcagt gattactgga tgaactgggt ccgccagtct 120

ccagagaagg ggcttgaatg ggttgctcaa attagattga aatctgataa ttatgcaaca 180

cattatgcgg agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagaagt 240

gtctacctgc aaatgaacaa cttaagggct gaagacactg gaacttatta ctgcaatgat 300

ggcccccccct cggggtgttg gggccaaggc accactctca tagtctcctc ag 352

<210> 338
<211> 322
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 338
gacatccaga tgactcagtc tccagcctcc ctatctgcat ctgtgggaga aactgtcacc 60

atcacatgtc gaataagtga gaatatttac agttatttag catggtatca gcagaaacag 120

ggaaaatctc ctcagctcct ggtctataat gcaaaaatct tagtagaagg tgtgccatca 180

aggttcagtg gcagtggatc aggcacacag ttttctctga agatcaacag cctgcagcct 240

gaagattttg ggaattatta ctgtcaacat cattatactg ttccgtggac gttcggtgga 300

ggcaccaaac tggaaatcaa ac 322

<210> 339
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 339
gaagtgaagc ttgaggagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc 60

tcctgtgttg cctctggatt cactttcagt aattactgga tgaactgggt ccgccagtct 120

ccagagaagg ggcttgaatg ggttgctcaa attagattga aatctgataa ttatgcaaca 180

cattatgcgg agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagaagt 240

gtctacctgc aaatgaacaa cttaagggct gaagacactg gaacttatta ctgcaatgat 300

ggcccccccct cggggtgttg gggccaaggc accactctca tagtctcctc ag 352

<210> 340
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 340
gatgttgtga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gatctagtca gagccttgta cacagtgatg gaaacaccta tttaaattgg 120

tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgtttt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240

aggagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttcct 300

tacacgttcg gaggggggac caagctggaa ataaaac 337

<210> 341
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 341
caggtccagt tgcagcagtc tggggctgaa ctggcaagac ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacctttact agctacacga tgcactggat aaaacagaga 120

cctggacagg gtcaggaatg gattggatac attaatccta gcagtactta tactcattac 180

attaagaaat tcaaggacaa ggccacattg actgcagaca aatcctccag cacagcctac 240

atgcaactgc gcagcctgac atctgaggac tctgcagtct attactgttc aagaggggaa 300

ctgggagggt ttgcttactg gggccaaggg actctggtca ctgtctctgc ag 352

<210> 342
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 342
gatgttttga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaaccctcc 60

atctcttgca gatctagtca gagcattgta catagtaatg gaaacaccta tttagattgg 120

tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240

agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaggttc acatgttcca 300

ttcacgttcg gctcggggac aaggttggaa ataaaac 337

<210> 343
<211> 361
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 343
gaagtccagc tgcagcagtc tggacctgag ctggtaaagc ctggggcttc agtgaagatg 60

tcctgcaagg cttctggata catattcact cactatatta tgcactgggt gaagcagaag 120

cctgggcagg gccttgagtg gattggatgt attaatcctt acaatgatgg tactaagtac 180

aatgagaagt tcaaaggcaa ggccacactg acttcagaca aatcctccag cacagcctac 240

atggagctca gcagcctgac ctctgaggac tctgcggtct attactgtgc aagatactac 300

ggctaccctt actattctat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 360

g 361

<210> 344
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 344
gccattgtga tgttccagtc tccatcctcc ctggttgtgt cagcaggaga gaaggtcact 60

atgagctgca aatccagtca gagtctgctc aacagtagaa cccgaaagaa ctacttggct 120

tggtaccagc agaaaccagg gcagtctcct aaactgctga tctactgggc atccactagg 180

gaatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc 240

atcagcagtg tgcaggctga agacctggca gtttattact gcaagcaatc ttattatctg 300

tacacgttcg gaggggggac caagctggaa ataaaac 337

<210> 345
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 345
gatgtgcagc ttcaggagtc aggacctggc ctcgtgaaat cttctcagtc tctgtctctc 60

acctgctctg tcactggcta ctccatcacc agtggttatt actggaaatg gatccggcag 120

tttccaggaa acaaactgga atggatgggc tacatcagct acgatggtgg cattaactac 180

aacccatctc tcaaaaatcg aatctccatc actcgtgaca catctaagaa ccagtttttc 240

ctgaagttga attctgtgac tactgaggac acagccaaat attactgtgc aagatttggt 300

aaggggggcta tggactactg gggtcaagga acctcagtca ccgtctcctc ag 352

<210> 346
<211> 325
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 346
caaattgttc tcacccagtc tccagcaatc atgtctgcat ctctgggggа ccgggtcacc 60

atgacctgca ctgccagctc aagtgtaagt tccagttact tgcactggta ccagcagaag 120

ccaggatcct cccccaaact ctggatttat agcacatcca acctggcttc tggagtccca 180

gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagcatggag 240

gctgaagatg ctgccactta ttactgccac cagtatcatc gttccccacc cacgttcggc 300

tcggggacaa agttggaaat aaaac 325

<210> 347
<211> 358
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 347
gaggtccagc tgcaacagtc tggacctgag ctggtgaagc ctggagcttc aatgaagata 60

tcctgcaagg cttctggtta ctcattcact ggctacacca tgaactgggt gaagcagagc 120

catggaaaga accttgagtg gattggactt attaatcctt acaatggtgg tactaactac 180

aaccagaagt tcaagggcaa ggccacatta actgtagaca agtcatccag cacagcctac 240

atggagctcc tcagtctgac atctgaggac tctgcagtct attactgtgc aagaggggtc 300

tatgattacg acggatttac ttactggggc caagggactc tggtcactgt ctctgcag 358

<210> 348
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 348
gatgttgtga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gatctagtca gagccttgta cacagtgatg gaaacaccta tttatattgg 120

tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240

agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttcct 300

tacacgttcg gaggggggac caagctggaa ataaaac 337

<210> 349
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 349
caggtccagc tgcagcagtc tggggctgaa ctggcaagac ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacctttact acctacacga tgcactggtt aaaacagagg 120

cctggacagg gtctggaatg gattggatac attaatcctc gcagtggtta tagtaattac 180

aatcagaagt tcaaggacaa ggccacattg actgcagaca agtcctccaa cacagcctac 240

atgcaactga acaccctgac atctgaggac tctaaagtct attactgttc aagaggggaa 300

ctgggagggt ttgcttactg gggccaaggg actctggtca ctgtctctgc ag 352

<210> 350
<211> 322
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 350
gacattcaga tgacccagtc tcctgcctcc cagtctgcat ctctgggaga aagtgtcacc 60

atcacatgcc tggcaagtca gaccattggt acatggttag catggtatca gcagaaacca 120

gggaaatctc ctcagctcct gatttatgct gcagccagct tggcagatgg ggtcccatca 180

aggttcagtg gtagtggatc tggcacaaga ttttctttca agatcagcag cctacaggct 240

gaagattttg taagttatta ctgtcaacaa ctttacagta ttcctcggac gttcggtgga 300

ggcaccaagc tggaaatcaa ac 322

<210> 351
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 351
gaggtccagc tgcaacagtc tggacctgag ctggtgaagc ctggggcttc agtgaagatg 60

tcctgcaagg cttctggata cagattcact gactacaaca tgcactgggt gaagcagagc 120

catggaaaga gccttgagtg gattggatat attaacccta acaatggtgg tactaactac 180

aaccaaaact tcaagggcaa ggccacattg actgtgaaca agtcctccag cacagcctac 240

atggagctcc gcagcctgac atcggaggat tctgcagcct attactgtgc aagagattac 300

ttgtacttct ttgactgctg gggccaaggc accactctca cagtctcctc ag 352

<210> 352
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 352
gatgttgtga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gagctagtca gagccttgta cacagtaatg gaaacaccta tttacattgg 120

ttcctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180

tctggggtcc cagacaggtt cagtggcagt ggatcacgga cagatttcac actcaagatc 240

agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaattac acatgttccg 300

tacacgttcg gaggggggac caagctggaa ataaaac 337

<210> 353
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 353
caaatccagt tggtgcagtc tggacctgcg ctgaagaagc ctggagagac agtcaagatc 60

tcctgcaagg cttctggtta taccttcaca gactattcaa tgcactggat aaagcaggct 120

ccaggaaagg gtttaaagtg gatgggctgg ataagcactg agactggtga gccaacatat 180

gcagatggct tcaagggacg gtttgacttc tctttggaaa cctctgccga cactgcctat 240

ttgtccatca acaacctcac aaatgaggac acggctacat atttctgtac tagaggtcta 300

tggtcctcgt ttgcttactg gggccaaggg actctggtca ctgtctctgc ag 352

<210> 354
<211> 334
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 354
gacattgtgc tgacacagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc 60

atctcatgca gggccagcaa aagtgtcagt acatctggct atagttatat acactggtac 120

caacagaaac caggacagcc acccaaactc ctcatctatc ttgcatccaa cctagaatct 180

ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 240

cctgtggagg aggaggatgc tgcaacctat tactgtcagc acagtaggga gcttccgctc 300

acgttcggtg ctgggaccaa gctggagctg aaac 334

<210> 355

<211> 355
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 355
gatgtgcagc tggtggagtc tgggggaggc ttggtgcagc ctagagggtc ccggaaactc 60

tcctgtgcag cctctggatt cactttcagt agctttggaa tgcactgggt tcgtcaggct 120

ccagagaagg ggctggagtg ggtcgcatac attagtagtg acagtaggac catctattat 180

gcagacacag tgaagggccg attcaccatc tccagagaca atcccacgaa caccctgttc 240

ctgcaaatga ccagtctcag gtctgaggac acggccatgt attactgtgc aagagactac 300

ggtagaacct acgaggctta ctggggccaa gggactctgg tcactgtctc tgcag 355

<210> 356
<211> 322
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 356
gacatccaga tgattcagtc tccatcgtcc atgtttgcct ctctgggaga cagagtcagt 60

ctctcttgtc gggctagtca ggacattgga ggaaatttag actggtatca gcagaaacca 120

ggtggaacta ttaaactcct gatctactcc acatccaatt taaattctgg tgtcccatca 180

aggttcagtg gcagtgggtc tgggtcagat tattctctca ccatcaccag cctggagtct 240

gaagattttg cagactatta ctgtctacag cgtaatgcgt atccgctcac tttcggtgct 300

gggaccaagc tggagctgaa ac 322

<210> 357
<211> 355
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 357
gaagtgaaac tgatggagtc tgggggagac ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cactttcagt agttatgcca tgtcttgggt tcgccagact 120

ccagagaaga ggctggagtg ggtcgcgtcc attagaagtg gtggtaccac ctactatcca 180

gacagtgtga agggccgatt caccatctcc agagataatg ccaggaacat cctgtacctg 240

cgaatgagta gtctgaggtc tgaggacacg gccatatatt actgtgcaaa agtgggcggt 300

aacccctatc ctatggacta ctggggtcaa ggaacctcag tcaccgtctc ctcag 355

<210> 358
<211> 325
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 358
gaaattgtgc tcacccagtc tccaaccacc atggctgcat ctcccgggga gaagatcact 60

atcacctgca gtgccagctc aagtataagt tccaattact tgcattggta tcagcagaag 120

ccaggattct cccctaaact cttgatttat aggacatcca atctggcttc tggagtccca 180

gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaattgg caccatggag 240

gctgaagatg ttgccactta ctactgccag cagggtagta gtataccgct cacgttcggt 300

gctgggacca agctggagct gaaac 325

<210> 359
<211> 367
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 359
caggtccagc tgcagcagtc tggagctgag ctggtaaggc ctgggacttc agtgaaggtg 60

tcctgcaagg cttctggata cgccttcagt aattacttga tagagtgggt taagcagagg 120

cctggacagg gccttgagtg gattggagtg attaatcctg gaagtggtgg tactaactac 180

aatgagaagt tcaagggcaa ggcaacaatg actgcagaca aatcctccag cactgcctac 240

atgcacctca gcaacctgac atctgaggac tctgtggtct atttctgtgc aagatcatac 300

ttcggtagaa gctaccccta tactatggac tactggggtc aaggaacctc agtcaccgtc 360

tcctcag 367

<210> 360
<211> 334
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 360
gatattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 60

atctcctgca aggccagcca aagtgttgat tatgatggtg ataattatgt gaactggtac 120

caacagaaag taggacagcc acccaaactc ctcatctctg ctgcatccaa tctagaatct 180

gggatcccag ccaggtttag tggcagtggg tctgggacag acttcaccct caacatccat 240

cctgtggagg aggaggatgc tgcaacctat tactgtcagc aaagtaatga ggatccattc 300

acgttcggct cggggacaaa gttggaaata aaac 334

<210> 361
<211> 361
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 361
caggtccagc tgcagcagtc tgggcctgag ctggtgaggc ctggggtctc agtgaagatt 60

tcctgcaagg gttccggcta cacattcact gattatgcta tgcactgggt gaagcagagt 120

catgcaaaga gtctagagtg gattggagtt attagtacat actctggtaa tacaaactac 180

aaccagaagt ttcaggacaa ggccaccatg actgtagaca aatcctccag cacagcctat 240

atggcacttg ccagattgac atctgacgat tctgccatct attactgtgc aagaaggggc 300

gattacagcc tctatgctat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 360

g 361

<210> 362
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 362
aacattatga tgacacagtc gccatcatct ctggctgtgt ctgcaggaga aaaggtcact 60

atgagctgta agtccagtca aagtgtttta ttcagttcaa atcagaaaaa ctacttggcc 120

tggtaccagc agaaaccagg gcagtctcct agactgctga tctactgggc atccactagg 180

gaatctggtg tccctgatcg cttcacaggc agtggatctg ggacagattt tactcttacc 240

atcagcaatg ttcaagctga agacctggca gtttattact gtcatcaata cctctcctcg 300

cgcacgttcg gtgctgggac caagctggag ctgaaac 337

<210> 363
<211> 355
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 363
gatgtgcagc tggtggagtc tgggggaggc ttggtgcagc ctagagggtc ccggaaactc 60

tcctgtgcag cctctggatt cactttcagt agctttggaa tgcactgggt tcgtcaggct 120

ccagagaagg ggctggagtg ggtcgcatac attagtagtg acagtaggac catctattat 180

gcagacacag tgaagggccg attcaccatc tccagagaca atcccacgaa caccctgttc 240

ctgcaaatga ccagtctcag gtctgaggac acggccatgt attactgtgc aagagactac 300

ggtagaacct acgaggctta ctggggccaa gggactctgg tcactgtctc tgcag 355

<210> 364
<211> 334
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 364
gacattgtgc tgacccaatc tccagcttct ttggctctgt ctctagggca gagggccacc 60

atctcctgca gagccagcga aagtgttgat aattatggca ttagttttat gaactggttc 120

caacagaaac ccggacagcc acccaaactc ctcatctatg ctgcatccaa ccaaggatcc 180

ggggtccctg ccaggtttag tggcagtggg tctgggacag acttcagcct caacatccat 240

cctatggagg aggatgatac tgcaatgtat ttctgtcagc aaagtaagga ggttccgctc 300

acgttcggtg ctgggaccaa gctggagctg aaac 334

<210> 365
<211> 358
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 365
gaagtgaggc tggtggagtc tgggggaggc ttgatgcagc ctggagggtc cctgaaactc 60

ccctgtgcag cctctggatt ccctttcagt agctctgcca tgtcttgggt tcgccagact 120

ccagagaaga ggctggagtg ggtcgcatcc attaatagtg atggtaacac ctactatccc 180

gacagtgtga agggccgatt caccatctcc agagatagtg ccaggaacat cctgtacctc 240

caaatgagca gtctgaggtc tgaggacacg gccatgtatt actgtacaag aaacggggac 300

tataggtacg acgagtttgc ttactggggc caagggactc tggtcactgt ctctgcag 358

<210> 366
<211> 325
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 366
caaattgttc tcacccagtc tccagcaatc atgtctgcat ctctagggga acgggtcacc 60

atgacctgca ctgccagctc aagtgtaagt tccagttact tgcactggta ccagcagaag 120

ccaggatcct cccccaaact ctggatttat agcacatcca acctggcttc tggagtccca 180

gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagcatggag 240

gctgaagatg ctgccactta ttactgccac cagtatcatc gttccccacc cacgttcgga 300

gctgggacca agctggagct gaaac 325

<210> 367
<211> 358
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 367
caggtccagc ttcagcagtc tggggctgaa ctggcaaaac ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacctttact ggctactgga tgcactgggt aaaacagagg 120

cctggacagg gtctggaatg gcttggatac attaatccta gcactggtta tactgagtcc 180

aatcagaagt tcaaggacaa ggccacattg actgcagaca aatcctccac cacagcctac 240

atgcaactga gaagcctgac acctgaggac tctgcagtct attactgtgc aagagagggg 300

attactactg tgctggttga ctactggggc caaggcacca ctctcacagt ctcctcag 358

<210> 368
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 368
aacattatga tgacacagtc gccatcatct ctggctgtgt ctgcaggaga aaaggtcact 60

atgagctgta agtccagtca aagtgtttta ttcagttcaa atcagaaaaa ctacttggcc 120

tggtaccagc agaaaccagg gcagtctcct agactgctga tctactgggc atccactagg 180

gaatctggtg tccctgatcg cttcacaggc agtggatctg ggacagattt tactcttacc 240

atcagcaatg ttcaagctga agacctggca gtttattact gtcatcaata cctctcctcg 300

cgcacgttcg gtgctgggac caagctggag ctgaaac 337

<210> 369
<211> 364
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 369
caggtgcagc tgaagcagtc tggacctgag ctggagaagc ctggcgcttc agtgaagata 60

tcctgcaagg cttctggtta ctctttcact ggctacaata tgaactgggt gaagcagagc 120

aatggaaaga gccttgagtg gattggaaat attgatcctt actatggtgg ttctacctac 180

aaccagaagt tcacgggcaa ggccacattg actgtagaca aatcctccag cacagcctac 240

atgcagctca agagcctgac atctgaggac tctgcagtgt attactgtgc aagagagagg 300

tcgggctacg ttttctctgc tatggactac tggggtcaag gaacctcagt caccgtctcc 360

tcag 364

<210> 370
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 370
aacattatga tgacacagtc gccatcatct ctggctgtgt ctgcaggaga aaaggtcact 60

atgagctgta agtccagtca aagtgtttta ttcagttcaa atcagaaaaa ctacttggcc 120

tggtaccagc agaaaccagg gcagtctcct agactgctga tctactgggc atccactagg 180

gaatctggtg tccctgatcg cttcacaggc agtggatctg ggacagattt tactcttacc 240

atcagcaatg ttcaagctga agacctggca gtttattact gtcatcaata cctctcctcg 300

cgcacgttcg gtgctgggac caagctggag ctgaaac 337

<210> 371
<211> 370
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 371
gaggtccagc tgcaacagtc tggacctgag ctggtgaagc ctggaggttc aatgaagata 60

tcctgcaagg cttctggtta ctcattcact ggctacacca tgaactgggt gaagcggagc 120

catggaaaga accttgagtg gattggactt attaatcctt acaatggtgt tactacctac 180

aaccagaact tcaagggcaa ggccacatta gctgtagaca agtcatccag cacagcctac 240

atggagctcc tcggtctgac atctgaggac tctgcagtct attactgtac aagagatccc 300

ctttactacg gctacaggga ctctactatg gactactggg gtcaaggaac ctcagtcacc 360

gtctcctcag 370

<210> 372
<211> 337
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 372
gatgttgtga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gatctagtca gagccttgta cacagtgatg gaaacaccta tttaaattgg 120

tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgtttt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240

aggagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttcct 300

tacacgttcg gaggggggac caagctggaa ataaaac 337

<210> 373
<211> 352
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 373
gaggtccagc tgcagcagtc tggggctgaa ctggcaagac ctggggcctc agtgaagatg 60

tcctgcaagg cttctggcta cacctttact agctacacga tgcactggat aaaacagaga 120

cctggacagg gtcaggaatg gattggatac attaatccta gcagtacgta tactcattac 180

attaagaagt tcaaggacaa ggccacattg actgcagaca aatcctccag cacagcctac 240

atgcaactgc gcagcctgac atctgaggac tctgcagtct attactgttc aagaggggaa 300

ctgggagggt ttgcttactg gggccaaggg actctggtca ctgtctctgc ag 352

<210> 374
<211> 322
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 374
gacatccaga tgattcagtc tccatcgtcc atgtttgcct ctctgggaga cagagtcagt 60

ctctcttgtc gggctagtca gggcattaga ggtaatttag actggtatca gcagaaacca 120

ggtggaacta ttaaactcct gatctactcc acatccattt taaattctgg tgtcccatca 180

aggttcagtg gcagtgggtc tgggtcagat tattctctca ccatcaccag cctagagtct 240

gaagattttg cagactatta ctgtctacag cgtaatgcgt atcctctcac gttcggttct 300

gggaccaagc tggagctgaa ac 322

<210> 375
<211> 358
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide

<400> 375
gaagtgaagt tggtggagtc tgggggaggc ttaatgaagc ctggagggtc cctgaaactc 60

tcctgtgcgg cctctggatt cactttcagt agttttgcct tgtcttgggt tcgccagact 120

ccagagaaga ggctggagtg ggtcgcatcc attagaagtg gtggtattac ctaccatgca 180

gacagtgtga agggccgatt caccatctcc agagataatg ccgggaacat cctgtacctg 240

caaatgaaca gtctgaggtc tgaggacacg gccatgtatt tctgtgcaag agttagtacg 300

gctacgtact atggtatgga ctactggggt caaggaacct cagtcaccgt ctcctcag 358

<210> 376
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 376

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Asp Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 377
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 377

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Asp Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Met Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Asn Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser

115

<210> 378
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 378

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Asp Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Asn Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 379
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 379

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20   25   30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Asp Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Asn Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
            100   105   110

Thr Val Ser Ser
        115

<210> 380
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 380

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1   5   10   15

```
Asp Arg Val Thr Ile Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Thr
            20                  25                  30

Tyr Phe His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
        35                  40                  45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
    50                  55                  60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
65                  70                  75                  80

Pro Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                85                  90                  95

Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105
```

<210> 381
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 381

```
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15

Asp Arg Val Thr Ile Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Thr
            20                  25                  30

Tyr Phe His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
        35                  40                  45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
    50                  55                  60
```

```
Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln
65                  70                  75                  80


Pro Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                85                  90                  95


Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  382
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  382

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Thr
            20                  25                  30


Tyr Phe His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
        35                  40                  45


Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
    50                  55                  60


Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Met Gln
65                  70                  75                  80


Pro Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                85                  90                  95


Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105
```

<210> 383
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 383

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Thr
20 25 30

Tyr Phe His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Trp
35 40 45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Met Gln
65 70 75 80

Pro Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
85 90 95

Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 384
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 384

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Ala Lys Gly Pro Pro Ser Gly Cys Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 385
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 385

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

```
        35                  40                  45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Asp
    50                  55                  60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65                  70                  75                  80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr
                85                  90                  95

Tyr Cys Asn Asp Gly Pro Pro Ser Gly Cys Trp Gly Gln Gly Thr Leu
            100                 105                 110

Leu Thr Val Ser Ser
        115


<210>  386
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  386

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Asp
    50                  55                  60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
```

65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr
85 90 95

Tyr Cys Asn Asp Gly Pro Pro Ser Gly Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Leu Thr Val Ser Ser
115

<210> 387
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 387

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr
85 90 95

Tyr Cys Asn Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu

100 105 110

Leu Thr Val Ser Ser
115

<210> 388
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 388

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ile Ser Glu Asn Ile Tyr Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asn Ala Lys Ile Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Thr Val Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 389
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 389

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1   5   10   15

Asp Arg Val Thr Ile Thr Cys Arg Ile Ser Glu Asn Ile Tyr Ser Tyr
            20   25   30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Val
        35   40   45

Tyr Asn Ala Lys Ile Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
    50   55   60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65   70   75   80

Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His His Tyr Thr Val Pro Trp
                85   90   95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105

<210> 390
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 390

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1   5   10   15

Asp Arg Val Thr Ile Thr Cys Arg Ile Ser Glu Asn Ile Tyr Ser Tyr
            20   25   30

```
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Val
        35                  40                  45

Tyr Asn Ala Lys Ser Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80

Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His His Tyr Thr Val Pro Trp
                85                  90                  95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105
```

<210> 391
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 391

```
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80
```

```
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110


Val Thr Val Ser Ser
        115


<210>  392
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  392

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45


Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ala Gln Lys Phe
    50                  55                  60


Gln Gly Arg Val Thr Met Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110
```

Val Thr Val Ser Ser
        115

<210> 393
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 393

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20   25   30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100   105   110

Val Thr Val Ser Ser
        115

<210> 394
<211> 117
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 394

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20   25   30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Gln Glu Trp Ile
        35   40   45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100   105   110

Val Thr Val Ser Ser
        115

<210> 395
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 395

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 396
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 396

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Gln Glu Trp Ile

35 40 45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 397
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 397

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30

Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
85 90 95

Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 398
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 398

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30

Asp Gly Asn Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
85 90 95

Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 399

<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 399

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1   5   10   15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20   25   30

Glu Gly Asn Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser
        35   40   45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
                85   90   95

Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 400
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 400

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1   5   10   15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20   25   30

Ser Gly Asn Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser
        35   40   45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
                85   90   95

Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 401
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 401

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1   5   10   15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20   25   30

Glu Gly Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser
        35   40   45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

```
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
                85                  90                  95


Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110


<210>  402
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  402

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1               5                   10                  15


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20                  25                  30


Ser Gly Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser
        35                  40                  45


Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50                  55                  60


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser
                85                  90                  95


Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110
```

<210> 403
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 403

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr
20 25 30

Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 404
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 404

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr
            20   25   30

Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35   40   45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Val Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Leu
            100   105   110

Val Thr Val Ser Ser
        115

<210> 405
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 405

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr

```
            20                  25                  30

Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Leu
            100                 105                 110

Leu Thr Val Ser Ser
        115


<210>  406
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  406

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr
            20                  25                  30

Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Ala Gln Lys Phe
```

50 55 60

Gln Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Leu
100 105 110

Leu Thr Val Ser Ser
115

<210> 407
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 407

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr
20 25 30

Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Ala Thr Leu Thr Val Asn Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Leu
100 105 110

Leu Thr Val Ser Ser
115

<210> 408
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 408

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr
20 25 30

Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Ala Thr Leu Thr Val Asn Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Leu
100 105 110

Leu Thr Val Ser Ser

115

<210> 409
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 409

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ala Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Tyr Ser Ile Pro Arg
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 410
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 410

```
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp
            20                  25                  30


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Ala Ala Ala Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Phe Val Thr Tyr Tyr Cys Gln Gln Leu Tyr Ser Ile Pro Arg
                85                  90                  95


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  411
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  411

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Gly Thr Trp
            20                  25                  30


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
        35                  40                  45
```

Tyr Ala Ala Ala Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
    50   55   60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65   70   75   80

Glu Asp Phe Val Thr Tyr Tyr Cys Gln Gln Leu Tyr Ser Ile Pro Arg
                85   90   95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105

<210> 412
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 412

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
            20   25   30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35   40   45

Ser Tyr Ile Ser Ser Asp Ser Arg Thr Ile Tyr Tyr Ala Asp Ser Val
    50   55   60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65   70   75   80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

```
Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr Trp Gly Gln Gly Thr
            100                 105                 110


Leu Val Thr Val Ser Ser
        115


<210>  413
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  413

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
            20                  25                  30


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45


Ala Tyr Ile Ser Ser Asp Ser Arg Thr Ile Tyr Tyr Ala Asp Ser Val
    50                  55                  60


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65                  70                  75                  80


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr Trp Gly Gln Gly Thr
            100                 105                 110


Leu Val Thr Val Ser Ser
        115
```

<210> 414
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 414

```
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1               5                  10                  15


Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
            20                  25                  30


Gly Tyr Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
        35                  40                  45


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Asp
    50                  55                  60


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65                  70                  75                  80


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Arg
                85                  90                  95


Glu Leu Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110
```

<210> 415
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 415

```
Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
```

1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
20 25 30

Gly Tyr Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Asp
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Val Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Arg
85 90 95

Glu Leu Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 416
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 416

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30

Asn Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Ser Thr Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 417
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 417

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30

Asn Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Ser Thr Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

```
                85                  90                  95

Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 418
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 418

```
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
            20                  25                  30

Asn Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Ser Thr Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
```

115 120

<210> 419
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 419

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30

Asn Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Ser Thr Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 420
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 420

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1   5   10   15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
            20   25   30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
        35   40   45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
    50   55   60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65   70   75   80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln
                85   90   95

Tyr Leu Ser Ser Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 421
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 421

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1   5   10   15

Glu Arg Val Thr Met Asn Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
            20   25   30

```
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
        35                  40                  45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
    50                  55                  60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65                  70                  75                  80

Ile Ser Ser Val Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln
                85                  90                  95

Tyr Leu Ser Ser Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110
```

<210> 422
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 422

```
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Asp
    50                  55                  60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65                  70                  75                  80
```

```
Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr
                85                  90                  95


Tyr Cys Asn Asp Gly Pro Pro Ser Gly Ala Trp Gly Gln Gly Thr Leu
            100                 105                 110


Leu Thr Val Ser Ser
        115
```

<210> 423
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 423

```
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45


Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ile Lys Lys Phe
    50                  55                  60


Lys Asp Arg Val Thr Met Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110
```

Val Thr Val Ser Ser
        115

<210> 424
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 424

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20   25   30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ile Lys Lys Phe
    50   55   60

Lys Asp Arg Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100   105   110

Val Thr Val Ser Ser
        115

<210> 425
<211> 117
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 425

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Gln Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ile Lys Lys Phe
50 55 60

Lys Asp Arg Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 426
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 426

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ile Lys Lys Phe
50 55 60

Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 427
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 427

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Thr Met His Trp Ile Arg Gln Ala Pro Gly Gln Gly Gln Glu Trp Ile

```
        35                  40                  45

Gly Tyr Ile Asn Pro Ser Ser Thr Tyr Thr His Tyr Ile Lys Lys Phe
    50                  55                  60

Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ser Arg Gly Glu Leu Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110

Val Thr Val Ser Ser
        115


<210>  428
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (11)..(13)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (20)..(20)
```

<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (31)..(31)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (33)..(33)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (35)..(35)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (38)..(38)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (40)..(40)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (50)..(50)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(55)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (57)..(57)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (59)..(59)

<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(61)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (65)..(68)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (72)..(72)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (74)..(76)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(80)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (82)..(82)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (87)..(87)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (90)..(91)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (98)..(98)

<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (101)..(101)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (116)..(116)
<223> Xaa can be any naturally occurring amino acid

<400> 428

Gln Val Gln Leu Xaa Gln Ser Xaa Ala Glu Xaa Xaa Xaa Pro Gly Ala
1   5   10   15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Xaa Tyr
            20   25   30

Xaa Met Xaa Trp Val Xaa Gln Xaa Pro Gly Gln Gly Leu Glu Trp Xaa
        35   40   45

Gly Xaa Ile Asn Pro Ser Xaa Gly Xaa Thr Xaa Tyr Xaa Gln Lys Phe
    50   55   60

Xaa Xaa Xaa Xaa Thr Xaa Thr Xaa Asp Xaa Ser Xaa Ser Thr Xaa Xaa
65   70   75   80

Met Xaa Leu Ser Ser Leu Xaa Ser Glu Xaa Xaa Ala Val Tyr Tyr Cys
                85   90   95

Ala Xaa Gly Asp Xaa Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
            100   105   110

Thr Val Ser Xaa
        115

<210> 429
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (31)..(31)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (35)..(35)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (50)..(50)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (59)..(59)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (67)..(67)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (74)..(74)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (98)..(98)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (101)..(101)
<223> Xaa can be any naturally occurring amino acid

<400> 429

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Xaa Tyr
            20   25   30

Thr Met Xaa Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Xaa
        35   40   45

Gly Xaa Ile Asn Pro Ser Ser Gly Tyr Thr Xaa Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Xaa Val Thr Xaa Thr Ala Asp Xaa Ser Thr Ser Thr Xaa Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Xaa Gly Asp Xaa Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
            100   105   110

Thr Val Ser Ser
        115

<210> 430

<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (3)..(4)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (9)..(11)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (15)..(15)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (17)..(17)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (27)..(27)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature

<222> (29)..(29)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (32)..(32)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (34)..(35)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (43)..(44)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (51)..(56)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(61)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (67)..(67)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (71)..(73)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(81)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature

<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (90)..(91)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (93)..(96)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (101)..(101)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (107)..(107)
<223> Xaa can be any naturally occurring amino acid

<400> 430

Xaa Ile Xaa Xaa Thr Gln Ser Pro Xaa Xaa Xaa Ser Ala Ser Xaa Gly
1   5   10   15

Xaa Arg Val Thr Xaa Thr Cys Xaa Ala Ser Xaa Ser Xaa Ser Ser Xaa
            20   25   30

Tyr Xaa Xaa Trp Tyr Gln Gln Lys Pro Gly Xaa Xaa Pro Lys Leu Xaa
        35   40   45

Ile Tyr Xaa Xaa Xaa Xaa Xaa Xaa Ser Gly Val Pro Xaa Arg Phe Ser
    50   55   60

Gly Ser Xaa Ser Gly Thr Xaa Xaa Xaa Leu Thr Ile Ser Ser Xaa Xaa
65   70   75   80

Xaa Glu Asp Xaa Ala Thr Tyr Tyr Cys Xaa Xaa Tyr Xaa Xaa Xaa Xaa
                85   90   95

Leu Thr Phe Gly Xaa Gly Thr Lys Leu Glu Xaa Lys

100 105

<210> 431
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (32)..(32)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (34)..(34)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (51)..(51)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (53)..(53)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(61)

<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (67)..(67)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (91)..(91)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (93)..(93)
<223> Xaa can be any naturally occurring amino acid

<400> 431

```
Asp Ile Gln Xaa Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Xaa Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Xaa
            20                  25                  30


Tyr Xaa His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Xaa
        35                  40                  45


Ile Tyr Xaa Thr Xaa Asn Leu Ala Ser Gly Val Pro Xaa Arg Phe Ser
    50                  55                  60


Gly Ser Xaa Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Xaa Gln
65                  70                  75                  80


Pro Glu Asp Xaa Ala Thr Tyr Tyr Cys His Xaa Tyr Xaa Arg Ser Pro
```

85 90 95

Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 432
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (23)..(23)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (31)..(31)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (33)..(33)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (35)..(35)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (40)..(40)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (42)..(42)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (49)..(50)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (52)..(59)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(61)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (64)..(64)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (76)..(76)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(81)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (87)..(87)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (94)..(95)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (99)..(99)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (106)..(106)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (112)..(112)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (114)..(114)
<223> Xaa can be any naturally occurring amino acid

<400> 432

Glu Val Xaa Leu Xaa Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15

Ser Xaa Xaa Leu Ser Cys Xaa Ala Ser Gly Phe Thr Phe Ser Xaa Tyr
            20   25   30

Xaa Met Xaa Trp Val Arg Gln Xaa Pro Xaa Lys Gly Leu Glu Trp Val
        35   40   45

Xaa Xaa Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Xaa Tyr Ala Xaa
    50   55   60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Xaa Ser Lys Xaa Xaa
65   70   75   80

Xaa Tyr Leu Gln Met Asn Xaa Leu Arg Ala Glu Asp Thr Xaa Xaa Tyr
                85   90   95

Tyr Cys Xaa Asp Gly Pro Pro Ser Gly Xaa Trp Gly Gln Gly Thr Xaa
            100   105   110

Leu Xaa Val Ser Ser
115

<210> 433
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (31)..(31)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (35)..(35)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (50)..(50)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(55)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (99)..(99)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (106)..(106)
<223> Xaa can be any naturally occurring amino acid

<400> 433

```
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Xaa Tyr
            20                  25                  30


Trp Met Xaa Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45


Ala Xaa Ile Arg Leu Lys Xaa Asp Asn Tyr Ala Thr His Tyr Ala Asp
    50                  55                  60


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Xaa Thr
65                  70                  75                  80


Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr
                85                  90                  95


Tyr Cys Xaa Asp Gly Pro Pro Ser Gly Xaa Trp Gly Gln Gly Thr Leu
            100                 105                 110


Leu Thr Val Ser Ser
        115


<210>  434
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (17)..(18)
```

<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (27)..(28)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (30)..(30)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (34)..(34)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (40)..(40)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (43)..(43)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (45)..(45)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (50)..(50)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (52)..(53)

<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(56)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (72)..(72)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (74)..(74)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (76)..(76)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(85)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (90)..(91)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (93)..(94)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (97)..(97)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (100)..(100)

<223> Xaa can be any naturally occurring amino acid

<400> 434

Asp Ile Gln Met Thr Gln Ser Pro Xaa Ser Leu Ser Ala Ser Val Gly
1   5   10   15

Xaa Xaa Val Thr Ile Thr Cys Arg Xaa Ser Xaa Xaa Ile Xaa Ser Tyr
            20   25   30

Leu Xaa Trp Tyr Gln Gln Lys Xaa Gly Lys Xaa Pro Xaa Leu Leu Xaa
        35   40   45

Tyr Xaa Ala Xaa Xaa Leu Xaa Xaa Gly Val Pro Ser Arg Phe Ser Gly
    50   55   60

Ser Gly Ser Gly Thr Xaa Phe Xaa Leu Xaa Ile Xaa Ser Leu Gln Pro
65   70   75   80

Glu Asp Phe Xaa Xaa Tyr Tyr Cys Gln Xaa Xaa Tyr Xaa Xaa Pro Trp
                85   90   95

Xaa Phe Gly Xaa Gly Thr Lys Leu Glu Ile Lys
            100   105

<210> 435
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (34)..(34)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (53)..(53)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(55)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(85)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (90)..(90)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (93)..(93)
<223> Xaa can be any naturally occurring amino acid

<400> 435

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1   5   10   15

Asp Arg Val Thr Ile Thr Cys Arg Xaa Ser Glu Asn Ile Tyr Ser Tyr
            20   25   30

Leu Xaa Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Xaa
        35   40   45

Tyr Asn Ala Lys Xaa Leu Xaa Glu Gly Val Pro Ser Arg Phe Ser Gly
    50   55   60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Xaa Xaa Tyr Tyr Cys Gln Xaa His Tyr Xaa Val Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 436
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (11)..(13)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (29)..(29)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (31)..(31)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (33)..(33)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (37)..(38)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (40)..(40)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (45)..(45)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (50)..(50)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(57)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (59)..(59)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(62)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (65)..(68)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (72)..(72)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (74)..(74)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (76)..(76)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (82)..(82)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (87)..(87)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (91)..(91)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (97)..(97)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (101)..(101)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (117)..(117)
<223> Xaa can be any naturally occurring amino acid

<400> 436

Gln Val Gln Leu Xaa Gln Ser Gly Ala Glu Xaa Xaa Xaa Pro Gly Ala
1 5 10 15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Thr Xaa Thr Xaa Tyr
20 25 30

Xaa Met His Trp Xaa Xaa Gln Xaa Pro Gly Gln Gly Xaa Glu Trp Xaa
35 40 45

Gly Xaa Ile Asn Pro Ser Xaa Xaa Xaa Thr Xaa Tyr Xaa Xaa Lys Phe
50 55 60

Xaa Xaa Xaa Xaa Thr Xaa Thr Xaa Asp Xaa Ser Xaa Ser Thr Xaa Tyr
65 70 75 80

Met Xaa Leu Xaa Ser Leu Xaa Ser Glu Asp Xaa Ala Val Tyr Tyr Cys
85 90 95

Xaa Arg Gly Glu Xaa Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Xaa
115

<210> 437
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature

<222> (20)..(20)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (29)..(29)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (31)..(31)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (37)..(37)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (45)..(45)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (56)..(56)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (59)..(59)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(62)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (65)..(66)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature

<222> (68)..(68)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (74)..(74)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (97)..(97)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (101)..(101)
<223> Xaa can be any naturally occurring amino acid

<400> 437

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Thr Xaa Thr Xaa Tyr
            20   25   30

Thr Met His Trp Xaa Arg Gln Ala Pro Gly Gln Gly Xaa Glu Trp Xaa
        35   40   45

Gly Tyr Ile Asn Pro Ser Ser Xaa Tyr Thr Xaa Tyr Xaa Xaa Lys Phe
    50   55   60

Xaa Xaa Arg Xaa Thr Xaa Thr Ala Asp Xaa Ser Thr Ser Thr Xaa Tyr
65 70 75 80

Met Glu Leu Xaa Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Xaa Arg Gly Glu Xaa Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 438
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (7)..(7)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (14)..(14)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (17)..(18)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (31)..(31)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (33)..(33)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (39)..(39)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (41)..(42)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (44)..(44)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (50)..(51)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(55)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (57)..(57)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (81)..(81)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (88)..(88)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (92)..(92)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (94)..(96)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (99)..(100)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (105)..(105)
<223> Xaa can be any naturally occurring amino acid

<400> 438

Asp Val Val Met Thr Gln Xaa Pro Leu Ser Leu Pro Val Xaa Leu Gly
1   5   10   15

Xaa Xaa Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Xaa Ser
            20   25   30

Xaa Gly Asn Thr Tyr Leu Xaa Trp Xaa Xaa Gln Xaa Pro Gly Gln Ser
        35   40   45

Pro Xaa Xaa Asn Pro Ser Xaa Thr Xaa Thr His Tyr Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Xaa Arg Val Glu Ala Glu Asp Xaa Gly Val Tyr Xaa Cys Xaa Xaa Xaa
                85   90   95

Thr His Xaa Xaa Tyr Thr Phe Gly Xaa Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 439
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (33)..(33)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (39)..(39)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(55)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (57)..(57)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (81)..(81)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (95)..(96)
<223> Xaa can be any naturally occurring amino acid

<400> 439

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30

Xaa Gly Asn Thr Tyr Leu Xaa Trp Tyr Gln Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Leu Leu Ile Tyr Xaa Val Xaa Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Xaa Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Xaa Xaa
85 90 95

Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 440
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (11)..(12)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (38)..(38)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (40)..(41)
<223> Xaa can be any naturally occurring amino acid

<220>

<221> misc_feature
<222> (43)..(44)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(61)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (65)..(65)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (67)..(68)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (72)..(72)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (74)..(74)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (76)..(76)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<220>

<221> misc_feature
<222> (82)..(82)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (87)..(87)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (91)..(91)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (116)..(116)
<223> Xaa can be any naturally occurring amino acid

<400> 440

```
Gln Val Gln Leu Xaa Gln Ser Gly Xaa Glu Xaa Xaa Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
            20                  25                  30


Asn Met Asn Trp Val Xaa Gln Xaa Xaa Gly Xaa Xaa Leu Glu Trp Xaa
        35                  40                  45


Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Ser Thr Tyr Xaa Gln Lys Phe
    50                  55                  60


Xaa Gly Xaa Xaa Thr Xaa Thr Xaa Asp Xaa Ser Xaa Ser Thr Xaa Tyr
65                  70                  75                  80


Met Xaa Leu Xaa Ser Leu Xaa Ser Glu Asp Xaa Ala Val Tyr Tyr Cys
                85                  90                  95
```

Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Xaa Val Thr Val Ser
115 120

<210> 441
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (68)..(68)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<400> 441

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30

```
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Xaa
        35                  40                  45

Gly Asn Ile Asp Pro Tyr Tyr Gly Gly Ser Thr Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Xaa Thr Xaa Thr Arg Asp Thr Ser Thr Ser Thr Xaa Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser
        115                 120
```

<210> 442
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (15)..(15)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (21)..(22)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (49)..(49)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (51)..(51)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (69)..(69)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (78)..(78)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (93)..(93)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (105)..(105)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (111)..(111)
<223> Xaa can be any naturally occurring amino acid

<400> 442

Xaa Ile Xaa Met Thr Gln Ser Pro Xaa Ser Leu Ala Val Ser Xaa Gly
1 5 10 15

Glu Xaa Xaa Thr Xaa Xaa Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
20 25 30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Xaa Pro Xaa Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Xaa Gly Ser Gly Ser Gly Thr Asp Phe Xaa Leu Thr
65 70 75 80

Ile Ser Ser Xaa Gln Ala Glu Asp Val Ala Val Tyr Xaa Cys His Gln
85 90 95

Tyr Leu Ser Ser Arg Thr Phe Gly Xaa Gly Thr Lys Leu Glu Xaa Lys
100 105 110

<210> 443
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa can be any naturally occurring amino acid

<220>

<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<400> 443

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Xaa Thr Xaa Asn Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
20 25 30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Xaa Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln
85 90 95

Tyr Leu Ser Ser Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 444
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature

<222> (1)..(1)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (11)..(12)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (38)..(38)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (40)..(41)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (43)..(44)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (48)..(48)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (61)..(61)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature

<222> (63)..(63)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (65)..(65)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (67)..(67)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (69)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (72)..(74)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (76)..(76)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (79)..(79)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (87)..(87)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (91)..(91)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature

<222> (93)..(93)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (112)..(113)
<223> Xaa can be any naturally occurring amino acid

<400> 444

Xaa Val Gln Leu Xaa Gln Ser Gly Xaa Glu Xaa Xaa Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr
            20   25   30

Asn Met His Trp Val Xaa Gln Xaa Xaa Gly Xaa Xaa Leu Glu Trp Xaa
        35   40   45

Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Xaa Gln Xaa Phe
    50   55   60

Xaa Gly Xaa Val Xaa Xaa Thr Xaa Xaa Xaa Ser Xaa Ser Thr Xaa Tyr
65   70   75   80

Met Glu Leu Xaa Ser Leu Xaa Ser Glu Asp Xaa Ala Xaa Tyr Tyr Cys
                85   90   95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Cys Trp Gly Gln Gly Thr Xaa
            100   105   110

Xaa Thr Val Ser Ser
        115

<210> 445
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (11)..(11)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (15)..(15)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (17)..(18)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (43)..(43)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (45)..(45)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (70)..(70)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (72)..(74)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (80)..(80)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(85)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (100)..(100)
<223> Xaa can be any naturally occurring amino acid

<400> 445

Asp Ile Gln Met Thr Gln Ser Pro Xaa Ser Xaa Ser Ala Ser Xaa Gly
1   5   10   15

Xaa Xaa Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp
            20   25   30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Xaa Pro Xaa Leu Leu Ile
        35   40   45

Tyr Ala Ala Ala Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
    50   55   60

Ser Gly Ser Gly Thr Xaa Phe Xaa Xaa Xaa Ile Ser Ser Leu Gln Xaa
65   70   75   80

Glu Asp Phe Xaa Xaa Tyr Tyr Cys Gln Gln Leu Tyr Ser Ile Pro Arg
                85   90   95

Thr Phe Gly Xaa Gly Thr Lys Leu Glu Ile Lys
            100   105

<210> 446
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (15)..(15)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (42)..(42)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (49)..(49)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (63)..(63)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (75)..(76)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (78)..(78)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (80)..(80)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (84)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (88)..(88)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (93)..(93)
<223> Xaa can be any naturally occurring amino acid

<400> 446

Xaa Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Xaa Gly
1 5 10 15

Ser Xaa Xaa Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Xaa Lys Gly Leu Glu Trp Val
35 40 45

Xaa Tyr Ile Ser Ser Asp Ser Arg Thr Ile Tyr Tyr Ala Asp Xaa Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Xaa Xaa Asn Xaa Leu Xaa
65 70 75 80

Leu Gln Met Xaa Ser Leu Arg Xaa Glu Asp Thr Ala Xaa Tyr Tyr Cys
85 90 95

Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr
100 105

<210> 447
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa can be any naturally occurring amino acid

<220>

<221> misc_feature
<222> (9)..(9)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (17)..(17)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (22)..(22)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (64)..(64)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (78)..(78)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (80)..(84)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (87)..(87)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (89)..(89)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (104)..(104)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (110)..(110)
<223> Xaa can be any naturally occurring amino acid

<400> 447

```
Asp Ile Val Xaa Thr Gln Ser Pro Xaa Ser Leu Ala Val Ser Leu Gly
1               5                  10                  15


Xaa Arg Ala Thr Ile Xaa Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
            20                  25                  30


Gly Tyr Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
        35                  40                  45


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Xaa
    50                  55                  60


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Xaa Ile Xaa
65                  70                  75                  80


Xaa Xaa Xaa Xaa Glu Asp Xaa Ala Xaa Tyr Tyr Cys Gln His Ser Arg
                85                  90                  95


Glu Leu Pro Leu Thr Phe Gly Xaa Gly Thr Lys Leu Glu Xaa Lys
            100                 105                 110


<210>  448
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (82)..(82)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
```

<222> (110)..(110)
<223> Xaa can be any naturally occurring amino acid

<400> 448

Asp Ile Val Xaa Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
20 25 30

Gly Tyr Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Asp
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Xaa Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Arg
85 90 95

Glu Leu Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Xaa Lys
100 105 110

<210> 449
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is T, V, F, or D

<400> 449

Ser Ser Val Ser Ser Xaa Tyr

1 5

<210> 450
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is S, T, Q, or A

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is S, T, D, or Q

<400> 450

Xaa Thr Xaa
1

<210> 451
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Q, H or S

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is H, Y, Q, or S

<400> 451

His Xaa Tyr Xaa Arg Ser Pro Leu Thr

1 5

<210> 452
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is T, V, D, or S

<400> 452

Tyr Thr Phe Thr Xaa Tyr Thr
1 5

<210> 453
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is N, Q, H, D, S, R, or A

<400> 453

Ala Xaa Gly Asp Tyr Tyr Val Ala Tyr
1 5

<210> 454
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is H, Q, S, or T

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is T, S, N, or G

<400> 454

Gln Xaa His Tyr Xaa Val Pro Trp Thr
1   5

<210> 455
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is N, S, R, q, s, or a

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is w, h, y, or f

<400> 455

Phe Thr Phe Ser Xaa Tyr Xaa
1   5

<210> 456
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is S, N, A, or T

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is Q, S,A, or N

<400> 456

Ile Arg Leu Lys Xaa Asp Xaa Tyr Ala Thr
1   5   10

<210> 457
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is N, D, A, or T

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is S, T, A, C, Y

<400> 457

Xaa Asp Gly Pro Pro Ser Gly Xaa
1   5

<210> 458
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is D, N, E, Q, S, or A

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa is Q, S, A, D, or N

<400> 458

Gln Ser Leu Val His Ser Xaa Gly Xaa Thr Tyr
1   5   10

<210> 459
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is K, Q, or R

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is S, T, or V

<400> 459

Xaa Val Xaa
1

<210> 460
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Q, H, or T

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is S, G, T, or D

<400> 460

Ser Xaa Xaa Thr His Val Pro Tyr Thr
1   5

<210> 461
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is F, Y, S, or T

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is S, T, Y , or D

<400> 461

Tyr Thr Xaa Thr Xaa Tyr Thr Met His
1   5

<210> 462
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Q, S, A, or N

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is T, S, V, D, or G

<400> 462

Ile Xaa Pro Ser Ser Xaa Tyr Thr
1   5

<210> 463
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is S, A, T, or V

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is L, V, or F

<400> 463

Xaa Arg Gly Glu Xaa Gly Gly Phe Ala Tyr
1   5   10

<210> 464
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is W, H, Y, or F

<400> 464

Gln Thr Ile Gly Tyr Xaa
1   5

<210> 465
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is R or T

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is N, Q, S, or A

<400> 465

Gly Tyr Xaa Phe Thr Asp Tyr Xaa
1   5

<210> 466
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)

<223> Xaa is N, Q, S, or A

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is N, Q, S, or A

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is N, Q, S, or A

<400> 466

Ile Xaa Pro Xaa Xaa Gly Gly Thr
1   5

<210> 467
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is C, Y, S, or A

<400> 467

Asp Tyr Leu Tyr Phe Phe Asp Xaa
1   5

<210> 468
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (4)..(4)

<223> Xaa is D, E, S, or A

<400> 468

Ile Ser Ser Xaa Ser Arg Thr Ile
1   5

<210> 469
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 469

Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr
1   5

<210> 470
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is Q, S, A, D, or N

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Xaa is Q, S, A, D, or N

<400> 470

Gln Ser Val Leu Phe Ser Ser Xaa Gln Lys Xaa Tyr
1   5   10

<210> 471
<211> 3
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is H, Y, F, or W

<400> 471

Xaa Ala Ser
1

<210> 472
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is N, Q, S, or A

<400> 472

Gly Tyr Ser Phe Thr Phe Tyr Xaa
1 5

<210> 473
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is A, S, E, or D

<400> 473

Ile Xaa Pro Tyr Tyr Gly Gly Ser
1 5

<210> 474
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<400> 474

Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr
1 5 10

<210> 475
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Q, S, A, or N

<400> 475

Ile Xaa Pro Ser Ser Gly Tyr Thr
1 5

<210> 476
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Q, S, A, D, or N

<400> 476

Glu Xaa Ile Tyr Ser Tyr
1 5

<210> 477
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is Q, S, A, D, or N

<400> 477

Xaa Ala Lys
1

<210> 478
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa is M or V

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Xaa is T, V, D, or S

<220>
<221> MISC_FEATURE
<222> (48)..(48)
<223> Xaa is I or M

<220>
<221> MISC_FEATURE
<222> (52)..(52)
<223> Xaa is Q, S, A, or N

<220>
<221> MISC_FEATURE
<222> (70)..(70)
<223> Xaa is L or M

<220>
<221> MISC_FEATURE
<222> (74)..(74)
<223> Xaa is T or K

<220>
<221> MISC_FEATURE
<222> (98)..(98)
<223> Xaa is N, Q, H, D, S, R,or A

<400> 478

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Xaa Tyr
            20   25   30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Xaa
        35   40   45

Gly Phe Ile Xaa Pro Ser Ser Gly Tyr Thr Asp Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Val Thr Xaa Thr Ala Asp Xaa Ser Thr Ser Thr Val Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Xaa Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 479
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is L or M

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Xaa is M or I

<220>
<221> MISC_FEATURE
<222> (32)..(32)
<223> Xaa is T, V, F, or D

<220>
<221> MISC_FEATURE
<222> (48)..(48)
<223> Xaa is W or L

<220>
<221> MISC_FEATURE
<222> (51)..(51)
<223> Xaa is S, t, Q or A

<220>
<221> MISC_FEATURE
<222> (53)..(53)
<223> Xaa is S,T, D or Q

<220>
<221> MISC_FEATURE

<222> (79)..(79)
<223> Xaa is M or L

<220>
<221> MISC_FEATURE
<222> (84)..(84)
<223> Xaa is A or F

<220>
<221> MISC_FEATURE
<222> (91)..(91)
<223> Xaa is Q, H or S

<220>
<221> MISC_FEATURE
<222> (93)..(93)
<223> Xaa is H, Y, Q, or S

<400> 479

Asp Ile Gln Xaa Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1   5   10   15

Asp Arg Val Thr Xaa Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Xaa
            20   25   30

Tyr Phe His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Xaa
        35   40   45

Ile Tyr Xaa Thr Xaa Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
    50   55   60

Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Xaa Gln
65   70   75   80

Pro Glu Asp Xaa Ala Thr Tyr Tyr Cys His Xaa Tyr Xaa Arg Ser Pro
                85   90   95

Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105

<210> 480
<211> 117

<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Xaa is N, S, R, Q or A

<220>
<221> MISC_FEATURE
<222> (33)..(33)
<223> Xaa is W, H, Y or F

<220>
<221> MISC_FEATURE
<222> (55)..(55)
<223> Xaa is S, N, A, or T

<220>
<221> MISC_FEATURE
<222> (57)..(57)
<223> Xaa is Q, S, A, or N

<220>
<221> MISC_FEATURE
<222> (99)..(99)
<223> Xaa is N, D, or T

<220>
<221> MISC_FEATURE
<222> (106)..(106)
<223> Xaa is S, T, A, C, or Y

<400> 480

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Xaa Tyr
20 25 30

Xaa Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

```
Ala Gln Ile Arg Leu Lys Xaa Asp Xaa Tyr Ala Thr His Tyr Ala Asp
    50                  55                  60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65                  70                  75                  80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr
                85                  90                  95

Tyr Cys Xaa Asp Gly Pro Pro Ser Gly Xaa Trp Gly Gln Gly Thr Leu
            100                 105                 110

Leu Thr Val Ser Ser
        115
```

<210> 481
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Xaa is Q, S, A, D, or N

<220>
<221> MISC_FEATURE
<222> (48)..(48)
<223> Xaa is V or I

<220>
<221> MISC_FEATURE
<222> (50)..(50)
<223> Xaa is S, T, Q or A

<220>
<221> MISC_FEATURE
<222> (84)..(84)
<223> Xaa is G or A

<220>
<221> MISC_FEATURE
<222> (90)..(90)
<223> Xaa is H, Q, S or T

<220>
<221> MISC_FEATURE
<222> (93)..(93)
<223> Xaa is T, S, N, or G

<400> 481

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ile Ser Glu Xaa Ile Tyr Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Xaa
35 40 45

Tyr Xaa Ala Lys Ile Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Xaa Thr Tyr Tyr Cys Gln Xaa His Tyr Xaa Val Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 482
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>

<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa is M or V

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> Xaa is F, Y, S or T

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Xaa is S, T, Y, or D

<220>
<221> MISC_FEATURE
<222> (37)..(37)
<223> Xaa is I or V

<220>
<221> MISC_FEATURE
<222> (45)..(45)
<223> Xaa is Q or L

<220>
<221> MISC_FEATURE
<222> (48)..(48)
<223> Xaa is I or M

<220>
<221> MISC_FEATURE
<222> (52)..(52)
<223> Xaa is Q, S, A, or N

<220>
<221> MISC_FEATURE
<222> (56)..(56)
<223> Xaa is T, S, V, D or G

<220>
<221> MISC_FEATURE
<222> (61)..(61)
<223> Xaa is I or A

<220>
<221> MISC_FEATURE
<222> (62)..(62)
<223> Xaa is K or Q

<220>

<221> MISC_FEATURE
<222> (65)..(65)
<223> Xaa is K or Q

<220>
<221> MISC_FEATURE
<222> (66)..(66)
<223> Xaa is D or G

<220>
<221> MISC_FEATURE
<222> (68)..(68)
<223> Xaa is A or V

<220>
<221> MISC_FEATURE
<222> (70)..(70)
<223> Xaa is L or M

<220>
<221> MISC_FEATURE
<222> (74)..(74)
<223> Xaa is T or K

<220>
<221> MISC_FEATURE
<222> (79)..(79)
<223> Xaa is A or V

<220>
<221> MISC_FEATURE
<222> (97)..(97)
<223> Xaa is S, A, T, or V

<220>
<221> MISC_FEATURE
<222> (101)..(97)
<223> Xaa is L, V, or F

<220>
<221> misc_feature
<222> (101)..(101)
<223> Xaa can be any naturally occurring amino acid

<400> 482

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Thr Xaa Thr Xaa Tyr
            20   25   30

Thr Met His Trp Xaa Arg Gln Ala Pro Gly Gln Gly Xaa Glu Trp Xaa
        35   40   45

Gly Tyr Ile Xaa Pro Ser Ser Xaa Tyr Thr His Tyr Xaa Xaa Lys Phe
    50   55   60

Xaa Xaa Arg Xaa Thr Xaa Thr Ala Asp Xaa Ser Thr Ser Thr Xaa Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Xaa Arg Gly Glu Xaa Gly Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu
            100   105   110

Val Thr Val Ser Ser
        115

<210> 483
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (33)..(33)
<223> Xaa is D, N, E, Q, S, or A

<220>
<221> MISC_FEATURE
<222> (35)..(35)
<223> Xaa is Q, S, A, D, or N

<220>
<221> MISC_FEATURE
<222> (55)..(55)

<223> Xaa is K, Q, or R

<220>
<221> MISC_FEATURE
<222> (57)..(57)
<223> Xaa is S, T, or V

<220>
<221> MISC_FEATURE
<222> (95)..(95)
<223> Xaa is Q, H, or T

<220>
<221> MISC_FEATURE
<222> (96)..(96)
<223> Xaa is S, G, T, or D

<400> 483

```
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1               5                   10                  15


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
            20                  25                  30


Asp Gly Xaa Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser
        35                  40                  45


Pro Arg Leu Leu Ile Tyr Xaa Val Xaa Asn Arg Phe Ser Gly Val Pro
    50                  55                  60


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Xaa Xaa
                85                  90                  95


Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110
```

<210> 484
<211> 121
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa is I or V

<220>
<221> MISC_FEATURE
<222> (33)..(33)
<223> Xaa is N, Q, S, or A

<220>
<221> MISC_FEATURE
<222> (48)..(48)
<223> Xaa is I or M

<220>
<221> MISC_FEATURE
<222> (52)..(52)
<223> Xaa is A, S, E or D

<220>
<221> MISC_FEATURE
<222> (68)..(68)
<223> Xaa is A or V

<220>
<221> MISC_FEATURE
<222> (70)..(70)
<223> Xaa is L or M

<220>
<221> MISC_FEATURE
<222> (79)..(79)
<223> Xaa is A or V

<400> 484

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30

```
Xaa Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Xaa
        35                  40                  45


Gly Asn Ile Xaa Pro Tyr Tyr Gly Gly Ser Thr Tyr Ala Gln Lys Phe
    50                  55                  60


Gln Gly Arg Xaa Thr Xaa Thr Val Asp Thr Ser Thr Ser Thr Xaa Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Glu Arg Ser Gly Tyr Val Phe Ser Ala Met Asp Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 485
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Xaa is V or A

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Xaa is M or I

<220>
<221> MISC_FEATURE
<222> (34)..(34)
<223> Xaa is Q, S, A, D, or N

<220>

<221> MISC_FEATURE
<222> (37)..(37)
<223> Xaa is Q, S, A, D, or N

<220>
<221> MISC_FEATURE
<222> (56)..(56)
<223> Xaa is H, Y, F, or W

<220>
<221> MISC_FEATURE
<222> (84)..(84)
<223> Xaa is V or L

<400> 485

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Xaa Thr Xaa Asn Cys Lys Ser Ser Gln Ser Val Leu Phe Ser
20 25 30

Ser Xaa Gln Lys Xaa Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Ile Tyr Xaa Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Xaa Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln
85 90 95

Tyr Leu Ser Ser Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 486
<211> 118
<212> PRT
<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (54)..(54)
<223> Xaa is D, E, S, or A

<400> 486

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
            20   25   30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35   40   45

Ala Tyr Ile Ser Ser Xaa Ser Arg Thr Ile Tyr Tyr Ala Asp Ser Val
    50   55   60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65   70   75   80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Arg Asp Tyr Gly Arg Thr Tyr Glu Ala Tyr Trp Gly Gln Gly Thr
            100   105   110

Leu Val Thr Val Ser Ser
        115

<210> 487
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is M or L

<220>
<221> MISC_FEATURE
<222> (82)..(82)
<223> Xaa is V or L

<220>
<221> MISC_FEATURE
<222> (110)..(110)
<223> Xaa is I or L

<400> 487

Asp Ile Val Xaa Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1   5   10   15

Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
            20   25   30

Gly Tyr Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
        35   40   45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Asp
    50   55   60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65   70   75   80

Ser Xaa Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Arg
                85   90   95

Glu Leu Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 488
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Xaa is R or T

<220>
<221> MISC_FEATURE
<222> (33)..(33)
<223> Xaa is N, Q, S or A

<220>
<221> MISC_FEATURE
<222> (52)..(52)
<223> Xaa is N, Q, S or A

<220>
<221> MISC_FEATURE
<222> (54)..(54)
<223> Xaa is N, Q, S or A

<220>
<221> MISC_FEATURE
<222> (55)..(55)
<223> Xaa is N, Q, S, or A

<220>
<221> MISC_FEATURE
<222> (106)..(106)
<223> Xaa is C, Y, S, or A

<400> 488

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Xaa Phe Thr Asp Tyr
            20   25   30

Xaa Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Tyr Ile Xaa Pro Xaa Xaa Gly Gly Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Tyr Leu Tyr Phe Phe Asp Xaa Trp Gly Gln Gly Thr Leu
100 105 110

Leu Thr Val Ser Ser
115

<210> 489
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (24)..(24)
<223> Xaa is L or R

<220>
<221> MISC_FEATURE
<222> (32)..(32)
<223> Xaa is W, H, Y, or F

<400> 489

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Xaa
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ala Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
    50   55   60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65   70   75   80

Glu Asp Phe Val Thr Tyr Tyr Cys Gln Gln Leu Tyr Ser Ile Pro Arg
                85   90   95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100   105

<210> 490
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 490

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20   25   30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35   40   45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Thr Asp
    50   55   60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Thr
65   70   75   80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Thr Tyr
                85   90   95

```
Tyr Cys Ser Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu
            100                 105                 110


Leu Thr Val Ser Ser
        115


<210>  491
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  491

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45


Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Asp
    50                  55                  60


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Thr
65                  70                  75                  80


Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Thr Tyr
                85                  90                  95


Tyr Cys Ser Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu
            100                 105                 110


Leu Thr Val Ser Ser
        115
```

<210> 492
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 492

```
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45


Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Val Thr His Tyr Thr Asp
    50                  55                  60


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Thr
65                  70                  75                  80


Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr
                85                  90                  95


Tyr Cys Ser Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu
            100                 105                 110


Leu Thr Val Ser Ser
        115
```

<210> 493
<211> 117
<212> PRT
<213> Artificial Sequence

<220>

<223> Synthetic Polypeptide

<400> 493

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15

Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20   25   30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35   40   45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Thr Asp
    50   55   60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65   70   75   80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Thr Tyr
                85   90   95

Tyr Cys Asn Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu
            100   105   110

Leu Thr Val Ser Ser
        115

<210> 494
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 494

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15

```
Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
        35                  40                  45


Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Thr Asp
    50                  55                  60


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Thr
65                  70                  75                  80


Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr
                85                  90                  95


Tyr Cys Ser Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu
            100                 105                 110


Leu Thr Val Ser Ser
        115


<210>  495
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  495

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
        35                  40                  45
```

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Val Thr His Tyr Ala Asp
    50   55   60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Thr
65   70   75   80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Thr Tyr
                85   90   95

Tyr Cys Asn Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu
            100   105   110

Leu Thr Val Ser Ser
        115

<210> 496
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 496

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20   25   30

Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Glu Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65   70   75   80

```
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95


Ala Asn Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
            100                 105                 110


Thr Val Ser Ser
        115


<210>  497
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  497

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20                  25                  30


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45


Gly Val Ile Asn Pro Ser Ser Gly Tyr Thr Glu Tyr Ala Gln Lys Phe
    50                  55                  60


Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95


Ala Asn Gly Asp Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr Leu Val
            100                 105                 110
```

Thr Val Ser Ser
        115

<210> 498
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 498

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20   25   30

Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Val Ile Asn Pro Ser Ser Gly Tyr Thr Asp Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
                85   90   95

Ala Asn Gly Asp Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr Leu Val
            100   105   110

Thr Val Ser Ser
        115

<210> 499
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 499

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20   25   30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Glu Tyr Ala Gln Lys Phe
    50   55   60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65   70   75   80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Asn Gly Asp Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr Leu Val
            100   105   110

Thr Val Ser Ser
        115

<210> 500
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 500

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1   5   10   15

```
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20                  25                  30

Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Val Ile Asn Pro Ser Ser Gly Tyr Thr Glu Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95

Ala Asn Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
            100                 105                 110

Thr Val Ser Ser
        115
```

<210> 501
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 501

```
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
            20                  25                  30

Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45
```

```
Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Glu Tyr Ala Gln Lys Phe
    50                  55                  60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95

Ala Asn Gly Asp Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr Leu Val
            100                 105                 110

Thr Val Ser Ser
        115
```

<210> 502
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<222> (48)..(48)
<223> Xaa is any aliphatic amino acid, optionally Ile or Leu

<220>
<221> MISC_FEATURE
<222> (59)..(59)
<223> Xaa is any aliphatic amino acid, optionally, Ala or Val

<220>
<221> MISC_FEATURE
<222> (63)..(63)
<223> Xaa is any aliphatic or any amino acid with a polar side chain, optionally, Ala or Thr

<220>
<221> MISC_FEATURE
<222> (79)..(79)

<223> Xaa is any basic amino acid or any amino acid with a polar side chain, optionally Arg or Ser

<220>
<221> MISC_FEATURE
<222> (95)..(95)
<223> Xaa is any aliphatic amino acid or any amino acid with a polar side chain, optionally, Thr or Ile

<220>
<221> MISC_FEATURE
<222> (99)..(99)
<223> Xaa is any acidic amino acid or any amino acid with a polar side chain, optionally, Ser or Asn

<400> 502

```
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15


Ser Met Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Xaa
        35                  40                  45


Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Xaa Thr His Tyr Xaa Asp
    50                  55                  60


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Xaa Thr
65                  70                  75                  80


Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Xaa Tyr
                85                  90                  95


Tyr Cys Xaa Asp Gly Pro Pro Ser Gly Ser Trp Gly Gln Gly Thr Leu
            100                 105                 110


Leu Thr Val Ser Ser
        115
```

<210> 503

<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<222> (34)..(34)
<223> Xaa is any aliphatic amino acid or any amino acid comprising a sulfur containing side chain; optionally, Ile or Met

<220>
<221> MISC_FEATURE
<222> (50)..(50)
<223> Xaa is any aliphatic amino acid or any aromatic amino acid, optionally, Phe or Val

<220>
<221> MISC_FEATURE
<222> (59)..(59)
<223> Xaa is any acidic amino acid, optionally, Glu or Asp

<220>
<221> MISC_FEATURE
<222> (95)..(95)
<223> Xaa is any aromatic amino acid, optionally, Phe or Tyr

<220>
<221> MISC_FEATURE
<222> (104)..(104)
<223> Xaa is any aliphatic amino acid, optionally, Gly or Ala

<400> 503

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30

Thr Xaa His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Xaa Ile Asn Pro Ser Ser Gly Tyr Thr Xaa Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Xaa Cys
85 90 95

Ala Asn Gly Asp Tyr Tyr Val Xaa Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 504
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 504

Gly Tyr Thr Phe Thr Thr Tyr Thr
1 5

<210> 505
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 505

Ile Asn Pro Ser Ser Gly Tyr Thr
1 5

<210> 506
<211> 9
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is any aliphatic amino acid, optionally, Gly or Ala

<400> 506

Ala Asn Gly Asp Tyr Tyr Val Xaa Tyr
1 5

<210> 507
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 507

Gly Phe Thr Phe Ser Asn Tyr Trp
1 5

<210> 508
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa is any aliphatic amino acid, optionally, Ala or Val

<400> 508

Ile Arg Leu Lys Ser Asp Asn Tyr Xaa Thr
1 5 10

<210> 509
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is any acidic amino acid or any amino acid with a polar side chain, optionally, Ser or Asn

<400> 509

Xaa Asp Gly Pro Pro Ser Gly Ser
1 5

<210> 510
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 510

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

```
Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr
                85                  90                  95


Tyr Cys Asn Asp Gly Pro Pro Ser Gly Cys Trp Gly Gln Gly Thr Thr
            100                 105                 110


Leu Thr Val Ser Ser
        115
```

<210> 511
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 511

```
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr
            20                  25                  30


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
        35                  40                  45


Tyr Asn Ala Lys Ile Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60


Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Phe Gly Asn Tyr Tyr Cys Gln His His Tyr Thr Val Pro Trp
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105
```

<210> 512
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 512

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
1 5 10 15

Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser
20 25 30

Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
85 90 95

Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 513
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 513

```
Gln Val Gln Leu Gln Gln Ser Ala Ala Glu Leu Ala Arg Pro Gly Ala
1               5                   10                  15


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20                  25                  30


Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45


Gly Phe Ile Asn Pro Ser Ser Gly Tyr Thr Asp Tyr Asn Gln Lys Phe
    50                  55                  60


Lys Asp Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Asn Gly Asp Tyr Tyr Val Ala Tyr Trp Gly Gln Gly Thr Leu Val
            100                 105                 110


Thr Val Ser Ala
        115
```